"PT","UT","PY","TI","AB","ID","DE","SO","AU","C1","WC","SC","CR","Z9","DA","FU","AF","CU"
"J","WOS:000243089900014",2006,"COMPARING CORRELATIONS OF CONTINUOUS OBSERVATIONS FROM TWO INDEPENDENT POPULATIONS USING A SEQUENTIAL APPROACH","A SEQUENTIAL STUDY DESIGN GENERALLY MAKES MORE EFFICIENT USE OF AVAILABLE INFORMATION THAN A FIXED SAMPLE COUNTERPART OF EQUAL POWER. THIS FEATURE IS GRADUALLY BEING EXPLOITED BY RESEARCHERS IN GENETIC AND EPIDEMIOLOGICAL INVESTIGATIONS THAT UTILIZE BANKED BIOLOGICAL RESOURCES AND IN STUDIES WHERE TIME, COST AND ETHICS ARE PROMINENT CONSIDERATIONS. RECENT WORK IN THIS AREA HAS FOCUSSED ON THE SEQUENTIAL ANALYSIS OF MATCHED CASE-CONTROL STUDIES WITH A DICHOTOMOUS TRAIT. IN THIS PAPER, WE EXTEND THE SEQUENTIAL APPROACH TO A COMPARISON OF THE ASSOCIATIONS WITHIN TWO INDEPENDENT GROUPS OF PAIRED CONTINUOUS OBSERVATIONS. SUCH A COMPARISON IS PARTICULARLY RELEVANT IN FAMILIAL STUDIES OF PHENOTYPIC CORRELATION USING TWINS. WE DEVELOP A SEQUENTIAL TWIN METHOD BASED ON THE INTRACLASS CORRELATION AND SHOW THAT USE OF SEQUENTIAL METHODOLOGY CAN LEAD TO A SUBSTANTIAL REDUCTION IN THE NUMBER OF OBSERVATIONS WITHOUT COMPROMISING THE STUDY ERROR RATES. ADDITIONALLY, OUR APPROACH PERMITS STRAIGHTFORWARD ALLOWANCE FOR OTHER EXPLANATORY FACTORS IN THE ANALYSIS. WE ILLUSTRATE OUR METHOD IN A SEQUENTIAL HERITABILITY STUDY OF DYSPLASIA THAT ALLOWS FOR THE EFFECT OF BODY MASS INDEX AND COMPARES MONOZYGOTES WITH PAIRS OF SINGLETON SISTERS. COPYRIGHT (C) 2006 JOHN WILEY & SONS, LTD.","LINKAGE; TESTS","GENETIC EPIDEMIOLOGY; INTRACLASS CORRELATION; SEQUENTIAL METHOD; TWIN STUDY","STATISTICS IN MEDICINE","BAKSH, MF##HAARS, G##TODD, S##VAN NOORD, PAH##WHITEHEAD, J","STRANGEWAYS RES LAB, MED RES COUNCIL, EPIDEMIOL UNIT, CAMBRIDGE CB1 8RN, ENGLAND. UNIV UTRECHT, MED CTR, STRATENUM, JULIUS CTR HLTH SCI & PRIMARY CARE, NL-3584 CG UTRECHT, NETHERLANDS. UNIV READING, MED & PHARMACEUT STAT RES UNIT, READING RG6 6FN, BERKS, ENGLAND.","MATHEMATICAL & COMPUTATIONAL BIOLOGY; PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH; MEDICAL INFORMATICS; MEDICINE, RESEARCH & EXPERIMENTAL; STATISTICS & PROBABILITY","MATHEMATICAL & COMPUTATIONAL BIOLOGY; PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH; MEDICAL INFORMATICS; RESEARCH & EXPERIMENTAL MEDICINE; MATHEMATICS","ARMITAGE P, 2002, BIOSTATISTICAL GENET, P171##BAKSH MF, 2005, STAT MED, V24, P853, DOI 10.1002/SIM.1968##BICKEL P., 1977, MATH STAT BASIC IDEA##BODDEKER IR, 2001, BIOMETRICAL J, V43, P501, DOI 10.1002/1521-4036(200108)43:4<501::AID-BIMJ501>3.0.CO;2-I##BRANDNER FA, 1933, BIOMETRIKA, V25, P102, DOI 10.2307/2332265##COX DR, 1974, THEORETICAL STAT##DEWAARD F, 1984, J CHRON DIS, V37, P1, DOI 10.1016/0021-9681(84)90123-1##DREYFUS M, 2001, OBSTET GYNECOL, V97, P29, DOI 10.1016/S0029-7844(00)01099-1##FISHER R., 1915, BIOMETRIKA, V10, P507, DOI DOI 10.2307/2331838##HAARS G, 2005, CANCER EPIDEM BIOMAR, V14, P2634, DOI 10.1158/1055-9965.EPI-05-0824##HAARS G, 2004, BREAST CANCER RES TR, V87, P149, DOI 10.1023/B:BREA.0000041621.48575.9B##HERINGS RMC, 1992, J EPIDEMIOL COMMUN H, V46, P136, DOI 10.1136/JECH.46.2.136##LAI TL, 1973, ANN STAT, V1, P659, DOI 10.1214/AOS/1176342461##*MPS RES UN, 2000, PEST 4 OP MAN##NEALE MC, 2002, BIOSTATISTICAL GENET, P743##SHAM P, 1998, STAT HUMAN GENETICS##THOMAS DC, 2004, STAT METHODS GENETIC##TURNBULL B. W., 2000, GROUP SEQUENTIAL MET##VAN DER TWEEL I, 2004, STAT MED, V23, P3755, DOI 10.1002/SIM.2071##VAN DER TWEEL I, 2000, STAT MED, V19, P3449, DOI 10.1002/1097-0258(20001230)19:24<3449::AID-SIM648>3.0.CO;2-Y##WHITEHEAD J., 1997, DESIGN ANAL SEQUENTI##ZAR J. H., 1999, BIOSTATISTICAL ANAL",1,2020-11-20,NA,"STRANGEWAYS RES LAB#UNIV UTRECHT#UNIV READING","ENGLAND#NETHERLANDS#ENGLAND"
"J","WOS:000242941700023",2006,"NATURALLY OCCURRING ESTROGENS IN PROCESSED MILK AND IN RAW MILK (FROM GESTATED COWS)","THE OCCURRENCE OF THE STEROID HORMONES ESTRONE (E-1), 17 ALPHA-ESTRADIOL (ALPHA E-2), 17 BETA-ESTRADIOL (BETA E-2), AND ESTRIOL (E-3) IN PROCESSED BOVINE MILK WITH DIFFERENT FAT CONTENTS AND IN RAW MILK FROM (NON)GESTATED COWS WAS INVESTIGATED. FOLLOWING LIQUID EXTRACTION, OPTIONAL ENZYMATICAL DECONJUGATION, C-18 SOLID-PHASE EXTRACTION, AND DERIVATIZATION, ESTROGENS WERE ANALYZED USING LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY (LC-MS/MS). FREE AND DECONJUGATED E-1 (6.2-1266 NG/L) WAS THE MAJOR ESTROGEN FOLLOWED BY ALPHA E-2 (7.2-322 NG/L) AND BETA E-2 (5.6-51 NG/L), WHEREAS E-3 WAS DETECTED REGULARLY AT THE DETECTION LIMIT OF 10 NG/L. THE LOWEST AND HIGHEST CONCENTRATIONS WERE DETERMINED IN RAW MILK FROM NONPREGNANT AND FROM COWS IN THE THIRD TRIMESTER OF GESTATION, RESPECTIVELY. THE ESTROGEN CONCENTRATION IN PROCESSED MILK COINCIDES WITH THAT OF RAW MILK BETWEEN FIRST AND SECOND TRIMESTERS, REFLECTING THE CONTRIBUTION OF LACTATING PREGNANT COWS TO THE FINAL CONSUMABLE PRODUCT. THE DAILY INTAKE OF TOTAL INVESTIGATED ESTROGENS THROUGH MILK IS 372 NG, WHICH IS DRAMATICALLY MORE THAN CURRENTLY RECOGNIZED.","ESTRONE SULFATE; MAMMARY-GLAND; FOOD; HORMONES; CANCER; PHYTOESTROGENS; SECRETION; ESTRADIOL; PLASMA; HEALTH","ENDOCRINE DISRUPTORS; FOOD SAFETY; STEROID HORMONES; ESTROGENIC ACTIVITY IN FOOD; VETERINARY PUBLIC HEALTH","JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY","MALEKINEJAD, H##SCHERPENISSE, P##BERGWERFF, AA","UNIV UTRECHT, VET PUBL HLTH DIV, INST RISK ASSESSMENT SCI, NL-3508 TD UTRECHT, NETHERLANDS.","AGRICULTURE, MULTIDISCIPLINARY; CHEMISTRY, APPLIED; FOOD SCIENCE & TECHNOLOGY","AGRICULTURE; CHEMISTRY; FOOD SCIENCE & TECHNOLOGY","ANARI MR, 2002, ANAL CHEM, V74, P4136, DOI 10.1021/AC025712H##ANDERSSON AM, 1999, EUR J ENDOCRINOL, V140, P477, DOI 10.1530/EJE.0.1400477##DAXENBERGER A, 2001, HUM REPROD UPDATE, V7, P340, DOI 10.1093/HUMUPD/7.3.340##DELOUIS C, 1980, J DAIRY SCI, V63, P1492, DOI 10.3168/JDS.S0022-0302(80)83110-9##ERB RE, 1977, J ANIM SCI, V45, P617##*EU COMM, 2002, OFF J EUR COMMUNIT L, V221##FORMAN D, 1994, CANCER SURV, V20, P323##FRITSCHE S, 1999, EUR FOOD RES TECHNOL, V209, P153, DOI 10.1007/S002170050475##GANMAA D, 2006, INT J CANCER, V118, P2363, DOI 10.1002/IJC.21659##GANMAA D, 2004, FERTIL STERIL, V82, P1106, DOI 10.1016/J.FERTNSTERT.2004.05.073##GANMAA D, 2005, MED HYPOTHESES, V65, P1028, DOI 10.1016/J.MEHY.2005.06.026##HARTMANN S, 1998, FOOD CHEM, V62, P7, DOI 10.1016/S0308-8146(97)00150-7##HEAP RB, 1979, BRIT VET J, V135, P462, DOI 10.1016/S0007-1935(17)32794-X##HEAP RB, 1984, J ENDOCRINOL, V101, P221, DOI 10.1677/JOE.0.1010221##HEAP RB, 1979, BRIT VET J, V135, P355, DOI 10.1016/S0007-1935(17)32838-5##JANOWSKI T, 2002, DOMEST ANIM ENDOCRIN, V23, P125, DOI 10.1016/S0739-7240(02)00151-0##LI JJ, 1995, CANCER RES, V55, P4347##LIEHR JG, 2000, ENDOCR REV, V21, P40, DOI 10.1210/ER.21.1.40##LIMER JL, 2006, INT J CANCER, V119, P515, DOI 10.1002/IJC.21863##MACDONALD IA, 1983, J LIPID RES, V24, P675##MALEKINEJAD H, 2005, VET RES, V36, P799, DOI 10.1051/VETRES:2005034##MCGARRIGLE HHG, 1983, J STEROID BIOCHEM, V18, P607, DOI 10.1016/0022-4731(83)90139-5##QIN LQ, 2004, MED HYPOTHESES, V62, P133, DOI 10.1016/S0306-9877(03)00295-0##REMESAR X, 1999, EUR J NUTR, V38, P247, DOI 10.1007/S003940050068##SCHAMS D, 1986, ANN NY ACAD SCI, V464, P75, DOI 10.1111/J.1749-6632.1986.TB15995.X##STEPHANY RW, 2004, P EUR 5 C NOORDW MAY##WALKER FMM, 1983, BRIT VET J, V139, P171##WOLFORD ST, 1979, J DAIRY SCI, V62, P1458, DOI 10.3168/JDS.S0022-0302(79)83446-3##XU X, 2004, ANAL CHEM, V76, P5829, DOI 10.1021/AC049405I##ZIERAU O, 2006, PLANTA MED, V72, P184, DOI 10.1055/S-2005-873182",104,2020-11-20,NA,"UNIV UTRECHT","NETHERLANDS"
"J","WOS:000243101500025",2006,"SEVERE MYOCLONIC EPILEPSY OF INFANCY (DRAVET SYNDROME): RECOGNITION AND DIAGNOSIS IN ADULTS","THERE IS A GROUP OF ADULT PATIENTS WITH INTRACTABLE EPILEPSY AND INTELLECTUAL DISABILITY IN WHOM NO ETIOLOGIC DIAGNOSIS HAS BEEN ESTABLISHED. DETERMINING THE ETIOLOGY IS IMPORTANT FOR TREATMENT AND FAMILY COUNSELING. MANY FAMILIES CARRY A BURDEN OF BLAME RELATED TO MISTAKEN BELIEFS ABOUT CAUSATION. SEVERE MYOCLONIC EPILEPSY OF INFANCY (SMEI; DRAVET SYNDROME) WAS DESCRIBED IN 1978(1) BUT HAS ONLY RECENTLY BEEN WIDELY RECOGNIZED AMONG CHILDHOOD EPILEPSY POPULATIONS, SPARKED BY THE DISCOVERY OF MUTATIONS IN THE NEURONAL SODIUM CHANNEL ALPHA 1 SUBUNIT (SCN1A) GENE.(2,3) PATIENTS WITH SMEI TYPICALLY PRESENT WITH RECURRENT FEBRILE HEMICLONIC OR GENERALIZED STATUS EPILEPTICUS AT AROUND AGE 6 MONTHS. BETWEEN AGES 1 AND 4, OTHER SEIZURE TYPES APPEAR, INCLUDING MYOCLONIC AND PARTIAL SEIZURES. PSYCHOMOTOR DEVELOPMENT IS NORMAL IN THE FIRST YEAR AND THEN SLOWS. THE EPILEPSY IS OFTEN INTRACTABLE, DEVELOPMENTAL OUTCOME IS POOR, AND DEATH IN CHILDHOOD IS NOT RARE.(4) """"BORDERLINE SMEI"""" (SMEB) REFERS TO CASES LACKING SOME OF THE TYPICAL FEATURES SUCH AS MYOCLONIC SEIZURES.(5) ALTHOUGH SMEI HAS A CHARACTERISTIC PRESENTATION IN CHILDHOOD, ADULTS WITH SMEI ARE UNDERRECOGNIZED. TO DATE, THERE ARE FEW DATA ON LONG-TERM EVOLUTION OR THE PHENOTYPE IN ADULTS.(6,7) THIS STUDY WAS PERFORMED TO DELINEATE THE ADULT PHENOTYPE OF SMEI AND SMEB.","MUTATIONS",NA,"NEUROLOGY","JANSEN, FE##SADLEIR, LG##HARKIN, LA##VADLAMUDI, L##MCMAHON, JM##MULLEY, JC##SCHEFFER, IE##BERKOVIC, SF","UNIV MELBOURNE, AUSTIN HLTH, DEPT MED, EPILEPSY RES CTR, HEIDELBERG, VIC, AUSTRALIA. WOMENS & CHILDRENS HOSP, DEPT GENET MED, ADELAIDE, SA, AUSTRALIA. CANBERRA HOSP, DEPT NEUROL, MELBOURNE, VIC, AUSTRALIA. UNIV MELBOURNE, DEPT PAEDIAT, MELBOURNE, VIC, AUSTRALIA. ROYAL CHILDRENS HOSP, MELBOURNE, VIC, AUSTRALIA. UNIV UTRECHT, MED CTR, RUDOLF MAGNUS INST NEUROSCI, DEPT NEUROL, NL-3508 TC UTRECHT, NETHERLANDS. CAPITAL COAST HLTH, DEPT PEDIAT, WELLINGTON, NEW ZEALAND. UNIV OTAGO, DEPT PEDIAT, WELLINGTON, NEW ZEALAND.","CLINICAL NEUROLOGY","NEUROSCIENCES & NEUROLOGY","[ANONYMOUS], 1989, EPILEPSIA, V30, P389, DOI 10.1111/J.1528-1157.1989.TB05316.X##CLAES L, 2001, AM J HUM GENET, V68, P1327, DOI 10.1086/320609##DRAVET C, 2002, CURR PROB E, V17, P81##DRAVET C, 1978, VIE MED, V8, P543##MULLEY JC, 2005, HUM MUTAT, V25, P535, DOI 10.1002/HUMU.20178##OGINO T, 1988, JPN J PSYCHIAT NEUR, V42, P554##OHKI T, 1997, SEIZURE-EUR J EPILEP, V6, P219, DOI 10.1016/S1059-1311(97)80009-X##OHTSUKA Y, 2003, BRAIN DEV-JPN, V25, P401, DOI 10.1016/S0387-7604(03)00025-1##OHTSUKA Y, 1991, JPN J PSYCHIAT NEUR, V45, P416",85,2020-11-20,NA,"UNIV MELBOURNE#WOMENS CHILDRENS HOSP#CANBERRA HOSP#UNIV MELBOURNE#ROYAL CHILDRENS HOSP#UNIV UTRECHT#CAPITAL COAST HLTH#UNIV OTAGO","AUSTRALIA#AUSTRALIA#AUSTRALIA#AUSTRALIA#AUSTRALIA#NETHERLANDS#NEW ZEALAND#NEW ZEALAND"
"J","WOS:000242898700040",2006,"LIPID RAFTS FACILITATE THE INTERACTION OF PECAM-1 WITH THE GLYCOPROTEIN VI-FCR GAMMA-CHAIN COMPLEX IN HUMAN PLATELETS","GLYCOPROTEIN ( GP) VI, THE MAIN SIGNALING RECEPTOR FOR COLLAGEN ON PLATELETS, IS EXPRESSED IN COMPLEX WITH THE FCR GAMMA-CHAIN. THE LATTER CONTAINS AN IMMUNORECEPTOR TYROSINE-BASED ACTIVATION MOTIF, WHICH BECOMES PHOSPHORYLATED, INITIATING A SIGNALING CASCADE LEADING TO THE RAPID ACTIVATION AND AGGREGATION OF PLATELETS. PREVIOUS STUDIES HAVE SHOWN THAT SIGNALING BY IMMUNORECEPTOR TYROSINE-BASED ACTIVATION MOTIF-CONTAINING RECEPTORS IS COUNTERACTED BY SIGNALS FROM RECEPTORS WITH IMMUNORECEPTOR TYROSINE-BASED INHIBITORY MOTIFS. HERE WE SHOW, BY IMMUNOPRECIPITATION, THAT THE GPVI-FCR GAMMA-CHAIN COMPLEX ASSOCIATES WITH THE IMMUNORECEPTOR TYROSINE-BASED INHIBITORY MOTIF-CONTAINING RECEPTOR, PECAM-1. IN PLATELETS STIMULATED WITH COLLAGEN-RELATED PEPTIDE (CRP-XL), TYROSINE PHOSPHORYLATION OF PECAM-1 PRECEDES THAT OF THE FCR GAMMA-CHAIN, IMPLYING DIRECT REGULATION OF THE FORMER. THE GPVI-FCR GAMMA-CHAIN COMPLEX AND PECAM-1 WERE PRESENT IN BOTH LIPID RAFT AND SOLUBLE FRACTIONS IN HUMAN PLATELETS; THIS DISTRIBUTION WAS UNALTERED BY ACTIVATION WITH CRP-XL. THEIR ASSOCIATION OCCURRED IN LIPID RAFTS AND WAS LOST AFTER LIPID RAFT DEPLETION USING METHYL-BETA-CYCLODEXTRIN. WE PROPOSE THAT LIPID RAFT CLUSTERING FACILITATES THE INTERACTION OF PECAM-1 WITH THE GPVI- FCR GAMMA-CHAIN COMPLEX, LEADING TO THE DOWN-REGULATION OF THE LATTER.","CELL-ADHESION MOLECULE-1; PROTEIN-TYROSINE-PHOSPHATASE; SRC FAMILY KINASES; COLLAGEN RECEPTOR; FUNCTIONAL ASSOCIATION; ACTIN CYTOSKELETON; MURINE PLATELETS; MEMBRANE DOMAINS; PLASMA-MEMBRANE; ACTIVATION",NA,"JOURNAL OF BIOLOGICAL CHEMISTRY","LEE, FA##VAN LIER, M##RELOU, IAM##FOLEY, L##AKKERMAN, JWN##HEIJNEN, HFG##FARNDALE, RW","UNIV CAMBRIDGE, DEPT BIOCHEM, CAMBRIDGE CB2 1QW, ENGLAND. UNIV UTRECHT, MED CTR, DEPT HAEMATOL, LAB THROMBOSIS & HAEMOSTASIS, NL-3584 CX UTRECHT, NETHERLANDS. UNIV UTRECHT, MED CTR, CELL MICROSCOPY CTR, NL-3584 CX UTRECHT, NETHERLANDS. UNIV UTRECHT, MED CTR, INST BIOMEMBRANES, NL-3584 CX UTRECHT, NETHERLANDS.","BIOCHEMISTRY & MOLECULAR BIOLOGY","BIOCHEMISTRY & MOLECULAR BIOLOGY","ASSELIN J, 1997, BLOOD, V89, P1235, DOI 10.1182/BLOOD.V89.4.1235##BARROW AD, 2004, J IMMUNOL, V172, P5838, DOI 10.4049/JIMMUNOL.172.10.5838##BODIN S, 2005, J CELL SCI, V118, P759, DOI 10.1242/JCS.01648##BODIN S, 2005, J CELL SCI, V25, P25##CICMIL M, 2002, BLOOD, V99, P137, DOI 10.1182/BLOOD.V99.1.137##CICMIL M, 2000, J BIOL CHEM, V275, P27339##CLEMETSON JM, 1999, J BIOL CHEM, V274, P29019, DOI 10.1074/JBC.274.41.29019##CLEMETSON KJ, 2001, THROMB HAEMOSTASIS, V86, P189##DORAHY DJ, 1996, BIOCHEM J, V319, P67, DOI 10.1042/BJ3190067##EZUMI Y, 1998, J EXP MED, V188, P267, DOI 10.1084/JEM.188.2.267##EZUMI Y, 2002, BLOOD, V99, P3250, DOI 10.1182/BLOOD.V99.9.3250##FALATI S, 1999, BLOOD, V94, P1648, DOI 10.1182/BLOOD.V94.5.1648.417K31_1648_1656##FARNDALE RW, 2004, J THROMB HAEMOST, V2, P561, DOI 10.1111/J.1538-7836.2004.00665.X##GIBBINS J, 1996, J BIOL CHEM, V271, P18095, DOI 10.1074/JBC.271.30.18095##GIBBINS JM, 1997, FEBS LETT, V413, P255, DOI 10.1016/S0014-5793(97)00926-5##HEIJNEN HFG, 2003, J THROMB HAEMOST, V1, P1161, DOI 10.1046/J.1538-7836.2003.00316.X##HUA CT, 1998, J BIOL CHEM, V273, P28332, DOI 10.1074/JBC.273.43.28332##JACKSON DE, 1997, J BIOL CHEM, V272, P6986, DOI 10.1074/JBC.272.11.6986##JONES KL, 2001, BLOOD, V98, P1456, DOI 10.1182/BLOOD.V98.5.1456##LIER M, 2005, J THROMB HAEMOST, V3, P2514##LOCKE D, 2002, J BIOL CHEM, V277, P18801, DOI 10.1074/JBC.M111520200##MORTON LF, 1995, BIOCHEM J, V306, P337, DOI 10.1042/BJ3060337##NIESWANDT B, 2003, BLOOD, V102, P449, DOI 10.1182/BLOOD-2002-12-3882##PASQUET JM, 2000, J BIOL CHEM, V275, P28526, DOI 10.1074/JBC.M001531200##PATIL S, 2001, BLOOD, V97, P1727, DOI 10.1182/BLOOD.V97.6.1727##QUEK LS, 2000, BLOOD, V96, P4246##QUINTON TM, 2005, J THROMB HAEMOST, V3, P1036, DOI 10.1111/J.1538-7836.2005.01325.X##RATHORE V, 2003, BLOOD, V102, P3658, DOI 10.1182/BLOOD-2003-06-1888##SCHROEDER RJ, 1998, J BIOL CHEM, V273, P1150, DOI 10.1074/JBC.273.2.1150##SIMONS K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052##THAI LM, 2003, BLOOD, V102, P3637, DOI 10.1182/BLOOD-2003-02-0496##TSUJI M, 1997, J BIOL CHEM, V272, P23528, DOI 10.1074/JBC.272.38.23528##VALENSIN S, 2002, EUR J IMMUNOL, V32, P435, DOI 10.1002/1521-4141(200202)32:2<435::AID-IMMU435>3.0.CO;2-H##VILLALBA M, 2001, J CELL BIOL, V155, P331, DOI 10.1083/JCB.200107080##WATSON SP, 2001, THROMB HAEMOSTASIS, V86, P276##WONEROW P, 2002, BIOCHEM J, V364, P755, DOI 10.1042/BJ20020128##WU XW, 1997, ARTERIOSCL THROM VAS, V17, P3154, DOI 10.1161/01.ATV.17.11.3154##WU Y, 2001, BLOOD, V97, P3836, DOI 10.1182/BLOOD.V97.12.3836##ZAJCHOWSKI LD, 2002, EUR J BIOCHEM, V269, P737, DOI 10.1046/J.0014-2956.2001.02715.X",18,2020-11-20,"MEDICAL RESEARCH COUNCILMEDICAL RESEARCH COUNCIL UK (MRC) [G0400701] FUNDING SOURCE: MEDLINE","UNIV CAMBRIDGE#UNIV UTRECHT#UNIV UTRECHT#UNIV UTRECHT","ENGLAND#NETHERLANDS#NETHERLANDS#NETHERLANDS"
"J","WOS:000243414600072",2006,"NONLINEAR SCREENING AND GAS-LIQUID SEPARATION IN SUSPENSIONS OF CHARGED COLLOIDS","WE CALCULATE PHASE DIAGRAMS OF CHARGED COLLOIDAL SPHERES (VALENCY Z AND RADIUS A) IN A 1:1 ELECTROLYTE FROM MULTICENTERED NONLINEAR POISSON-BOLTZMANN THEORY. OUR THEORY TAKES INTO ACCOUNT CHARGE RENORMALIZATION OF THE COLLOIDAL INTERACTIONS AND VOLUME TERMS DUE TO MANY-BODY EFFECTS. FOR VALENCIES AS SMALL AS Z = 1 AND AS LARGE AS 104 WE FIND A GAS-LIQUID SPINODAL INSTABILITY IN THE COLLOID-SALT PHASE DIAGRAM PROVIDED Z LAMBDA(B)/A GREATER THAN OR SIMILAR TO 24 +/- 1, WHERE LAMBDA(B) IS THE BJERRUM LENGTH.","DEBYE-HUCKEL THEORY; PHASE-SEPARATION; TRIPLET CORRELATIONS; RENORMALIZATION; FORCES; CONDENSATION; DISPERSIONS; CRYSTALS; THERMODYNAMICS; ELECTROLYTE",NA,"PHYSICAL REVIEW LETTERS","ZOETEKOUW, B##VAN ROIJ, R","UNIV UTRECHT, INST THEORET PHYS, NL-3584 CE UTRECHT, NETHERLANDS.","PHYSICS, MULTIDISCIPLINARY","PHYSICS","ALEXANDER S, 1984, J CHEM PHYS, V80, P5776, DOI 10.1063/1.446600##BELLONI L, 1998, COLLOID SURFACE A, V140, P227, DOI 10.1016/S0927-7757(97)00281-1##BELLONI L, 2000, J PHYS-CONDENS MAT, V12, PR549, DOI 10.1088/0953-8984/12/46/201##BERESFORDSMITH B, 1985, J COLLOID INTERF SCI, V105, P216, DOI 10.1016/0021-9797(85)90362-5##CHAN DYC, 2001, LANGMUIR, V17, P4202, DOI 10.1021/LA001560E##DENTON AR, 2006, PHYS REV E, V73, DOI 10.1103/PHYSREVE.73.041407##DENTON AR, 2004, PHYS REV E, V70, DOI 10.1103/PHYSREVE.70.031404##DENTON AR, 2000, PHYS REV E, V62, P3855, DOI 10.1103/PHYSREVE.62.3855##DERJAGUIN BV, 1941, ACTA PHYSICOCHIM URS, V14, P633, DOI DOI 10.1016/0079-6816(93)90013-L##DIEHL A, 2001, EUROPHYS LETT, V53, P86, DOI 10.1209/EPL/I2001-00127-X##DOBNIKAR J, 2003, J CHEM PHYS, V119, P4971, DOI 10.1063/1.1595642##FISHER ME, 1993, PHYS REV LETT, V71, P3826, DOI 10.1103/PHYSREVLETT.71.3826##FUSHIKI M, 1992, J CHEM PHYS, V97, P6700, DOI 10.1063/1.463676##HYNNINEN AP, 2005, J CHEM PHYS, V123, DOI 10.1063/1.1979490##HYNNINEN AP, 2005, J CHEM PHYS, V123, DOI 10.1063/1.2138693##ISE N, 1983, J CHEM PHYS, V78, P536, DOI 10.1063/1.444479##ITO K, 1994, SCIENCE, V263, P66, DOI 10.1126/SCIENCE.263.5143.66##LANGMUIR I, 1938, J CHEM PHYS, V6, P873, DOI 10.1063/1.1750183##LARSEN AE, 1997, NATURE, V385, P230, DOI 10.1038/385230A0##LEVIN Y, 2003, J PHYS-CONDENS MAT, V15, PS3523, DOI 10.1088/0953-8984/15/48/012##LINSE P, 2000, J CHEM PHYS, V113, P4359, DOI 10.1063/1.1288022##LOWEN H, 1992, PHYS REV LETT, V68, P1081, DOI 10.1103/PHYSREVLETT.68.1081##MCGAHAY V, 1992, J CHEM PHYS, V97, P2609, DOI 10.1063/1.463049##MONOVOUKAS Y, 1989, J COLLOID INTERF SCI, V128, P533, DOI 10.1016/0021-9797(89)90368-8##NEU JC, 1999, PHYS REV LETT, V82, P1072, DOI 10.1103/PHYSREVLETT.82.1072##PALBERG T, 1994, PHYS REV LETT, V72, P786, DOI 10.1103/PHYSREVLETT.72.786##PANAGIOTOPOULOS AZ, 2002, PHYS REV LETT, V88, DOI 10.1103/PHYSREVLETT.88.045701##PETRIS SN, 2003, J CHEM PHYS, V118, P5248, DOI 10.1063/1.1541610##RUSS C, 2005, EUROPHYS LETT, V69, P468, DOI 10.1209/EPL/I2004-10345-8##RUSS C, 2003, J PHYS-CONDENS MAT, V15, PS3509, DOI 10.1088/0953-8984/15/48/011##RUSS C, 2002, PHYS REV E, V66, DOI 10.1103/PHYSREVE.66.011402##SHAPRAN L, 2005, COLLOID SURFACE A, V270, P220, DOI 10.1016/J.COLSURFA.2005.06.002##TATA BVR, 1997, PHYS REV LETT, V78, P2660, DOI 10.1103/PHYSREVLETT.78.2660##TATA BVR, 1992, PHYS REV LETT, V69, P3778, DOI 10.1103/PHYSREVLETT.69.3778##TRIZAC E, 2003, LANGMUIR, V19, P4027, DOI 10.1021/LA027056M##TRIZAC E, 1999, PHYS REV E, V60, P6530, DOI 10.1103/PHYSREVE.60.6530##VAN ROIJ R, 1999, PHYS REV E, V59, P2010, DOI 10.1103/PHYSREVE.59.2010##VANROIJ R, 1997, PHYS REV LETT, V79, P3082, DOI 10.1103/PHYSREVLETT.79.3082##VERWEY J. W., 1948, THEORY STABILITY LYO##VON GRUNBERG HH, 2001, EUROPHYS LETT, V55, P580, DOI 10.1209/EPL/I2001-00455-9##WARREN PB, 2006, PHYS REV E, V73, DOI 10.1103/PHYSREVE.73.011411##WARREN PB, 2000, J CHEM PHYS, V112, P4683, DOI 10.1063/1.481024##WETTE P, 2002, J CHEM PHYS, V116, P10981, DOI 10.1063/1.1480010##YOSHIDA H, 1999, LANGMUIR, V15, P2684, DOI 10.1021/LA981316B##ZOETEKOUW B, 2006, PHYS REV E, V73, DOI 10.1103/PHYSREVE.73.021403##ZOETEKOUW B, IN PRESS",31,2020-11-20,NA,"UNIV UTRECHT","NETHERLANDS"
"J","WOS:000243107100002",2006,"LINEARIZATION OF A RADIATIVE TRANSFER MODEL IN SPHERICAL GEOMETRY","[1] FOR THE INTERPRETATION OF SATELLITE LIMB OBSERVATIONS WE INVESTIGATE THE LINEARIZATION CAPABILITY OF SPHERICAL RADIATIVE TRANSFER IN THE ULTRAVIOLET AND VISIBLE PART OF THE SOLAR SPECTRUM, WHERE MULTIPLE SCATTERING OF LIGHT COMPLICATES THE MODEL SIMULATIONS. FROM PLANE-PARALLEL RADIATIVE TRANSFER IT IS KNOWN THAT THE FORWARD-ADJOINT PERTURBATION THEORY PROVIDES A POWERFUL LINEARIZATION TOOL. ITS APPLICATION TO LIMB MEASUREMENT SIMULATIONS IS THE SUBJECT OF THIS PAPER. FIRST, WE SOLVE THE SCALAR RADIATIVE TRANSFER PROBLEM IN SPHERICAL GEOMETRY IN ITS FORWARD AND ADJOINT FORMULATION. SUBSEQUENTLY, WE APPLY THE PERTURBATION THEORY APPROACH IN THE CALCULATION OF THE DERIVATIVES OF THE INTENSITY AT THE TOP OF THE ATMOSPHERE WITH RESPECT TO THE ABSORPTION PROPERTIES OF A TRACE GAS SPECIES IN THE CASE OF A LIMB-VIEWING SATELLITE INSTRUMENT. THE CALCULATED DERIVATIVES ARE VALIDATED WITH A REFERENCE METHOD, AND THE AGREEMENT IN THE UPPER ATMOSPHERE IS VERY GOOD, WHEREAS DEVIATIONS OCCUR BELOW THE TANGENT HEIGHT. HERE THE DETERMINATION OF THE DERIVATIVES IS CLEARLY SENSITIVE TO THE DISCRETIZATION OF THE PROBLEM. FINALLY, WE PERFORM AN ANALYSIS FOR DIFFERENT VIEWING SCENARIOS TO CHARACTERIZE THE CAPABILITY OF THE DESCRIBED LINEARIZATION APPROACH.","DIFFERENTIAL-INTEGRAL APPROACH; OZONE PROFILE RETRIEVAL; WEIGHTING FUNCTIONS; SHELL ATMOSPHERE; SUNLIGHT; RESPECT",NA,"JOURNAL OF GEOPHYSICAL RESEARCH-ATMOSPHERES","WALTER, HH##LANDGRAF, J##SPADA, F##DOICU, A","NETHERLAND INST SPACE RES, NL-3584 CA UTRECHT, NETHERLANDS. INST METHOD FERNERKUNDUNG, GERMAN AEROSP CTR, D-82234 WESSLING, GERMANY. UNIV UTRECHT, INST MARINE & ATMOSPHER RES UTRECHT, NL-3584 CA UTRECHT, NETHERLANDS.","METEOROLOGY & ATMOSPHERIC SCIENCES","METEOROLOGY & ATMOSPHERIC SCIENCES","BELL G., 1970, NUCL REACTOR THEORY##BOVENSMANN H, 1999, J ATMOS SCI, V56, P127, DOI 10.1175/1520-0469(1999)056<0127:SMOAMM>2.0.CO;2##BOX MA, 1989, BEITR PHYS ATMOS, V62, P193##BOX MA, 1988, BEITR PHYS ATMOS, V61, P303##CASE K.M., 1967, LINEAR TRANSPORT THE##HASEKAMP OP, 2005, J GEOPHYS RES-ATMOS, V110, DOI 10.1029/2004JD005260##HASEKAMP OP, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2002JD002387##HERMAN BM, 1994, APPL OPTICS, V33, P1760, DOI 10.1364/AO.33.001760##KAISER JW, 2003, J QUANT SPECTROSC RA, V77, P273, DOI 10.1016/S0022-4073(02)00125-5##KUNASZ P, 1988, J QUANT SPECTROSC RA, V39, P67, DOI 10.1016/0022-4073(88)90021-0##LANDGRAF J, 2001, J GEOPHYS RES-ATMOS, V106, P27291, DOI 10.1029/2001JD000636##LANDGRAF J, 2002, J QUANT SPECTROSC RA, V72, P327, DOI 10.1016/S0022-4073(01)00126-1##LEWINS J., 1965, IMPORTANCE ADJOINT F##LOUGHMAN RP, 2004, J GEOPHYS RES-ATMOS, V109, DOI 10.1029/2003JD003854##MARCHUK G., 1964, COSMIC RES, V2, P394##MCLINDEN CA, 2002, CAN J PHYS, V80, P375, DOI 10.1139/P01-156##OIKARINEN L, 1999, J GEOPHYS RES-ATMOS, V104, P31261, DOI 10.1029/1999JD900969##PAYNE WF, 1995, 46 INT ASTR C AM I A##POSTYLYAKOV OV, 2004, J QUANT SPECTROSC RA, V88, P297, DOI 10.1016/J.JQSRT.2004.01.009##ROZANOV A, 2001, J QUANT SPECTROSC RA, V69, P491, DOI 10.1016/S0022-4073(00)00100-X##ROZANOV AV, 2000, J GEOPHYS RES-ATMOS, V105, P22937, DOI 10.1029/2000JD900378##ROZANOV VV, 1998, J QUANT SPECTROSC RA, V60, P277, DOI 10.1016/S0022-4073(97)00150-7##ROZANOV VV, 2002, ADV SPACE RES-SERIES, V29, P1831, DOI 10.1016/S0273-1177(02)00095-9##SPADA F, 2006, ATMOS CHEM PHYS DISC, V6, P1199##USTINOV E. A., 1992, COSMIC RESEARCH, V30, P170##USTINOV E. A., 1991, COSMIC RESEARCH, V29, P785##USTINOV E. A., 1991, COSMIC RESEARCH, V29, P519##WALTER HH, 2005, J QUANT SPECTROSC RA, V95, P175, DOI 10.1016/J.JQSRT.2004.08.043",8,2020-11-20,NA,"NETHERLAND INST SPACE RES#INST METHOD FERNERKUNDUNG#UNIV UTRECHT","NETHERLANDS#GERMANY#NETHERLANDS"
"J","WOS:000243108100002",2006,"LATERAL ENTRAPMENT OF SEDIMENT IN TIDAL ESTUARIES: AN IDEALIZED MODEL STUDY","[ 1] TWO PHYSICAL MECHANISMS LEADING TO LATERAL ACCUMULATION OF SEDIMENT IN TIDALLY DOMINATED ESTUARIES ARE INVESTIGATED, INVOLVING CORIOLIS FORCING AND LATERAL DENSITY GRADIENTS. AN IDEALIZED MODEL IS USED THAT CONSISTS OF THE THREE-DIMENSIONAL SHALLOW WATER EQUATIONS AND SEDIMENT MASS BALANCE. CONDITIONS ARE ASSUMED TO BE UNIFORM IN THE ALONG-ESTUARY DIRECTION. A SEMIDIURNAL TIDAL DISCHARGE AND TIDALLY AVERAGED DENSITY GRADIENTS ARE PRESCRIBED. THE EROSIONAL SEDIMENT FLUX AT THE BED DEPENDS BOTH ON THE BED SHEAR STRESS AND ON THE AMOUNT OF SEDIMENT AVAILABLE IN MUD REACHES FOR RESUSPENSION. THE DISTRIBUTION OF MUD REACHES OVER THE BED IS SELECTED SUCH THAT SEDIMENT TRANSPORT IS IN MORPHODYNAMIC EQUILIBRIUM, THAT IS, TIDALLY AVERAGED EROSION AND DEPOSITION OF SEDIMENT AT THE BED BALANCE. ANALYTICAL SOLUTIONS ARE OBTAINED BY USING PERTURBATION ANALYSIS. RESULTS SUGGEST THAT IN MOST ESTUARIES LATERAL DENSITY GRADIENTS INDUCE MORE SEDIMENT TRANSPORT THAN CORIOLIS FORCING. WHEN FRICTIONAL FORCES ARE SMALL (EKMAN NUMBER E < 0.02), THE CORIOLIS MECHANISM DOMINATES AND ACCUMULATES SEDIMENT ON THE RIGHT BANK ( LOOKING UP-ESTUARY IN THE NORTHERN HEMISPHERE). ON THE OTHER HAND, WHEN FRICTIONAL FORCES ARE MODERATE TO HIGH ( E > 0.02), THE LATERAL DENSITY GRADIENT MECHANISM DOMINATES AND ENTRAPS SEDIMENT IN AREAS WITH FRESHER WATER. RESULTS ALSO SHOW THAT THE LATERAL SEDIMENT TRANSPORT INDUCED BY THE SEMIDIURNAL TIDAL FLOW IS SIGNIFICANT WHEN FRICTIONAL FORCES ARE SMALL ( E SIMILAR TO 0.02). MODEL PREDICTIONS ARE IN GOOD AGREEMENT WITH OBSERVATIONS FROM THE JAMES RIVER ESTUARY.","TURBIDITY MAXIMUM; CIRCULATION; VARIABILITY; PATTERNS; STRAIGHT",NA,"JOURNAL OF GEOPHYSICAL RESEARCH-OCEANS","HUIJTS, KMH##SCHUTTELAARS, HM##DE SWART, HE##VALLE-LEVINSON, A","UNIV UTRECHT, INST MARINE & ATMOSPHER RES UTRECHT, NL-3584 CC UTRECHT, NETHERLANDS. DELFT UNIV TECHNOL, DELFT INST APPL MATH, NL-2600 GA DELFT, NETHERLANDS. UNIV FLORIDA, DEPT CIVIL & COASTAL ENGN, GAINESVILLE, FL 32611 USA.","OCEANOGRAPHY","OCEANOGRAPHY","BATTISTO GM, 2003, COASTAL SEDIMENTS 20##BOWDEN KF, 1959, GEOPHYS J ROY ASTR S, V2, P288, DOI 10.1111/J.1365-246X.1959.TB05801.X##DYER K.R., 1973, ESTUARIES PHYS INTRO##DYER KR, 1986, COASTAL ESTUARINE SE##FESTA JF, 1978, ESTUAR COAST MAR SCI, V7, P347, DOI 10.1016/0302-3524(78)90087-7##FESTA JF, 1976, ESTUAR COAST MAR SCI, V4, P309, DOI 10.1016/0302-3524(76)90063-3##FISCHER H.B., 1979, MIXING INLAND COASTA##FRIEDRICHS CT, 1994, J GEOPHYS RES-OCEANS, V99, P3321, DOI 10.1029/93JC03219##FRIEDRICHS CT, 1998, PHYSICS OF ESTUARIES AND COASTAL SEAS, P315##FRIEDRICHS CT, 2003, COASTAL SEDIMENTS 20##GEYER WR, 2001, ESTUARIES, V24, P670, DOI 10.2307/1352875##GEYER WR, 1998, PHYSICS OF ESTUARIES AND COASTAL SEAS, P115##GEYER WR, 1993, ESTUARIES, V16, P113, DOI 10.2307/1352769##GILL AE, 1982, INT GEOPHYS SER, V30##HANSEN DONALD V., 1965, J MAR RES, V23, P104##JAY DA, 1990, J GEOPHYS RES-OCEANS, V95, P733, DOI 10.1029/JC095IC01P00733##JAY DA, 1994, J GEOPHYS RES-OCEANS, V99, P20445, DOI 10.1029/94JC00971##KAPPENBERG J, 2001, ESTUARIES, V24, P699, DOI 10.2307/1352878##KASAI A, 2000, J GEOPHYS RES-OCEANS, V105, P16961, DOI 10.1029/2000JC900058##LERCZAK JA, 2004, J PHYS OCEANOGR, V34, P1410, DOI 10.1175/1520-0485(2004)034<1410:MTLCIS>2.0.CO;2##LIN J, 2001, ESTUARIES, V24, P707, DOI 10.2307/1352879##MUNK WH, 1948, J MAR RES, V7, P276##NICHOLS M. M., 1972, GEOLOGICAL SOC AM ME, V133, P169##NORTH EW, 2004, ESTUARIES, V27, P132, DOI 10.1007/BF02803567##OFFICER C.B., 1976, PHYS OCEANOGRAPHY ES##PRANDLE D, 2004, ESTUAR COAST SHELF S, V59, P385, DOI 10.1016/J.ECSS.2003.10.001##SANFORD LP, 2001, ESTUARIES, V24, P655, DOI 10.2307/1352874##SCHRAMKOWSKI GP, 2002, J GEOPHYS RES-OCEANS, V107, DOI 10.1029/2000JC000693##UNCLES RJ, 1993, ESTUARIES, V16, P126, DOI 10.2307/1352770##VALLE-LEVINSON A, 2003, J PHYS OCEANOGR, V33, P2375, DOI 10.1175/1520-0485(2003)033<2375:EOBFAR>2.0.CO;2##VALLE-LEVINSON A, 2000, J GEOPHYS RES-OCEANS, V105, P3413, DOI 10.1029/1999JC900307##VALLE-LEVINSON A, 2001, ESTUAR COAST SHELF S, V53, P825, DOI 10.1006/ECSS.2000.0813##VALLE-LEVINSON A, 2003, J GEOPHYS RES-OCEANS, V108, DOI 10.1029/2003JC001786##VALLELEVINSON A, 1997, J MARINE SYST, V12, P221, DOI 10.1016/S0924-7963(96)00099-1##VAN RIJN L.C., 1993, PRINCIPLES SEDIMENT##VANDEKREEKE J, 1990, SEA A, V9, P495##WINTERWERP JC, 2002, CONT SHELF RES, V22, P1339, DOI 10.1016/S0278-4343(02)00010-9##WOODRUFF JD, 2001, MAR GEOL, V179, P105, DOI 10.1016/S0025-3227(01)00182-7",63,2020-11-20,NA,"UNIV UTRECHT#DELFT UNIV TECHNOL#UNIV FLORIDA","NETHERLANDS#NETHERLANDS#FL USA"
"J","WOS:000242955200050",2006,"DISCOVERY OF TWIN KHZ QPOS IN THE PECULIAR X-RAY BINARY CIRCINUS X-1","WE REPORT THE DISCOVERY WITH THE RXTE PCA OF TWIN KHZ QPOS IN THE PECULIAR X-RAY BINARY CIRCINUS X-1. ELEVEN CASES OF SIMULTANEOUS DOUBLE QPOS OCCURRED, WITH SIGNIFICANCES OF UP TO 6.3 AND 5.5 SIGMA AND CENTROID FREQUENCIES RANGING BETWEEN APPROXIMATELY 56 AND 225 AND 230 AND 500 HZ FOR THE TWO QPO PEAKS, RESPECTIVELY, I.E., FOR THE MOST PART AT FREQUENCIES WELL BELOW THOSE OF OTHER SOURCES. THE QPO PROPERTIES CLEARLY INDICATE THAT THESE DOUBLE PEAKS ARE THE KHZ QPOS KNOWN FROM LOW MAGNETIC FIELD NEUTRON STARS, AND NOT BLACK HOLE HIGH-FREQUENCY QPOS, CONFIRMING THAT CIR X-1 IS A NEUTRON STAR, AS SUSPECTED SINCE THE DETECTION OF TYPE I X-RAY BURSTS FROM THE FIELD OF THE SOURCE 20 YEARS AGO. THE KHZ QPO PEAK SEPARATION VARIES OVER A WIDE RANGE, SIMILAR TO 175-340 HZ, AND INCREASES AS A FUNCTION OF KHZ QPO FREQUENCY. THIS IS CONTRARY TO WHAT HAS BEEN OBSERVED IN OTHER SOURCES BUT IN GOOD AGREEMENT WITH PREDICTIONS OF THE RELATIVISTIC PRECESSION MODEL AND ALFVEN WAVE MODELS; BEAT-FREQUENCY MODELS REQUIRE MODIFICATION TO ACCOMMODATE THIS. IN OTHER OBSERVATIONS, SINGLE KHZ QPOS CAN BE SEEN DOWN TO FREQUENCIES AS LOW AS SIMILAR TO 12HZ, AS WELL AS A STRONG LOW-FREQUENCY QUASI-PERIODIC OSCILLATION (LF QPO) BETWEEN 1 AND 30 HZ. THE RELATIONS BETWEEN THE KHZ QPOS AND THE LF QPO ARE IN GOOD AGREEMENT WITH THOSE FOUND PREVIOUSLY IN Z SOURCES, CONFIRMING THAT CIR X-1 MAY BE A PECULIAR Z SOURCE. WE SUGGEST THAT THE LOW-FREQUENCY RANGE OVER WHICH THE KHZ QPOS OCCUR IN CIR X-1 AND TO A LESSER EXTENT IN (OTHER) Z SOURCES, MIGHT BE DUE TO A STRONGER RADIAL ACCRETION FLOW RELATIVE TO THE DISK FLOW THAN IN OTHER KHZ QPO SOURCES, POSSIBLY RELATED TO THE NATURE OF THE COMPANION STAR.","QUASI-PERIODIC OSCILLATIONS; NEUTRON-STAR; CIR X-1; TIMING-EXPLORER; BRIGHTNESS OSCILLATIONS; 4U 1608-52; FREQUENCY; BEHAVIOR; MODEL; SPECTRUM","X-RAYS : BINARIES; X-RAYS : INDIVIDUAL (CIRCINUS X-1)","ASTROPHYSICAL JOURNAL","BOUTLOUKOS, S##VAN DER KLIS, M##ALTAMIRANO, D##KLEIN-WOLT, M##WIJNANDS, R##JONKER, PG##FENDER, RP","UNIV AMSTERDAM, ASTRON INST ANTON PANNEKOEK, NL-1098 SJ AMSTERDAM, NETHERLANDS. CTR HIGH ENERGY ASTROPHYS, NL-1098 SJ AMSTERDAM, NETHERLANDS. UNIV TUBINGEN, D-72076 TUBINGEN, GERMANY. NETHERLANDS INST SPACE RES, SRON, NL-3584 CA UTRECHT, NETHERLANDS. HARVARD SMITHSONIAN CTR ASTROPHYS, CAMBRIDGE, MA 02138 USA. UNIV UTRECHT, INST ASTRON, NL-3508 TA UTRECHT, NETHERLANDS. UNIV SOUTHAMPTON, SCH PHYS & ASTRON, SOUTHAMPTON SO17 1BJ, HANTS, ENGLAND.","ASTRONOMY & ASTROPHYSICS","ASTRONOMY & ASTROPHYSICS","ALTAMIRANO D, 2005, ASTROPHYS J, V633, P358, DOI 10.1086/447761##BELLONI T, 2005, ASTRON ASTROPHYS, V437, P209, DOI 10.1051/0004-6361:20041377##BELLONI T, 2002, ASTROPHYS J, V572, P392, DOI 10.1086/340290##DING GQ, 2003, ASTROPHYS J, V596, PL219, DOI 10.1086/379338##DONE C, 2003, MON NOT R ASTRON SOC, V342, P1041, DOI 10.1046/J.1365-8711.2003.06614.X##FENDER R, 2004, NATURE, V427, P222, DOI 10.1038/NATURE02137##FENDER R, 2005, ASTRON TEL, V563, P1##GLASS IS, 1994, MON NOT R ASTRON SOC, V268, P742, DOI 10.1093/MNRAS/268.3.742##GOSS WM, 1977, MON NOT R ASTRON SOC, V181, P255, DOI 10.1093/MNRAS/181.2.255##HASINGER G, 1989, ASTRON ASTROPHYS, V225, P79##HOMAN J, 2002, ASTROPHYS J, V568, P878, DOI 10.1086/339057##IARIA R, 2005, ASTROPHYS J, V619, P503, DOI 10.1086/426422##IARIA R, 2001, ASTROPHYS J, V547, P412, DOI 10.1086/318366##JAHODA K, 2006, ASTROPHYS J SUPPL S, V163, P401, DOI 10.1086/500659##JOHNSTON HM, 1999, MON NOT R ASTRON SOC, V308, P415, DOI 10.1046/J.1365-8711.1999.02702.X##JONES C, 1974, ASTROPHYS J, V191, PL71, DOI 10.1086/181551##JONKER PG, 2002, MON NOT R ASTRON SOC, V333, P665, DOI 10.1046/J.1365-8711.2002.05442.X##JONKER PG, 2004, MON NOT R ASTRON SOC, V354, P355, DOI 10.1111/J.1365-2966.2004.08193.X##JONKER PG, 2006, IN PRESS MNRAS##KLEIN-WOLT M, 2004, NUCL PHYS B-PROC SUP, V132, P381, DOI 10.1016/J.NUCLPHYSBPS.2004.04.067##KLUZNIAK W, 2003, ASTROPH0304345##KLUZNIAK W, 2001, ASTROPH0105057##KUULKERS E, 1994, ASTRON ASTROPHYS, V289, P795##LAMB FK, 2001, ASTROPHYS J, V554, P1210, DOI 10.1086/323148##LAMB FK, 2003, ASTROPH0308179##LINARES M, 2005, ASTROPHYS J, V634, P1250, DOI 10.1086/497025##MAISACK M, 1995, ADV SPACE RES, V16, P91, DOI 10.1016/0273-1177(95)00051-F##MCCLINTOCK J.E., 2006, COMPACT STELLAR XRAY, P157, DOI DOI 10.2277/0521826594##MENDEZ M, 2001, ASTROPHYS J, V561, P1016, DOI 10.1086/323486##MIGLIARI S, 2003, MON NOT R ASTRON SOC, V345, PL35, DOI 10.1046/J.1365-8711.2003.07186.X##MILLER MC, 1998, ASTROPHYS J, V508, P791, DOI 10.1086/306408##MURDIN P, 1980, ASTRON ASTROPHYS, V87, P292##OOSTERBROEK T, 1995, ASTRON ASTROPHYS, V297, P141##PSALTIS D, 1998, ASTROPHYS J, V501, PL95, DOI 10.1086/311455##PSALTIS D, 1999, ASTROPHYS J, V520, P262, DOI 10.1086/307436##PSALTIS D, 1995, ASTROPHYS J, V454, PL137, DOI 10.1086/309780##REVNIVTSEV M, 2000, ASTRON ASTROPHYS, V363, P1013##REZANIA V, 2005, ASTRON ASTROPHYS, V436, P999, DOI 10.1051/0004-6361:20041796##SAMIMI J, 1979, NATURE, V278, P434, DOI 10.1038/278434A0##SHIREY RE, 1998, ASTROPHYS J, V506, P374, DOI 10.1086/306247##SHIREY RE, 1999, ASTROPHYS J, V517, P472, DOI 10.1086/307188##SHIREY RE, 1996, ASTROPHYS J, V469, PL21, DOI 10.1086/310264##STELLA L, 1999, PHYS REV LETT, V82, P17, DOI 10.1103/PHYSREVLETT.82.17##STROHMAYER TE, 2001, ASTROPHYS J, V552, PL49, DOI 10.1086/320258##TENNANT A. F., 1986, MNRAS, V221, P27##TENNANT AF, 1987, MON NOT R ASTRON SOC, V226, P971, DOI 10.1093/MNRAS/226.4.971##VAN DER KLIS M, 2001, ASTROPHYS J, V561, P943, DOI 10.1086/323378##VAN DER KLIS M., 2006, COMPACT STELLAR XRAY, P39##VAN STRAATEN S, 2003, ASTROPHYS J, V596, P1155, DOI 10.1086/378155##VAN STRAATEN S, 2005, ASTROPHYS J, V619, P455, DOI 10.1086/426183##VAN STRAATEN S, 2002, ASTROPHYS J, V568, P912, DOI 10.1086/338948##ZHANG C, 2004, ASTRON ASTROPHYS, V423, P401, DOI 10.1051/0004-6361:20035808##ZHANG CM, 2005, ASTROPH0502102##ZHANG W, 1996, ASTROPHYS J, V469, PL29, DOI 10.1086/310259##ZHANG W, 1995, ASTROPHYS J, V449, P930, DOI 10.1086/176111",75,2020-11-20,"SCIENCE AND TECHNOLOGY FACILITIES COUNCILSCIENCE & TECHNOLOGY FACILITIES COUNCIL (STFC) [PP/D001013/1] FUNDING SOURCE: RESEARCHFISH","UNIV AMSTERDAM#CTR HIGH ENERGY ASTROPHYS#UNIV TUBINGEN#NETHERLANDS INST SPACE RES#HARVARD SMITHSONIAN CTR ASTROPHYS#UNIV UTRECHT#UNIV SOUTHAMPTON","NETHERLANDS#NETHERLANDS#GERMANY#NETHERLANDS#MA USA#NETHERLANDS#ENGLAND"
"J","WOS:000242637500005",2006,"ONTOGENY OF HIPPOCAMPAL CORTICOSTEROID RECEPTORS: EFFECTS OF ANTENATAL GLUCOCORTICOIDS IN HUMAN AND MOUSE","WOMEN AT RISK FOR PRETERM DELIVERY ARE TREATED WITH SYNTHETIC GLUCOCORTICOIDS (GCS) TO ENHANCE FETAL LUNG MATURATION. GCS CAN BIND TO TWO INTRACELLULAR RECEPTORS, THE GLUCOCORTICOID RECEPTOR (GR) AND THE MINERALOCORTICOID RECEPTOR (MR), WHICH FUNCTION AS TRANSCRIPTION FACTORS. BOTH ARE HIGHLY EXPRESSED IN THE HIPPOCAMPUS. SEVERAL STUDIES HAVE FOCUSED ON ADVERSE SIDE EFFECTS OF ANTENATAL GC TREATMENT. HOWEVER, RELATIVELY LITTLE IS KNOWN ABOUT THE ONTOGENY OF GR AND MR, ESPECIALLY IN HUMAN. THEREFORE, WE STUDIED THE ONTOGENY OF BOTH RECEPTORS IN THE HUMAN AND MOUSE HIPPOCAMPUS AND INVESTIGATED THE EFFECTS OF ANTENATAL DEXAMETHASONE (DEX) TREATMENT, A SYNTHETIC GLUCOCORTICOID, ON MR AND GR MRNA LEVELS DURING HIPPOCAMPAL DEVELOPMENT. THE RESULTS DEMONSTRATE THAT MR MRNA WAS FIRST EXPRESSED IN MOUSE HIPPOCAMPUS AT EMBRYONIC DAY (E)15.5, AT THE TIMEPOINT WHEN DEX WAS ADMINISTERED. IN CONTRAST, GR MRNA EXPRESSION WAS FIRST OBSERVED AFTER BIRTH AT POSTNATAL DAY (P)5. HOWEVER, IN THE HUMAN HIPPOCAMPUS BOTH RECEPTORS ARE EXPRESSED AT 24 WEEKS OF GESTATION, WHEN ANTENATAL GCS ARE ADMINISTERED IN CLINICAL PRACTICE. QUANTITATIVE IN SITU HYBRIDIZATION DEMONSTRATED THAT MR MRNA LEVELS WERE REDUCED ONLY SHORTLY AFTER DEX TREATMENT AT E16, BUT WERE UNAFFECTED FROM E18 ONWARDS. THESE FINDINGS INDICATE THAT A SINGLE ANTENATAL DEX ADMINISTRATION AT E15.5 TRANSIENTLY AFFECTS MR MRNA LEVELS IN THE MOUSE HIPPOCAMPUS. NO EFFECT OF ANTENATAL DEX TREATMENT WAS FOUND ON THE HUMAN HIPPOCAMPUS AT THE THIRD TRIMESTER OF PREGNANCY. THESE DATA ON THE PRENATAL ONTOGENY OF BOTH CORTICOSTEROID RECEPTORS IN THE HUMAN HIPPOCAMPUS IS IMPORTANT FOR UNDERSTANDING THE SIGNIFICANCE OF FETAL GLUCOCORTICOID OR STRESS EXPOSURE AND ITS POTENTIAL EFFECTS ON HEALTH AND DISEASE.","PITUITARY-ADRENOCORTICAL AXIS; GUINEA-PIG BRAIN; MINERALOCORTICOID RECEPTOR; MESSENGER-RNA; DEXAMETHASONE-TREATMENT; GENE-EXPRESSION; ADRENAL AXIS; MATERNAL DEXAMETHASONE; POSTNATAL ONTOGENY; HORMONAL-CONTROL","HIPPOCAMPUS; DEXAMETHASONE; MINERALOCORTICOID RECEPTOR; GLUCOCORTICOID RECEPTOR","JOURNAL OF COMPARATIVE NEUROLOGY","NOORLANDER, CW##DE GRAAN, PNE##MIDDELDORP, J##VAN BEERS, JJBC##VISSER, GHA","UNIV UTRECHT, CTR MED, RUDOLF MAGNUS INST NEUROSCI, NL-3584 CG UTRECHT, NETHERLANDS. UNIV UTRECHT, CTR MED, DEPT OBSTET NEONATOL & GYNAECOL, NL-3584 CG UTRECHT, NETHERLANDS.","NEUROSCIENCES; ZOOLOGY","NEUROSCIENCES & NEUROLOGY; ZOOLOGY","BAKKER JM, 1995, J NEUROIMMUNOL, V63, P183, DOI 10.1016/0165-5728(95)00152-2##BALLARD PL, 1989, BAILLIERE CLIN ENDOC, V3, P723, DOI 10.1016/S0950-351X(89)80051-5##BALLARD R A, 1996, J PERINATOL, V16, P390##BEERS MF, 2000, AM J RESP CELL MOL, V22, P380, DOI 10.1165/AJRCMB.22.3.3645##BROWN SD, 1996, J CRIT CARE, V11, P2, DOI 10.1016/S0883-9441(96)90014-3##CROWLEY PA, 1995, AM J OBSTET GYNECOL, V173, P322, DOI 10.1016/0002-9378(95)90222-8##DALLMAN MF, 1987, ANN NY ACAD SCI, V512, P402, DOI 10.1111/J.1749-6632.1987.TB24976.X##DASILVA SL, 1995, MOL BRAIN RES, V30, P131, DOI 10.1016/0169-328X(94)00289-Q##DE KLOET ER, 1998, ENDOCR REV, V19, P269, DOI 10.1210/ER.19.3.269##DEAN F, 1999, BRAIN RES, V846, P253, DOI 10.1016/S0006-8993(99)02064-8##DEAN F, 2001, NEUROENDOCRINOLOGY, V73, P194, DOI 10.1159/000054636##DIAZ R, 1998, J NEUROSCI, V18, P2570##ERDELJAN P, 2001, BRAIN RES, V896, P130, DOI 10.1016/S0006-8993(01)02075-3##HERMAN JP, 1996, CRIT REV NEUROBIOL, V10, P371, DOI 10.1615/CRITREVNEUROBIOL.V10.I3-4.50##HERMAN JP, 1989, MOL ENDOCRINOL, V3, P1886, DOI 10.1210/MEND-3-11-1886##JACOBSON L, 2005, ENDOCRIN METAB CLIN, V34, P271, DOI 10.1016/J.ECL.2005.01.003##JACOBSON L, 1991, ENDOCR REV, V12, P118, DOI 10.1210/EDRV-12-2-118##JONGEN-RELO AL, 2002, BRAIN RES, V953, P223, DOI 10.1016/S0006-8993(02)03293-6##KELLENDONK C, 2002, BRAIN RES BULL, V57, P73, DOI 10.1016/S0361-9230(01)00638-4##LEVITT NS, 1996, NEUROENDOCRINOLOGY, V64, P412, DOI 10.1159/000127146##LIU D, 1997, SCIENCE, V277, P1659, DOI 10.1126/SCIENCE.277.5332.1659##MATTHEWS SG, 2000, PEDIATR RES, V47, P291, DOI 10.1203/00006450-200003000-00003##MATTHEWS SG, 1998, DEV BRAIN RES, V107, P123, DOI 10.1016/S0165-3806(98)00008-X##MEANEY M.J., 1985, BRAIN RES, V350, P159, DOI DOI 10.1016/0165-3806(85)90259-7##MEIJER OC, 1998, CRIT REV NEUROBIOL, V12, P1##MENDELSON CR, 1991, ANNU REV PHYSIOL, V53, P415, DOI 10.1146/ANNUREV.PHYSIOL.53.1.415##PRYCE CR, 2005, EUR J NEUROSCI, V21, P1521, DOI 10.1111/J.1460-9568.2005.04003.X##RAUBENHEIMER PJ, 2006, CLIN ENDOCRINOL, V65, P22, DOI 10.1111/J.1365-2265.2006.02540.X##ROSENFELD P, 1988, DEV BRAIN RES, V42, P113, DOI 10.1016/0165-3806(88)90206-4##SANCHEZ MM, 2000, J NEUROSCI, V20, P4657, DOI 10.1523/JNEUROSCI.20-12-04657.2000##SCHELLHASE DE, 1991, AM J RESP CELL MOL, V4, P304, DOI 10.1165/AJRCMB/4.4.304##SCHMIDT M, 2003, INT J DEV NEUROSCI, V21, P125, DOI 10.1016/S0736-5748(03)00030-3##SHOENER JA, 2006, AM J PHYSIOL-REG I, V290, PR1366, DOI 10.1152/AJPREGU.00757.2004##SMIDT MP, 2004, DEVELOPMENT, V131, P1145, DOI 10.1242/DEV.01022##SPEIRS HJL, 2004, J ENDOCRINOL, V181, P105, DOI 10.1677/JOE.0.1810105##UNO H, 1994, HORM BEHAV, V28, P336, DOI 10.1006/HBEH.1994.1030##VANEEKELEN JAM, 1988, J NEUROSCI RES, V21, P88, DOI 10.1002/JNR.490210113##VANEEKELEN JAM, 1991, DEV BRAIN RES, V61, P33, DOI 10.1016/0165-3806(91)90111-U##VELDHUIS HD, 1982, ENDOCRINOLOGY, V110, P2044, DOI 10.1210/ENDO-110-6-2044##VELLUCCI SV, 2002, NEUROPEPTIDES, V36, P291, DOI 10.1016/S0143-4179(02)00048-3",61,2020-11-20,NA,"UNIV UTRECHT#UNIV UTRECHT","NETHERLANDS#NETHERLANDS"
"J","WOS:000207443600012",2006,"THE EFFECTIVENESS OF CONTACT TRACING IN EMERGING EPIDEMICS","BACKGROUND. CONTACT TRACING PLAYS AN IMPORTANT ROLE IN THE CONTROL OF EMERGING INFECTIOUS DISEASES, BUT LITTLE IS KNOWN YET ABOUT ITS EFFECTIVENESS. HERE WE DEDUCE FROM A GENERIC MATHEMATICAL MODEL HOW EFFECTIVENESS OF TRACING RELATES TO VARIOUS ASPECTS OF TIME, SUCH AS THE COURSE OF INDIVIDUAL INFECTIVITY, THE (VARIABILITY IN) TIME BETWEEN INFECTION AND SYMPTOM-BASED DETECTION, AND DELAYS IN THE TRACING PROCESS. IN ADDITION, THE POSSIBILITY OF ITERATIVELY TRACING OF YET ASYMPTOMATIC INFECTEDS IS CONSIDERED. WITH THESE INSIGHTS WE EXPLAIN WHY CONTACT TRACING WAS AND WILL BE EFFECTIVE FOR CONTROL OF SMALLPOX AND SARS, ONLY PARTIALLY EFFECTIVE FOR FOOT-AND-MOUTH DISEASE, AND LIKELY NOT EFFECTIVE FOR INFLUENZA. METHODS AND FINDINGS. WE INVESTIGATE CONTACT TRACING IN A MODEL OF AN EMERGING EPIDEMIC THAT IS FLEXIBLE ENOUGH TO USE FOR MOST INFECTIONS. WE CONSIDER ISOLATION OF SYMPTOMATIC INFECTEDS AS THE BASIC SCENARIO, AND EXPRESS EFFECTIVENESS AS THE PROPORTION OF CONTACTS THAT NEED TO BE TRACED FOR A REPRODUCTION RATIO SMALLER THAN 1. WE OBTAIN GENERAL RESULTS FOR SPECIAL CASES, WHICH ARE INTERPRETED WITH RESPECT TO THE LIKELY SUCCESS OF TRACING FOR INFLUENZA, SMALLPOX, SARS, AND FOOT-AND-MOUTH DISEASE EPIDEMICS. CONCLUSIONS. WE CONCLUDE THAT (1) THERE IS NO GENERAL PREDICTIVE FORMULA FOR THE PROPORTION TO BE TRACED AS THERE IS FOR THE PROPORTION TO BE VACCINATED; (2) VARIABILITY IN TIME TO DETECTION IS FAVOURABLE FOR EFFECTIVE TRACING; (3) TRACING EFFECTIVENESS NEED NOT BE SENSITIVE TO THE DURATION OF THE LATENT PERIOD AND TRACING DELAYS; (4) ITERATIVE TRACING PRIMARILY IMPROVES EFFECTIVENESS WHEN SINGLE-STEP TRACING IS ON THE BRINK OF BEING EFFECTIVE.",NA,NA,"PLOS ONE","KLINKENBERG, D##FRASER, C##HEESTERBEEK, H","[KLINKENBERG, DON; HEESTERBEEK, HANS] UNIV UTRECHT, FAC VET MED, DEPT FARM ANIM HLTH, UTRECHT, NETHERLANDS. [FRASER, CHRISTOPHE] UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, DEPT INFECT DIS EPIDEMIOL, LONDON, ENGLAND.","MULTIDISCIPLINARY SCIENCES","SCIENCE & TECHNOLOGY - OTHER TOPICS","ALDIS GK, 2005, MATH BIOSCI, V195, P1, DOI 10.1016/J.MBS.2005.01.006##BECKER NG, 2005, MATH BIOSCI, V193, P205, DOI 10.1016/J.MBS.2004.07.006##BELL D, 2006, EMERG INFECT DIS, V12, P81##DIEKMANN O., 2000, MATH EPIDEMIOLOGY IN##DONNELLY CA, 2003, LANCET, V361, P1761, DOI 10.1016/S0140-6736(03)13410-1##EAMES KTD, 2003, P ROY SOC B-BIOL SCI, V270, P2565, DOI 10.1098/RSPB.2003.2554##EICHNER M, 2003, AM J EPIDEMIOL, V158, P118, DOI 10.1093/AJE/KWG104##FENNER FH, 1988, SMALLPOX ITS ERADICA##FERGUSON NM, 2001, NATURE, V413, P542, DOI 10.1038/35097116##FERGUSON NM, 2005, NATURE, V437, P209, DOI 10.1038/NATURE04017##FRASER C, 2004, P NATL ACAD SCI USA, V101, P6146, DOI 10.1073/PNAS.0307506101##KISS IZ, 2005, P ROY SOC B-BIOL SCI, V272, P1407, DOI 10.1098/RSPB.2005.3092##LLOYD-SMITH JO, 2003, P ROY SOC B-BIOL SCI, V270, P1979, DOI 10.1098/RSPB.2003.2481##MULLER J, 2000, MATH BIOSCI, V164, P39, DOI 10.1016/S0025-5564(99)00061-9##PORCO TC, 2004, BMC PUBLIC HEALTH, V4, DOI 10.1186/1471-2458-4-34",57,2020-11-20,"EU SIXTH FRAMEWORK PROGRAMMEEUROPEAN UNION (EU) [SP22-CT-2004-511066]; NETHERLANDS ORGANISATION FOR SCIENTIFIC RESEARCH (NWO)NETHERLANDS ORGANIZATION FOR SCIENTIFIC RESEARCH (NWO) [918.56.620]","UNIV UTRECHT#UNIV LONDON IMPERIAL COLL SCI TECHNOL MED","NETHERLANDS#ENGLAND"
"J","WOS:000243057400013",2006,"QUESTIONNAIRE TO DISTINGUISH BETWEEN STRESS AND URGE URINARY INCONTINENCE",NA,NA,NA,"ANNALS OF INTERNAL MEDICINE","MOONS, KGM","JULIUS CTR HLTH SCI & PRIMARY CARE, NL-3508 GA UTRECHT, NETHERLANDS. UNIV UTRECHT, MED CTR, NL-3508 GA UTRECHT, NETHERLANDS.","MEDICINE, GENERAL & INTERNAL","GENERAL & INTERNAL MEDICINE","BROWN JS, 2006, ANN INTERN MED, V144, P715, DOI 10.7326/0003-4819-144-10-200605160-00005##BROWN JS, 1999, OBSTET GYNECOL, V94, P66, DOI 10.1016/S0029-7844(99)00263-X##MOONS KGM, 1999, EPIDEMIOLOGY, V10, P276, DOI 10.1097/00001648-199905000-00015##MOONS KGM, 2004, CLIN CHEM, V50, P473, DOI 10.1373/CLINCHEM.2003.024752",0,2020-11-20,NA,"JULIUS CTR HLTH SCI PRIMARY CARE#UNIV UTRECHT","NETHERLANDS#NETHERLANDS"
"J","WOS:000423838100001",2006,"LONGITUDINAL DOUBLE-SPIN ASYMMETRY AND CROSS SECTION FOR INCLUSIVE JET PRODUCTION IN POLARIZED PROTON COLLISIONS AT ROOT S=200 GEV","WE REPORT A MEASUREMENT OF THE LONGITUDINAL DOUBLE-SPIN ASYMMETRY A(LL) AND THE DIFFERENTIAL CROSS SECTION FOR INCLUSIVE MIDRAPIDITY JET PRODUCTION IN POLARIZED PROTON COLLISIONS AT ROOT S = 200 GEV. THE CROSS SECTION DATA COVER TRANSVERSE MOMENTA 5 < P(T) < 50 GEV/C AND AGREE WITH NEXT-TO-LEADING ORDER PERTURBATIVE QCD EVALUATIONS. THE A(LL) DATA COVER 5 < P(T) < 17 GEV/C AND DISFAVOR AT 98% C.L. MAXIMAL POSITIVE GLUON POLARIZATION IN THE POLARIZED NUCLEON.",NA,NA,"PHYSICAL REVIEW LETTERS","ABELEV, BI##AGGARWAL, MM##AHAMMED, Z##AMONETT, J##ANDERSON, BD##ANDERSON, M##ARKHIPKIN, D##AVERICHEV, GS##BAI, Y##BALEWSKI, J##BARANNIKOVA, O##BARNBY, LS##BAUDOT, J##BEKELE, S##BELAGA, VV##BELLINGERI-LAURIKAINEN, A##BELLWIED, R##BENEDOSSO, F##BHARDWAJ, S##BHASIN, A##BHATI, AK##BICHSEL, H##BIELCIK, J##BIELCIKOVA, J##BLAND, LC##BLYTH, SL##BONNER, BE##BOTJE, M##BOUCHET, J##BRANDIN, AV##BRAVAR, A##BURTON, TP##BYSTERSKY, M##CADMAN, RV##CAI, XZ##CAINES, H##SANCHEZ, MCDLB##CASTILLO, J##CATU, O##CEBRA, D##CHAJECKI, Z##CHALOUPKA, P##CHATTOPADHYAY, S##CHEN, HF##CHEN, JH##CHENG, J##CHERNEY, M##CHIKANIAN, A##CHRISTIE, W##COFFIN, JP##CORMIER, TM##COSENTINO, MR##CRAMER, JG##CRAWFORD, HJ##DAS, D##DAS, S##DASH, S##DAUGHERITY, M##DE MOURA, MM##DEDOVICH, TG##DEPHILLIPS, M##DEREVSCHIKOV, AA##DIDENKO, L##DIETEL, T##DJAWOTHO, P##DOGRA, SM##DONG, WJ##DONG, X##DRAPER, JE##DU, F##DUNIN, VB##DUNLOP, JC##MAZUMDAR, MRD##ECKARDT, V##EDWARDS, WR##EFIMOV, LG##EMELIANOV, V##ENGELAGE, J##EPPLEY, G##ERAZMUS, B##ESTIENNE, M##FACHINI, P##FATEMI, R##FEDORISIN, J##FILIP, P##FINCH, E##FINE, V##FISYAK, Y##FU, J##GAGLIARDI, CA##GAILLARD, L##GANTI, MS##GHAZIKHANIAN, V##GHOSH, P##GONZALEZ, JE##GORBUNOV, YG##GOS, H##GREBENYUK, O##GROSNICK, D##GUERTIN, SM##GUIMARAES, KSFF##GUPTA, N##GUTIERREZ, TD##HAAG, B##HALLMAN, TJ##HAMED, A##HARRIS, JW##HE, W##HEINZ, M##HENRY, TW##HEPPLEMANN, S##HIPPOLYTE, B##HIRSCH, A##HJORT, E##HOFFMAN, AM##HOFFMANN, GW##HORNER, MJ##HUANG, HZ##HUANG, SL##HUGHES, EW##HUMANIC, TJ##IGO, G##JACOBS, P##JACOBS, WW##JAKL, P##JIA, F##JIANG, H##JONES, PG##JUDD, EG##KABANA, S##KANG, K##KAPITAN, J##KAPLAN, M##KEANE, D##KECHECHYAN, A##KHODYREV, VY##KIM, BC##KIRYLUK, J##KISIEL, A##KISLOV, EM##KLEIN, SR##KOCOLOSKI, A##KOETKE, DD##KOLLEGGER, T##KOPYTINE, M##KOTCHENDA, L##KOUCHPIL, V##KOWALIK, KL##KRAMER, M##KRAVTSOV, P##KRAVTSOV, VI##KRUEGER, K##KUHN, C##KULIKOV, AI##KUMAR, A##KUZNETSOV, AA##LAMONT, MAC##LANDGRAF, JM##LANGE, S##LAPOINTE, S##LAUE, F##LAURET, J##LEBEDEV, A##LEDNICKY, R##LEE, CH##LEHOCKA, S##LEVINE, MJ##LI, C##LI, Q##LI, Y##LIN, G##LIN, X##LINDENBAUM, SJ##LISA, MA##LIU, F##LIU, H##LIU, J##LIU, L##LIU, Z##LJUBICIC, T##LLOPE, WJ##LONG, H##LONGACRE, RS##LOVE, WA##LU, Y##LUDLAM, T##LYNN, D##MA, GL##MA, JG##MA, YG##MAGESTRO, D##MAHAPATRA, DP##MAJKA, R##MANGOTRA, LK##MANWEILER, R##MARGETIS, S##MARKERT, C##MARTIN, L##MATIS, HS##MATULENKO, YA##MCCLAIN, CJ##MCSHANE, TS##MELNICK, Y##MESCHANIN, A##MILLANE, J##MILLER, ML##MINAEV, NG##MIODUSZEWSKI, S##MIRONOV, C##MISCHKE, A##MISHRA, DK##MITCHELL, J##MOHANTY, B##MOLNAR, L##MOORE, CF##MOROZOV, DA##MUNHOZ, MG##NANDI, BK##NATTRASS, C##NAYAK, TK##NELSON, JM##NETRAKANTI, PK##NOGACH, LV##NURUSHEV, SB##ODYNIEC, G##OGAWA, A##OKOROKOV, V##OLDENBURG, M##OLSON, D##PACHR, M##PAL, SK##PANEBRATSEV, Y##PANITKIN, SY##PAVLINOV, AI##PAWLAK, T##PEITZMANN, T##PEREVOZTCHIKOV, V##PERKINS, C##PERYT, W##PHATAK, SC##PICHA, R##PLANINIC, M##PLUTA, J##POLJAK, N##PORILE, N##PORTER, J##POSKANZER, AM##POTEKHIN, M##POTREBENIKOVA, E##POTUKUCHI, BVKS##PRINDLE, D##PRUNEAU, C##PUTSCHKE, J##RAKNESS, G##RANIWALA, R##RANIWALA, S##RAY, RL##RAZIN, SV##REINNARTH, J##RELYEA, D##RIDIGER, A##RITTER, HG##ROBERTS, JB##ROGACHEVSKIY, OV##ROMERO, JL##ROSE, A##ROY, C##RUAN, L##RUSSCHER, MJ##SAHOO, R##SAKUMA, T##SALUR, S##SANDWEISS, J##SARSOUR, M##SAZHIN, PS##SCHAMBACH, J##SCHARENBERG, RP##SCHMITZ, N##SEGER, J##SELYUZHENKOV, I##SEYBOTH, P##SHABETAI, A##SHAHALIEV, E##SHAO, M##SHARMA, M##SHEN, WQ##SHIMANSKIY, SS##SICHTERMANN, EP##SIMON, F##SINGARAJU, RN##SMIRNOV, N##SNELLINGS, R##SOOD, G##SORENSEN, P##SOWINSKI, J##SPELTZ, J##SPINKA, HM##SRIVASTAVA, B##STADNIK, A##STANISLAUS, TDS##STOCK, R##STOLPOVSKY, A##STRIKHANOV, M##STRINGFELLOW, B##SUAIDE, AAP##SUGARBAKER, E##SUMBERA, M##SUN, Z##SURROW, B##SWANGER, M##SYMONS, TJM##DE TOLEDO, AS##TAI, A##TAKAHASHI, J##TANG, AH##TARNOWSKY, T##THEIN, D##THOMAS, JH##TIMMINS, AR##TIMOSHENKO, S##TOKAREV, M##TRAINOR, TA##TRENTALANGE, S##TRIBBLE, RE##TSAI, OD##ULERY, J##ULLRICH, T##UNDERWOOD, DG##VAN BUREN, G##VAN DER KOLK, N##VAN LEEUWEN, M##MOLEN, AMV##VARMA, R##VASILEVSKI, IM##VASILIEV, AN##VERNET, R##VIGDOR, SE##VIYOGI, YP##VOKAL, S##VOLOSHIN, SA##WAGGONER, WT##WANG, F##WANG, G##WANG, JS##WANG, XL##WANG, Y##WATSON, JW##WEBB, JC##WESTFALL, GD##WETZLER, A##WHITTEN, C##WIEMAN, H##WISSINK, SW##WITT, R##WOOD, J##WU, J##XU, N##XU, QH##XU, Z##YEPES, P##YOO, IK##YUREVICH, VI##ZHAN, W##ZHANG, H##ZHANG, WM##ZHANG, Y##ZHANG, ZP##ZHAO, Y##ZHONG, C##ZOULKARNEEV, R##ZOULKARNEEVA, Y##ZUBAREV, AN##ZUO, JX","[CADMAN, R. V.; KRUEGER, K.; MCCLAIN, C. J.; SPINKA, H. M.; UNDERWOOD, D. G.] ARGONNE NATL LAB, ARGONNE, IL 60439 USA. [BARNBY, L. S.; BURTON, T. P.; GAILLARD, L.; JONES, P. G.; NELSON, J. M.; TIMMINS, A. R.] UNIV BIRMINGHAM, BIRMINGHAM, W MIDLANDS, ENGLAND. [BLAND, L. C.; BRAVAR, A.; CHRISTIE, W.; DEPHILLIPS, M.; DIDENKO, L.; DUNLOP, J. C.; FACHINI, P.; FINE, V.; FISYAK, Y.; HALLMAN, T. J.; LANDGRAF, J. M.; LAUE, F.; LAURET, J.; LEBEDEV, A.; LEVINE, M. J.; LJUBICIC, T.; LONGACRE, R. S.; LOVE, W. A.; LUDLAM, T.; LYNN, D.; OGAWA, A.; PANITKIN, S. Y.; PEREVOZTCHIKOV, V.; POTEKHIN, M.; SORENSEN, P.; TANG, A. H.; ULLRICH, T.; VAN BUREN, G.; XU, Z.; ZHANG, H.] BROOKHAVEN NATL LAB, UPTON, NY 11973 USA. [HUGHES, E. W.; RELYEA, D.] CALTECH, PASADENA, CA 91125 USA. [CRAWFORD, H. J.; ENGELAGE, J.; JUDD, E. G.; PERKINS, C.] UNIV CALIF BERKELEY, BERKELEY, CA 94720 USA. [ANDERSON, M.; SANCHEZ, M. CALDERON DE LA BARCA; CEBRA, D.; DRAPER, J. E.; GUTIERREZ, T. D.; HAAG, B.; PICHA, R.; ROMERO, J. L.] UNIV CALIF DAVIS, DAVIS, CA 95616 USA. [DONG, W. J.; GHAZIKHANIAN, V.; GONZALEZ, J. E.; GUERTIN, S. M.; HUANG, H. Z.; IGO, G.; JIANG, H.; LONG, H.; MA, J. G.; TAI, A.; THEIN, D.; TRENTALANGE, S.; TSAI, O. D.; WANG, G.; WHITTEN, C., JR.; WOOD, J.] UNIV CALIF LOS ANGELES, LOS ANGELES, CA 90095 USA. [KAPLAN, M.] CARNEGIE MELLON UNIV, PITTSBURGH, PA 15213 USA. [BARANNIKOVA, O.] UNIV ILLINOIS, CHICAGO, IL USA. [CHERNEY, M.; GORBUNOV, Y. G.; MCSHANE, T. S.; SEGER, J.; SWANGER, M.; WAGGONER, W. T.] CREIGHTON UNIV, OMAHA, NE 68178 USA. [BYSTERSKY, M.; CHALOUPKA, P.; JAKL, P.; KAPITAN, J.; KOUCHPIL, V.; PACHR, M.; SUMBERA, M.] NUCL PHYS INST AS CR, PRAGUE 25068, CZECH REPUBLIC. [AVERICHEV, G. S.; BELAGA, V. V.; DEDOVICH, T. G.; DUNIN, V. B.; EFIMOV, L. G.; FEDORISIN, J.; KECHECHYAN, A.; KISLOV, E. M.; KULIKOV, A. I.; KUZNETSOV, A. A.; LEHOCKA, S.; PANEBRATSEV, Y.; POTREBENIKOVA, E.; RAZIN, S. V.; ROGACHEVSKIY, O. V.; SAZHIN, P. S.; SHAHALIEV, E.; SHIMANSKIY, S. S.; STADNIK, A.; TOKAREV, M.; VOKAL, S.; YUREVICH, V. I.; ZUBAREV, A. N.] LAB HIGH ENERGY JINR, DUBNA, RUSSIA. [ARKHIPKIN, D.; FILIP, P.; LEDNICKY, R.; VASILEVSKI, I. M.; ZOULKARNEEV, R.; ZOULKARNEEVA, Y.] PARTICLE PHYS LAB JINR, DUBNA, RUSSIA. [DIETEL, T.; KOLLEGGER, T.; LANGE, S.; STOCK, R.] GOETHE UNIV FRANKFURT, FRANKFURT, GERMANY. [DASH, S.; MAHAPATRA, D. P.; MISHRA, D. K.; PHATAK, S. C.; SAHOO, R.; VIYOGI, Y. P.] INST PHYS, BHUBANESWAR 751005, ORISSA, INDIA. [NANDI, B. K.; VARMA, R.] INDIAN INST TECHNOL, MUMBAI, MAHARASHTRA, INDIA. [BALEWSKI, J.; DJAWOTHO, P.; HE, W.; JACOBS, W. W.; SOWINSKI, J.; VIGDOR, S. E.; WISSINK, S. W.] INDIANA UNIV, BLOOMINGTON, IN 47408 USA. [BAUDOT, J.; COFFIN, J. P.; ESTIENNE, M.; HIPPOLYTE, B.; KUHN, C.; SPELTZ, J.; VERNET, R.] INST RECHERCHES SUBATOM, STRASBOURG, FRANCE. [BHASIN, A.; DOGRA, S. M.; GUPTA, N.; MANGOTRA, L. K.; POTUKUCHI, B. V. K. S.] UNIV JAMMU, JAMMU 180001, INDIA. [AMONETT, J.; ANDERSON, B. D.; KEANE, D.; KOPYTINE, M.; MARGETIS, S.; MIRONOV, C.; SHABETAI, A.; WATSON, J. W.; ZHANG, W. M.] KENT STATE UNIV, KENT, OH 44242 USA. [JIA, F.; SUN, Z.; WANG, J. S.; ZHAN, W.] INST MODERN PHYS, LANZHOU, PEOPLES R CHINA. [BLYTH, S-L.; EDWARDS, W. R.; HJORT, E.; HORNER, M. J.; JACOBS, P.; KLEIN, S. R.; KOWALIK, K. L.; MATIS, H. S.; ODYNIEC, G.; OLDENBURG, M.; OLSON, D.; POSKANZER, A. M.; PUTSCHKE, J.; RITTER, H. G.; ROSE, A.; RUAN, L.; SICHTERMANN, E. P.; SYMONS, T. J. M.; THOMAS, J. H.; VAN LEEUWEN, M.; WETZLER, A.; WIEMAN, H.; XU, N.; XU, Q. H.] LAWRENCE BERKELEY NATL LAB, BERKELEY, CA 94720 USA. [FATEMI, R.; HOFFMAN, A. M.; KIRYLUK, J.; KOCOLOSKI, A.; MILLANE, J.; MILLER, M. L.; SAKUMA, T.; SIMON, F.; SURROW, B.] MIT, CAMBRIDGE, MA 02139 USA. [ECKARDT, V.; SCHMITZ, N.; SEYBOTH, P.] MAX PLANCK INST PHYS & ASTROPHYS, MUNICH, GERMANY. [MOLEN, A. M. VANDER; WESTFALL, G. D.] MICHIGAN STATE UNIV, E LANSING, MI 48824 USA. [BRANDIN, A. V.; EMELIANOV, V.; KOTCHENDA, L.; KRAVTSOV, P.; OKOROKOV, V.; RIDIGER, A.; STRIKHANOV, M.; TIMOSHENKO, S.] MOSCOW ENGN PHYS INST, MOSCOW, RUSSIA. [KRAMER, M.; LINDENBAUM, S. J.] CUNY CITY COLL, NEW YORK, NY 10031 USA. [BAI, Y.; BENEDOSSO, F.; BOTJE, M.; CASTILLO, J.; GREBENYUK, O.; MISCHKE, A.; PEITZMANN, T.; RUSSCHER, M. J.; SNELLINGS, R.; VAN DER KOLK, N.] NIKHEF, AMSTERDAM, NETHERLANDS. [BAI, Y.; BENEDOSSO, F.; BOTJE, M.; CASTILLO, J.; GREBENYUK, O.; MISCHKE, A.; PEITZMANN, T.; RUSSCHER, M. J.; SNELLINGS, R.; VAN DER KOLK, N.] UNIV UTRECHT, AMSTERDAM, NETHERLANDS. [BEKELE, S.; CHAJECKI, Z.; HUMANIC, T. J.; LISA, M. A.; MAGESTRO, D.; SUGARBAKER, E.] OHIO STATE UNIV, COLUMBUS, OH 43210 USA. [AGGARWAL, M. M.; BHATI, A. K.; KUMAR, A.; SHARMA, M.] PANJAB UNIV, CHANDIGARH 160014, INDIA. [HEPPLEMANN, S.; RAKNESS, G.] PENN STATE UNIV, UNIVERSITY PK, PA 16802 USA. [DEREVSCHIKOV, A. A.; KHODYREV, V. YU.; KRAVTSOV, V. I.; MATULENKO, YU. A.; MELNICK, YU.; MESCHANIN, A.; MINAEV, N. G.; MOROZOV, D. A.; NOGACH, L. V.; NURUSHEV, S. B.; VASILIEV, A. N.] INST HIGH ENERGY PHYS, PROTVINO, RUSSIA. [HIRSCH, A.; MOLNAR, L.; PORILE, N.; SCHARENBERG, R. P.; SRIVASTAVA, B.; STRINGFELLOW, B.; TARNOWSKY, T.; ULERY, J.; WANG, F.] PURDUE UNIV, WEST LAFAYETTE, W LAFAYETTE, IN 47907 USA. [KIM, B. C.; LEE, C. -H.] PUSAN NATL UNIV, PUSAN, SOUTH KOREA. [BHARDWAJ, S.; RANIWALA, R.; RANIWALA, S.; YOO, I. -K.] UNIV RAJASTHAN, JAIPUR 302004, RAJASTHAN, INDIA. [BONNER, B. E.; EPPLEY, G.; LIU, J.; LLOPE, W. J.; MITCHELL, J.; ROBERTS, J. B.; YEPES, P.] RICE UNIV, HOUSTON, TX 77251 USA. [COSENTINO, M. R.; DE MOURA, M. M.; GUIMARAES, K. S. F. F.; MUNHOZ, M. G.; SUAIDE, A. A. P.; DE TOLEDO, A. SZANTO; TAKAHASHI, J.] UNIV SAO PAULO, SAO PAULO, BRAZIL. [CHEN, H. F.; DONG, X.; HUANG, S. L.; LI, C.; LIU, H.; SHAO, M.; WANG, X. L.; WU, J.; ZHANG, Y.; ZHANG, Z. P.; ZHAO, Y.] UNIV SCI TECHNOL CHINA, HEFEI 230026, ANHUI, PEOPLES R CHINA. [CAI, X. Z.; CHEN, J. H.; MA, G. L.; MA, Y. G.; SHEN, W. Q.; ZHONG, C.; ZUO, J. X.] SHANGHAI INST APPL PHYS, SHANGHAI 201800, PEOPLES R CHINA. [BELLINGERI-LAURIKAINEN, A.; BOUCHET, J.; ERAZMUS, B.; KABANA, S.; MARTIN, L.; REINNARTH, J.; ROY, C.] SUBATECH, NANTES, FRANCE. [GAGLIARDI, C. A.; HENRY, T. W.; MIODUSZEWSKI, S.; SARSOUR, M.; TRIBBLE, R. E.] TEXAS A&M UNIV, COLLEGE STN, TX 77843 USA. [DAUGHERITY, M.; HOFFMANN, G. W.; MARKERT, C.; MOORE, C. F.; RAY, R. L.; SCHAMBACH, J.] UNIV TEXAS, AUSTIN, TX 78712 USA. [CHENG, J.; KANG, K.; LI, Y.; WANG, Y.] TSINGHUA UNIV, BEIJING 100084, PEOPLES R CHINA. [GROSNICK, D.; KOETKE, D. D.; MANWEILER, R.; SOOD, G.; STANISLAUS, T. D. S.; WEBB, J. C.] VALPARAISO UNIV, VALPARAISO, IN 46383 USA. [AHAMMED, Z.; CHATTOPADHYAY, S.; DAS, D.; DAS, S.; MAZUMDAR, M. R. DUTTA; GANTI, M. S.; GHOSH, P.; MOHANTY, B.; NAYAK, T. K.; NETRAKANTI, P. K.; PAL, S. K.; SINGARAJU, R. N.] CTR VARIABLE ENERGY CYCLOTRON, KOLKATA 700064, INDIA. [GOS, H.; KISIEL, A.; PAWLAK, T.; PERYT, W.; PLUTA, J.] WARSAW UNIV TECHNOL, WARSAW, POLAND. [BICHSEL, H.; CRAMER, J. G.; PORTER, J.; PRINDLE, D.; TRAINOR, T. A.] UNIV WASHINGTON, SEATTLE, WA 98195 USA. [BELLWIED, R.; CORMIER, T. M.; HAMED, A.; LAPOINTE, S.; LI, Q.; PAVLINOV, A. I.; PRUNEAU, C.; SELYUZHENKOV, I.; STOLPOVSKY, A.; VOLOSHIN, S. A.] WAYNE STATE UNIV, DETROIT, MI 48201 USA. [FU, J.; LIN, X.; LIU, F.; LIU, L.; LIU, Z.; LU, Y.] INST PARTICLE PHYS, CCNU HZNU, WUHAN 430079, HUBEI, PEOPLES R CHINA. [ABELEV, B. I.; BIELCIK, J.; BIELCIKOVA, J.; CAINES, H.; CATU, O.; CHIKANIAN, A.; DU, F.; FINCH, E.; HARRIS, J. W.; HEINZ, M.; LAMONT, M. A. C.; LIN, G.; MAJKA, R.; NATTRASS, C.; SALUR, S.; SANDWEISS, J.; SMIRNOV, N.; WITT, R.] YALE UNIV, NEW HAVEN, CT 06520 USA. [PLANINIC, M.; POLJAK, N.] UNIV ZAGREB, HR-10002 ZAGREB, CROATIA.","PHYSICS, MULTIDISCIPLINARY","PHYSICS","ADAMS DL, 1994, PHYS LETT B, V336, P269, DOI 10.1016/0370-2693(94)00998-8##ADAMS J, 2003, PHYS REV LETT, V91, DOI 10.1103/PHYSREVLETT.91.172302##ADEVA B, 2004, PHYS REV D, V70, DOI 10.1103/PHYSREVD.70.012002##ADEVA B, 1998, PHYS REV D, V58, DOI 10.1103/PHYSREVD.58.112002##ADLER SS, 2004, PHYS REV LETT, V93, DOI 10.1103/PHYSREVLETT.93.202002##AGEEV ES, 2006, PHYS LETT B, V633, P25, DOI 10.1016/J.PHYSLETB.2005.11.049##AIRAPETIAN A, 2000, PHYS REV LETT, V84, P2584, DOI 10.1103/PHYSREVLETT.84.2584##ALTARELLI G, 1988, PHYS LETT B, V212, P391, DOI 10.1016/0370-2693(88)91335-4##ASHMAN J, 1989, NUCL PHYS B, V328, P1, DOI 10.1016/0550-3213(89)90089-8##BLAZEY GC, HEPEX0005012##BUNCE G, 2000, ANNU REV NUCL PART S, V50, P525, DOI 10.1146/ANNUREV.NUCL.50.1.525##CORCELLA G, 2001, J HIGH ENERGY PHYS, DOI 10.1088/1126-6708/2001/01/010##FIELD R, HEPPH0510198##FILIPPONE BW, 2001, ADV NUCL PHYS, V26, P1##GLUCK M, 2001, PHYS REV D, V63, DOI 10.1103/PHYSREVD.63.094005##HARRISON M, 2003, NUCL INSTRUM METHO A, V499##HIRAI M, 2004, PHYS REV D, V69, DOI 10.1103/PHYSREVD.69.054021##JAGER B, 2004, PHYS REV D, V70, DOI 10.1103/PHYSREVD.70.034010##JINNOUCHI O, 2004, 171 RHICCAD##KARLITZ R. D., 1988, PHYS LETT B, V214, P229##KIRYLUK J., HEPEX0501072##MEYER HO, 1998, PHYS REV LETT, V81, P3096, DOI 10.1103/PHYSREVLETT.81.3096##OKADA H., PHYS LETT B IN PRESS##PUMPLIN J, 2002, J HIGH ENERGY PHYS, DOI 10.1088/1126-6708/2002/07/012##SJOSTRAND T, 2001, COMPUT PHYS COMMUN, V135, P238, DOI 10.1016/S0010-4655(00)00236-8",134,2020-11-20,"RHIC OPERATIONS GROUP; RCF AT BNL; NERSC CENTER AT LBNL; OFFICE OF NP WITHIN THE US. DOE OFFICE OF SCIENCEUNITED STATES DEPARTMENT OF ENERGY (DOE); OFFICE OF HEP WITHIN THE US. DOE OFFICE OF SCIENCEUNITED STATES DEPARTMENT OF ENERGY (DOE); U.S. NSFNATIONAL SCIENCE FOUNDATION (NSF); BMBF OF GERMANYFEDERAL MINISTRY OF EDUCATION & RESEARCH (BMBF); CNRS/IN2P3 OF FRANCE; RA OF FRANCE; RPL OF FRANCE; EMN OF FRANCE; EPSRC OF THE UNITED KINGDOMENGINEERING & PHYSICAL SCIENCES RESEARCH COUNCIL (EPSRC); FAPESP OF BRAZILFUNDACAO DE AMPARO A PESQUISA DO ESTADO DE SAO PAULO (FAPESP); RUSSIAN MINISTRY OF SCIENCE AND TECHNOLOGY; MINISTRY OF EDUCATION OF CHINAMINISTRY OF EDUCATION, CHINA; NNSFC OF CHINANATIONAL NATURAL SCIENCE FOUNDATION OF CHINA (NSFC); IRP OF THE CZECH REPUBLIC; GA OF THE CZECH REPUBLIC; FOM OF THE NETHERLANDSFOM (THE NETHERLANDS); DAE OF THE GOVERNMENT OF INDIA; DST OF THE GOVERNMENT OF INDIA; CSIR OF THE GOVERNMENT OF INDIACOUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (CSIR) - INDIA; SWISS NSFSWISS NATIONAL SCIENCE FOUNDATION (SNSF); POLISH STATE COMMITTEE FOR SCIENTIFIC RESEARCHPOLISH STATE COMMITTEE FOR SCIENTIFIC RESEARCH; SRDA OF SLOVAKIA; KOREA SCI. & ENG. FOUNDATION","ARGONNE NATL LAB#UNIV BIRMINGHAM#BROOKHAVEN NATL LAB#CALTECH#UNIV CALIF BERKELEY#UNIV CALIF DAVIS#UNIV CALIF LOS ANGELES#CARNEGIE MELLON UNIV#UNIV ILLINOIS#CREIGHTON UNIV#NUCL PHYS INST AS CR#LAB HIGH ENERGY JINR#PARTICLE PHYS LAB JINR#GOETHE UNIV FRANKFURT#INST PHYS#INDIAN INST TECHNOL#INDIANA UNIV#INST RECHERCHES SUBATOM#UNIV JAMMU#KENT STATE UNIV#INST MODERN PHYS#LAWRENCE BERKELEY NATL LAB#MIT#MAX PLANCK INST PHYS ASTROPHYS#MICHIGAN STATE UNIV#MOSCOW ENGN PHYS INST#CUNY CITY COLL#NIKHEF#UNIV UTRECHT#OHIO STATE UNIV#PANJAB UNIV#PENN STATE UNIV#INST HIGH ENERGY PHYS#PURDUE UNIV#PUSAN NATL UNIV#UNIV RAJASTHAN#RICE UNIV#UNIV SAO PAULO#UNIV SCI TECHNOL CHINA#SHANGHAI INST APPL PHYS#SUBATECH#TEXAS A M UNIV#UNIV TEXAS#TSINGHUA UNIV#VALPARAISO UNIV#CTR VARIABLE ENERGY CYCLOTRON#WARSAW UNIV TECHNOL#UNIV WASHINGTON#WAYNE STATE UNIV#INST PARTICLE PHYS#YALE UNIV#UNIV ZAGREB","IL USA#ENGLAND#NY USA#CA USA#CA USA#CA USA#CA USA#PA USA#IL USA#NE USA#CZECH REPUBLIC#RUSSIA#RUSSIA#GERMANY#INDIA#INDIA#IN USA#FRANCE#INDIA#OH USA#PEOPLES R CHINA#CA USA#MA USA#GERMANY#MI USA#RUSSIA#NY USA#NETHERLANDS#NETHERLANDS#OH USA#INDIA#PA USA#RUSSIA#IN USA#SOUTH KOREA#INDIA#TX USA#BRAZIL#PEOPLES R CHINA#PEOPLES R CHINA#FRANCE#TX USA#TX USA#PEOPLES R CHINA#IN USA#INDIA#POLAND#WA USA#MI USA#PEOPLES R CHINA#CT USA#CROATIA"
"J","WOS:000242953400003",2006,"SIMULATING HOLOCENE CARBON ACCUMULATION IN A WESTERN SIBERIAN WATERSHED MIRE USING A THREE-DIMENSIONAL DYNAMIC MODELING APPROACH","THE VAST UNDISTURBED MIRES IN WESTERN SIBERIA FORMED A SIGNIFICANT SINK OF ATMOSPHERIC CARBON DIOXIDE DURING THE HOLOCENE. HOWEVER, THE LACK OF SPATIALLY RESOLVED SIMULATION MODELS HAMPERS THE QUANTIFICATION OF HOLOCENE CARBON ACCUMULATION OF THE ENTIRE MIRE SYSTEMS. HERE WE DEVELOPED A THREE-DIMENSIONAL DYNAMIC MODEL, BASED ON A HYDROLOGICAL APPROACH. WE APPLIED THE MODEL TO A LARGE MIRE COMPLEX IN WESTERN SIBERIA TO SIMULATE ITS HOLOCENE DEVELOPMENT AND TO QUANTIFY THE LONG-TERM CARBON ACCUMULATION RATE (LORCA). OUR MODEL SIMULATED A LORCA WITH A SPATIAL VARIATION OF 10-85 G C M(-2) YR(-1). THE AVERAGE OVER THE HOLOCENE WAS 16.2 G C M(-2) YR(-1). SIMULATION SCENARIOS FOR THE 21ST CENTURY SHOW THAT THE AVERAGE LORCA DROPPED TO 5.2 G C M(-2) YR(-1) BECAUSE OF OXIDATION AND DECOMPOSITION OF PEAT FOLLOWING MIRE DRAINAGE AFTER THE 1950S. EVEN IN THE UNDRAINED PARTS OF THE MIRE COMPLEX THE LORCA IS LOWERED SUBSTANTIALLY BECAUSE OF THE DROPPED WATER TABLE AND RESULTING DECREASE IN PEAT GROWTH. OUR RESULTS SHOW THAT CARBON ACCUMULATION IN WESTERN SIBERIAN WATERSHED MIRES WILL CONTINUE IN THE FUTURE. THUS THESE MIRES MIGHT REMAIN A SIGNIFICANT SINK OF CARBON.","HYDRAULIC CONDUCTIVITY; RAISED MIRE; PEAT BOG; PEATLANDS; CALIBRATION; HYDROLOGY; PROGRAM; FLOW",NA,"WATER RESOURCES RESEARCH","BORREN, W##BLEUTEN, W","UNIV UTRECHT, PHYS GEOG RES INST, NL-3508 TC UTRECHT, NETHERLANDS.","ENVIRONMENTAL SCIENCES; LIMNOLOGY; WATER RESOURCES","ENVIRONMENTAL SCIENCES & ECOLOGY; MARINE & FRESHWATER BIOLOGY; WATER RESOURCES","BECKWITH CW, 2003, HYDROL PROCESS, V17, P89, DOI 10.1002/HYP.1116##BLEUTEN W., 2001, CARBON STORAGE ATMOS##BORREN W, 2004, QUATERNARY RES, V61, P42, DOI 10.1016/J.YQRES.2003.09.002##BOTCH MS, 1995, GLOBAL BIOGEOCHEM CY, V9, P37, DOI 10.1029/94GB03156##CAMPBELL DI, 1997, J HYDROL, V193, P142, DOI 10.1016/S0022-1694(96)03149-6##CLYMO RS, 1984, PHILOS T ROY SOC B, V303, P605, DOI 10.1098/RSTB.1984.0002##CLYMO RS, 2004, HYDROL PROCESS, V18, P261, DOI 10.1002/HYP.1374##DOHERTY J, 2003, PEST MODEL INDEPENDE##FETTER CW, 2001, APPL HYDROGEOLOGY##HARBAUGH AW, 2000, 0092 US GEOL SURV, P121##HEMOND HF, 1985, J ECOL, V73, P579, DOI 10.2307/2260495##HOLDEN J, 2003, HYDROL PROCESS, V17, P1227, DOI 10.1002/HYP.1182##INGRAM HAP, 1967, J ECOL, V55, P711, DOI 10.2307/2258420##INGRAM HAP, 1982, NATURE, V297, P300, DOI 10.1038/297300A0##IVANOV KE, 1981, WATER MOVEMENT MIREL##KLIMANOV VA, 1984, LATE QUATERNARY ENV, P297##KORHOLA A, 1996, J QUATERNARY SCI, V11, P161, DOI 10.1002/(SICI)1099-1417(199603/04)11:2<161::AID-JQS248>3.0.CO;2-J##KREMENETSKI KV, 2003, QUATERNARY SCI REV, V22, P703, DOI 10.1016/S0277-3791(02)00196-8##LAPSHINA ED, 2001, CARBON STORAGE ATMOS, P23##MEHL SW, 2001, 01177 US GEOL SURV##PEBESMA EJ, 1998, COMPUT GEOSCI-UK, V24, P17, DOI 10.1016/S0098-3004(97)00082-4##RAMSEY CB, 1995, RADIOCARBON, V37, P425, DOI 10.1017/S0033822200030903##REEVE AS, 2000, J HYDROL, V227, P207, DOI 10.1016/S0022-1694(99)00183-3##RYCROFT DW, 1975, J ECOL, V63, P535, DOI 10.2307/2258734##SHENG YW, 2004, GLOBAL BIOGEOCHEM CY, V18, DOI 10.1029/2003GB002190##STUIVER M, 1998, RADIOCARBON, V40, P1041, DOI 10.1017/S0033822200019123##TURUNEN J, 2001, GLOBAL BIOGEOCHEM CY, V15, P285, DOI 10.1029/2000GB001312##WESSELING C.G., 1996, T GIS, V1, P40, DOI DOI 10.1111/J.1467-9671.1996.TB00032.X##WINSTON RB, 1994, GEOL SOC AM BULL, V106, P1594, DOI 10.1130/0016-7606(1994)106&LT;1594:MOTGHA&GT;2.3.CO;2##YEFREMOV SP, 2001, CARBON STORAGE ATMOS, P73##YU ZC, 2001, ECOL MODEL, V145, P197, DOI 10.1016/S0304-3800(01)00391-X",14,2020-11-20,NA,"UNIV UTRECHT","NETHERLANDS"
"J","WOS:000242782100012",2006,"A NOTE ON REWARD-RELATED BEHAVIOUR AND EMOTIONAL EXPRESSIONS IN FARMED SILVER FOXES (VULPES VULPES) - BASIS FOR A NOVEL TOOL TO STUDY ANIMAL WELFARE","THE PRESENT STUDY AIMED TO INVESTIGATE THE PROFILE AND QUANTITATIVE ASPECTS OF REWARD-RELATED BEHAVIOUR AND EMOTIONAL EXPRESSIONS DURING ANTICIPATION OF POSITIVE (PREDICTABLE OR VARIOUS UNPREDICTABLE) OR NEGATIVE (PREDICTABLE) REWARDS IN A PAVLOVIAN TRACE CONDITIONING PARADIGM IN FARMED SILVER FOXES. WHEN ANTICIPATING A POSITIVE REWARD, SILVER FOXES WERE MORE ACTIVE, PERFORMED MORE STEREOTYPICAL BEHAVIOUR, HAD MORE ERECTED EARS AND SPENT MORE TIME IN THE FRONT OF THE CAGE COMPARED TO ANTICIPATING AVERSIVE STIMULI. FOXES WERE ONLY TO A MINOR DEGREE ABLE TO DISCRIMINATE THE TWO DIFFERENT POSITIVE PARADIGMS. IN CONCLUSION, STUDIES RELATED TO ANTICIPATORY BEHAVIOUR MAY BE USEFUL FOR THE DEVELOPMENT OF INDICATORS OF POSITIVE EMOTIONAL STATES AND, THUS, POSITIVE WELFARE, IN FARMED SILVER FOXES. (C) 2006 ELSEVIER B.V. ALL RIGHTS RESERVED.","ANTICIPATORY BEHAVIOR; SYSTEMS; RATS","REWARD-RELATED BEHAVIOUR; EMOTIONS; ANIMAL WELFARE; POSITIVE WELFARE; FUR ANIMALS; CONDITIONED LEARNING; PREDICTABILITY; STEREOTYPIES","APPLIED ANIMAL BEHAVIOUR SCIENCE","MOE, RO##BAKKEN, M##KITTILSEN, S##KINGSLEY-SMITH, H##SPRUIJT, BM","NORWEGIAN UNIV LIFE SCI, DEPT ANIM & AQUACULTURAL SCI, N-1432 AS, NORWAY. UNIV UTRECHT, FAC VET MED, DEPT ANIM SCI & SOC, NL-3584 CL UTRECHT, NETHERLANDS.","AGRICULTURE, DAIRY & ANIMAL SCIENCE; BEHAVIORAL SCIENCES; VETERINARY SCIENCES","AGRICULTURE; BEHAVIORAL SCIENCES; VETERINARY SCIENCES","BAKKEN M., 1994, SCIENTIFUR, V18, P233##BAKKEN M, 1993, P INT C APPL ETH BER, P591##DAWKINS MS, 2001, COPING CHALLENGE WEL, P63##DESIRE L, 2002, BEHAV PROCESS, V60, P165, DOI 10.1016/S0376-6357(02)00081-5##FOX MW, 1970, BEHAVIOUR, V36, P49, DOI 10.1163/156853970X00042##FOX MW, 1975, WILD CANIDS THEIR SY##LEVINE S, 1976, PHYSIOL BEHAV, V17, P35, DOI 10.1016/0031-9384(76)90265-1##MARTIN P., 1993, MEASURING BEHAV INTR##MASON G, 1997, APPL ANIM BEHAV SCI, V53, P45, DOI 10.1016/S0168-1591(96)01150-1##SPRUIJT BM, 2001, APPL ANIM BEHAV SCI, V72, P145, DOI 10.1016/S0168-1591(00)00204-5##VAN DEN BOS R, 2003, BEHAV BRAIN RES, V141, P83, DOI 10.1016/S0166-4328(02)00318-2##VAN DER HARST JE, 2003, BEHAV BRAIN RES, V142, P151, DOI 10.1016/S0166-4328(02)00403-5##VINKE CM, 2004, APPL ANIM BEHAV SCI, V89, P145, DOI 10.1016/J.APPLANIM.2004.06.002##WIEPKEMA PR, 1990, NATO ADV SCI I D-BEH, V54, P1",35,2020-11-20,NA,"NORWEGIAN UNIV LIFE SCI#UNIV UTRECHT","NORWAY#NETHERLANDS"
"J","WOS:000242892400015",2006,"EFFECTIVENESS OF BEHAVIORAL GRADED ACTIVITY IN PATIENTS WITH OSTEOARTHRITIS OF THE HIP AND/OR KNEE: A RANDOMIZED CLINICAL TRIAL","OBJECTIVE: TO DETERMINE THE EFFECTIVENESS OF A BEHAVIORAL GRADED ACTIVITY PROGRAM (BGA) COMPARED WITH USUAL CARE (UC; EXERCISE THERAPY AND ADVICE) ACCORDING TO THE DUTCH GUIDELINES FOR PHYSIOTHERAPY IN PATIENTS WITH OSTEOARTHRITIS (OA) OF THE HIP AND/OR KNEE. THE BGA INTERVENTION IS INTENDED TO INCREASE ACTIVITY IN THE LONG TERM AND CONSISTS OF AN EXERCISE PROGRAM WITH BOOSTER SESSIONS, USING OPERANT TREATMENT PRINCIPLES. METHODS. WE CONDUCTED A CLUSTER RANDOMIZED TRIAL INVOLVING 200 PATIENTS WITH HIP AND/OR KNEE OA. PRIMARY OUTCOME MEASURES WERE PAIN (VISUAL ANALOG SCALE [VAS] AND WESTERN ONTARIO AND MCMASTER UNIVERSITIES OSTEOARTHRITIS INDEX [WOMAC]), PHYSICAL FUNCTION (WOMAC), AND PATIENT GLOBAL ASSESSMENT, ASSESSED AT WEEKS 0, 13, 39, AND 65. SECONDARY OUTCOME MEASURES COMPRISED TIREDNESS (VAS), PATIENT-ORIENTED PHYSICAL FUNCTION (MCMASTER TORONTO ARTHRITIS PATIENT PREFERENCE DISABILITY QUESTIONNAIRE [MACTAR]), 5-METER WALKING TIME, MUSCLE STRENGTH, AND RANGE OF MOTION. DATA WERE ANALYZED ACCORDING TO INTENT-TO-TREAT PRINCIPLE. RESULTS. BOTH TREATMENTS SHOWED SHORT-TERM AND LONG-TERM BENEFICIAL WITHIN-GROUP EFFECTS. THE MEAN DIFFERENCES BETWEEN THE 2 GROUPS FOR PAIN AND FUNCTIONAL STATUS WERE NOT STATISTICALLY SIGNIFICANT. SIGNIFICANT DIFFERENCES IN FAVOR OF BGA WERE FOUND FOR THE MACTAR FUNCTIONAL SCALE AND 5-METER WALKING TEST AT WEEK 65. CONCLUSION. BECAUSE BOTH INTERVENTIONS RESULTED IN BENEFICIAL LONG-TERM EFFECTS, THE SUPERIORITY OF BGA OVER UC HAS NOT BEEN DEMONSTRATED. THEREFORE, BGA SEEMS TO BE AN ACCEPTABLE METHOD TO TREAT PATIENTS WITH HIP AND/OR KNEE OA, WITH EQUIVALENT RESULTS COMPARED WITH UC.","LOW-BACK-PAIN; EXERCISE THERAPY; DISABILITY; REHABILITATION; GUIDELINES; STRENGTH; PROGRAM; WOMAC; RECOMMENDATIONS; CLASSIFICATION","OSTEOARTHRITIS; PHYSIOTHERAPY; BEHAVIORAL TREATMENT; GRADED ACTIVITY; EXERCISE THERAPY; BOOSTER SESSIONS; RANDOMIZED CONTROLLED TRIAL","ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH","VEENHOF, C##KOKE, AJA##DEKKER, J##OOSTENDORP, RA##BIJLSMA, JWJ##VAN TULDER, MW##VAN DEN ENDE, CHM","NETHERLANDS INST HLTH SERV RES, UTRECHT, NETHERLANDS. UNIV HOSP MAASTRICHT, MAASTRICHT, NETHERLANDS. HOENSBROEK REHABIL CTR, HOENSBROEK, NETHERLANDS. VRIJE UNIV AMSTERDAM MED CTR, INST RES EXTRAMURAL MED, AMSTERDAM, NETHERLANDS. RADBOUD UNIV NIJMEGEN MED CTR, NIJMEGEN, NETHERLANDS. UNIV UTRECHT, MED CTR, UTRECHT, NETHERLANDS.","RHEUMATOLOGY","RHEUMATOLOGY","ALBRIGHT J, 2001, PHYS THER, V81, P1675##ALEXANDER NB, 2001, J AM GERIATR SOC, V49, P1418, DOI 10.1046/J.1532-5415.2001.4911232.X##ALTMAN R, 1991, ARTHRITIS RHEUM, V34, P505, DOI 10.1002/ART.1780340502##ALTMAN R, 1986, ARTHRITIS RHEUM, V29, P1039, DOI 10.1002/ART.1780290816##ANGST F, 2001, ARTHRIT RHEUM-ARTHR, V45, P384, DOI 10.1002/1529-0131(200108)45:4<384::AID-ART352>3.0.CO;2-0##BEKKERING GE, 2005, QUAL SAF HEALTH CARE, V14, P107, DOI 10.1136/QSHC.2003.009357##BELLAMY N, 1997, J RHEUMATOL, V24, P799##BELLAMY N, 1988, J RHEUMATOL, V15, P1833##BIJLSMA JW, 2005, NED T REUM, V1, P27##BOHANNON RW, 1990, MUSCLE STRENGTH TEST, P69##BRYK AS, 1992, HIERARCHICAL LINEAR##COHEN J, 1976, STAT POWER ANAL BEHA##DE VREEDE PL, 2005, J AM GERIATR SOC, V53, P2, DOI 10.1111/J.1532-5415.2005.53003.X##DEKKER J, 1992, J BEHAV MED, V15, P189, DOI 10.1007/BF00848325##FORDYCE WE, 1973, ARCH PHYS MED REHAB, V54, P399##FRANSEN M, 2002, J RHEUMATOL, V29, P1737##GERAETS JJXR, 2005, AUST J PHYSIOTHER, V51, P87, DOI 10.1016/S0004-9514(05)70037-4##GOLDSTEIN H., 1995, MULTILEVEL STAT MODE##HOCHBERG MC, 1995, ARTHRITIS RHEUM, V38, P1541, DOI 10.1002/ART.1780381104##JETTE AM, 1997, PHYS THER, V77, P145, DOI 10.1093/PTJ/77.2.145##JORDAN KM, 2003, ANN RHEUM DIS, V62, P1145, DOI 10.1136/ARD.2003.011742##KELLGREN JH, 1957, ANN RHEUM DIS, V16, P494, DOI 10.1136/ARD.16.4.494##KETELAAR M, 2001, PHYS THER, V81, P1534, DOI 10.1093/PTJ/81.9.1534##KING M, 2002, BRIT MED J, V324, P947, DOI 10.1136/BMJ.324.7343.947##LEQUESNE MG, 1987, SCAND J RHEUMATOL, P85##LINDSTROM I, 1992, SPINE, V17, P641, DOI 10.1097/00007632-199206000-00003##LINDSTROM I, 1992, PHYS THER, V72, P279, DOI 10.1093/PTJ/72.4.279##LINTON SJ, 1993, PAIN, V54, P353, DOI 10.1016/0304-3959(93)90037-P##NORKIN C, 1986, MEASUREMENT JOINT MO##OSTELO RWJG, 2003, EUR SPINE J, V12, P637, DOI 10.1007/S00586-003-0560-9##RAVAUD P, 1997, J RHEUMATOL, V24, P786##ROORDA LD, 2004, ANN RHEUM DIS, V63, P36, DOI 10.1136/ARD.2002.001784##SMIDT N, 2005, AUST J PHYSIOTHER, V51, P71, DOI 10.1016/S0004-9514(05)70036-2##STAAL JB, 2004, ANN INTERN MED, V140, P77, DOI 10.7326/0003-4819-140-2-200401200-00007##STEULTJENS MPM, 2000, RHEUMATOLOGY, V39, P955, DOI 10.1093/RHEUMATOLOGY/39.9.955##STEULTJENS MPM, 2001, CLIN REHABIL, V15, P331, DOI 10.1191/026921501673178408##TAN J. C., 1998, PRACTICAL MANUAL PHY##TUBACH F, 2005, ANN RHEUM DIS, V64, P29, DOI 10.1136/ARD.2004.022905##TUGWELL P, 1987, J RHEUMATOL, V14, P446##VAN BAAR ME, 2001, ANN RHEUM DIS, V60, P1123, DOI 10.1136/ARD.60.12.1123##VAN BAAR ME, 1998, J RHEUMATOL, V25, P2432##VAN BAAR ME, 1999, ARTHRITIS RHEUM, V42, P1361, DOI 10.1002/1529-0131(199907)42:7<1361::AID-ANR9>3.0.CO;2-9##VAN BAAR ME, 1998, J RHEUMATOL, V25, P125##VANDERHEIJDEN GJM, 1996, SHOULDER DISORDER TR##VEENHOF C, 2005, ARTHRIT RHEUM-ARTHR, V53, P375, DOI 10.1002/ART.21171##VLAEYEN JWS, 1995, BRIT J CLIN PSYCHOL, V34, P95, DOI 10.1111/J.2044-8260.1995.TB01443.X##VOGELS EMH, 2001, CLIN PRACTICE GUIDEL##WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002##WENDEL-VOS GCW, 2003, J CLIN EPIDEMIOL, V56, P1163, DOI 10.1016/S0895-4356(03)00220-8",74,2020-11-20,NA,"NETHERLANDS INST HLTH SERV RES#UNIV HOSP MAASTRICHT#HOENSBROEK REHABIL CTR#VRIJE UNIV AMSTERDAM MED CTR#RADBOUD UNIV NIJMEGEN MED CTR#UNIV UTRECHT","NETHERLANDS#NETHERLANDS#NETHERLANDS#NETHERLANDS#NETHERLANDS#NETHERLANDS"
"J","WOS:000242898100001",2006,"CLASPIN - TIMING THE CELL CYCLE ARREST WHEN THE GENOME IS DAMAGED","DNA DAMAGE CHECKPOINTS MAINTAIN GENOMIC INTEGRITY BY DELAYING CELL CYCLE PROGRESSION IN RESPONSE TO GENOTOXIC STRESS AND STALLED REPLICATION FORKS. ONE CENTRAL PATHWAY IN THE CHECKPOINT RESPONSE IS THE ATR-CHK1 PATHWAY, IN WHICH, UPON DNA DAMAGE, ATR PHOSPHORYLATES AND ACTIVATES THE EFFECTOR KINASE CHK1. THIS PROCESS DEPENDS ON THE ADAPTOR PROTEIN CLASPIN THAT BRIDGES ATR AND CHK1. ONCE THE DAMAGE IS REPAIRED, THIS PATHWAY MUST SOMEHOW BE SWITCHED OFF TO ALLOW THE CELL TO CONTINUE THE CELL DIVISION PROCESS, AN EVENT KNOWN AS CHECKPOINT RECOVERY. POLO-LIKE KINASE 1 (PLK1) PLAYS A CENTRAL ROLE DURING CHECKPOINT RECOVERY. INTERESTINGLY, THE XENOPUS HOMOLOGUE OF PLK1, PLX1, IS ABLE TO BIND AND PHOSPHORYLATE CLASPIN, RELEASING IT FROM DNA AND THEREBY CONTRIBUTING TO CHK1 INACTIVATION. MOREOVER, IT WAS RECENTLY DEMONSTRATED THAT CLASPIN LEVELS ARE CONTROLLED BY PROTEASOMAL DEGRADATION, AND THIS IS REGULATED BY PLK1. IMPORTANTLY, PLK1-MEDIATED PROTEOSOMAL DEGRADATION OF CLASPIN APPEARS TO BE ESSENTIAL FOR CHECK POINT RECOVERY. HERE WE REVIEW THESE RECENT FINDINGS AND DISCUSS THE MECHANISMS OF CHECKPOINT REGULATION BY CLASPIN.","REPLICATION CHECKPOINT RESPONSE; SCF-BETA-TRCP; REPEATED PHOSPHOPEPTIDE MOTIFS; DOUBLE-STRAND BREAK; POLO-LIKE KINASE-1; DNA-DAMAGE; SIGNALING PATHWAYS; CHK1; RECOVERY; PROTEIN","CLASPIN; CHK1; PLK1; DNA DAMAGE CHECKPOINT; CHECKPOINT RECOVERY; MITOSIS; PROTEASOME; BETA-TRCP-SCF; F-BOX PROTEIN; PHOSPHO-DEGRON","CELL CYCLE","FREIRE, R##VAN VUGT, MATM##MAMELY, I##MEDEMA, RH","HOSP UNIV CANARIAS, UNIDAD INVEST, E-38320 TENERIFE, SPAIN. MIT, CANC RES CTR, CAMBRIDGE, MA 02139 USA. UNIV UTRECHT, MED CTR, DEPT MED ONCOL, UTRECHT, NETHERLANDS.","CELL BIOLOGY","CELL BIOLOGY","ALCASABAS AA, 2001, NAT CELL BIOL, V3, P958, DOI 10.1038/NCB1101-958##AMERIK AY, 2004, BBA-MOL CELL RES, V1695, P189, DOI 10.1016/J.BBAMCR.2004.10.003##BARTKOVA J, 2005, NATURE, V434, P864, DOI 10.1038/NATURE03482##BENNETT LN, 2006, FEBS LETT, V580, P4176, DOI 10.1016/J.FEBSLET.2006.06.071##BUSINO L, 2003, NATURE, V426, P87, DOI 10.1038/NATURE02082##CHINI C, 2006, ONCOGENE, V25, P4165, DOI 10.1038/SJ.ONC.1209447##CHINI CCS, 2004, DNA REPAIR, V3, P1033, DOI 10.1016/J.DNAREP.2004.03.001##CHINI CCS, 2006, J BIOL CHEM, V281, P33276, DOI 10.1074/JBC.M604373200##CHOWDHURY D, 2005, MOL CELL, V20, P801, DOI 10.1016/J.MOLCEL.2005.10.003##CHRISTIANO C, 2003, J BIOL CHEM, V278, P30057, DOI 10.1074/JBC.M301136200##CLARKE CAL, 2005, BIOCHEM J, V388, P705, DOI 10.1042/BJ20041966##DEN ELZEN N, 2004, CELL CYCLE, V3, P529##DEN ELZEN NR, 2004, EMBO J, V23, P908, DOI 10.1038/SJ.EMBOJ.7600105##FISCELLA M, 1997, P NATL ACAD SCI USA, V94, P6048, DOI 10.1073/PNAS.94.12.6048##GORGOULIS VG, 2005, NATURE, V434, P907, DOI 10.1038/NATURE03485##JAZAYERI A, 2006, NAT CELL BIOL, V8, P37, DOI 10.1038/NCB1337##KEOGH MC, 2006, NATURE, V439, P497, DOI 10.1038/NATURE04384##KUMAGAI A, 2000, MOL CELL, V6, P839, DOI 10.1016/S1097-2765(00)00082-4##KUMAGAI A, 2003, NAT CELL BIOL, V5, P161, DOI 10.1038/NCB921##LEROY C, 2003, MOL CELL, V11, P827, DOI 10.1016/S1097-2765(03)00058-3##LIU QH, 2000, GENE DEV, V14, P1448##LU XB, 2005, CELL CYCLE, V4, P1060##LU XB, 2005, GENE DEV, V19, P1162, DOI 10.1101/GAD.1291305##MAILAND N, 2006, MOL CELL, V23, P307, DOI 10.1016/J.MOLCEL.2006.06.016##MAMELY I, 2006, CURR BIOL##MANIATIS T, 1999, GENE DEV, V13, P505, DOI 10.1101/GAD.13.5.505##MATSUOKA S, 1998, SCIENCE, V282, P1893, DOI 10.1126/SCIENCE.282.5395.1893##OSBORN AJ, 2003, GENE DEV, V17, P1755, DOI 10.1101/GAD.1098303##PELLICIOLI A, 2001, MOL CELL, V7, P293, DOI 10.1016/S1097-2765(01)00177-0##PESCHIAROLI A, 2006, MOL CELL, V23, P319, DOI 10.1016/J.MOLCEL.2006.06.013##SAR F, 2004, J BIOL CHEM, V279, P39289, DOI 10.1074/JBC.M405793200##SHREERAM S, 2006, MOL CELL, V23, P757, DOI 10.1016/J.MOLCEL.2006.07.010##SMITS VAJ, 2000, NAT CELL BIOL, V2, P672##TANAKA K, 2001, NAT CELL BIOL, V3, P966, DOI 10.1038/NCB1101-966##VAN DE WEERDT BCM, 2006, CELL CYCLE, V5, P853, DOI 10.4161/CC.5.8.2692##VAN VUGT MATM, 2004, CELL CYCLE, V3, P1383, DOI 10.4161/CC.3.11.1248##VAN VUGT MATM, 2005, CANCER RES, V65, P7037, DOI 10.1158/0008-5472.CAN-05-1054##VAN VUGT MATM, 2004, MOL CELL, V15, P799, DOI 10.1016/J.MOLCEL.2004.07.015##WATANABE N, 2004, P NATL ACAD SCI USA, V101, P4419, DOI 10.1073/PNAS.0307700101##YOO HY, 2006, GENE DEV, V20, P772, DOI 10.1101/GAD.1398806##YOO HY, 2004, CELL, V117, P575, DOI 10.1016/S0092-8674(04)00417-9##ZHANG D, 2006, CELL, V126, P529, DOI 10.1016/J.CELL.2006.06.039##ZOU L, 2002, GENE DEV, V16, P198, DOI 10.1101/GAD.950302",33,2020-11-20,NA,"HOSP UNIV CANARIAS#MIT#UNIV UTRECHT","SPAIN#MA USA#NETHERLANDS"
"J","WOS:000242215100011",2006,"NOVEL BINDING PARTNERS OF LDB1 ARE REQUIRED FOR HAEMATOPOIETIC DEVELOPMENT","LDB1, A UBIQUITOUSLY EXPRESSED LIM DOMAIN BINDING PROTEIN, IS ESSENTIAL IN A NUMBER OF TISSUES DURING DEVELOPMENT. IT INTERACTS WITH GATA1, TAL1, E2A AND LMO2 TO FORM A TRANSCRIPTION FACTOR COMPLEX REGULATING LATE ERYTHROID GENES. WE IDENTIFY A NUMBER OF NOVEL LDB1 INTERACTING PROTEINS IN ERYTHROLEUKAEMIC CELLS, IN PARTICULAR THE REPRESSOR PROTEIN ETO-2 (AND ITS FAMILY MEMBER MTGR1), THE CYCLIN-DEPENDENT KINASE CDK9, AND THE BRIDGING FACTOR LMO4. MO-MEDIATED KNOCKDOWNS IN ZEBRAFISH SHOW THESE FACTORS TO BE ESSENTIAL FOR DEFINITIVE HAEMATOPOIESIS. IN ACCORDANCE WITH THE ZEBRAFISH RESULTS THESE FACTORS ARE COEXPRESSED IN PREHAEMATOPOIETIC CELLS OF THE EARLY MOUSE EMBRYO, ALTHOUGH WE ORIGINALLY IDENTIFIED THE COMPLEX IN LATE ERYTHROID CELLS. BASED ON THE CHANGE IN SUBCELLULLAR LOCALISATION OF ETO-2 WE POSTULATE THAT IT PLAYS A CENTRAL ROLE IN THE TRANSITION FROM THE MIGRATION AND EXPANSION PHASE OF THE PREHAEMATOPOIETIC CELLS TO THE ESTABLISHMENT OF DEFINITIVE HAEMATOPOIETIC STEM CELLS.","NEURAL-TUBE CLOSURE; STEM-CELLS; MICE LACKING; YOLK-SAC; ERYTHROID-DIFFERENTIATION; HOMEODOMAIN PROTEINS; ZEBRAFISH EMBRYOS; TRANSGENIC MICE; SMALL-INTESTINE; GLOBIN GENE","LDB1; TRANSCRIPTION FACTOR COMPLEXES; HAEMATOPOIETIC STEM CELLS; HAEMATOPOIESIS","DEVELOPMENT","MEIER, N##KRPIC, S##RODRIGUEZ, P##STROUBOULIS, J##MONTI, M##KRIJGSVELD, J##GERING, M##PATIENT, R##HOSTERT, A##GROSVELD, F","ERASMUS MC, DEPT CELL BIOL & GENET, NL-3000 CA ROTTERDAM, NETHERLANDS. UNIV UTRECHT, DEPT BIOMOL MASS SPECT, BIJVOET CTR BIOMOL RES, NL-3584 CA UTRECHT, NETHERLANDS. UNIV UTRECHT, UTRECHT INST PHARMACEUT SCI, NL-3584 CA UTRECHT, NETHERLANDS. UNIV OXFORD, WEATHERALL INST MOL MED, MRC MOL HAEMATOL UNIT, OXFORD OX3 9DS, ENGLAND.","DEVELOPMENTAL BIOLOGY","DEVELOPMENTAL BIOLOGY","AGULNICK AD, 1996, NATURE, V384, P270, DOI 10.1038/384270A0##AMANN JM, 2005, MOL CELL BIOL, V25, P9576, DOI 10.1128/MCB.25.21.9576-9585.2005##ANGUITA E, 2004, EMBO J, V23, P2841, DOI 10.1038/SJ.EMBOJ.7600274##ANTONIOU M, 1991, METHODS MOL BIOL, V7, P421, DOI 10.1385/0-89603-178-0:421##BAGELLA L, 1998, J CELL PHYSIOL, V177, P206, DOI 10.1002/(SICI)1097-4652(199811)177:2<206::AID-JCP2>3.0.CO;2-R##BETTENCOURT-DIAS M, 2004, NATURE, V432, P980, DOI 10.1038/NATURE03160##BRAND M, 2004, NAT STRUCT MOL BIOL, V11, P73, DOI 10.1038/NSMB713##CANTOR AB, 2001, CURR OPIN GENET DEV, V11, P513, DOI 10.1016/S0959-437X(00)00226-4##CHEN L, 2002, P NATL ACAD SCI USA, V99, P14320, DOI 10.1073/PNAS.212532399##CUMANO A, 2001, IMMUNITY, V15, P477, DOI 10.1016/S1074-7613(01)00190-X##DAVIS JN, 2003, GENE, V303, P1, DOI 10.1016/S0378-1119(02)01172-1##DAVIS JN, 1999, ONCOGENE, V18, P1375, DOI 10.1038/SJ.ONC.1202412##DE BOER E, 2003, P NATL ACAD SCI USA, V100, P7480, DOI 10.1073/PNAS.1332608100##DE BRUIJN MFTR, 2000, EMBO J, V19, P2465, DOI 10.1093/EMBOJ/19.11.2465##DE BRUIJN MFTR, 2002, IMMUNITY, V16, P673, DOI 10.1016/S1074-7613(02)00313-8##DE LA CALLE-MUSTIENES E, 2003, DEV BIOL, V264, P564, DOI 10.1016/J.YDBIO.2003.09.002##DURAND C, 2005, HAEMATOLOGICA, V90, P100##GARRIGA J, 2003, MOL CELL BIOL, V23, P5165, DOI 10.1128/MCB.23.15.5165-5173.2003##GEKAS C, 2005, DEV CELL, V8, P365, DOI 10.1016/J.DEVCEL.2004.12.016##GELMETTI V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185##GERING M, 2005, DEV CELL, V8, P389, DOI 10.1016/J.DEVCEL.2005.01.010##GIRAUD S, 2004, ONCOGENE, V23, P7391, DOI 10.1038/SJ.ONC.1207972##GOARDON N, 2006, EMBO J, V25, P357, DOI 10.1038/SJ.EMBOJ.7600934##GRANA X, 1994, P NATL ACAD SCI USA, V91, P3834, DOI 10.1073/PNAS.91.9.3834##GUYOT B, 2004, BLOOD, V104, P89, DOI 10.1182/BLOOD-2004-01-0108##HAHM KM, 2004, MOL CELL BIOL, V24, P2074, DOI 10.1128/MCB.24.5.2074-2082.2004##JOWETT T, 1996, TRENDS GENET, V12, P387, DOI 10.1016/S0168-9525(96)90091-8##KALEV-ZYLINSKA ML, 2002, DEVELOPMENT, V129, P2015##KENNY DA, 1998, P NATL ACAD SCI USA, V95, P11257, DOI 10.1073/PNAS.95.19.11257##KORINEK V, 1998, NAT GENET, V19, P379##LAHLIL R, 2004, MOL CELL BIOL, V24, P1439, DOI 10.1128/MCB.24.4.1439-1452.2004##LANE MARY ELLEN, 2002, GENE EXPRESSION PATTERNS, V2, P207, DOI 10.1016/S1567-133X(02)00061-3##LEE SK, 2005, MOL CELL NEUROSCI, V28, P205, DOI 10.1016/J.MCN.2004.04.010##LIU HB, 2005, J CELL PHYSIOL, V203, P251, DOI 10.1002/JCP.20224##LUTTERBACH B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176##MARSHALL NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/JBC.271.43.27176##MCDEVITT MA, 1997, P NATL ACAD SCI USA, V94, P7976, DOI 10.1073/PNAS.94.15.7976##MEDVINSKY A, 1996, CELL, V86, P897, DOI 10.1016/S0092-8674(00)80165-8##MORCILLO P, 1997, GENE DEV, V11, P2729, DOI 10.1101/GAD.11.20.2729##MUKHOPADHYAY M, 2003, DEVELOPMENT, V130, P495, DOI 10.1242/DEV.00225##NASEVICIUS A, 2000, NAT GENET, V26, P216, DOI 10.1038/79951##NISHIOKA N, 2005, DEVELOPMENT, V132, P2535, DOI 10.1242/DEV.01844##ONODERA K, 1997, P NATL ACAD SCI USA, V94, P4487, DOI 10.1073/PNAS.94.9.4487##OTTERSBACH K, 2005, DEV CELL, V8, P377, DOI 10.1016/J.DEVCEL.2005.02.001##PALSTRA RJ, 2003, NAT GENET, V35, P190, DOI 10.1038/NG1244##PATRINOS GP, 2004, GENE DEV, V18, P1495, DOI 10.1101/GAD.289704##QUINKERTZ A, 1999, DEV GENES EVOL, V209, P126, DOI 10.1007/S004270050235##RAMAIN P, 2000, MOL CELL, V6, P781, DOI 10.1016/S1097-2765(00)00077-0##ROBB L, 1995, P NATL ACAD SCI USA, V92, P7075, DOI 10.1073/PNAS.92.15.7075##RODRIGUEZ P, 2005, EMBO J, V24, P2354, DOI 10.1038/SJ.EMBOJ.7600702##SCHUH AH, 2005, MOL CELL BIOL, V25, P10235, DOI 10.1128/MCB.25.23.10235-10250.2005##SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432A0##SHORE SM, 2003, GENE, V307, P175, DOI 10.1016/S0378-1119(03)00466-9##TOLHUIS B, 2002, MOL CELL, V10, P1453, DOI 10.1016/S1097-2765(02)00781-5##TORIGOI E, 2000, P NATL ACAD SCI USA, V97, P2686, DOI 10.1073/PNAS.050586397##TSE E, 2004, MOL CELL BIOL, V24, P2063, DOI 10.1128/MCB.24.5.2063-2073.2004##VAN MEYEL DJ, 2003, DEVELOPMENT, V130, P1915, DOI 10.1242/DEV.00389##WADMAN IA, 1997, EMBO J, V16, P3145, DOI 10.1093/EMBOJ/16.11.3145##WANG L, 1998, EUR T ELECTR POWER, V8, P21##WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1##WESTERFIELD M., 1993, ZEBRAFISH BOOK GUIDE##WHYATT DAVID J., 1997, GENES AND FUNCTION, V1, P11##YODER MC, 1997, IMMUNITY, V7, P335, DOI 10.1016/S1074-7613(00)80355-6##ZHU YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/GAD.11.20.2622##ZHUANG Y, 1996, MOL CELL BIOL, V16, P2898",106,2020-11-20,"MEDICAL RESEARCH COUNCILMEDICAL RESEARCH COUNCIL UK (MRC) [MC_U137981013] FUNDING SOURCE: MEDLINE","ERASMUS MC#UNIV UTRECHT#UNIV UTRECHT#UNIV OXFORD","NETHERLANDS#NETHERLANDS#NETHERLANDS#ENGLAND"
"J","WOS:000243230900020",2006,"AUTOCORRELATED GROWTH OF TROPICAL FOREST TREES: UNRAVELING PATTERNS AND QUANTIFYING CONSEQUENCES","TROPICAL TREES SHOW CONSIDERABLE VARIATION IN GROWTH RATES. OFTEN THIS VARIATION IS NOT RANDOM, AS SOME TREES PERFORM BETTER THAN OTHERS AND AS GROWTH MAY BE TEMPORALLY CORRELATED. USING LONG-TERM GROWTH DATA OBTAINED FROM TREE RING ANALYSIS, WE STUDIED THE DEGREE TO WHICH GROWTH RATES OF FOUR BOLIVIAN RAINFOREST TREE SPECIES WERE AUTOCORRELATED AND HOW THIS AFFECTED THE OUTPUT OF GROWTH SIMULATIONS. AUTOCORRELATED GROWTH IS COMMONLY DEFINED AS THE CORRELATION BETWEEN GROWTH IN ONE TIME INTERVAL WITH THAT IN A SUBSEQUENT INTERVAL CALCULATED OVER ALL INDIVIDUALS OF THE POPULATION. WE TERMED THIS TOTAL AUTOCORRELATED GROWTH AND IDENTIFIED ITS TWO COMPONENTS: TEMPORALLY COT-RELATED GROWTH RATES OF INDIVIDUAL TREES (WITHIN-TREE AUTOCORRELATED GROWTH) AND PERSISTENT GROWTH DIFFERENCES BETWEEN TREES (AMONG-TREE AUTOCORRELATED GROWTH). TOTAL AUTOCORRELATED GROWTH WAS HIGH (PEARSON'S R SIMILAR TO 0.75) BETWEEN GROWTH RATES OF SUBSEQUENT YEARS AND DECREASED GRADUALLY AT LARGER TIME LAGS. AT TIME LAGS OF 20 YEARS GROWTH RATES WERE STILL POSITIVELY AUTOCORRELATED IN SOME SPECIES. JUVENILE TREES TEND TO HAVE STRONG WITHIN-TREE AUTOCORRELATED GROWTH (PEARSON'S R SIMILAR TO 0.4-0.5), PROBABLY MAINLY CAUSED BY TEMPORALLY CORRELATED VARIATION IN LIGHT AVAILABILITY DUE TO CANOPY DYNAMICS. THE WITHIN-TREE AUTOCORRELATION WAS CONSIDERABLY LOWER IN LARGER TREES (PEARSON'S R < 0.2), AND DID - IN CONTRAST TO JUVENILE TREES - NOT CONTRIBUTE MUCH TO TOTAL AUTOCORRELATION. IN LARGER TREES TOTAL AUTOCORRELATION ORIGINATED MOSTLY FROM PERSISTENT GROWTH DIFFERENCES AMONG TREES, CAUSED BY FACTORS AS SITE-SPECIFIC DIFFERENCES OR DIFFERENCES AMONG TREES IN CROWN AREA OR LIANA INFESTATIONS. AMONG-TREE AUTOCORRELATED GROWTH WAS STRONG AND LONG-LASTING: DIFFERENCES BETWEEN FAST AND SLOW GROWING TREES WERE MAINTAINED FOR LONG PERIODS. INCORPORATION OF AUTOCORRELATED GROWTH IN BOOTSTRAP SIMULATION MODELS LED TO HIGHER VARIATION IN AGE ESTIMATES COMPARED TO SIMULATIONS WITHOUT AUTOCORRELATION. STILL, THIS VARIATION WAS LOWER THAN THAT OBSERVED IN TREE RINGS. BY USING 5-YEAR GROWTH STEPS INSTEAD OF THE I-YEAR GROWTH STEPS THE OBSERVED VARIATION INCREASED AND CLOSELY MATCHED THOSE IN TREE RINGS. OUR FINDINGS EMPHASIZE THE IMPORTANCE OF INCORPORATING AUTOCORRELATED GROWTH IN TREE GROWTH SIMULATION MODELS, FOR OBTAINING MORE REALISTIC ESTIMATES OF LONG-TERM GROWTH AND TREE AGES. (C) 2006 ELSEVIER B.V. ALL RIGHTS RESERVED.","NEOTROPICAL RAIN-FOREST; TIME-SERIES ANALYSES; POPULATION-DYNAMICS; RING ANALYSIS; CANOPY; HISTORY; RECRUITMENT; STORAGE; HEIGHT; CURVES","BOOTSTRAPPED SIMULATIONS; SIZE-DEPENDENT GROWTH; SIZE VARIABILITY; TREE AGE; TEMPORAL AUTOCORRELATION","FOREST ECOLOGY AND MANAGEMENT","BRIENEN, RJW##ZUIDEMA, PA##DURING, HJ","UNIV UTRECHT, DEPT PLANT ECOL, NL-3508 TB UTRECHT, NETHERLANDS. PROGRAMA MANEJO BOSQUES AMAZONIA BOLIVIANA, PROMAB, RIBERALTA, BOLIVIA.","FORESTRY","FORESTRY","ARETS EJM, 2005, TROPENBOS GUYANA SER, V13, P191##BOX G. E. P., 1976, TIME SERIES ANAL##BRIENEN RJW, 2006, J ECOL, V94, P481, DOI 10.1111/J.1365-2745.2005.01080.X##BRIENEN RJW, 2005, OECOLOGIA, V146, P1, DOI 10.1007/S00442-005-0160-Y##BULLOCK SH, 2004, ECOLOGY, V85, P2114, DOI 10.1890/03-3115##CANHAM CD, 1985, B TORREY BOT CLUB, V112, P145##CASPER BB, 1997, ANNU REV ECOL SYST, V28, P545, DOI 10.1146/ANNUREV.ECOLSYS.28.1.545##CHAPIN FS, 1990, ANNU REV ECOL SYST, V21, P423, DOI 10.1146/ANNUREV.ECOLSYS.21.1.423##CLARK DA, 2001, ECOLOGY, V82, P1460, DOI 10.1890/0012-9658(2001)082[1460:GTTCTH]2.0.CO;2##CLARK DA, 1999, ECOL APPL, V9, P981, DOI 10.1890/1051-0761(1999)009[0981:ATGOTR]2.0.CO;2##CLARK DA, 1992, ECOL MONOGR, V62, P315, DOI 10.2307/2937114##CLARK DB, 1990, J TROP ECOL, V6, P321, DOI 10.1017/S0266467400004570##CONDIT R, 1993, FOREST ECOL MANAG, V62, P123, DOI 10.1016/0378-1127(93)90046-P##CONDIT R, 1995, ECOL MONOGR, V65, P419, DOI 10.2307/2963497##DEANGELIS DL, 1993, AM NAT, V142, P604, DOI 10.1086/285560##FOX JC, 2001, FOREST ECOL MANAG, V154, P261, DOI 10.1016/S0378-1127(00)00632-0##FRITTS H.C., 1976, TREE RINGS CLIMATE##FUJIWARA M, 2004, ECOL LETT, V7, P106, DOI 10.1046/J.1461-0248.2003.00556.X##KAMMESHEIDT L, 2003, FOREST ECOL MANAG, V174, P437, DOI 10.1016/S0378-1127(02)00077-4##KOBE RK, 1997, OIKOS, V80, P226, DOI 10.2307/3546590##KOHYAMA T, 1989, ANN BOT-LONDON, V64, P47, DOI 10.1093/OXFORDJOURNALS.AOB.A087807##KOHYAMA T, 2005, ECOL RES, V20, P11, DOI 10.1007/S11284-004-0007-8##LANDIS RM, 2005, ECOLOGY, V86, P63, DOI 10.1890/03-0848##LANDIS RM, 1999, THESIS DARTMOUTH COL, P111##LAURANCE WF, 2004, FOREST ECOL MANAG, V190, P131, DOI 10.1016/J.FORECO.2003.09.011##LIEBERMAN D, 1985, J ECOL, V73, P915, DOI 10.2307/2260157##LIEBERMAN M, 1985, ECOLOGY, V66, P632, DOI 10.2307/1940415##LUSK CH, 1998, ECOLOGY, V79, P795, DOI 10.1890/0012-9658(1998)079[0795:LHDATS]2.0.CO;2##MONSERUD RA, 1986, FOREST SCI, V32, P349##OBRIEN ST, 1995, ECOLOGY, V76, P1926, DOI 10.2307/1940724##ORWIG DA, 1994, CAN J FOREST RES, V24, P2141, DOI 10.1139/X94-276##PACIOREK CJ, 2000, J ECOL, V88, P765, DOI 10.1046/J.1365-2745.2000.00494.X##PFISTER CA, 2003, ECOLOGY, V84, P496, DOI 10.1890/0012-9658(2003)084[0496:IVAESI]2.0.CO;2##PFISTER CA, 2002, ECOLOGY, V83, P59##PUTZ FE, 1984, ECOLOGY, V65, P1713, DOI 10.2307/1937767##SHEIL D, 1995, FOREST ECOL MANAG, V77, P11, DOI 10.1016/0378-1127(95)03583-V##SWAINE MD, 1987, J TROP ECOL, V3, P331, DOI 10.1017/S0266467400002315##SWAINE MD, 1988, VEGETATIO, V75, P81, DOI 10.1007/BF00044629##TERBORGH J., 1997, JOURNAL OF TROPICAL ECOLOGY, V13, P833, DOI 10.1017/S0266467400011020##VANDERMEER PJ, 1996, VEGETATIO, V126, P167, DOI 10.1007/BF00045602##WOOLLONS RC, 1990, NEW ZEAL J ECOL, V13, P9##ZAGT R. J., 1997, TREE DEMOGRAPHY IN THE TROPICAL RAIN FOREST OF GUYANA.##ZUIDEMA PA, 2002, J TROP ECOL, V18, P1, DOI 10.1017/S0266467402002018##1999, SUPERINTENDENCIA FOR",56,2020-11-20,NA,"UNIV UTRECHT#PROGRAMA MANEJO BOSQUES AMAZONIA BOLIVIANA","NETHERLANDS#BOLIVIA"
"J","WOS:000242307800039",2006,"HELICOBACTER PYLORI INFECTION APPEARS THE PRIME RISK FACTOR FOR STOMACH CANCER - REPLY TO THE LETTER TO THE EDITOR",NA,"GASTRIC-CANCER",NA,"INTERNATIONAL JOURNAL OF CANCER","GONZALEZ, CA##PERA, G##AGUDO, A##PALLI, D##LINSEISEN, J##BOEING, H##JENAB, M##BUENO-DE-MESQUITA, HB##NUMANS, ME##RIBOLI, E","IDIBELL, CATALAN INST ONCOL, DEPT EPIDEMIOL, BARCELONA, SPAIN. CSPO, SCI INST TUSCANY, MOL & NUTRIT EPIDEMIOL UNIT, FLORENCE, ITALY. DEUTSCH KREBSFORSCHUNGSZENTRUM, DIV CLIN EPIDEMIOL, D-6900 HEIDELBERG, GERMANY. GERMAN INST HUMAN NUTR, POTSDAM, GERMANY. INT AGCY RES CANC, NUTR & HORMONES GRP, F-69372 LYON, FRANCE. NATL INST PUBL HLTH & ENVIRONM, CTR NUTR & HLTH, NL-3720 BA BILTHOVEN, NETHERLANDS. UNIV UTRECHT, CTR MED, JULIUS CTR HLTH SCI & PRIMARY CARE, UTRECHT, NETHERLANDS. UNIV LONDON IMPERIAL COLL SCI & TECHNOL, FAC MED, DEPT EPIDEMIOL & PUBL HLTH, LONDON, ENGLAND.","ONCOLOGY","ONCOLOGY","BLASER MJ, 2000, NAT MED, V6, P376, DOI 10.1038/74627##CORREA P, 1994, CANCER RES, V54, PS1941##GONZALEZ CA, 2003, INT J CANCER, V107, P629, DOI 10.1002/IJC.11426##GONZALEZ CA, 2006, JNCI-J NATL CANCER I, V98, P345, DOI 10.1093/JNCI/DJJ071##PARKIN DM, 2006, INT J CANCER, V118, P3030, DOI 10.1002/IJC.21731##WONG BCY, 2004, JAMA-J AM MED ASSOC, V291, P187, DOI 10.1001/JAMA.291.2.187",0,2020-11-20,NA,"IDIBELL#CSPO#DEUTSCH KREBSFORSCHUNGSZENTRUM#GERMAN INST HUMAN NUTR#INT AGCY RES CANC#NATL INST PUBL HLTH ENVIRONM#UNIV UTRECHT#UNIV LONDON IMPERIAL COLL SCI TECHNOL","SPAIN#ITALY#GERMANY#GERMANY#FRANCE#NETHERLANDS#NETHERLANDS#ENGLAND"
"J","WOS:000242797700025",2006,"AGREEMENT BETWEEN COMPUTED TOMOGRAPHY, MAGNETIC RESONANCE IMAGING, AND SURGICAL FINDINGS IN DOGS WITH DEGENERATIVE LUMBOSACRAL STENOSIS","OBJECTIVE-TO ASSESS THE EXTENT OF AGREEMENT BETWEEN COMPUTED TOMOGRAPHY (CT), MAGNETIC RESONANCE IMAGING (MRI), AND SURGICAL FINDINGS IN DOGS WITH DEGENERATIVE LUMBOSACRAL STENOSIS. DESIGN-OBSERVATIONAL STUDY. ANIMALS-35 DOGS WITH DEGENERATIVE LUMBOSACRAL STENOSIS. PROCEDURES-RESULTS OF PREOPERATIVE CT AND MRI WERE COMPARED WITH SURGICAL FINDINGS WITH RESPECT TO DEGREE AND LOCATION OF DISK PROTRUSION, POSITION OF THE DURAL SAC, AMOUNT OF EPIDURAL FAT, AND SWELLING OF SPINAL NERVE ROOTS. RESULTS-A LUMBOSACRAL STEP WAS SEEN ON RADIOGRAPHIC IMAGES FROM 22 OF 32 (69%) DOGS, ON CT IMAGES FROM 23 OF 35 (66%) DOGS, AND ON MR IMAGES FROM 21 OF 35 (60%) DOGS. MOST DOGS HAD SLIGHT OR MODERATE DISK PROTRUSION THAT WAS CENTRALLY LOCATED. THERE WAS SUBSTANTIAL OR NEAR PERFECT AGREEMENT BETWEEN CT AND MRI FINDINGS IN REGARD TO DEGREE OF DISK PROTRUSION (KAPPA, 0.88), LOCATION OF DISK PROTRUSION (0.63), POSITION OF THE DURAL SAC (0.89), AMOUNT OF EPIDURAL FAT (0.72), AND SWELLING OF SPINAL NERVE ROOTS (0.60). THE DEGREE OF AGREEMENT BETWEEN CT AND SURGICAL FINDINGS AND BETWEEN MRI AND SURGICAL FINDINGS WAS MODERATE IN REGARD TO DEGREE AND LOCATION OF DISK PROTRUSION (KAPPA, 0.44 TO 0.56) AND SWELLING OF SPINAL NERVE ROOTS (0.40 AND 0.50). CONCLUSIONS AND CLINICAL RELEVANCE-RESULTS INDICATE THAT THERE IS A HIGH DEGREE OF AGREEMENT BETWEEN CT AND MRI FINDINGS IN DOGS WITH DEGENERATIVE LUMBOSACRAL STENOSIS BUT THAT THE DEGREE OF AGREEMENT BETWEEN DIAGNOSTIC IMAGING FINDINGS AND SURGICAL FINDINGS IS LOWER.","CAUDA-EQUINA SYNDROME; LARGE-BREED DOGS; RADIOGRAPHIC EVALUATION; INTERVERTEBRAL DISC; VACUUM PHENOMENON; SPINE; DIAGNOSIS; LUMBAR; ABNORMALITIES; ASSOCIATION",NA,"JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION","SUWANKONG, N##VOORHOUT, G##HAZEWINKEL, HAW##MEIJ, BP","CHIANG MAI UNIV, FAC VET MED, SMALL ANIM CLIN, CHIANG MAI 50100, THAILAND. UNIV UTRECHT, FAC VET MED, DEPT CLIN SCI COMPAN ANIM, NL-3508 TD UTRECHT, NETHERLANDS. UNIV UTRECHT, FAC VET MED, DIV DIAGNOST IMAGING, NL-3508 TD UTRECHT, NETHERLANDS.","VETERINARY SCIENCES","VETERINARY SCIENCES","ADAMS WH, 1995, VET RADIOL ULTRASOUN, V36, P3, DOI 10.1111/J.1740-8261.1995.TB00204.X##AXLUND TW, 2003, VET RADIOL ULTRASOUN, V44, P630, DOI 10.1111/J.1740-8261.2003.TB00521.X##BENNETT D, 1981, J SMALL ANIM PRACT, V22, P539, DOI 10.1111/J.1748-5827.1981.TB00640.X##BRAY JP, 1998, J AM ANIM HOSP ASSOC, V34, P135, DOI 10.5326/15473317-34-2-135##CHAMBERS JN, 1997, J AM ANIM HOSP ASSOC, V33, P296, DOI 10.5326/15473317-33-4-296##DANIELSSON F, 1999, VET SURG, V28, P91, DOI 10.1053/JVET.1999.0091##DAVIDSON A.P., 2000, HEREDITARY BONE JOIN, P209##DE RISIO L, 2000, VET CLIN N AM-SMALL, V30, P111, DOI 10.1016/S0195-5616(00)50005-9##DEHAAN JJ, 1993, VET SURG, V22, P1, DOI 10.1111/J.1532-950X.1993.TB00359.X##DOHOO I., 2003, VET EPIDEMIOLOGIC RE, P85##HATHCOCK JT, 1994, VET RADIOL ULTRASOUN, V35, P285, DOI 10.1111/J.1740-8261.1994.TB02043.X##INDRIERI RJ, 1988, VET CLIN N AM-SMALL, V18, P697, DOI 10.1016/S0195-5616(88)50062-1##JONES JC, 1994, VET RADIOL ULTRASOUN, V35, P339, DOI 10.1111/J.1740-8261.1994.TB02051.X##JONES JC, 1999, VET RADIOL ULTRASOUN, V40, P108, DOI 10.1111/J.1740-8261.1999.TB01892.X##JONES JC, 1996, VET RADIOL ULTRASOUN, V37, P247, DOI 10.1111/J.1740-8261.1996.TB01226.X##JONES JC, 1995, AM J VET RES, V56, P1125##JONES JC, 1995, VET RADIOL ULTRASOUN, V36, P91, DOI 10.1111/J.1740-8261.1995.TB00223.X##JONES JC, 2000, J AM VET MED ASSOC, V216, P1769, DOI 10.2460/JAVMA.2000.216.1769##JONES JC, 2000, VET RADIOL ULTRASOUN, V41, P19, DOI 10.1111/J.1740-8261.2000.TB00421.X##KARKKAINEN M, 1993, VET RADIOL ULTRASOUN, V34, P399, DOI 10.1111/J.1740-8261.1993.TB02028.X##MATTOON JS, 1993, VET RADIOL ULTRASOUN, V34, P194, DOI 10.1111/J.1740-8261.1993.TB02005.X##MAYHEW PD, 2002, J AM ANIM HOSP ASSOC, V38, P555, DOI 10.5326/0380555##MORGAN JP, 1993, J AM VET MED ASSOC, V202, P1877##MORGAN JP, 1999, J SMALL ANIM PRACT, V40, P167, DOI 10.1111/J.1748-5827.1999.TB03784.X##MORGAN JP, 1990, J SMALL ANIM PRACT, V31, P69, DOI 10.1111/J.1748-5827.1990.TB00724.X##NESS MG, 1994, J SMALL ANIM PRACT, V35, P185, DOI 10.1111/J.1748-5827.1994.TB01683.X##QUIST JJ, 1998, J BONE JOINT SURG BR, V80B, P520, DOI 10.1302/0301-620X.80B3.8010##RAMIREZ O, 1998, VET RADIOL ULTRASOUN, V39, P283, DOI 10.1111/J.1740-8261.1998.TB01608.X##SCHMID V, 1993, J SMALL ANIM PRACT, V34, P437, DOI 10.1111/J.1748-5827.1993.TB03897.X##SCHWARZ T, 2000, J AM VET MED ASSOC, V217, P862, DOI 10.2460/JAVMA.2000.217.862##SEILER G, 2003, VET RADIOL ULTRASOUN, V44, P179, DOI 10.1111/J.1740-8261.2003.TB01268.X##SISSON AF, 1992, J VET INTERN MED, V6, P253, DOI 10.1111/J.1939-1676.1992.TB00349.X##STIKEL RL, 1993, VET CLIN N AM-SMALL, V23, P417##TAGA A, 1998, J VET MED SCI, V60, P1345, DOI 10.1292/JVMS.60.1345##TARVIN G, 1980, J AM VET MED ASSOC, V177, P154##TERTTI M, 1991, SPINE, V16, P629, DOI 10.1097/00007632-199106000-00006##WATT PR, 1991, J SMALL ANIM PRACT, V32, P125, DOI 10.1111/J.1748-5827.1991.TB00527.X##WEBER WJ, 1995, VET RADIOL ULTRASOUN, V36, P493, DOI 10.1111/J.1740-8261.1995.TB00301.X##WHEELER SJ, 1992, VET CLIN N AM-SMALL, V22, P937, DOI 10.1016/S0195-5616(92)50085-7",43,2020-11-20,NA,"CHIANG MAI UNIV#UNIV UTRECHT#UNIV UTRECHT","THAILAND#NETHERLANDS#NETHERLANDS"
"J","WOS:000242947300003",2006,"ORIGIN AND MECHANICAL SIGNIFICANCE OF FOLIATED CATACLASTIC ROCKS IN THE CORES OF CRUSTAL-SCALE FAULTS: EXAMPLES FROM THE MEDIAN TECTONIC LINE, JAPAN","THE MEDIAN TECTONIC LINE (MTL) IS JAPAN'S LARGEST ONSHORE FAULT AND HAS BEEN ACTIVE SINCE THE MID-CRETACEOUS. FOLIATED CATACLASTIC FAULT ROCKS ARE EXCEPTIONALLY WELL EXPOSED IN THE FAULT CORE AT ANKO, NAGANO PREFECTURE. FOLLOWING AN EARLY PHASE OF MYLONITIZATION AND EXHUMATION DURING LEFT-LATERAL SHEARING, BRITTLE FRACTURE AND CATACLASIS OCCURRED LEADING TO THE DEVELOPMENT OF CENTIMETER- TO SUBMILLIMETER-SPACED, FAULT ZONE PARALLEL FRACTURE SYSTEMS. THESE FRACTURE SYSTEMS ESTABLISHED AN INITIAL ARCHITECTURAL HIERARCHY THAT INFLUENCED THE SUBSEQUENT DEVELOPMENT OF FOLIATED CATACLASITES AND GOUGE. INITIALLY, FRACTURE SYSTEMS COALESCED TO FORM INTERCONNECTED ZONES OF FINE-GRAINED ULTRACATACLASITE. FLUID INFLUX AT THE ONSET OF GRAIN-SCALE BRITTLE DEFORMATION LED TO PRECIPITATION OF FIBROUS CHLORITE WITHIN THE ULTRACATACLASITES, ULTIMATELY LEADING TO THE DEVELOPMENT OF AN INTERCONNECTED NETWORK OF FOLIATED, PHYLLOSILICATE-RICH CATACLASITES AND GOUGES IN THE CORE OF THE MTL. THE BRITTLE REDUCTION OF GRAIN SIZE AND INGRESS OF A CHEMICALLY ACTIVE FLUID PHASE SIMULTANEOUSLY PROMOTED REACTION SOFTENING AND DIFFUSIVE MASS TRANSFER IN THE FOLIATED ULTRACATACLASITES, LEADING TO RATE-DEPENDENT """"FRICTIONAL-VISCOUS"""" FLOW AT SUB-BYERLEE FRICTION VALUES. ASSOCIATED WEAKENING IS INDICATED BY THE PREFERENTIAL LOCALIZATION OF DEFORMATION WITHIN THE ULTRACATACLASITES. A PROTRACTED SEQUENCE OF CARBONATE MINERALIZATION AND CEMENTATION EVENTS IS ALSO RECOGNIZED DURING THE FAULT ROCK EVOLUTION AND SUGGESTS EPISODIC PERIODS OF FLUID OVERPRESSURING. A CRUSTAL-SCALE FAULT ZONE MODEL IS PROPOSED, SUGGESTING THAT THE FOLIATED CATACLASITES/GOUGES ARE WEAK IN THE LONG TERM AND REPRESENT SHALLOWER CRUSTAL EQUIVALENTS OF PHYLLONITIC FAULT ROCKS EXPOSED IN MORE DEEPLY EXHUMED FAULT ZONES, INCLUDING OTHER PARTS OF THE MTL.","BRITTLE-DUCTILE TRANSITION; FRICTIONAL-VISCOUS FLOW; GOUGE-BEARING FAULTS; EXPERIMENTAL DEFORMATION; WEAKENING MECHANISMS; INTERNAL STRUCTURE; PRESSURE SOLUTION; SOUTHWEST JAPAN; ZONE; SLIP",NA,"JOURNAL OF GEOPHYSICAL RESEARCH-SOLID EARTH","JEFFERIES, SP##HOLDSWORTH, RE##SHIMAMOTO, T##TAKAGI, H##LLOYD, GE##SPIERS, CJ","UNIV DURHAM, DEPT EARTH SCI, REACTIVAT RES GRP, DURHAM DH1 3LE, ENGLAND. KYOTO UNIV, GRAD SCH SCI, DEPT GEOL & MINERAL, KYOTO 6068501, JAPAN. WASEDA UNIV, DEPT EARTH SCI, SHINJUKU KU, TOKYO 1698050, JAPAN. UNIV LEEDS, DEPT EARTH SCI, LEEDS LS2 9JT, W YORKSHIRE, ENGLAND. UNIV UTRECHT, DEPT EARTH SCI, HPT LAB, NL-3508 TA UTRECHT, NETHERLANDS.","GEOCHEMISTRY & GEOPHYSICS","GEOCHEMISTRY & GEOPHYSICS","BEELER NM, 1996, J GEOPHYS RES-SOL EA, V101, P8697, DOI 10.1029/96JB00411##BOS B, 2002, J GEOPHYS RES-SOL EA, V107, DOI 10.1029/2001JB000301##BOS B, 2000, TECTONOPHYSICS, V327, P173, DOI 10.1016/S0040-1951(00)00168-2##BOS B, 2000, EARTH PLANET SC LETT, V184, P199, DOI 10.1016/S0012-821X(00)00304-6##BOS B, 2000, J GEOPHYS RES-SOL EA, V105, P16699, DOI 10.1029/2000JB900089##CHESTER FM, 1986, PURE APPL GEOPHYS, V124, P79, DOI 10.1007/BF00875720##CHESTER FM, 1985, TECTONOPHYSICS, V111, P139, DOI 10.1016/0040-1951(85)90071-X##CHESTER FM, 1995, J GEOPHYS RES-SOL EA, V100, P13033, DOI 10.1029/95JB00313##CHESTER FM, 1993, J GEOPHYS RES-SOL EA, V98, P771, DOI 10.1029/92JB01866##COLLETTINI C, 2004, J GEOL SOC LONDON, V161, P1039, DOI 10.1144/0016-764903-179##DIETERICH JH, 1979, J GEOPHYS RES, V84, P2162, DOI DOI 10.1029/JB084IB05P02151##EVANS JP, 1995, J GEOPHYS RES-SOL EA, V100, P13007, DOI 10.1029/94JB02625##GUEYDAN F, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2001JB000611##HANDY MR, 1990, J GEOPHYS RES-SOLID, V95, P8647, DOI 10.1029/JB095IB06P08647##HANDY MR, 1994, J STRUCT GEOL, V16, P287, DOI 10.1016/0191-8141(94)90035-3##HARA I, 1980, MEM GEOL SOC JPN, V18, P27##HAYAMA Y, 1980, MEM GEOL SOC JPN, V18, P5##HAYAMA Y, 1963, EARTH SCI, V66, P23##HOLDSWORTH RE, 2004, SCIENCE, V303, P181, DOI 10.1126/SCIENCE.1092491##HOLDSWORTH RE, 2001, GEOL SOC SPEC PUBL, V184, P115, DOI 10.1144/GSL.SP.2001.184.01.07##ICHIKAWA K., 1980, MEMOIRS GEOL SOC JAP, V18, P187##IMBER J, 2001, TECTONICS, V20, P601, DOI 10.1029/2000TC001250##ITO M, 1978, MTL, V3, P99##JEFFERIES SP, 2006, J STRUCT GEOL, V28, P220, DOI 10.1016/J.JSG.2005.10.008##LUAN FC, 1992, J GEOPHYS RES-SOL EA, V97, P301, DOI 10.1029/91JB01748##MARES VM, 1993, J STRUCT GEOL, V15, P1061, DOI 10.1016/0191-8141(93)90156-5##MARIANI E, 2006, J STRUCT GEOL, V28, P1569, DOI 10.1016/J.JSG.2006.06.009##NIEMEIJER AR, 2005, GEOL SOC SPEC PUBL, V245, P303, DOI 10.1144/GSL.SP.2005.245.01.15##OHTOMO Y., 1993, J SCI HIROSHIMA U C, V9, P611##OKADA A, 1980, MEM GEOL SOC JPN, V18, P79##SCHMID S.M., 1991, CONTROVERSIES MODERN, P339##SIBSON RH, 1977, J GEOL SOC LONDON, V133, P191, DOI [10.1144/GSJGS.133.3.0191, DOI 10.1144/GSJGS.133.3.0191]##SNOKE A. W., 1998, FAULT RELATED ROCKS##STEWART M, 2000, J STRUCT GEOL, V22, P543, DOI 10.1016/S0191-8141(99)00164-9##SUZUKI K, 1998, J METAMORPH GEOL, V16, P23, DOI 10.1111/J.1525-1314.1998.00057.X##TAKAGI H, 1986, J STRUCT GEOL, V8, P3, DOI 10.1016/0191-8141(86)90013-1##TAKAGI H., 1992, J GEOLOGICAL SOC JAP, V98, P1069##TAKAGI H., 1984, J GEOL SOC JPN, V90, P81##TANAKA H, 1996, J TECTONIC RES GROUP, V41, P31##WIBBERLEY CAJ, 2005, GEOL SOC SPEC PUBL, V245, P347, DOI 10.1144/GSL.SP.2005.245.01.17##WIBBERLEY CAJ, 2003, J STRUCT GEOL, V25, P59, DOI 10.1016/S0191-8141(02)00014-7##WINTSCH RP, 1995, J GEOPHYS RES-SOL EA, V100, P13021, DOI 10.1029/94JB02622##YAMAMOTO H, 1994, J STRUCT GEOL, V16, P61, DOI 10.1016/0191-8141(94)90018-3##YUNG RA, 1990, J GEOPHYS RES-SOLID, V95, P15589, DOI 10.1029/JB095IB10P15589",48,2020-11-20,"GRANTS-IN-AID FOR SCIENTIFIC RESEARCHMINISTRY OF EDUCATION, CULTURE, SPORTS, SCIENCE AND TECHNOLOGY, JAPAN (MEXT)JAPAN SOCIETY FOR THE PROMOTION OF SCIENCEGRANTS-IN-AID FOR SCIENTIFIC RESEARCH (KAKENHI) [17654097] FUNDING SOURCE: KAKEN","UNIV DURHAM#KYOTO UNIV#WASEDA UNIV#UNIV LEEDS#UNIV UTRECHT","ENGLAND#JAPAN#JAPAN#ENGLAND#NETHERLANDS"
"J","WOS:000242888700037",2006,"DROP FORMATION BY THERMAL FLUCTUATIONS AT AN ULTRALOW SURFACE TENSION","WE PRESENT EXPERIMENTAL EVIDENCE THAT DROP BREAKUP IS CAUSED BY THERMAL NOISE IN A SYSTEM WITH A SURFACE TENSION THAT IS MORE THAN 10(6) TIMES SMALLER THAN THAT OF WATER. WE OBSERVE THAT AT VERY SMALL SCALES CLASSICAL HYDRODYNAMICS BREAKS DOWN AND THE CHARACTERISTIC SIGNATURES OF PINCH-OFF DUE TO THERMAL NOISE ARE OBSERVED. SURPRISINGLY, THE NOISE MAKES THE DROP SIZE DISTRIBUTION MORE UNIFORM, BY SUPPRESSING THE FORMATION OF SATELLITE DROPLETS OF THE SMALLEST SIZES. THE CROSSOVER BETWEEN DETERMINISTIC HYDRODYNAMIC MOTION AND STOCHASTIC THERMALLY DRIVEN MOTION HAS REPERCUSSIONS FOR OUR UNDERSTANDING OF SMALL-SCALE HYDRODYNAMICS, IMPORTANT IN MANY PROBLEMS SUCH AS MICRO- OR NANOFLUIDICS AND INTERFACIAL SINGULARITIES.","THIN-FILM FLOW; BREAKUP; DYNAMICS; FLUID",NA,"PHYSICAL REVIEW LETTERS","HENNEQUIN, Y##AARTS, DGAL##VAN DER WIEL, JH##WEGDAM, G##EGGERS, J##LEKKERKERKER, HNW##BONN, D","UNIV AMSTERDAM, WAALS ZEEMAN INST, COMPLEX FLUIDS GRP, NL-1018 XE AMSTERDAM, NETHERLANDS. UNIV UTRECHT, VANT HOFF LAB, NL-3584 CH UTRECHT, NETHERLANDS. ECOLE NORMALE SUPER, LAB PHYS STAT, F-75231 PARIS 05, FRANCE. UNIV BRISTOL, SCH MATH, BRISTOL BS8 1TW, AVON, ENGLAND.","PHYSICS, MULTIDISCIPLINARY","PHYSICS","AARTS DGA, 2005, THESIS U UTRECHT, P59801##AARTS DGAL, 2004, SCIENCE, V304, P847, DOI 10.1126/SCIENCE.1097116##AARTS DGAL, 2003, J PHYS-CONDENS MAT, V15, PS245, DOI 10.1088/0953-8984/15/1/332##ASAKURA S, 1954, J CHEM PHYS, V22, P1255, DOI 10.1063/1.1740347##BERGERON V, 2000, NATURE, V405, P772, DOI 10.1038/35015525##BRENNER MP, 1994, PHYS REV LETT, V73, P3391, DOI 10.1103/PHYSREVLETT.73.3391##COHEN I, 1999, PHYS REV LETT, V83, P1147, DOI 10.1103/PHYSREVLETT.83.1147##DAVIDOVITCH B, 2005, PHYS REV LETT, V95, DOI 10.1103/PHYSREVLETT.95.244505##DE GENNES P.G., 1979, SCALING CONCEPTS POL##DOSHI P, 2003, SCIENCE, V302, P1185, DOI 10.1126/SCIENCE.1089272##EGGERS J, 1993, PHYS REV LETT, V71, P3458, DOI 10.1103/PHYSREVLETT.71.3458##EGGERS J, 2002, PHYS REV LETT, V89, DOI 10.1103/PHYSREVLETT.89.084502##EGGERS J, 1997, REV MOD PHYS, V69, P865, DOI 10.1103/REVMODPHYS.69.865##*EPAPS, EPRLTAO97013650##GRUN G, 2006, J STAT PHYS, V122, P1261, DOI 10.1007/S10955-006-9028-8##HENDERSON D, 2000, PHYS FLUIDS, V12, P550, DOI 10.1063/1.870261##LISTER JR, 1998, PHYS FLUIDS, V10, P2758, DOI 10.1063/1.869799##MARMOTTANT PH, 2004, J FLUID MECH, V498, P73, DOI 10.1017/S0022112003006529##MECKE K, 2005, J PHYS-CONDENS MAT, V17, PS3515, DOI 10.1088/0953-8984/17/45/042##MOSELER M, 2000, SCIENCE, V289, P1165, DOI 10.1126/SCIENCE.289.5482.1165##PEREGRINE DH, 1990, J FLUID MECH, V212, P25, DOI 10.1017/S0022112090001835##ROWLINSON JS, 1982, MOL THEORY CAPILLARI##SHI XD, 1994, SCIENCE, V265, P219, DOI 10.1126/SCIENCE.265.5169.219##VRIJ A, 1976, PURE APPL CHEM, V48, P471, DOI 10.1351/PAC197648040471",39,2020-11-20,NA,"UNIV AMSTERDAM#UNIV UTRECHT#ECOLE NORMALE SUPER#UNIV BRISTOL","NETHERLANDS#NETHERLANDS#FRANCE#ENGLAND"
"J","WOS:000243462000002",2006,"NEONATAL DIARRHOEA IN PIGS: ALPHA- AND BETA(2)-TOXIN PRODUCED BY CLOSTRIDIUM PERFRINGENS","SINCE 2001 THE PIG HEALTH UNIT OF UTRECHT UNIVERSITY HAS BEEN CONSULTED BY VARIOUS PIG FARMS REGARDING NEONATAL DIARRHOEA. WHEN PREVENTIVE MEASURES AGAINST E. COLI-INDUCED DIARRHOEA HAD NO OR LIMITED RESULTS, THE DIARRHOEIC PIGLETS WERE INVESTIGATED FURTHER THE MICROBIOLOGICAL AND PATHOLOGICAL FINDINGS WERE INDICATIVE OF INFECTION WITH CLOSTRIDIUM PERFRINGENS. TOXIN TYPING BY POLYMERASE CHAIN REACTION LED TO THE DETECTION OF GENES ENCODING ALPHA-TOXIN (CPA) AND BETA(2)-TOXIN (CPB2). SURPRISINGLY, ALPHA- AND BETA(2)-TOXIN-PRODUCING C. PERFRINGENS WAS ISOLATED FROM ALL TESTED HERDS WITH PIGLETS WITH NEONATAL DIARRHOEA. FROM OUR OBSERVATIONS, IT IS LIKELY THAT MANY HERDS IN THE NETHERLANDS ARE INFECTED WITH BETA(2)-TOXIN-PRODUCING C. PERFRINGENS STRAINS. AS PRESENT VACCINES LACK BETA(2)-TOXOID AND THUS DO NOT PROVIDE PIGLETS WITH PROTECTION AGAINST BETA(2)-INDUCED DIARRHOEA.","BETA2 TOXIN; ANIMALS; PREVALENCE; PIGLETS; GENE",NA,"TIJDSCHRIFT VOOR DIERGENEESKUNDE","HENDRIKSEN, SWM##VAN LEENGOED, LAMG##ROEST, HIJ##VAN NES, A","UNIV UTRECHT, FAC DIERGENEESKUNDE, DEPT GEZONDHEIDSZORG LANDBOUWHUISDIEREN, AFDELING VARKENSGEZOND HEIDSZORG, NL-3584 CL UTRECHT, NETHERLANDS. WAGENINGEN UR, DIV BACTERIOL TSES, CIDC, WAGENINGEN, NETHERLANDS.","VETERINARY SCIENCES","VETERINARY SCIENCES","BRAUN M, 2000, FEMS MICROBIOL LETT, V184, P29, DOI 10.1111/J.1574-6968.2000.TB08985.X##BUESCHEL DM, 2003, VET MICROBIOL, V94, P121, DOI 10.1016/S0378-1135(03)00081-6##BUOGO C, 1995, J VET MED B, V42, P51, DOI 10.1111/J.1439-0450.1995.TB00681.X##GARMORY HS, 2000, EPIDEMIOL INFECT, V124, P61, DOI 10.1017/S0950268899003295##GIBERT M, 1997, GENE, V203, P65, DOI 10.1016/S0378-1119(97)00493-9##HATHEWAY CL, 1990, CLIN MICROBIOL REV, V3, P66, DOI 10.1128/CMR.3.1.66-98.1990##HERHOLZ C, 1999, J CLIN MICROBIOL, V37, P358, DOI 10.1128/JCM.37.2.358-361.1999##HOLMGREN N, 2004, 18 INT PIG VET SOC C, P828##KLAASEN HLBM, 1999, FEMS IMMUNOL MED MIC, V24, P325, DOI 10.1111/J.1574-695X.1999.TB01301.X##ROOD JI, 1991, MICROBIOL REV, V55, P621, DOI 10.1128/MMBR.55.4.621-648.1991##ROOD JI, 1998, ANNU REV MICROBIOL, V52, P333, DOI 10.1146/ANNUREV.MICRO.52.1.333##SCHMIDT AS, 2004, 18 INT PIG VET SOC C, P330##SCHOTTE U, 2004, J VET MED B, V51, P423, DOI 10.1111/J.1439-0450.2004.00802.X##SHIMIZU T, 2002, P NATL ACAD SCI USA, V99, P996, DOI 10.1073/PNAS.022493799##SONGER JG, 1996, CLIN MICROBIOL REV, V9, P216, DOI 10.1128/CMR.9.2.216##SPRINGER S, 1999, FEMS IMMUNOL MED MIC, V24, P333, DOI 10.1111/J.1574-695X.1999.TB01302.X##ZIZLAVSKY M, 2004, 18 INT PIG VET SOC C, P296",5,2020-11-20,NA,"UNIV UTRECHT#WAGENINGEN UR","NETHERLANDS#NETHERLANDS"
"J","WOS:000242942800001",2006,"ISOTOPIC COMPOSITION OF H-2 FROM CH4 OXIDATION IN THE STRATOSPHERE AND THE TROPOSPHERE","[1] ENRICHMENT IN DEUTERIUM (D) OF STRATOSPHERIC H-2 IS INVESTIGATED USING NEW AND PUBLISHED DATA. APPLYING A RAYLEIGH MODEL TO ACCOUNT FOR THE ISOTOPIC FRACTIONATIONS IN THE PHOTOCHEMICAL CHAIN REACTIONS FROM CH4 TO THE FINAL PRODUCT H2O VIA H-2 REVEALS A STRONG ENRICHMENT OF PHOTOCHEMICALLY PRODUCED H-2. THIS IS CONSISTENT WITH PREVIOUS STUDIES, BUT THE DEGREE OF ENRICHMENT OBTAINED IN THIS STUDY APPEARS TO BE 100 - 120% LARGER THAN THE PREVIOUS ESTIMATES ON AVERAGE. THE DISCREPANCY PRIMARILY STEMS FROM THE FORMER USE OF EITHER AN ISOTOPIC FRACTIONATION FACTOR OF H-2 THAT DOES NOT TAKE INTO ACCOUNT THE EFFECT OF STRATOSPHERIC TRANSPORT OR AN H-2 YIELD FROM CH2O PHOTOLYSIS THAT IS NOT APPLICABLE TO STRATOSPHERIC CONDITIONS. WE FURTHER INVESTIGATE THE SAME ISOTOPIC FRACTIONATION PROCESS UNDER TROPOSPHERIC CONDITIONS BY CONSIDERING THE DIFFERENCES IN BOTH THE SPECIES AND AMOUNTS OF OXIDIZING AGENTS AND THE WAVELENGTHS THAT ARE EFFECTIVE IN THE PHOTOLYSIS OF CH2O. THESE WERE NOT CONSIDERED IN THE FORMER STUDIES WHEN THEY DERIVED THE DELTA D VALUE UNDER THE TROPOSPHERIC CONDITIONS. WE THEREBY ANTICIPATE THE DELTA D VALUE OF H-2 FROM PHOTOCHEMICAL OXIDATION OF CH4 IN THE TROPOSPHERE TO BE 190 ( +/- 50)%.","MOLECULAR-HYDROGEN; ATMOSPHERIC METHANE; RATE COEFFICIENTS; RADICAL REACTIONS; NITROUS-OXIDE; WATER-VAPOR; CARBON; BUDGET; RATIO; ENRICHMENT",NA,"JOURNAL OF GEOPHYSICAL RESEARCH-ATMOSPHERES","RHEE, TS##BRENNINKMEIJER, CAM##BRASS, M##BRUHL, C","KOREA POLAR RES INST, ANSAN 426744, SOUTH KOREA. MAX PLANCK INST CHEM, DIV ATMOSPHER CHEM, D-55020 MAINZ, GERMANY. UNIV UTRECHT, INST MARINE & ATMOSPHER RES UTRECHT, NL-3508 TC UTRECHT, NETHERLANDS.","METEOROLOGY & ATMOSPHERIC SCIENCES","METEOROLOGY & ATMOSPHERIC SCIENCES","BERGAMASCHI P, 2000, J GEOPHYS RES-ATMOS, V105, P14531, DOI 10.1029/1999JD901176##BERGAMASCHI P, 1996, GEOPHYS RES LETT, V23, P2227, DOI 10.1029/96GL02139##BIGELEISEN J, 1959, J CHEM PHYS, V30, P1340, DOI 10.1063/1.1730183##BRASS M, 2006, THESIS RUPRECHT KARL##BRASSEUR G, 1986, AERONOMY MIDDLE ATMO##BRENNINKMEIJER CAM, 1999, J ATMOS OCEAN TECH, V16, P1373, DOI 10.1175/1520-0426(1999)016<1373:CCAFGM>2.0.CO;2##DEMORE W. B., 1997, JPL PUBL, V97-4##EHHALT DH, 1989, J GEOPHYS RES-ATMOS, V94, P9831, DOI 10.1029/JD094ID07P09831##ENGEL A, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2001JD000584##ENGEL A, 2003, 16 ESA S EUR ROCK BA##ERIKSSON E, 1965, TELLUS, V18, P498##FEILBERG KL, 2004, J PHYS CHEM A, V108, P7393, DOI 10.1021/JP048329K##GERST S, 2001, J GEOPHYS RES-ATMOS, V106, P5021, DOI 10.1029/2000JD900593##GIERCZAK T, 1997, J PHYS CHEM A, V101, P3125, DOI 10.1021/JP963892R##GROOSS JU, 1998, ATMOS ENVIRON, V32, P3173, DOI 10.1016/S1352-2310(98)00016-8##HAGEMANN R, 1970, TELLUS, V22, P712##HARTECK P, 1949, NATURWISSENSCHAFTEN, V36, P218, DOI 10.1007/BF00590320##JOCKEL P, 2005, ATMOS CHEM PHYS, V5, P433##KAISER J, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2001JD001506##KAYE JA, 1987, REV GEOPHYS, V25, P1609, DOI 10.1029/RG025I008P01609##LASSEY KR, 2000, GLOBAL BIOGEOCHEM CY, V14, P41, DOI 10.1029/1999GB900094##LETEXIER H, 1988, Q J ROY METEOR SOC, V114, P281, DOI 10.1002/QJ.49711448002##LEVIN I, 1999, J GEOPHYS RES-ATMOS, V104, P3447, DOI 10.1029/1998JD100064##MCCARTHY MC, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2002JD003183##MCQUIGG RD, 1969, J AM CHEM SOC, V91, P1590, DOI 10.1021/JA01035A002##MELANDER L., 1980, REACTION RATES ISOTO##MOORTGAT GK, 1983, J CHEM PHYS, V78, P1185, DOI 10.1063/1.444911##MORGAN CG, 2004, J GEOPHYS RES-ATMOS, V109, DOI 10.1029/2003JD003402##NOVELLI PC, 1999, J GEOPHYS RES-ATMOS, V104, P30427, DOI 10.1029/1999JD900788##PARK M, 2004, J GEOPHYS RES-ATMOS, V109, DOI 10.1029/2003JD003706##PARK SY, 2004, J GEOPHYS RES-ATMOS, V109, DOI 10.1029/2003JD003731##PERSKY A, 1966, J CHEM PHYS, V44, P3617, DOI 10.1063/1.1727273##QUAY P, 1999, GLOBAL BIOGEOCHEM CY, V13, P445, DOI 10.1029/1998GB900006##RAHN T, 1997, SCIENCE, V278, P1776, DOI 10.1126/SCIENCE.278.5344.1776##RAHN T, 2003, NATURE, V424, P918, DOI 10.1038/NATURE01917##RAHN T, 2002, GEOCHIM COSMOCHIM AC, V66, P2475, DOI 10.1016/S0016-7037(02)00858-X##RAVISHANKARA AR, 1988, ANNU REV PHYS CHEM, V39, P367, DOI 10.1146/ANNUREV.PC.39.100188.002055##RAYLEIGH L, 1902, PHILOS MAG, V4, P521##RHEE TS, 2006, ATMOS CHEM PHYS, V6, P1611, DOI 10.5194/ACP-6-1611-2006##RHEE TS, 2004, RAPID COMMUN MASS SP, V18, P299, DOI 10.1002/RCM.1309##RICE AL, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2002JD003042##ROCKMANN T, 2003, ATMOS CHEM PHYS, V3, P2015##ROCKMANN T, 2001, J GEOPHYS RES-ATMOS, V106, P10403, DOI 10.1029/2000JD900822##ROLSTON JH, 1976, J PHYS CHEM-US, V80, P1064, DOI 10.1021/J100551A008##SAUERESSIG G, 2001, J GEOPHYS RES-ATMOS, V106, P23127, DOI 10.1029/2000JD000120##SAUERESSIG G, 1996, GEOPHYS RES LETT, V23, P3619, DOI 10.1029/96GL03292##SCHMIDT U, 1987, PLANET SPACE SCI, V35, P647, DOI 10.1016/0032-0633(87)90131-0##SUESS HE, 1953, ECO T AGU, V34, P343##SUGAWARA S, 1997, GEOPHYS RES LETT, V24, P2989, DOI 10.1029/97GL03044##TAATJES CA, 1999, CHEM PHYS LETT, V306, P33, DOI 10.1016/S0009-2614(99)00420-0##TALUKDAR RK, 1996, CHEM PHYS LETT, V253, P177, DOI 10.1016/0009-2614(96)00203-5##TALUKDAR RK, 1996, J PHYS CHEM-US, V100, P3037, DOI 10.1021/JP9518724##TOYODA S, 2004, J GEOPHYS RES-ATMOS, V109, DOI 10.1029/2003JD004316##WAHLEN M, 1989, EOS T AGU, V70, P1017##WETTER T, 1998, MESSUNGEN CO H2 MISC",19,2020-11-20,NA,"KOREA POLAR RES INST#MAX PLANCK INST CHEM#UNIV UTRECHT","SOUTH KOREA#GERMANY#NETHERLANDS"
"J","WOS:000242786500013",2006,"PHASE-CORRELATED NONDIRECTIONAL LASER EMISSION FROM THE END FACETS OF A ZNO NANOWIRE","WE INVESTIGATED THE LASER EMISSION FROM INDIVIDUAL ZNO NANOWIRES AND OBSERVED AN INTERFERENCE PATTERN DUE TO COHERENT LASER EMISSION FROM THE WIRE END FACETS. COMPARISON WITH NUMERICAL SIMULATIONS SHOWS THAT THE LASER LIGHT IS EMITTED NEARLY SPHERICALLY FROM THE WIRE ENDS. THE ENERGY SPACING BETWEEN SHARP LASING MODES SCALES WITH THE INVERSE LENGTH OF THE NANOWIRE; THUS, LASER EMISSION PEAKS CORRESPOND TO FABRY-PEROT MODES OF THE NANOWIRE CAVITY.","SUBWAVELENGTH PHOTONICS INTEGRATION; ROOM-TEMPERATURE; WAVE-GUIDES",NA,"NANO LETTERS","VAN VUGT, LK##RUHLE, S##VANMAEKELBERGH, D","UNIV UTRECHT, DEBYE INST, NL-3508 TA UTRECHT, NETHERLANDS.","CHEMISTRY, MULTIDISCIPLINARY; CHEMISTRY, PHYSICAL; NANOSCIENCE & NANOTECHNOLOGY; MATERIALS SCIENCE, MULTIDISCIPLINARY; PHYSICS, APPLIED; PHYSICS, CONDENSED MATTER","CHEMISTRY; SCIENCE & TECHNOLOGY - OTHER TOPICS; MATERIALS SCIENCE; PHYSICS","AGARWAL R, 2005, NANO LETT, V5, P917, DOI 10.1021/NL050440U##BAYER M, 2002, PHYS STATUS SOLIDI A, V191, P3, DOI 10.1002/1521-396X(200205)191:1<3::AID-PSSA3>3.0.CO;2-M##BORN M., 1933, OPTIK, P235##CHIN AH, 2006, APPL PHYS LETT, V88, DOI 10.1063/1.2198017##DING JX, 2004, APPL PHYS LETT, V85, P2361, DOI 10.1063/1.1791326##DUAN XF, 2003, NATURE, V421, P241, DOI 10.1038/NATURE01353##GRADECAK S, 2005, APPL PHYS LETT, V87, DOI 10.1063/1.2115087##HAUSCHILD R, 2006, PHYS STATUS SOLIDI B, V243, P853, DOI 10.1002/PSSB.200564718##HUANG MH, 2001, SCIENCE, V292, P1897, DOI 10.1126/SCIENCE.1060367##HUANG MH, 2001, ADV MATER, V13, P113, DOI 10.1002/1521-4095(200101)13:2<113::AID-ADMA113>3.0.CO;2-H##HUANG Y, 2005, SMALL, V1, P142, DOI 10.1002/SMLL.200400030##JOHNSON JC, 2003, J PHYS CHEM B, V107, P8816, DOI 10.1021/JP034482N##LAW M, 2004, SCIENCE, V305, P1269, DOI 10.1126/SCIENCE.1100999##MASLOV AV, 2004, OPT LETT, V29, P572, DOI 10.1364/OL.29.000572##MASLOV AV, 2006, J APPL PHYS, V99, DOI 10.1063/1.2164538##NOBIS T, 2004, PHYS REV LETT, V93, DOI 10.1103/PHYSREVLETT.93.103903##PAN AL, 2005, J PHYS CHEM B, V109, P24268, DOI 10.1021/JP055164M##PETTERSSON H, 2006, NANO LETT, V6, P229, DOI 10.1021/NL052170L##PRASANTH R, 2006, APPL PHYS LETT, V88, DOI 10.1063/1.2200230##SIRBULY DJ, 2005, J PHYS CHEM B, V109, P15190, DOI 10.1021/JP051813I##TONG LM, 2003, NATURE, V426, P816, DOI 10.1038/NATURE02193##WANG D, 2006, J APPL PHYS, V99, DOI 10.1063/1.2196148",129,2020-11-20,NA,"UNIV UTRECHT","NETHERLANDS"
"J","WOS:000242750900038",2006,"NEUROLOGIC AND HEMATOLOGIC RESPONSE TO FLUDARABINE TREATMENT IN IGM MGUS POLYNEUROPATHY","WE STUDIED THE EFFICACY OF FLUDARABINE IN 16 PATIENTS WITH IMMUNOGLOBULIN M MONOCLONAL GAMMOPATHY OF UNKNOWN SIGNIFICANCE POLYNEUROPATHY IN A PROSPECTIVE UNCONTROLLED TRIAL. THE MODIFIED RANKIN SCALE IMPROVED IN 5/16 PATIENTS, ALL OF WHOM HAD A DEMYELINATING POLYNEUROPATHY. THE MOTOR CONDUCTION VELOCITY IMPROVED BY MORE THAN 10% IN TWO OR MORE NERVES FOR FOUR OF FIVE OF THESE PATIENTS. HEMATOLOGIC RESPONSE IN BONE MARROW OCCURRED IN THREE OF FIVE OF THESE PATIENTS, WHEREAS TWO OF FIVE ALREADY HAD SMALL POLYCLONAL B CELL POPULATIONS. THERE WERE NO SERIOUS SIDE EFFECTS.","MONOCLONAL GAMMOPATHY; INTRAVENOUS IMMUNOGLOBULIN; UNDETERMINED SIGNIFICANCE; DEMYELINATING NEUROPATHY",NA,"NEUROLOGY","NIERMEIJER, JMF##EURELINGS, M##LOKHORST, H##FRANSSEN, H##FIJNHEER, R##WOKKE, JHJ##NOTERMANS, NC","UNIV UTRECHT, MED CTR, DEPT NEUROL & NEUROSURG, RUDOLF MAGNUS INST NEUROSCI, NL-3508 GA UTRECHT, NETHERLANDS. UNIV UTRECHT, MED CTR, DEPT NEUROL, NL-3508 GA UTRECHT, NETHERLANDS. UNIV UTRECHT, MED CTR, DEPT CLIN NEUROPHYSIOL, NL-3508 GA UTRECHT, NETHERLANDS. UNIV UTRECHT, MED CTR, DEPT HEMATOL, NL-3508 GA UTRECHT, NETHERLANDS.","CLINICAL NEUROLOGY","NEUROSCIENCES & NEUROLOGY","BRIL V, 1998, MUSCLE NERVE, V21, P1368, DOI 10.1002/(SICI)1097-4598(199811)21:11<1368::AID-MUS2>3.0.CO;2-7##COMI G, 2002, J NEUROL, V249, P1370, DOI 10.1007/S00415-002-0808-Z##DALAKAS MC, 1996, ANN NEUROL, V40, P792, DOI 10.1002/ANA.410400516##DYCK PJ, 1991, NEW ENGL J MED, V325, P1482, DOI 10.1056/NEJM199111213252105##DYCK PJ, 1990, NEUROLOGY, V40, P327##LUNN M.P., 2003, COCHRANE DB SYST REV##NOTERMANS NC, 1994, BRAIN, V117, P1385, DOI 10.1093/BRAIN/117.6.1385##NOTERMANS NC, 1996, NEUROLOGY, V47, P1227, DOI 10.1212/WNL.47.5.1227##SHERMAN WH, 1994, ANN NEUROL, V36, P326##WILSON HC, 1999, J NEUROL NEUROSUR PS, V66, P575, DOI 10.1136/JNNP.66.5.575",20,2020-11-20,NA,"UNIV UTRECHT#UNIV UTRECHT#UNIV UTRECHT#UNIV UTRECHT","NETHERLANDS#NETHERLANDS#NETHERLANDS#NETHERLANDS"
"J","WOS:000242479700049",2006,"SYNTHESIS, CHARACTERIZATION, AND DNA-BINDING STUDIES OF NITRO(OLIGOPYRIDINE) RUTHENIUM(II) COMPLEXES","THE COMPLEXES OF GENERAL FORMULAS [RU-II(TERPY)(4-CO2H-4'-MEBPY)(X)](N+) (X = NO (N = 3) AND NO2 (N = 1); 1, 2) AND [RU-II(TERPY)(4-COGHK-4'-MEBPY)(X)] (X = NO (N = 3) AND NO2 (N = 1); 3, 4) WERE SYNTHESIZED AND CHARACTERIZED. THE COMPLEX [RU-II(TERPY)(4-CO2-4'-MEBPY)(NO2)](-)7.5H(2)O HAS ALSO BEEN CHARACTERIZED BY X-RAY CRYSTALLOGRAPHIC STUDIES. IT CRYSTALLIZES IN THE TRICLINIC SYSTEM: A = 9.4982(1) ANGSTROM, B = 13.1330(1) ANGSTROM, C = 14.2498(2) ANGSTROM; ALPHA = 110.5870(6)XBC, BETA = 98.4048(5)XBC, GAMMA = 106.4353(5), P (1) OVER BAR, Z = 2. THE CRYSTAL STRUCTURE REVEALS AN EXTENDED HYDROGEN-BONDING NETWORK. TWO WATER MOLECULES FORM STRONG HYDROGEN BONDS WITH THE NITRO AND THE CARBOXYLIC OXYGEN ATOMS OF TWO SEPARATE UNITS OF THE COMPLEX, RESULTING IN A DIMERIC UNIT. THE DIMERS ARE BRIDGED BY A (H2O)(15) CLUSTER, CONSISTING OF TWO CYCLO-(H2O)(6) SPECIES, WHILE AN EXO-H2O(8) CONNECTS THEM. TWO MORE EXO-H2O MOLECULES ARE JOINED TOGETHER AND CONNECT THE CYCLO-(H2O)(6) UNITS WITH THE H2O(1) OF THE DIMERIC UNIT. IT WAS FOUND THAT COMPLEXES 1 AND 3 CAN BE TRANSFORMED INTO THEIR NITRO DERIVATIVES IN AQUEOUS MEDIA AT NEUTRAL PH. PHOTORELEASE OF NO IN DRY MECN SOLUTIONS WAS OBSERVED FOR COMPLEXES 1 AND 3. ALSO, COMPLEX 2 PARTIALLY RELEASES (NO2)(-) IN MECN UPON VISIBLE LIGHT IRRADIATION. COMPLEX 2 INTERACTS WITH SHORT FRAGMENTS (70-300 BP) OF CALF THYMUS DNA SHORTENING SLIGHTLY THE APPARENT POLYNUCLEOTIDE LENGTH, WHILE THE CONJUGATION OF THE PEPTIDE GHK TO IT (2) AFFECTS ITS DNA-BINDING MODE. THE PEPTIDE MOIETY OF COMPLEX 4 WAS FOUND TO INTERACT WITH THE DNA HELIX IN A SYNERGISTIC WAY WITH THE WHOLE COMPLEX. PRELIMINARY RESULTS OF PHOTOCLEAVAGE OF DNA BY COMPLEX 2 ARE ALSO REPORTED.","CALF THYMUS DNA; CRYSTAL-STRUCTURE; NITRIC-OXIDE; DEOXYNUCLEOTIDE DUPLEX; NITROSYL COMPLEXES; ELECTRON-TRANSFER; POLYPYRIDINE COMPLEXES; STEREOSPECIFIC BINDING; CIRCULAR-DICHROISM; ANCILLARY LIGANDS",NA,"INORGANIC CHEMISTRY","KARIDI, K##GAROUFIS, A##HADJILIADIS, N##LUTZ, M##SPEK, AL##REEDIJK, J","UNIV IOANNINA, LAB INORGAN & GEN CHEM, DEPT CHEM, GR-45110 IOANNINA, GREECE. UNIV UTRECHT, BIJVOET CTR BIOMOL CTR CRYSTAL & STRUCT CHEM, NL-3584 CH UTRECHT, NETHERLANDS. LEIDEN UNIV, GORLAEUS LABS, LEIDEN INST CHEM, NL-2300 RA LEIDEN, NETHERLANDS.","CHEMISTRY, INORGANIC & NUCLEAR","CHEMISTRY","ALTOMARE A, 1999, J APPL CRYSTALLOGR, V32, P115, DOI 10.1107/S0021889898007717##BLESSING RH, 1997, J APPL CRYSTALLOGR, V30, P421, DOI 10.1107/S0021889896014628##BORDINI J, 2002, INORG CHEM, V41, P5410, DOI 10.1021/IC011273D##BRYANT GM, 1971, AUST J CHEM, V24, P257, DOI 10.1071/CH9710257##CALLAHAN RW, 1977, INORG CHEM, V16, P574, DOI 10.1021/IC50169A015##CATTE A, 2002, J BIOMOL STRUCT DYN, V20, P99, DOI 10.1080/07391102.2002.10506827##CHANDA N, 2005, INORG CHEM, V44, P3499, DOI 10.1021/IC048184W##CHANDA N, 2004, INORG CHEM, V43, P5128, DOI 10.1021/IC049605C##CHANDA N, 2004, INORG CHEM, V43, P1056, DOI 10.1021/IC034902N##COPELAND KD, 2002, BIOCHEMISTRY-US, V41, P343, DOI 10.1021/BI011793K##COPELAND KD, 2002, BIOCHEMISTRY-US, V41, P12785, DOI 10.1021/BI020407B##ERKKILA KE, 1999, CHEM REV, V99, P2777, DOI 10.1021/CR9804341##ERSHOV AY, 2004, RUSS J GEN CHEM+, V74, P651, DOI 10.1023/B:RUGC.0000039071.51270.43##FORD PC, 2005, COORDIN CHEM REV, V249, P391, DOI 10.1016/J.CCR.2004.04.006##FORD PC, 2002, CHEM REV, V102, P993, DOI 10.1021/CR0000271##FORD PC, 2005, COORDIN CHEM REV, V249, P1382, DOI 10.1016/J.CCR.2004.10.022##GARCIAFRESNADILLO D, 1996, HELV CHIM ACTA, V79, P1222, DOI 10.1002/HLCA.19960790428##GHOSH SK, 2005, INORG CHEM, V44, P3856, DOI 10.1021/IC050102W##GHOSH SK, 2003, INORG CHEM, V42, P8250, DOI 10.1021/IC034976Z##GODWIN JB, 1971, INORG CHEM, V10, P471##HARTSHORN CM, 2001, INORG CHEM, V40, P601, DOI 10.1021/IC9911724##HERGUETA-BRAVO A, 2002, J PHYS CHEM B, V106, P4010, DOI 10.1021/JP013542R##IVANOV VI, 1973, BIOPOLYMERS, V12, P89, DOI 10.1002/BIP.1973.360120109##JI LN, 2001, COORDIN CHEM REV, V216, P513, DOI 10.1016/S0010-8545(01)00338-1##KANE-MAGUIRE NAP, 2001, COORDIN CHEM REV, V211, P145, DOI 10.1016/S0010-8545(00)00280-0##KANKIA BI, 2001, NUCLEIC ACIDS RES, V29, P2795, DOI 10.1093/NAR/29.13.2795##KANKIA BI, 2000, BIOPHYS CHEM, V84, P227, DOI 10.1016/S0301-4622(00)00125-3##KAR S, 2005, CHEM-EUR J, V11, P4901, DOI 10.1002/CHEM.200500202##KARIDI K, 2005, DALTON T, P1176, DOI 10.1039/B418838A##KARIDI K, 2005, DALTON T, P728, DOI 10.1039/B410402A##KUMAR CV, 1985, J AM CHEM SOC, V107, P5518, DOI 10.1021/JA00305A032##LANG DR, 2000, INORG CHEM, V39, P2294, DOI 10.1021/IC9912979##LASEY RC, 2000, INORG CHIM ACTA, V300, P822, DOI 10.1016/S0020-1693(99)00589-7##LEISING RA, 1990, INORG CHEM, V29, P1306, DOI 10.1021/IC00332A004##LOPES LGF, 2001, INORG CHIM ACTA, V312, P15, DOI 10.1016/S0020-1693(00)00341-8##LUO Y, 1996, INORG CHEM, V35, P5445, DOI 10.1021/IC950694Q##MCCLEVERTY JA, 2004, CHEM REV, V104, P403, DOI 10.1021/CR020623Q##MONDAL B, 2001, J CHEM SOC DALTON, P481, DOI 10.1039/B007975H##MYARI A, 2005, BIOINORG CHEM APPL, V3, P109, DOI 10.1155/BCA.2005.109##MYARI A, 2005, J INORG BIOCHEM, V99, P616, DOI 10.1016/J.JINORGBIO.2004.11.010##MYARI A, 2004, EUR J INORG CHEM, P1427, DOI 10.1002/EJIC.200300725##ONEILL MA, 2004, LONG RANGE CHARGE TR, V236##PATEL DJ, 1976, BIOPOLYMERS, V15, P533, DOI 10.1002/BIP.1976.360150310##PATRA AK, 2003, INORG CHEM, V42, P7363, DOI 10.1021/IC030110H##PEEK BM, 1991, INT J PEPT PROT RES, V38, P114##PIPES DW, 1984, INORG CHEM, V23, P2466, DOI 10.1021/IC00184A021##ROBINSON K, 1971, SCIENCE, V172, P567, DOI 10.1126/SCIENCE.172.3983.567##SARDESAI NY, 1995, BIOCONJUGATE CHEM, V6, P302, DOI 10.1021/BC00033A011##SARDESAI NY, 1994, J AM CHEM SOC, V116, P7502, DOI 10.1021/JA00096A005##SARKAR S, 2005, INORG CHEM, V44, P6092, DOI 10.1021/IC050533E##SHELDRICK G. M., 1997, SHELXL97 PROGRAM CRY##SLOCIK JM, 2000, INORG CHIM ACTA, V311, P80, DOI 10.1016/S0020-1693(00)00309-1##SPEEDY RJ, 1987, J PHYS CHEM-US, V91, P909, DOI 10.1021/J100288A029##SPEK AL, 2003, J APPL CRYSTALLOGR, V36, P7, DOI 10.1107/S0021889802022112##SULLIVAN BP, 1980, INORG CHEM, V19, P1404, DOI 10.1021/IC50207A066##WILSON WD, 1982, NUCLEIC ACIDS RES, V10, P1399, DOI 10.1093/NAR/10.4.1399##XIONG Y, 1999, COORDIN CHEM REV, V185-6, P711, DOI 10.1016/S0010-8545(99)00019-3##YAMAGISHI A, 1983, J CHEM SOC CHEM COMM, P572, DOI 10.1039/C39830000572##YAMAGISHI A, 1984, J PHYS CHEM-US, V88, P5709, DOI 10.1021/J150667A050##YE BH, 2004, INORG CHEM, V43, P6866, DOI 10.1021/IC049232F",25,2020-11-20,NA,"UNIV IOANNINA#UNIV UTRECHT#LEIDEN UNIV","GREECE#NETHERLANDS#NETHERLANDS"
"J","WOS:000242924000009",2006,"THE ALICE VERTEX DETECTOR: FOCUS ON THE MICRO-STRIP LAYERS","THE ALICE EXPERIMENT, WHICH IS BEING INSTALLED AT THE LARGE HADRON COLLIDER AT CERN, IS DESIGNED TO OPERATE IN A HIGH-TRACK DENSITY ENVIRONMENT WHICH IS TYPICAL OF RELATIVISTIC HEAVY IONS PHYSICS. THIS PAPER REPORTS THE MAIN CHARACTERISTICS OF THE INNER TRACKING SYSTEM (ITS) OF ALICE AND DESCRIBES THE SILICON STRIP DETECTOR, WHICH FORMS THE TWO OUTERMOST LAYERS OF THE ITS. (C) 2006 ELSEVIER B.V. ALL RIGHTS RESERVED.",NA,"ALICE ITS; DOUBLE-SIDED AC SILICON STRIP DETECTOR","NUCLEAR INSTRUMENTS & METHODS IN PHYSICS RESEARCH SECTION A-ACCELERATORS SPECTROMETERS DETECTORS AND ASSOCIATED EQUIPMENT","BREGANT, M##BORYSOV, O##BOSISIO, L##CAMERINI, P##CONTIN, G##FALESCHINI, F##FRAGIACOMO, E##GRION, N##MARGAGLIOTTI, GV##PIANO, S##RACHEVSKAIA, I##RUI, R##DE HAAS, AP##KLUIT, R##KUIJER, PG##NOOREN, GJL##OSKAMP, CJ##SOKOLOV, AN##VAN DEN BRINK, A##AGNESE, F##BONNET, D##CLAUSSE, O##IMHOFF, M##KUHN, C##LITTEL, F##LUTZ, JR##PLUMERI, S##SIGWARD, MH##WABNITZ, C##ZETER, V##OINONEN, M##AALTONEN, J##KASSAMAKOV, I##NIKKINEN, S##RADIVOJEVIC, Z##SEPPANEN, H##OSTERBERG, M##ANTONOVA, V##BORSHCHOV, V##LISTRATENKO, A##PROTSENKO, M##KOSTYSHIN, J##TYMCHUK, I##ZINOVJEV, G","IST NAZL FIS NUCL, SEZ TRIESTE, TRIESTE, ITALY. UNIV TRIESTE, DIPARTIMENTO FIS, TRIESTE, ITALY. UNIV UTRECHT, UTRECHT, NETHERLANDS. CNRS, INST RECH SUBATOM, IN2P3, STRASBOURG, FRANCE. UNIV HELSINKI, HELSINKI INST PHYS, HELSINKI, FINLAND. UNIV HELSINKI, DEPT PHYS SCI, ELECT RES UNIT, HELSINKI, FINLAND. NOKIA RES CTR, HELSINKI, FINLAND. NATL ACAD SCI UKRAINE, DEPT HIGH ENERGY DENS PHYS, BAGOLYUBOV INST THEORET PHYS, KIEV, UKRAINE. SCI & TECHNOL RES INST INSTRUMENT ENGN, KHARKOV, UKRAINE.","INSTRUMENTS & INSTRUMENTATION; NUCLEAR SCIENCE & TECHNOLOGY; PHYSICS, NUCLEAR; PHYSICS, PARTICLES & FIELDS","INSTRUMENTS & INSTRUMENTATION; NUCLEAR SCIENCE & TECHNOLOGY; PHYSICS","BORSHCHOV V., 2002, P 8 WORKSH EL LHC EX##BORSHCHOV V, 2002034 CERNLHCC##*CERN LHCC, 200001 CERNLHCC##*CERN LHCC, 9912 CERNLHCC##*CERN LHCC, 2005030 CERNLHCC, V2##CORTESE P, 2004, J PHYS G NUCL PARTIC, V30, P1517, DOI 10.1088/0954-3899/30/11/001##HUGUO C, 2002, P 8 WORKSH EL LHC EX##HUGUO C, 2001, P 7 WORKSH EL LHC EX##*LEPSI, IN2P3 ULP##LUTZ JR, 2003, P 9 WORKSH EL LHC EX##SOKOLOV A, 2004, ALICEINT2004028",4,2020-11-20,NA,"IST NAZL FIS NUCL#UNIV TRIESTE#UNIV UTRECHT#CNRS#UNIV HELSINKI#UNIV HELSINKI#NOKIA RES CTR#NATL ACAD SCI UKRAINE#SCI TECHNOL RES INST INSTRUMENT ENGN","ITALY#ITALY#NETHERLANDS#FRANCE#FINLAND#FINLAND#FINLAND#UKRAINE#UKRAINE"
"J","WOS:000242477100078",2006,"STRUCTURAL CHARACTERIZATION OF SPO0E-LIKE PROTEIN-ASPARTIC ACID PHOSPHATASES THAT REGULATE SPORULATION IN BACILLI","SPORE FORMATION IS AN EXTREME RESPONSE OF MANY BACTERIAL SPECIES TO STARVATION. IN THE CASE OF PATHOGENIC SPECIES OF BACILLUS AND CLOSTRIDIUM, IT IS ALSO A COMPONENT OF DISEASE TRANSMISSION. ENTRY INTO THE PATHWAY OF SPORULATION IN BACILLUS SUBTILIS AND ITS RELATIVES IS CONTROLLED BY AN EXPANDED TWO-COMPONENT SYSTEM IN WHICH STARVATION SIGNALS LEAD TO THE ACTIVATION OF SENSOR KINASES AND PHOSPHORYLATION OF THE MASTER SPORULATION RESPONSE REGULATOR SPO0A. ACCUMULATION OF THRESHOLD CONCENTRATIONS OF SPO0A SIMILAR TO P HERALDS THE COMMITMENT TO SPORULATION. COUNTERING THE ACTIVITIES OF THE SENSOR KINASES ARE PHOSPHATASES SUCH AS SPO0E, WHICH DEPHOSPHORYLATE SPO0A SIMILAR TO P AND INHIBIT SPORULATION. SPO0E-LIKE PROTEIN-ASPARTIC ACID-PHOSPHATE PHOSPHATASES, CONSISTING OF 50-90 RESIDUES, ARE CONSERVED IN SPOREFORMING BACTERIA AND UNRELATED IN SEQUENCE TO PROTEINS OF KNOWN STRUCTURE. HERE WE DETERMINED THE STRUCTURES OF THE SPO0A SIMILAR TO P PHOSPHATASES BA1655 AND BA5174 FROM BACILLUS ANTHRACIS USING NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY. EACH IS COMPOSED OF TWO ANTI-PARALLEL ALPHA-HELICES FLANKED BY FLEXIBLE REGIONS AT THE TERMINI. THE SIGNATURE SQELD MOTIF (SRDLD IN BA1655) IS SITUATED IN THE MIDDLE OF HELIX ALPHA 2 WITH ITS POLAR RESIDUES PROJECTING OUTWARD. BA5174 IS A MONOMER, WHEREAS BA1655 IS A DIMER. THE FOUR-HELIX BUNDLE STRUCTURE IN THE DIMER IS REMINISCENT OF THE PHOSPHOTRANSFERASE SPO0B AND THE CHEMOTAXIS PHOSPHATASE CHEZ, ALTHOUGH IN CONTRAST TO THESE SYSTEMS, THE SUBUNITS IN BA1655 ARE IN HEAD-TO-TAIL RATHER THAN HEAD-TO-HEAD APPOSITION. THE IMPLICATIONS OF THE STRUCTURES FOR INTERACTIONS BETWEEN THE PHOSPHATASES AND THEIR SUBSTRATE SPO0A SIMILAR TO P ARE DISCUSSED.","TRANSCRIPTION FACTOR SPO0A; TORSION ANGLE DYNAMICS; RESPONSE REGULATOR; MOLECULAR RECOGNITION; SUBTILIS SPORULATION; HISTIDINE KINASES; ESCHERICHIA-COLI; PHOSPHORELAY; ASSIGNMENT; MECHANISM",NA,"JOURNAL OF BIOLOGICAL CHEMISTRY","GRENHA, R##RZECHORZEK, NJ##BRANNIGAN, JA##DE JONG, RN##AB, E##DIERCKS, T##TRUFFAULT, V##LADDS, JC##FOGG, MJ##BONGIORNI, C##PEREGO, M##KAPTEIN, R##WILSON, KS##FOLKERS, GE##WILKINSON, AJ","UNIV UTRECHT, BIJVOET CTR, NMR DEPT, NL-3584 CH UTRECHT, NETHERLANDS. UNIV YORK, DEPT CHEM, STRUCT BIOL LAB, YORK YO10 5YW, N YORKSHIRE, ENGLAND. SCRIPPS RES INST, DIV CELLULAR BIOL, DEPT MOL & EXPT MED, LA JOLLA, CA 92037 USA.","BIOCHEMISTRY & MOLECULAR BIOLOGY","BIOCHEMISTRY & MOLECULAR BIOLOGY","ARANTES O, 1991, GENE, V108, P115, DOI 10.1016/0378-1119(91)90495-W##BRUNGER AT, 1997, CRYSTALLOGRAPHY NMR##BRUNSING RL, 2005, J BACTERIOL, V187, P6972, DOI 10.1128/JB.187.20.6972-6981.2005##BURBULYS D, 1991, CELL, V64, P545, DOI 10.1016/0092-8674(91)90238-T##CORNILESCU G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740##DAUMKE O, 2004, NATURE, V429, P197, DOI 10.1038/NATURE02505##DELANO W. L., 2002, PYMOL MOL GRAPHICS S##DIERCKS T, 1999, J BIOMOL NMR, V15, P177, DOI 10.1023/A:1008367912535##FERRARI E, 1986, J BACTERIOL, V166, P173, DOI 10.1128/JB.166.1.173-179.1986##FOLKERS G. E., 2004, JOURNAL OF STRUCTURAL AND FUNCTIONAL GENOMICS, V5, P119, DOI 10.1023/B:JSFG.0000029200.66197.0C##GODDARD TD, 2006, SPARKY 3##GOUET P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/BIOINFORMATICS/15.4.305##GUNTERT P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/JMBI.1997.1284##HERRMANN T, 2002, J MOL BIOL, V319, P209, DOI 10.1016/S0022-2836(02)00241-3##JANSSON M, 1996, J BIOMOL NMR, V7, P131##JIANG M, 2000, MOL MICROBIOL, V38, P535, DOI 10.1046/J.1365-2958.2000.02148.X##KOBAYASHI K, 1995, J BACTERIOL, V177, P176, DOI 10.1128/JB.177.1.176-182.1995##KOEHLER TM, 1994, J BACTERIOL, V176, P586, DOI 10.1128/JB.176.3.586-595.1994##KORADI R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4##LANDAU M, 2005, NUCLEIC ACIDS RES, V33, PW299, DOI 10.1093/NAR/GKI370##LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944##LEDEAUX JR, 1995, J BACTERIOL, V177, P166, DOI 10.1128/JB.177.1.166-175.1995##LEE SY, 2001, NAT STRUCT BIOL, V8, P52##LEUTNER M, 1998, J BIOMOL NMR, V11, P31, DOI 10.1023/A:1008298226961##LEWIS RJ, 1999, J MOL BIOL, V294, P9, DOI 10.1006/JMBI.1999.3261##LEWIS RJ, 2002, J MOL BIOL, V316, P235, DOI 10.1006/JMBI.2001.5331##LO CONTE L, 1999, J MOL BIOL, V285, P2177##MADHUSUDAN, 1996, STRUCTURE, V4, P679, DOI 10.1016/S0969-2126(96)00074-3##MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/PROT.340120407##MUCHOVA K, 2004, MOL MICROBIOL, V53, P829, DOI 10.1111/J.1365-2958.2004.04171.X##NEDERVEEN AJ, 2005, PROTEINS, V59, P662, DOI 10.1002/PROT.20408##OHLSEN KL, 1994, P NATL ACAD SCI USA, V91, P1756, DOI 10.1073/PNAS.91.5.1756##PARK SY, 2004, MOL CELL, V16, P563, DOI 10.1016/J.MOLCEL.2004.10.018##PEREGO M, 1997, P NATL ACAD SCI USA, V94, P8612, DOI 10.1073/PNAS.94.16.8612##PEREGO M, 1994, CELL, V79, P1047, DOI 10.1016/0092-8674(94)90035-3##PEREGO M, 2001, PEPTIDES, V22, P1541, DOI 10.1016/S0196-9781(01)00490-9##PEREGO M, 2001, MOL MICROBIOL, V42, P133, DOI 10.1046/J.1365-2958.2001.02611.X##PEREGO M, 1991, J BACTERIOL, V173, P2514, DOI 10.1128/JB.173.8.2514-2520.1991##PIGGOT PJ, 2004, CURR OPIN MICROBIOL, V7, P579, DOI 10.1016/J.MIB.2004.10.001##PIGGOT PJ, 1976, BACTERIOL REV, V40, P908, DOI 10.1128/MMBR.40.4.908-962.1976##POTTERTON L, 2004, ACTA CRYSTALLOGR D, V60, P2288, DOI 10.1107/S0907444904023716##POYART C, 1997, FEMS MICROBIOL LETT, V156, P193, DOI 10.1111/J.1574-6968.1997.TB12726.X##SATTLER M, 1999, PROG NUCL MAG RES SP, V34, P93, DOI 10.1016/S0079-6565(98)00025-9##SCHAEFFER P, 1965, P NATL ACAD SCI USA, V54, P704, DOI 10.1073/PNAS.54.3.704##STEPHENSON K, 2002, MOL MICROBIOL, V46, P297, DOI 10.1046/J.1365-2958.2002.03186.X##STEPHENSON SJ, 2002, MOL MICROBIOL, V44, P1455, DOI 10.1046/J.1365-2958.2002.02974.X##VARUGHESE KI, 1998, MOL CELL, V2, P485, DOI 10.1016/S1097-2765(00)80148-3##VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V##WHITEHEAD B, 1997, J BIOMOL NMR, V9, P313, DOI 10.1023/A:1018687127330##ZAPF J, 2000, STRUCTURE, V8, P851, DOI 10.1016/S0969-2126(00)00174-X##ZAPF JW, 1996, BIOCHEMISTRY-US, V35, P2926, DOI 10.1021/BI9519361##ZHAO R, 2002, NAT STRUCT BIOL, V9, P570##ZIMMERMAN DE, 1997, J MOL BIOL, V269, P592, DOI 10.1006/JMBI.1997.1052",12,2020-11-20,"NIAID NIH HHSUNITED STATES DEPARTMENT OF HEALTH & HUMAN SERVICESNATIONAL INSTITUTES OF HEALTH (NIH) - USANIH NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES (NIAID) [AI52289] FUNDING SOURCE: MEDLINE; NIGMS NIH HHSUNITED STATES DEPARTMENT OF HEALTH & HUMAN SERVICESNATIONAL INSTITUTES OF HEALTH (NIH) - USANIH NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES (NIGMS) [GM55594] FUNDING SOURCE: MEDLINE; WELLCOME TRUSTWELLCOME TRUST FUNDING SOURCE: MEDLINE; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUNITED STATES DEPARTMENT OF HEALTH & HUMAN SERVICESNATIONAL INSTITUTES OF HEALTH (NIH) - USANIH NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES (NIAID) [R01AI052289, R01AI052289, R01AI052289, R01AI052289, R01AI052289] FUNDING SOURCE: NIH REPORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUNITED STATES DEPARTMENT OF HEALTH & HUMAN SERVICESNATIONAL INSTITUTES OF HEALTH (NIH) - USANIH NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES (NIGMS) [R01GM055594, R01GM055594, R01GM055594, R01GM055594, R01GM055594, R01GM055594, R01GM055594, R01GM055594, R01GM055594] FUNDING SOURCE: NIH REPORTER","UNIV UTRECHT#UNIV YORK#SCRIPPS RES INST","NETHERLANDS#ENGLAND#CA USA"
"J","WOS:000242581100021",2006,"CLAIM OF BIAS AGAINST CRITICS IS REFUTED BY PUBLICATION",NA,NA,NA,"NATURE","DE JONG, G##KORTHOF, G","UNIV UTRECHT, NL-3584 CH UTRECHT, NETHERLANDS.","MULTIDISCIPLINARY SCIENCES","SCIENCE & TECHNOLOGY - OTHER TOPICS","GIERTYCH M, 2006, NATURE, V444, P265, DOI 10.1038/444265D",0,2020-11-20,NA,"UNIV UTRECHT","NETHERLANDS"
"J","WOS:000242619200014",2006,"CELL MODEL FOR EFFICIENT SIMULATION OF WAVE PROPAGATION IN HUMAN VENTRICULAR TISSUE UNDER NORMAL AND PATHOLOGICAL CONDITIONS","IN THIS PAPER, WE FORMULATE A MODEL FOR HUMAN VENTRICULAR CELLS THAT IS EFFICIENT ENOUGH FOR WHOLE ORGAN ARRHYTHMIA SIMULATIONS YET DETAILED ENOUGH TO CAPTURE THE EFFECTS OF CELL LEVEL PROCESSES SUCH AS CURRENT BLOCKS AND CHANNELOPATHIES. THE MODEL IS OBTAINED FROM OUR DETAILED HUMAN VENTRICULAR CELL MODEL BY USING MATHEMATICAL TECHNIQUES TO REDUCE THE NUMBER OF VARIABLES FROM 19 TO NINE. WE CAREFULLY COMPARE OUR FULL AND REDUCED MODEL AT THE SINGLE CELL, CABLE AND 2D TISSUE LEVEL AND SHOW THAT THE REDUCED MODEL HAS A VERY SIMILAR BEHAVIOUR. IMPORTANTLY, THE NEW MODEL CORRECTLY PRODUCES THE EFFECTS OF CURRENT BLOCKS AND CHANNELOPATHIES ON AP AND SPIRAL WAVE BEHAVIOUR, PROCESSES AT THE CORE OF CURRENT DAY ARRHYTHMIA RESEARCH. THE NEW MODEL IS WELL OVER FOUR TIMES MORE EFFICIENT THAN THE FULL MODEL. WE CONCLUDE THAT THE NEW MODEL CAN BE USED FOR EFFICIENT SIMULATIONS OF THE EFFECTS OF CURRENT CHANGES ON ARRHYTHMIAS IN THE HUMAN HEART.","RECTIFIER K+ CURRENT; LONG-QT SYNDROME; TRANSIENT OUTWARD CURRENT; ELECTRICAL RESTITUTION; BRUGADA-SYNDROME; CARDIAC RESTITUTION; SPIRAL BREAKUP; HEART-FAILURE; DIADIC SPACE; 2 COMPONENTS",NA,"PHYSICS IN MEDICINE AND BIOLOGY","TEN TUSSCHER, KHWJ##PANFILOV, AV","UNIV UTRECHT, DEPT THEORET BIOL, NL-3584 CH UTRECHT, NETHERLANDS.","ENGINEERING, BIOMEDICAL; RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","ENGINEERING; RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","ALIEV RR, 1996, CHAOS SOLITON FRACT, V7, P293, DOI 10.1016/0960-0779(95)00089-5##ANTZELEVITCH C, 1999, CURR OPIN CARDIOL, V14, P274, DOI 10.1097/00001573-199905000-00013##BOSCH RF, 1998, CARDIOVASC RES, V38, P441, DOI 10.1016/S0008-6363(98)00021-2##BOYETT MR, 1988, J THEOR BIOL, V132, P15, DOI 10.1016/S0022-5193(88)80187-5##CAO JM, 1999, CIRC RES, V84, P1318, DOI 10.1161/01.RES.84.11.1318##CHERRY EM, 2004, AM J PHYSIOL-HEART C, V286, PH2332, DOI 10.1152/AJPHEART.00747.2003##CLANCY CE, 2002, CIRCULATION, V105, P1208, DOI 10.1161/HC1002.105183##COURTEMANCHE M, 1998, AM J PHYSIOL-HEART C, V275, PH301##DROUIN E, 1995, J AM COLL CARDIOL, V26, P185, DOI 10.1016/0735-1097(95)00167-X##DUMAINE R, 1999, CIRC RES, V85, P803, DOI 10.1161/01.RES.85.9.803##FENTON F, 1998, CHAOS, V8, P20, DOI 10.1063/1.166311##FISH JM, 2003, J ELECTROCARDIOL, V36, P173, DOI 10.1016/J.JELECTROCARD.2003.09.054##FITZHUGH R, 1961, BIOPHYS J, V1, P445, DOI 10.1016/S0006-3495(61)86902-6##FITZHUGH R, 1960, J GEN PHYSIOL, V43, P867, DOI 10.1085/JGP.43.5.867##GARFINKEL A, 2000, P NATL ACAD SCI USA, V97, P6061, DOI 10.1073/PNAS.090492697##GRANT AO, 2001, AM J MED, V110, P296, DOI 10.1016/S0002-9343(00)00714-2##IOST N, 1998, CARDIOVASC RES, V40, P508, DOI 10.1016/S0008-6363(98)00204-1##IYER V, 2004, BIOPHYS J, V87, P1507, DOI 10.1529/BIOPHYSJ.104.043299##KARMA A, 1993, PHYS REV LETT, V71, P1103, DOI 10.1103/PHYSREVLETT.71.1103##KARMA A, 1994, CHAOS, V4, P461, DOI 10.1063/1.166024##KEENER J., 1998, MATH PHYSL##KELLER DI, 2003, J MOL CELL CARDIOL, V35, P1513, DOI 10.1016/J.YJMCC.2003.08.007##KOLLER ML, 2000, AM J PHYSIOL-HEART C, V279, PH2665##LI GR, 1998, AM J PHYSIOL-HEART C, V275, PH369##LI GR, 1996, CIRC RES, V78, P689, DOI 10.1161/01.RES.78.4.689##LUO CH, 1991, CIRC RES, V68, P1501, DOI 10.1161/01.RES.68.6.1501##LUO CH, 1994, CIRC RES, V74, P1071, DOI 10.1161/01.RES.74.6.1071##NABAUER M, 1996, CIRCULATION, V93, P168, DOI 10.1161/01.CIR.93.1.168##NAGUMO J, 1962, P IRE, V50, P2061, DOI 10.1109/JRPROC.1962.288235##NASH MP, 2006, EXP PHYSIOL, V91, P339, DOI 10.1113/EXPPHYSIOL.2005.031070##NOBLE D, 1998, CAN J CARDIOL, V14, P123##PANFILOV AV, 1990, PHYS LETT A, V147, P463, DOI 10.1016/0375-9601(90)90607-P##PEREON Y, 2000, AM J PHYSIOL-HEART C, V278, PH1908##PRIEBE L, 1998, CIRC RES, V82, P1206, DOI 10.1161/01.RES.82.11.1206##QU ZL, 1999, AM J PHYSIOL-HEART C, V276, PH269##RICCIO ML, 1999, CIRC RES, V84, P955##RICE JJ, 1999, BIOPHYS J, V77, P1871, DOI 10.1016/S0006-3495(99)77030-X##RIVOLTA I, 2001, J BIOL CHEM, V276, P30623, DOI 10.1074/JBC.M104471200##RUSH S, 1978, IEEE T BIO-MED ENG, V25, P389, DOI 10.1109/TBME.1978.326270##TAGGART P, 2000, J MOL CELL CARDIOL, V32, P621, DOI 10.1006/JMCC.2000.1105##TEN TUSSCHER KHWJ, 2006, AM J PHYSIOL-HEART C, V291, PH1088, DOI 10.1152/AJPHEART.00109.2006##TEN TUSSCHER KHWJ, 2004, PHYS REV LETT, V93, DOI 10.1103/PHYSREVLETT.93.108106##TEN TUSSCHER KHWJ, 2004, AM J PHYSIOL-HEART C, V286, PH1573, DOI 10.1152/AJPHEART.00794.2003##WEI J, 1999, CIRCULATION, V99, P3165, DOI 10.1161/01.CIR.99.24.3165##WETTWER E, 1994, CIRC RES, V75, P473, DOI 10.1161/01.RES.75.3.473##WINSLOW RL, 1999, CIRC RES, V84, P571, DOI 10.1161/01.RES.84.5.571##XIE F, 2001, AM J PHYSIOL-HEART C, V280, PH1667##ZENG JL, 1995, CIRC RES, V77, P140, DOI 10.1161/01.RES.77.1.140##ZHANG H, 2000, AM J PHYSIOL-HEART C, V279, PH397",120,2020-11-20,NA,"UNIV UTRECHT","NETHERLANDS"
"J","WOS:000242575100012",2006,"CHANGE IN THE MORPHOLOGY OF RBTIOPO4 INTRODUCED BY THE PRESENCE OF NB","RBTIOPO4 CRYSTALS DOPED WITH NB SHOW AN IMPORTANT FLATTENING OF THE MORPHOLOGY THAT MAKES THEIR USE DIFFICULT IN NONLINEAR OPTICS APPLICATIONS. HERE, WE IDENTIFY THE POSSIBLE CAUSES OF THIS MORPHOLOGICAL CHANGE: NB ACTS AS AN IMPURITY THAT BRAKES THE VELOCITY OF GROWTH OF THE {100} FACES AND MODIFIES THE GROWTH MECHANISM OF {201} FACES OF THE CRYSTALS. WE ALSO PROPOSE A WAY OF OBTAINING ISOMETRIC CRYSTALS BY FORCING CRYSTAL GROWTH IN THE A CRYSTALLOGRAPHIC DIRECTION. THIS CAUSES A NEW CHANGE IN MORPHOLOGY WITH BENEFITS FOR LATER NONLINEAR OPTICS APPLICATIONS DUE TO THE LARGER USEFUL AREA OBTAINED IN THE X-Y PLANE.","POTASSIUM TITANYL PHOSPHATE; SEEDED SOLUTION GROWTH; KTP SINGLE-CRYSTALS; KTIOPO4; NIOBIUM",NA,"CRYSTAL GROWTH & DESIGN","CARVAJAL, JJ##WOENSDREGT, CF##SOLE, R##DIAZ, F##AGUILO, M","UNIV ROVIRA & VIRGILI, TARRAGONA 43007, SPAIN. UNIV UTRECHT, DEPT PETROL, FAC GEOSCI, NL-3508 TA UTRECHT, NETHERLANDS.","CHEMISTRY, MULTIDISCIPLINARY; CRYSTALLOGRAPHY; MATERIALS SCIENCE, MULTIDISCIPLINARY","CHEMISTRY; CRYSTALLOGRAPHY; MATERIALS SCIENCE","BOLT RJ, 1992, J CRYST GROWTH, V19, P329##CARVAJAL JJ, 2000, CHEM MATER, V12, P3171, DOI 10.1021/CM000305C##CARVAJAL JJ, 2003, CHEM MATER, V15, P2730, DOI 10.1021/CM0340936##CARVAJAL JJ, 2001, CRYST GROWTH DES, V1, P479, DOI 10.1021/CG015528##CARVAJAL JJ, 2003, CHEM MATER, V15, P2338, DOI 10.1021/CM034044T##CARVAJAL JJ, 2002, CHEM MATER, V14, P3136, DOI 10.1021/CM0200745##CARVAJAL JJ, UNPUB##CARVAJAL JJ, 2001, J ALLOY COMPD, V231, P323##CHENG L. K., 1993, FERROELECTRICS, V142, P209, DOI 10.1080/00150199308237899##CHENG LT, 1994, APPL PHYS LETT, V64, P155, DOI 10.1063/1.111549##DOWTY E, 1995, SHAPE WINDOWS VERSIO##HAGERMAN ME, 1995, CHEM MATER, V7, P602, DOI 10.1021/CM00052A004##ILIEV K, 1990, J CRYST GROWTH, V100, P225, DOI 10.1016/0022-0248(90)90626-V##KIM JH, 1995, J CRYST GROWTH, V147, P343, DOI 10.1016/0022-0248(94)00637-7##MOORTHY SG, 1999, MAT SCI ENG B-SOLID, V60, P88, DOI 10.1016/S0921-5107(99)00031-8##OSELEDCHIK YS, 1994, OPT MATER, V3, P237, DOI 10.1016/0925-3467(94)90035-3##PAVLOVA N. I., 1986, SOVIET PHYSICS - CRYSTALLOGRAPHY, V31, P87##PUOCHOU JL, 1984, RECH AEROSPATIALE, V3, P13##RICO M, 1998, J PHYS-CONDENS MAT, V10, P10101, DOI 10.1088/0953-8984/10/44/015##SATYANARAYAN MN, 1999, CRIT REV SOLID STATE, V24, P103, DOI 10.1080/10408439991329189##SOLE R, 1997, CHEM MATER, V9, P2745, DOI 10.1021/CM960644Z##THOMAS PA, 1992, ACTA CRYSTALLOGR B, V48, P401, DOI 10.1107/S0108768192002465##VORONKOVA V. I., 1986, SOVIET PHYSICS - CRYSTALLOGRAPHY, V31, P123##VORONKOVA VI, 2005, CRYSTALLOGR REP+, V50, P137, DOI 10.1134/1.1857260##WANG JY, 1997, CRYST RES TECHNOL, V32, P319, DOI 10.1002/CRAT.2170320216",12,2020-11-20,NA,"UNIV ROVIRA VIRGILI#UNIV UTRECHT","SPAIN#NETHERLANDS"
"J","WOS:000242642300025",2006,"THE SCOPE AND LIMITS OF TOP-DOWN ATTENTION IN UNCONSCIOUS VISUAL PROCESSING","ATTENTIONAL SELECTION PLAYS A CRITICAL ROLE IN CONSCIOUS PERCEPTION. WHEN ATTENTION IS DIVERTED, EVEN SALIENT STIMULI FAIL TO REACH VISUAL AWARENESS [1, 2]. ATTENTION CAN BE VOLUNTARILY DIRECTED TO A SPATIAL LOCATION [3-9] OR A VISUAL FEATURE [9-14] FOR FACILITATING THE PROCESSING OF INFORMATION RELEVANT TO CURRENT GOALS. IN EVERYDAY SITUATIONS, ATTENTION AND AWARENESS ARE TIGHTLY COUPLED. THIS HAS LED SOME TO SUGGEST THAT ATTENTION AND AWARENESS MIGHT BE BASED ON A COMMON NEURAL FOUNDATION [15, 16], WHEREAS OTHERS ARGUE THAT THEY ARE MEDIATED BY DISTINCT MECHANISMS [17-19]. A BODY OF EVIDENCE SHOWS THAT VISUAL STIMULI CAN BE PROCESSED AT MULTIPLE STAGES OF THE VISUAL-PROCESSING STREAMS WITHOUT EVOKING VISUAL AWARENESS [20-22]. TO ILLUMINATE THE RELATIONSHIP BETWEEN VISUAL ATTENTION AND CONSCIOUS PERCEPTION, WE INVESTIGATED WHETHER TOP-DOWN ATTENTION CAN TARGET AND MODULATE THE NEURAL REPRESENTATIONS OF UNCONSCIOUSLY PROCESSED VISUAL STIMULI. OUR EXPERIMENTS SHOW THAT SPATIAL ATTENTION CAN TARGET ONLY CONSCIOUSLY PERCEIVED STIMULI, WHEREAS FEATURE-BASED ATTENTION CAN MODULATE THE PROCESSING OF INVISIBLE STIMULI. THE ATTENTIONAL MODULATION OF UNCONSCIOUS SIGNALS IMPLIES THAT ATTENTION AND AWARENESS CAN BE DISSOCIATED, CHALLENGING A SIMPLISTIC VIEW OF THE BOUNDARY BETWEEN CONSCIOUS AND UNCONSCIOUS VISUAL PROCESSING.","LATERAL GENICULATE-NUCLEUS; BINOCULAR-RIVALRY; SELECTIVE ATTENTION; NEURAL MECHANISMS; AREAS V1; CORTEX; V4; ORIENTATION; ADAPTATION; AWARENESS",NA,"CURRENT BIOLOGY","KANAI, R##TSUCHIYA, N##VERSTRATEN, FAJ","UNIV UTRECHT, HELMHOLTZ INST, DEPT EXPT PSYCHOL, NL-3584 CS UTRECHT, NETHERLANDS. CALTECH, DIV BIOL, PASADENA, CA 91125 USA. CALTECH, DIV HUMANITIES & SOCIAL SCI, PASADENA, CA 91125 USA.","BIOCHEMISTRY & MOLECULAR BIOLOGY; BIOLOGY; CELL BIOLOGY","BIOCHEMISTRY & MOLECULAR BIOLOGY; LIFE SCIENCES & BIOMEDICINE - OTHER TOPICS; CELL BIOLOGY","CLIFFORD CWG, 2000, P ROY SOC B-BIOL SCI, V267, P1705, DOI 10.1098/RSPB.2000.1198##DEHAENE S, 2006, TRENDS COGN SCI, V10, P204, DOI 10.1016/J.TICS.2006.03.007##DESIMONE R, 1995, ANNU REV NEUROSCI, V18, P193, DOI 10.1146/ANNUREV.NEURO.18.1.193##GIBSON JJ, 1937, J EXP PSYCHOL, V20, P453, DOI 10.1037/H0059826##HAYDEN BY, 2005, NEURON, V47, P637, DOI 10.1016/J.NEURON.2005.07.020##HAYNES JD, 2005, NATURE, V438, P496, DOI 10.1038/NATURE04169##HAYNES JD, 2005, NAT NEUROSCI, V8, P686, DOI 10.1038/NN1445##HE S, 2001, NATURE, V411, P473, DOI 10.1038/35078072##HUK AC, 2001, NEURON, V32, P161, DOI 10.1016/S0896-6273(01)00452-4##JIN DZ, 2005, J NEUROPHYSIOL, V94, P4038, DOI 10.1152/JN.00571.2004##JOSEPH JS, 1997, NATURE, V387, P805, DOI 10.1038/42940##KASTNER S, 1999, NEURON, V22, P751, DOI 10.1016/S0896-6273(00)80734-5##KENTRIDGE RW, 1999, P ROY SOC B-BIOL SCI, V266, P1805, DOI 10.1098/RSPB.1999.0850##KOCH C, IN PRESS TRENDS COGN##KOHN A, 2004, NAT NEUROSCI, V7, P764, DOI 10.1038/NN1267##LAMME VAF, 2003, TRENDS COGN SCI, V7, P12, DOI 10.1016/S1364-6613(02)00013-X##LAMME VAF, 2000, TRENDS NEUROSCI, V23, P571, DOI 10.1016/S0166-2236(00)01657-X##LEOPOLD DA, 1996, NATURE, V379, P549, DOI 10.1038/379549A0##LOGOTHETIS NK, 1989, SCIENCE, V245, P761, DOI 10.1126/SCIENCE.2772635##LUCK SJ, 1997, J NEUROPHYSIOL, V77, P24##MACK A., 1998, INATTENTIONAL BLINDN##MARTINEZ-TRUJILLO JC, 2004, CURR BIOL, V14, P744, DOI 10.1016/J.CUB.2004.04.028##MCADAMS CJ, 2000, J NEUROPHYSIOL, V83, P1751##MEHTA SD, 2000, CEREB CORTEX, V10, P343, DOI 10.1093/CERCOR/10.4.343##MELCHER D, 2005, NEURON, V46, P723, DOI 10.1016/J.NEURON.2005.04.023##MITCHELL JF, 2004, NATURE, V429, P410, DOI 10.1038/NATURE02584##MORAN J, 1985, SCIENCE, V229, P782, DOI 10.1126/SCIENCE.4023713##MOTTER BC, 1993, J NEUROPHYSIOL, V70, P909##NACCACHE L, 2002, PSYCHOL SCI, V13, P416, DOI 10.1111/1467-9280.00474##O'REGAN JK, 2001, BEHAV BRAIN SCI, V24, P939, DOI 10.1017/S0140525X01000115##RAJIMEHR R, 2004, NEURON, V41, P663, DOI 10.1016/S0896-6273(04)00041-8##REYNOLDS JH, 1999, J NEUROSCI, V19, P1736##REYNOLDS JH, 2000, NEURON, V26, P703, DOI 10.1016/S0896-6273(00)81206-4##ROSSI AF, 1995, VISION RES, V35, P621, DOI 10.1016/0042-6989(94)00156-G##SAENZ M, 2002, NAT NEUROSCI, V5, P631, DOI 10.1038/NN876##SPIVEY MJ, 2000, PERCEPT PSYCHOPHYS, V62, P1525, DOI 10.3758/BF03212153##SUMNER P, 2006, P NATL ACAD SCI USA, V103, P10520, DOI 10.1073/PNAS.0601974103##TONG F, 2001, NATURE, V411, P195, DOI 10.1038/35075583##TOOTELL RBH, 1998, NEURON, V21, P1409, DOI 10.1016/S0896-6273(00)80659-5##TREUE S, 1999, NATURE, V399, P575, DOI 10.1038/21176##TREUE S, 1996, NATURE, V382, P539, DOI 10.1038/382539A0##TSUCHIYA N, 2005, NAT NEUROSCI, V8, P1096, DOI 10.1038/NN1500##WUNDERLICH K, 2005, NAT NEUROSCI, V8, P1595, DOI 10.1038/NN1554",93,2020-11-20,NA,"UNIV UTRECHT#CALTECH#CALTECH","NETHERLANDS#CA USA#CA USA"
"J","WOS:000243077400011",2006,"NICKEL THIOLATE COMPLEXES AS LIGANDS FOR COPPER AND ZINC: NOVEL ADDITIONS TO A LIBRARY OF BINDING MODES","THE REACTIVITY OF THE TWO NICKEL COMPLEXES [NI(XBSMS)] AND [NI(BSMS)(2)] [H(2)XBSMS = ALPHA,ALPHA'-BIS(4-MERCAPTO-3,3-DIMETHYL-2-THIABUTYL)-O-XYLENE; HBSMS = 4-MERCAPTO-3,3-DIMETHYL-LPHENYL-2-THIABUTANE] TOWARDS COPPER IODIDE AND ZINC BROMIDE HAS BEEN INVESTIGATED. THE REACTIONS YIELD NOVEL AGGREGATES OF HIGHER NUCLEARITY WITH TOPOLOGIES THAT ARE DIFFERENT FROM PREVIOUS REPORTS; THE NICKEL COMPLEXES IN ALL CASES CAN BE CONSIDERED AS DIDENTATE S LIGANDS. THE X-RAY STRUCTURE OF THE NOVEL OCTANUCLEAR CLUSTER [{NI(BSMS)(2)}(3)(CUI)(5)] SHOWS A UNIQUE ARRANGEMENT IN WHICH THE CIS-NIS2S'(2) UNITS ACT AS DIDENTATE LIGANDS TO A TRIGONAL-BIPYRAMIDAL ARRAY OF FIVE CU-I IONS. THE TETRANUCLEAR STRUCTURE OF [{NI(XBSMS)CUI}(2)] SHOWS UNPRECEDENTED ASYMMETRIC BRIDGING OF THE THIOLATE SULFUR ATOMS, WITH ONE OF THE THIOLATE GROUPS BINDING TO ONE COPPER ION AND THE OTHER ONE MU(3)-BRIDGING TO TWO COPPER IONS. THE COMPLEX IS LOCATED ON A CRYSTALLOGRAPHIC TWOFOLD AXIS AND THE COMPLEX IN A SINGLE CRYSTAL IS ENANTIOMERICALLY PURE. THE TRINUCLEAR COMPLEX [NI-2(BSMS)(3)ZNBR3] IS FORMED AS A RESULT OF DISSOCIATION OF THE DIDENTATE BSMS LIGAND FROM PART OF THE MONONUCLEAR COMPLEX AND REASSEMBLY TO FORM A DINUCLEAR CORE TO WHICH THE ZNBR3- UNIT IS COORDINATED TO A SINGLE THIOLATE SULFUR ATOM. A COMPLEX OF STOICHIOMETRY [NI-3(XBSMS)(2)-(ZNBR3)(2)] HAS ALSO BEEN ISOLATED AND A STRUCTURE PROPOSAL BASED ON SPECTROSCOPIC PROPERTIES IS GIVEN. ALL COMPLEXES HAVE BEEN CHARACTERISED BY ANALYTICAL AND SPECTROSCOPIC METHODS. (C) WILEY-VCH VERLAG GMBH & CO.","COENZYME-A SYNTHASE; DEHYDROGENASE/ACETYL-COA SYNTHASE; CRYSTAL-STRUCTURES; CATALYTIC SITE; ACTIVE-SITE; CLUSTER; CU; HYDROGENASES; REFINEMENT; REACTIVITY","NICKEL; COPPER; ZINC; S LIGANDS; CLUSTER COMPOUNDS","EUROPEAN JOURNAL OF INORGANIC CHEMISTRY","VERHAGEN, JAW##TOCK, C##LUTZ, M##SPEK, AL##BOUWMAN, E","LEIDEN UNIV, GORLAEUS LABS, LEIDEN INST CHEM, NL-2300 RA LEIDEN, NETHERLANDS. UNIV UTRECHT, BIJVOET CTR BIOMOL RES CRYSTAL & STRUCT CHEM, NL-3508 TC UTRECHT, NETHERLANDS.","CHEMISTRY, INORGANIC & NUCLEAR","CHEMISTRY","ALTOMARE A, 1999, J APPL CRYSTALLOGR, V32, P115, DOI 10.1107/S0021889898007717##AMOROSO AJ, 2003, CHEM COMMUN, P2020, DOI 10.1039/B303851C##BAUMGARTNER M, 1993, INORG CHIM ACTA, V208, P135, DOI 10.1016/S0020-1693(00)85113-0##BOUWMAN E, 1999, EUR J INORG CHEM, P217##BOWMAKER GA, 1984, POLYHEDRON, V3, P535, DOI 10.1016/S0277-5387(00)88084-5##CHALBOT MU, 2003, EUR J INORG CHEM, P453##DARNAULT C, 2003, NAT STRUCT BIOL, V10, P271, DOI 10.1038/NSB912##DOUKOV TI, 2002, SCIENCE, V298, P567, DOI 10.1126/SCIENCE.1075843##DRENNAN CL, 2004, J BIOL INORG CHEM, V9, P511, DOI 10.1007/S00775-004-0563-Y##DUISENBERG AJM, 2003, J APPL CRYSTALLOGR, V36, P220, DOI 10.1107/S0021889802022628##GOLDEN ML, 2003, CHEM COMMUN, P1824, DOI 10.1039/B304884P##GOLDEN ML, 2004, EUR J INORG CHEM, P231, DOI 10.1002/EJIC.200300675##GOLDEN ML, 2005, INORG CHEM, V44, P875, DOI 10.1021/IC0489701##HARROP TC, 2004, J AM CHEM SOC, V126, P14714, DOI 10.1021/JA045284S##HERBST-IRMER R, 1998, ACTA CRYSTALLOGR B, V54, P443, DOI 10.1107/S0108768197018454##KAASJAGER VE, 2002, INORG CHEM, V41, P1837, DOI 10.1021/IC010784X##KAASJAGER VE, 1998, ANGEW CHEM INT EDIT, V37, P1668, DOI 10.1002/(SICI)1521-3773(19980703)37:12<1668::AID-ANIE1668>3.0.CO;2-J##KAASJAGER VE, 2001, INORG CHIM ACTA, V316, P99, DOI 10.1016/S0020-1693(01)00393-0##KAASJAGER VE, 2000, INORG CHIM ACTA, V310, P183, DOI 10.1016/S0020-1693(00)00285-1##KONNO T, 2004, CHEM COMMUN, P2296, DOI 10.1039/B404512B##KRISHNAN R, 2003, J AM CHEM SOC, V125, P4422, DOI 10.1021/JA0346577##KRISHNAN R, 2004, J AM CHEM SOC, V126, P4484, DOI 10.1021/JA038086U##LINCK RC, 2003, J AM CHEM SOC, V125, P8700, DOI 10.1021/JA035606C##MILLER ML, 2003, INORG CHEM, V42, P2999, DOI 10.1021/IC0262684##RAO CP, 1986, INORG CHEM, V25, P428, DOI 10.1021/IC00224A011##RAO PV, 2004, INORG CHEM, V43, P5833, DOI 10.1021/IC040055S##SPEK AL, 2003, J APPL CRYSTALLOGR, V36, P7, DOI 10.1107/S0021889802022112##VERHAGEN JAW, 2004, INORG CHIM ACTA, V357, P2687, DOI 10.1016/J.ICA.2004.02.003##VERHAGEN JAW, 2003, EUR J INORG CHEM, P3968, DOI 10.1002/EJIC.200300285##VERHAGEN JAW, 2002, J CHEM SOC DALTON, P1275, DOI 10.1039/B110332F##VERHAGEN JAW, 2004, THESIS LEIDEN U LEID##WANG Q, 2004, CHEM-EUR J, V10, P3384, DOI 10.1002/CHEM.200305738##WANG Q, 2003, CHEM COMMUN, P3012, DOI 10.1039/B310183E##WINGE DR, 1993, BIOINORGANIC CHEM CO, V1, P110",7,2020-11-20,NA,"LEIDEN UNIV#UNIV UTRECHT","NETHERLANDS#NETHERLANDS"
"J","WOS:000242864100010",2006,"CARPAL MYXOSARCOMA AND FORELIMB AMPUTATION IN A FERRET (MUSTELA PUTORIUS FURO)",NA,"SURGICAL EXCISION; VACCINATION; PROGNOSIS; TUMORS",NA,"VETERINARY RECORD","VAN ZEELAND, YRA##HERNANDEZ-DIVERS, SJ##BLASIER, MW##VILA-GARCIA, G##DELONG, D##STEDMAN, NL","UNIV UTRECHT, FAC VET MED, DEPT SMALL ANIM MED, NL-3508 TC UTRECHT, NETHERLANDS. UNIV GEORGIA, DEPT SMALL ANIM MED & SURG, COLL VET MED, ATHENS, GA 30602 USA. UNIV GEORGIA, DEPT PATHOL, COLL VET MED, ATHENS, GA 30602 USA. UNIV LONDON ROYAL VET COLL, LONDON NW1 0TU, ENGLAND. AVALON ANIM HOSP, LAWRENCEVILLE, GA 30044 USA.","VETERINARY SCIENCES","VETERINARY SCIENCES","BEACH JE, 1993, J COMP PATHOL, V108, P133, DOI 10.1016/S0021-9975(08)80217-4##BOSTOCK DE, 1980, VET PATHOL, V17, P581, DOI 10.1177/030098588001700507##BRIGGS OM, 1997, J S AFR VET ASSOC, V68, P144##BRISCOE CM, 1998, J VET DIAGN INVEST, V10, P79, DOI 10.1177/104063879801000114##BROWN SA, 1997, FERRETS RABBITS RODE, P99##COUTO CG, 1998, J AM VET MED ASSOC, V213, P1426##CRAIG LE, 2002, VET PATHOL, V39, P66, DOI 10.1354/VP.39-1-66##DAVIDSON EB, 1997, VET SURG, V26, P265, DOI 10.1111/J.1532-950X.1997.TB01497.X##FUDGE AM, 2000, LAB MED AVIAN EXOTIC, P375##GOAD MEP, 1998, BIOL DIS FERRET, P274##GOLDSCHMIDT M. H., 2002, TUMORS IN DOMESTIC ANIMALS, P45, DOI 10.1002/9780470376928.CH2##HERSHEY AE, 2000, J AM VET MED ASSOC, V216, P58, DOI 10.2460/JAVMA.2000.216.58##KASS PH, 1993, J AM VET MED ASSOC, V203, P396##MACKENZIE DH, 1981, AM J SURG PATHOL, V5, P443, DOI 10.1097/00000478-198107000-00004##MADEWELL BR, 1987, VET CANCER MED, P233##MUNDAY JS, 2003, VET PATHOL, V40, P288, DOI 10.1354/VP.40-3-288##MURRAY J, 1998, J AM VET MED ASSOC, V213, P955##PARKER GA, 1993, VET PATHOL, V30, P499, DOI 10.1177/030098589303000602##RICHTER M, 2003, VET OPHTHALMOL, V6, P183, DOI 10.1046/J.1463-5224.2003.00289.X##STANNARD AA, 1978, TUMOURS DOMESTIC ANI, P48##WEIGEL JP, 2002, TXB SMALL ANIMAL SUR, P2180",7,2020-11-20,NA,"UNIV UTRECHT#UNIV GEORGIA#UNIV GEORGIA#UNIV LONDON ROYAL VET COLL#AVALON ANIM HOSP","NETHERLANDS#GA USA#GA USA#ENGLAND#GA USA"
"J","WOS:000242434600079",2006,"GAMMA-TRIS(2,4-PENTANEDIONATO-KAPPA O-2,O ')ALUMINIUM(III) AT 110 K","THE TITLE COMPOUND, [AL(C5H7O2)(3)], WAS REINVESTIGATED AT 110 K TO PROVIDE INFORMATION ON THERMAL VIBRATIONS IN THE STRUCTURE, COMPARING IT TO THE PREVIOUSLY PUBLISHED STRUCTURE BY MCCLELLAND [ACTA CRYST. (1975), B31, 2496-2498] BASED ON ROOM-TEMPERATURE DATA. THE GAMMA-POLYMORPH CONTAINS FOUR INDEPENDENT MOLECULES IN THE ASYMMETRIC UNIT WITH THEIR CENTERS OF GRAVITY AT PSEUDO-SPECIAL POSITIONS.","PROGRAM",NA,"ACTA CRYSTALLOGRAPHICA SECTION E-CRYSTALLOGRAPHIC COMMUNICATIONS","VON CHRZANOWSKI, LS##LUTZ, M##SPEK, AL","UNIV UTRECHT, BIJVOET CTR BIOMOL RES CRYSTAL & STRUCT CHEM, NL-3584 CH UTRECHT, NETHERLANDS.","CRYSTALLOGRAPHY","CRYSTALLOGRAPHY","ABRAHAMS SC, 1971, ACTA CRYSTALL A-CRYS, VA 27, P157, DOI 10.1107/S0567739471000305##DUISENBERG AJM, 2003, J APPL CRYSTALLOGR, V36, P220, DOI 10.1107/S0021889802022628##FLACK HD, 2000, J APPL CRYSTALLOGR, V33, P1143, DOI 10.1107/S0021889800007184##FLACK HD, 1983, ACTA CRYSTALLOGR A, V39, P876, DOI 10.1107/S0108767383001762##HUMMEL W, 1990, J MOL GRAPHICS, V8, P214, DOI 10.1016/0263-7855(90)80006-2##MCCLELLAND BW, 1975, ACTA CRYSTALLOGR B, V31, P2496, DOI 10.1107/S056774087500787X##NONIUS, 1999, COLLECT##PILATI T, 1998, J APPL CRYSTALLOGR, V31, P503, DOI 10.1107/S0021889898002180##SCHOMAKER V, 1998, ACTA CRYSTALLOGR B, V54, P507, DOI 10.1107/S0108768198003243##SCHREURS AMM, 2005, PEAKREF##SHELDRICK G. M., 1997, SHELXL97##SHELDRICK G.M., 2002, SADABS##SPEK AL, 2003, J APPL CRYSTALLOGR, V36, P7, DOI 10.1107/S0021889802022112",8,2020-11-20,NA,"UNIV UTRECHT","NETHERLANDS"
"J","WOS:000242623300012",2006,"RELATION BETWEEN SIZE OF ANEURYSMS AND RISK OF REBLEEDING IN PATIENTS WITH SUBARACHNOID HAEMORRHAGE","BACKGROUND AND PURPOSE. FEW RISK FACTORS HAVE BEEN IDENTIFIED FOR REBLEEDING IN PATIENTS WITH SUBARACHNOID HAEMORRHAGE. WE STUDIED WHETHER SIZE OF ANEURYSM AFTER RUPTURE IS A RISK FACTOR FOR REBLEEDING. SINCE INTRACRANIAL ANEURYSMS DEVELOP DURING LIFE AND MAY THEREFORE BE LARGER AT AN OLDER AGE, WE ALSO ASSESSED WHETHER AGE CONFOUNDS A RELATION BETWEEN SIZE AND REBLEEDING. METHODS. WE STUDIED ALL PATIENTS WITH ANEURYSMAL SUBARACHNOID HAEMORRHAGE ADMITTED BETWEEN 1995 AND 2000. SINCE 1995 CT-ANGIOGRAPHY IS OBTAINED IN ALL PATIENTS ON ADMISSION. PATIENTS WERE FOLLOWED UNTIL REBLEEDING, OPERATION, DISCHARGE OR DEATH. FOR THE RELATION BETWEEN SIZE AND RISK OF REBLEEDING WE USED COX PROPORTIONAL HAZARDS MODELLING. RESULTS. WE INCLUDED 354 PATIENTS. REBLEEDING OCCURRED IN 22 (30%) OF THE 73 PATIENTS WITH A LARGE (> 10 MM) ANEURYSM, AND IN 68 (24%) OF THE 281 PATIENTS WITH A SMALL (<= 10 MM) ANEURYSM (HAZARD RATIO FOR LARGE ANEURYSMS 1.6 (95% CONFIDENCE INTERVAL [CI] 1.0-2.6)). WITHIN THE FIRST THREE DAYS REBLEEDING OCCURRED IN 14 (19.2%) PATIENTS WITH A LARGE ANEURYSM AND IN 25 (8.9%) PATIENTS WITH A SMALL ANEURYSM (HAZARD RATIO 2.4 (95% CI 1.2-4.5)). AFTER ADJUSTMENT FOR AGE, ALL HAZARD RATIOS REMAINED ESSENTIALLY THE SAME. CONCLUSION. PATIENTS WITH LARGE ANEURYSMS HAVE A HIGHER RISK FOR REBLEEDING, IN PARTICULAR WITHIN THE FIRST THREE DAYS AFTER THE INITIAL HAEMORRHAGE. THIS INCREASED RISK IS INDEPENDENT OF AGE.","INTRACRANIAL ANEURYSMS","ANEURYSM; SUBARACHNOID HAEMORRHAGE; COMPLICATION; AGE","ACTA NEUROCHIRURGICA","PLEIZIER, CM##ALGRA, A##VELTHUIS, BK##RINKEL, GJE","UNIV UTRECHT, MED CTR, DEPT NEUROL, RUDOLF MAGNUS INST NEUROSCI, NL-3500 GA UTRECHT, NETHERLANDS. UNIV UTRECHT, MED CTR, JULIUS CTR HLTH SCI & PRIMARY CARE, NL-3500 GA UTRECHT, NETHERLANDS. UNIV UTRECHT, MED CTR, DEPT RADIOL, NL-3500 GA UTRECHT, NETHERLANDS.","CLINICAL NEUROLOGY; SURGERY","NEUROSCIENCES & NEUROLOGY; SURGERY","DRAKE CG, 1988, J NEUROSURG, V68, P985##JUVELA S, 2001, STROKE, V32, P485, DOI 10.1161/01.STR.32.2.485##LANZINO G, 1996, J NEUROSURG, V85, P410, DOI 10.3171/JNS.1996.85.3.0410##LINN FHH, 1996, STROKE, V27, P625, DOI 10.1161/01.STR.27.4.625##POCOCK SJ, 2002, LANCET, V359, P1686, DOI 10.1016/S0140-6736(02)08594-X##RINKEL GJE, 1998, STROKE, V29, P251, DOI 10.1161/01.STR.29.1.251##ROOS EJ, 2000, NEUROLOGY, V54, P2334, DOI 10.1212/WNL.54.12.2334##ROOS YBWEM, 2000, J NEUROL NEUROSUR PS, V68, P337, DOI 10.1136/JNNP.68.3.337##WIEBERS D, 2003, LANCET, V362, P103, DOI 10.1016/S0140-6736(03)13860-3",16,2020-11-20,NA,"UNIV UTRECHT#UNIV UTRECHT#UNIV UTRECHT","NETHERLANDS#NETHERLANDS#NETHERLANDS"
"J","WOS:000241762500017",2006,"THE KEY ROLE OF ELECTROPHYSIOLOGY IN THE DIAGNOSIS OF VISUALLY IMPAIRED CHILDREN","PURPOSE: TO DESCRIBE THE OUTCOME OF SPECIALIZED ELECTROPHYSIOLOGY IN VISUALLY IMPAIRED CHILDREN. METHODS: WE CARRIED OUT A RETROSPECTIVE EVALUATION OF 340 ELECTROPHYSIOLOGICAL EXAMINATIONS PERFORMED IN 298 CHILDREN OVER A 3-YEAR PERIOD (2001-2003), WITH REGARD TO DEMOGRAPHIC DATA, REFERRAL PATTERN, DEGREE OF COMPLIANCE, AND DIAGNOSTIC RESULTS. ELECTROPHYSIOLOGY WAS PERFORMED WITHOUT SEDATION OR ANAESTHESIA. IN ELECTRORETINOGRAMS, DTL ELECTRODES WERE USED IN COMBINATION WITH ONLINE SELECTION OF RESPONSES. VISUAL EVOKED POTENTIALS TESTING WAS PERFORMED WITH SEVEN ACTIVE OCCIPITAL ELECTRODES. RESULTS: THE MEAN AGE OF THE CHILDREN WAS 7 +/- 5 YEARS; 72 (24%) OF THE CHILDREN WERE MENTALLY AS WELL AS VISUALLY IMPAIRED. MAIN REASONS FOR REFERRAL WERE SUSPECTED POSTERIOR SEGMENT DISEASE, ABNORMAL VISUAL DEVELOPMENT, UNEXPLAINED LOW VISION, HIGH MYOPIA, AND SUSPECTED ALBINISM. COMPLIANCE WAS GOOD IN 302/340 (88%), PARTIAL IN 24/340 (7%), AND ABSENT IN 14/340 (4%) OF THE EXAMINATIONS. OF THE 326 SUCCESSFUL PROCEDURES, 215 (66%) SHOWED ABNORMAL RESULTS. TAPETORETINAL DYSTROPHY (22%), OPTICOPATHY (16%), CONGENITAL STATIONARY NIGHT BLINDNESS (13%), AND CONE DYSTROPHY (11%) WERE THE MOST FREQUENTLY ESTABLISHED DIAGNOSES. ALBINISM WAS CONFIRMED IN 14 OF 24 SUSPECTED PATIENTS; ADDITIONALLY, UNSUSPECTED MISROUTING WAS FOUND IN SIX. IN 26 (9%) OF THE PATIENTS, A PREVIOUSLY ESTABLISHED DIAGNOSIS WAS CHANGED. CONCLUSIONS: IN A SPECIALIZED SETTING, ELECTROPHYSIOLOGICAL EXAMINATIONS CAN BE PERFORMED SUCCESSFULLY IN VISUALLY IMPAIRED CHILDREN. THE RESULTS ARE ESSENTIAL FOR THE FINAL OPHTHALMOLOGICAL DIAGNOSIS AND HAVE IMPORTANT CONSEQUENCES FOR REHABILITATION.","STATIONARY NIGHT BLINDNESS; ERG RESPONSES; DYSFUNCTION; MATURATION; CHILDHOOD; ACUITY; MATURE","ELECTRORETINOGRAPHY; VISUAL EVOKED POTENTIALS; VISUALLY IMPAIRED CHILDREN; CHILDHOOD BLINDNESS; DTL ELECTRODES; MISROUTING","ACTA OPHTHALMOLOGICA SCANDINAVICA","VAN GENDEREN, M##RIEMSLAG, F##JORRITSMA, F##HOEBEN, F##MEIRE, F##STILMA, J","BARTIMEUS INST VISUALLY IMPAIRED, ZEIST, NETHERLANDS. UNIV CHILDRENS HOSP KONINGIN FABIOLA, BRUSSELS, BELGIUM. GHENT UNIV HOSP, B-9000 GHENT, BELGIUM. UNIV UTRECHT, MED CTR, DEPT OPHTHALMOL, UTRECHT, NETHERLANDS.","OPHTHALMOLOGY","OPHTHALMOLOGY","ALAGARATNAM J, 2002, EYE, V16, P557, DOI 10.1038/SJ.EYE.6700149##ALTMAN DG, 1997, PRACTICAL STAT MED R, P60##APKARIAN P, 1984, EXP BRAIN RES, V53, P285##BLOHME J, 1997, ACTA OPHTHALMOL SCAN, V75, P681##BRECELJ J, 2003, DOC OPHTHALMOL, V107, P215, DOI 10.1023/B:DOOP.0000005330.62543.9C##BRECELJ J, 2004, CLIN NEUROPHYSIOL, V115, P461, DOI 10.1016/J.CLINPH.2003.10.011##DAWSON WW, 1979, INVEST OPHTH VIS SCI, V18, P988##DUTTON G N, 2001, SEMIN NEONATOL, V6, P477, DOI 10.1053/SINY.2001.0078##FLANAGAN NM, 2003, CHILD CARE HLTH DEV, V29, P493, DOI 10.1046/J.1365-2214.2003.00369.X##FLITCROFT DI, 2005, BRIT J OPHTHALMOL, V89, P484, DOI 10.1136/BJO.2004.045328##FULTON AB, 2003, DOC OPHTHALMOL, V107, P235, DOI 10.1023/B:DOOP.0000005332.88367.B8##HANSEN E, 1992, ACTA OPHTHALMOL, V70, P597##HENNESSY MP, 1995, DOC OPHTHALMOL, V89, P235, DOI 10.1007/BF01203377##JACOBSON LK, 2000, SURV OPHTHALMOL, V45, P1, DOI 10.1016/S0039-6257(00)00134-X##KELLY JP, 2003, DOC OPHTHALMOL, V106, P289, DOI 10.1023/A:1022909328103##KOCUR I, 2002, BRIT J OPHTHALMOL, V86, P716, DOI 10.1136/BJO.86.7.716##KRISS A, 1994, INT J PSYCHOPHYSIOL, V16, P137, DOI 10.1016/0167-8760(89)90040-8##LOEWERSIEGER DH, 1975, CHILD CARE HLTH DEV, V1, P275, DOI 10.1111/J.1365-2214.1975.TB00207.X##LORENZ B, 2001, KLIN MONATSBL AUGENH, V218, P3, DOI 10.1055/S-2001-11254##MANAHILOV V, 1992, ELECTROEN CLIN NEURO, V82, P220, DOI 10.1016/0013-4694(92)90171-D##MARMOR MF, 1995, DOC OPHTHALMOL, V89, P199, DOI 10.1007/BF01203373##MARR JE, 2001, EYE, V15, P70, DOI 10.1038/EYE.2001.17##MCCULLOCH DL, 1997, DOC OPHTHALMOL, V94, P327, DOI 10.1007/BF02580858##MICHAELIDES M, 2005, PEDIAT OPHTHALMOLOGY, P531##MIYAKE Y, 1987, INVEST OPHTH VIS SCI, V28, P1816##PONJAVIC V, 1999, OPHTHALMIC GENET, V20, P251, DOI 10.1076/OPGE.20.4.251.2270##RAHI JS, 2003, LANCET, V362, P1359, DOI 10.1016/S0140-6736(03)14631-4##ROSENBERG T, 1996, BRIT J OPHTHALMOL, V80, P49, DOI 10.1136/BJO.80.1.49##SALOMAO SR, 1995, INVEST OPHTH VIS SCI, V36, P657##SPEKREIJSE H, 1999, VISION RES, P216##SUNDIN OH, 2000, NAT GENET, V25, P289, DOI 10.1038/77162##TELLER DY, 1974, VISION RES, V14, P1433, DOI 10.1016/0042-6989(74)90018-2##TREMBLAY F, 2003, DOC OPHTHALMOL, V107, P271, DOI 10.1023/B:DOOP.0000005336.08147.FC##WELEBER RG, 1987, ARCH OPHTHALMOL-CHIC, V105, P360##WESTALL CA, 1999, DOC OPHTHALMOL, V96, P355, DOI 10.1023/A:1001856911730##*WHO, 1992, 457 WHO##YZER S, 2003, J MED GENET, V40, P709, DOI 10.1136/JMG.40.9.709##ZEITZ C, 2005, INVEST OPHTH VIS SCI, V46, P4328, DOI 10.1167/IOVS.05-0526",15,2020-11-20,NA,"BARTIMEUS INST VISUALLY IMPAIRED#UNIV CHILDRENS HOSP KONINGIN FABIOLA#GHENT UNIV HOSP#UNIV UTRECHT","NETHERLANDS#BELGIUM#BELGIUM#NETHERLANDS"
"J","WOS:000243125800027",2006,"DETERMINANTS OF COMPLIANCE WITH METHYLPHENIDATE THERAPY IN CHILDREN","AIM: TO GET MORE INSIGHT INTO FACTORS THAT INFLUENCE COMPLIANCE WITH THE USE OF METHYLPHENIDATE. METHODS: 22 PHARMACIES DETECTED CHILDREN WHO USED METHYLPHENIDATE. THEIR PARENTS WERE SENT A QUESTIONNAIRE ON THE USE OF METHYLPHENIDATE. IN A CASE-CONTROL STUDY, THE INFLUENCE OF PATIENT- AND DRUG-RELATED FACTORS ON COMPLIANCE, AS REPORTED BY PARENTS, WAS DETERMINED. RESULTS: PARENTS RETURNED 117 (75%) OF 157 QUESTIONNAIRES SENT OUT. OF THESE, 47.8% OF THE CHILDREN MISSED A DOSE TWO TIMES A MONTH OR MORE. FORGETTING TO TAKE THE MEDICATION (87.9%) WAS THE MOST IMPORTANT REASON. THE CASE-CONTROL STUDY SHOWED THAT CHILDREN OF 16-18 Y WERE MORE LIKELY TO MISS DOSES. OTHER PATIENT- AND DRUG-RELATED FACTORS DID NOT INFLUENCE THE MISSING OF DOSES. CONCLUSION: A NUMBER OF KNOWN DETERMINANTS FOR COMPLIANCE DO NOT INFLUENCE THE MISSING OF DOSES OF METHYLPHENIDATE. WITH ABOUT 80% OF THE PARENTS REPORTING THAT THEIR CHILD MISSED DOSES OF METHYLPHENIDATE LESS THAN 5 TIMES PER MONTH, COMPLIANCE WAS QUITE GOOD FOR THE MAJORITY OF THE CHILDREN.","ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; DEFICIT HYPERACTIVITY DISORDER; TRIAL","CASE-CONTROL STUDY; CHILDREN; COMPLIANCE; DETERMINANTS; EFFICACY; METHYLPHENIDATE; SIDE EFFECTS","ACTA PAEDIATRICA","HUGTENBURG, JG##WITTE, I##HEERDINK, ER","VRIJE UNIV AMSTERDAM, MED CTR, DEPT MED PHARMACOL, NL-1081 BT AMSTERDAM, NETHERLANDS. UNIV UTRECHT, FAC PHARMACEUT SCI, DEPT PHARMACOEPIDEMIOL & PHARMACOTHERAPY, NL-3508 TC UTRECHT, NETHERLANDS.","PEDIATRICS","PEDIATRICS","BARKLEY RA, 1990, PEDIATRICS, V86, P184##BROWN RT, 1987, J AM ACAD CHILD PSY, V26, P521, DOI 10.1097/00004583-198707000-00010##DIMATTEO MR, 2004, MED CARE, V42, P200, DOI 10.1097/01.MLR.0000114908.90348.F9##EFRON D, 1997, PEDIATRICS, V100, P662, DOI 10.1542/PEDS.100.4.662##EPSTEIN LH, 1984, HEALTH PSYCHOL, V3, P385, DOI 10.1037/0278-6133.3.4.385##FIRESTONE P, 1982, AM J ORTHOPSYCHIAT, V21, P474##*GEZ, 2000, PUBL GEZ##GREENHILL LL, 1999, J AM ACAD CHILD PSY, V38, P503, DOI 10.1097/00004583-199905000-00011##HUGTENBURG JG, 2005, PHARM WORLD SCI, V27, P197, DOI 10.1007/S11096-004-2848-1##JENSEN PS, 1999, ARCH GEN PSYCHIAT, V56, P1073##PAES AHP, 1997, DIABETES CARE, V20, P1512, DOI 10.2337/DIACARE.20.10.1512##PULLAR T, 1988, CLIN PHARMACOL THER, V44, P540, DOI 10.1038/CLPT.1988.191##SCHACHTER HA, 2001, CAN MED ASSOC J, V165, P1475##SWANSON J, 2003, CNS DRUGS, V17, P117, DOI 10.2165/00023210-200317020-00004##WEINTRAUB M, 1973, JAMA-J AM MED ASSOC, V224, P481, DOI 10.1001/JAMA.224.4.481",4,2020-11-20,NA,"VRIJE UNIV AMSTERDAM#UNIV UTRECHT","NETHERLANDS#NETHERLANDS"
"J","WOS:000241832900004",2006,"THE PERSISTENCE OF DEPRESSION SCORE","OBJECTIVE: TO CONSTRUCT A SCORE THAT ALLOWS PREDICTION OF MAJOR DEPRESSIVE EPISODE (MDE) PERSISTENCE IN INDIVIDUALS WITH MDE USING DETERMINANTS OF PERSISTENCE IDENTIFIED IN PREVIOUS RESEARCH. METHOD: DATA WERE DERIVED FROM 250 SUBJECTS FROM THE GENERAL POPULATION WITH NEW MDE ACCORDING TO DSM-III-R. THESE SUBJECTS WERE RECRUITED FROM THE NETHERLANDS MENTAL HEALTH SURVEY AND INCIDENCE STUDY (NEMESIS), USING THE COMPOSITE INTERNATIONAL DIAGNOSTIC INTERVIEW. DETERMINANTS FOR PERSISTENCE WERE TRANSFORMED INTO A PRACTICAL RISK SCORE USING PROPORTIONAL HAZARDS MODELS AND BOOTSTRAPPING TECHNIQUES. RESULTS: THE RISK OF MDE PERSISTENCE AFTER 12 MONTHS WAS 23%. THE SCORE COMPRISED MEASURES OF PHYSICAL ILLNESS, SOCIAL SUPPORT, DEPRESSION SEVERITY AND RECURRENCY, AND DURATION OF PREVIOUS EPISODES. WITH INCREASING CATEGORIES OF THESE MEASURES, THE PREDICTED RISKS INCREASED FROM 7 TO 40%. CONCLUSION: WE CONSTRUCTED THE PERSISTENCE OF DEPRESSION SCORE (PDS) SHOWING REASONABLE PERFORMANCE. THE PDS COULD BE OF IMPORTANCE IN CLINICAL PRACTICE TO SUPPORT TREATMENT DECISIONS.","MENTAL-HEALTH SURVEY; GENERAL-POPULATION; MAJOR DEPRESSION; PRIMARY-CARE; NEMESIS; EPISODES; PSYCHOPATHOLOGY; DISABILITY; DISORDERS; INTERVIEW","DEPRESSION; PROGNOSIS; RISK ASSESSMENT; GENERAL POPULATION","ACTA PSYCHIATRICA SCANDINAVICA","SPIJKER, J##DE GRAAF, R##ORMEL, J##NOLEN, WA##GROBBEE, DE##BURGER, H","NETHERLANDS INST MENTAL HLTH & ADDICT, TRIMBOS INST, NL-3500 AS UTRECHT, NETHERLANDS. INST MENTAL HLTH CARE, WOLFHEZE, NETHERLANDS. UNIV GRONINGEN, DEPT PSYCHIAT, MED CTR, GRONINGEN, NETHERLANDS. UNIV UTRECHT, JULIUS CTR HLTH SCI & PRIMARY CARE, MED CTR, UTRECHT, NETHERLANDS.","PSYCHIATRY","PSYCHIATRY","AMERICAN PSYCHIATRIC ASSOCIATION, 1987, DIAGN STAT MAN MENT##BIJL RV, 1998, SOC PSYCH PSYCH EPID, V33, P581, DOI 10.1007/S001270050097##DE GRAAF R, 2000, AM J EPIDEMIOL, V152, P1039, DOI 10.1093/AJE/152.11.1039##EFRON B, 1993, MONOGRAPHS STAT APPL, V57##FURUKAWA TA, 2000, BRIT J PSYCHIAT, V177, P331, DOI 10.1192/BJP.177.4.331##GILMER WS, 2005, ACTA PSYCHIAT SCAND, V112, P425, DOI 10.1111/J.1600-0447.2005.00633.X##HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/RADIOLOGY.143.1.7063747##HARRELL FE, 1982, JAMA-J AM MED ASSOC, V247, P2543, DOI 10.1001/JAMA.247.18.2543##HARRELL FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4##JUDD LL, 1997, ARCH GEN PSYCHIAT, V54, P989##KALKMAN CJ, 2003, PAIN, V105, P415, DOI 10.1016/S0304-3959(03)00252-5##KELLER MB, 1994, BRIT J PSYCHIAT, V165, P9, DOI 10.1192/S0007125000293239##LYKETSOS CG, 1994, INT J METHOD PSYCH, V4, P143##NASSER EH, 2005, ACTA PSYCHIAT SCAND, V111, P125, DOI 10.1111/J.1600-0447.2004.00423.X##*NAT I CLIN EXC, 2004, CLIN GUID NAT I CLIN, V23##ORMEL J, 1993, ARCH GEN PSYCHIAT, V50, P759##PAYKEL ES, 1996, PSYCHOL MED, V26, P121, DOI 10.1017/S0033291700033766##RAMANA R, 1995, PSYCHOL MED, V25, P1161, DOI 10.1017/S0033291700033134##SARGEANT JK, 1990, ARCH GEN PSYCHIAT, V47, P519##SMEETS R., 1993, COMPOSITE INT DIAGNO##SPIJKER J, 2004, J AFFECT DISORDERS, V81, P231, DOI 10.1016/J.JAD.2003.08.005##SPIJKER J, 2004, ACTA PSYCHIAT SCAND, V110, P208, DOI 10.1111/J.1600-0447.2004.00335.X##SPIJKER J, 2002, BRIT J PSYCHIAT, V181, P208, DOI 10.1192/BJP.181.3.208##SPIJKER J, 2001, ACTA PSYCHIAT SCAND, V104, P19, DOI 10.1034/J.1600-0447.2001.00363.X##TIEMENS BG, 1996, AM J PSYCHIAT, V153, P636##VAN DEN BRINK RHS, 2001, BRIT J PSYCHIAT, V178, P18##VERGOUWE YVONNE, 2002, SEMIN UROL ONCOL, V20, P96, DOI 10.1053/SURO.2002.32521##*WHO, 1990, COMP DIAGN INT CIDI##WITTCHEN HU, 1994, J PSYCHIAT RES, V28, P57, DOI 10.1016/0022-3956(94)90036-1",7,2020-11-20,NA,"NETHERLANDS INST MENTAL HLTH ADDICT#INST MENTAL HLTH CARE#UNIV GRONINGEN#UNIV UTRECHT","NETHERLANDS#NETHERLANDS#NETHERLANDS#NETHERLANDS"
"J","WOS:000242776800034",2006,"DEPRESSION AND CARDIOVASCULAR MORTALITY: A ROLE FOR N-3 FATTY ACIDS?","BACKGROUND: RECENT STUDIES INDICATE THAT DEPRESSION PLAYS AN IMPORTANT ROLE IN THE OCCURRENCE OF CARDIOVASCULAR DISEASES (CVDS). THE UNDERLYING MECHANISMS ARE NOT WELL UNDERSTOOD. OBJECTIVE: WE INVESTIGATED WHETHER DIETARY INTAKE OF THE N-3 FATTY ACIDS (FAS) EICOSAPENTAENIC ACID AND DOCOSAHEXAENOIC ACID COULD EXPLAIN THE RELATION BETWEEN DEPRESSIVE SYMPTOMS AND CARDIOVASCULAR MORTALITY. DESIGN: THE ZUTPHEN ELDERLY STUDY IS A PROSPECTIVE COHORT STUDY CONDUCTED IN THE NETHERLANDS. DEPRESSIVE SYMPTOMS WERE MEASURED IN 1990 WITH THE ZUNG SELF-RATING DEPRESSION SCALE IN 332 MEN AGED 70-90 Y AND FREE FROM CVD AND DIABETES. DIETARY FACTORS WERE ASSESSED WITH A CROSS-CHECK DIETARY HISTORY METHOD IN 1990. MORTALITY DATA WERE COLLECTED BETWEEN 1990 AND 2000. LOGISTIC AND COX REGRESSION ANALYSES WERE PERFORMED, WITH ADJUSTMENT FOR DEMOGRAPHICS AND CVD RISK FACTORS. RESULTS: COMPARED WITH A LOW INTAKE ((X) OVER BAR: 21 MG/D), A HIGH INTAKE ((X) OVER BAR: 407 MG/D) OF N-3 FAS WAS ASSOCIATED WITH FEWER DEPRESSIVE SYMPTOMS [ODDS RATIO: 0.46; 95% CI: 0.22, 0.95; P FOR TREND = 0.04] AT BASELINE AND NO SIGNIFICANT REDUCED RISK OF 10-Y CVD MORTALITY [HAZARD RATIO (HR): 0.88; 95% CI: 0.51, 1.50]. THE ADJUSTED HR FOR AN INCREASE IN DEPRESSIVE SYMPTOMS WITH 1 SD FOR CVD MORTALITY WAS 1.28 (95% CI: 1.03, 1.57) AND DID NOT CHANGE AFTER ADDITIONAL ADJUSTMENT FOR THE INTAKE OF N-3 FAS. CONCLUSION: AN AVERAGE INTAKE OF APPROXIMATE TO 400 MG N-3 FA/D MAY REDUCE THE RISK OF DEPRESSION. OUR RESULTS, HOWEVER, DO NOT SUPPORT THE HYPOTHESIS THAT THE INTAKE OF N-3 FAS EXPLAINS THE RELATION BETWEEN DEPRESSION AND CVD.","PRELIMINARY DOUBLE-BLIND; CORONARY-HEART-DISEASE; FISH CONSUMPTION; DIETARY-INTAKE; RISK-FACTOR; OMEGA-3-FATTY-ACIDS; SYMPTOMS; FINLAND; SCALE; METAANALYSIS","DEPRESSIVE SYMPTOMS; N-3 FATTY ACIDS; CARDIOVASCULAR DISEASE; MORTALITY; EPIDEMIOLOGY","AMERICAN JOURNAL OF CLINICAL NUTRITION","KAMPHUIS, MH##GEERLINGS, MI##TIJHUIS, MAR##KALMIJN, S##GROBBEE, DE##KROMHOUT, D","UNIV UTRECHT, CTR MED, JULIUS CTR HLTH SCI & PRIMARY CARE, NL-3508 GA UTRECHT, NETHERLANDS. NATL INST PUBL HLTH & ENVIRONM, CTR PREVENT & HLTH SERV RES, NL-3720 BA BILTHOVEN, NETHERLANDS. UNIV WAGENINGEN & RES CTR, DIV HUMAN NUTR, WAGENINGEN, NETHERLANDS.","NUTRITION & DIETETICS","NUTRITION & DIETETICS","BIGGS JT, 1978, BRIT J PSYCHIAT, V132, P381, DOI 10.1192/BJP.132.4.381##BLOEMBERG BPM, 1989, AM J EPIDEMIOL, V130, P1047, DOI 10.1093/OXFORDJOURNALS.AJE.A115405##CARNEY RM, 2005, ARCH INTERN MED, V165, P1486, DOI 10.1001/ARCHINTE.165.13.1486##CARNEY RM, 2005, PSYCHOSOM MED, V67, PS29, DOI 10.1097/01.PSY.0000162254.61556.D5##CARNEY RM, 2002, J PSYCHOSOM RES, V53, P897, DOI 10.1016/S0022-3999(02)00311-2##DEFORGE BR, 1988, INT J PSYCHIAT MED, V18, P325##DUNN VK, 1989, PSYCHOL AGING, V4, P125, DOI 10.1037/0882-7974.4.1.125##FESKENS EJM, 1993, NETHERLANDS J CARDIO, V6, P200##FRASURE-SMITH N, 2004, BIOL PSYCHIAT, V55, P891, DOI 10.1016/J.BIOPSYCH.2004.01.021##FRASURE-SMITH N, 2005, PSYCHOSOM MED, V67, PS19, DOI 10.1097/01.PSY.0000162253.07959.DB##HAAG M, 2003, CAN J PSYCHIAT, V48, P195##HAKKARAINEN R, 2004, AM J PSYCHIAT, V161, P567, DOI 10.1176/APPI.AJP.161.3.567##HE K, 2004, CIRCULATION, V109, P2705, DOI 10.1161/01.CIR.0000132503.19410.6B##HE K, 2004, STROKE, V35, P1538, DOI 10.1161/01.STR.0000130856.31468.47##HEMINGWAY H, 1999, BMJ-BRIT MED J, V318, P1460, DOI 10.1136/BMJ.318.7196.1460##HIBBELN JR, 1998, BIOL PSYCHIAT, V44, P235, DOI 10.1016/S0006-3223(98)00141-3##HIBBELN JR, 1995, AM J CLIN NUTR, V62, P1##HIBBELN JR, 1998, LANCET, V351, P1213, DOI 10.1016/S0140-6736(05)79168-6##JACKA E, 2004, NUTR NEUROSCI, V7, P101, DOI 10.1080/10284150410001710438##KALMIJN S, 1997, AM J EPIDEMIOL, V145, P33, DOI 10.1093/OXFORDJOURNALS.AJE.A009029##KAMPHUIS MH, 2006, EUR J CARDIOV PREV R, V13, P199, DOI 10.1097/01.HJR.0000188242.64590.92##KEYS A, 1980, 7 COUNTRIES MULTIVAR##KIVELA SL, 1986, PSYCHOL REP, V59, P587, DOI 10.2466/PR0.1986.59.2.587##KROMHOUT D, 1990, AM J EPIDEMIOL, V131, P855, DOI 10.1093/OXFORDJOURNALS.AJE.A115576##MAMALAKIS G, 2004, PROSTAG LEUKOTR ESS, V70, P495, DOI 10.1016/J.PLEFA.2003.10.005##MEYER BJ, 2003, LIPIDS, V38, P391, DOI 10.1007/S11745-003-1074-0##MURRAY CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2##MUSSELMAN DL, 1998, ARCH GEN PSYCHIAT, V55, P580, DOI 10.1001/ARCHPSYC.55.7.580##PENNINX BWJH, 2003, BIOL PSYCHIAT, V54, P566, DOI 10.1016/S0006-3223(02)01811-5##ROSE GA, 1968, WHO MONOGR SER, V56, P1##ROSS R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207##SAS INSTITUTE, 2004, STAT AN SYST VERS 9##SEVERUS WE, 2001, HARVARD REV PSYCHIAT, V9, P280, DOI 10.1093/HRP/9.6.280##STOLL AL, 1999, ARCH GEN PSYCHIAT, V56, P407, DOI 10.1001/ARCHPSYC.56.5.407##SU KP, 2003, EUR NEUROPSYCHOPHARM, V13, P267, DOI 10.1016/S0924-977X(03)00032-4##TANSKANEN A, 2001, PSYCHIATR SERV, V52, P529, DOI 10.1176/APPI.PS.52.4.529##TIEMEIER H, 2003, EPIDEMIOLOGY, V14, P103, DOI 10.1097/00001648-200301000-00025##TIEMEIER H, 2003, AM J CLIN NUTR, V78, P40##TIMONEN M, 2004, J AFFECT DISORDERS, V82, P447, DOI 10.1016/J.JAD.2004.02.002##WESTERTERP KR, 1992, MED SCI SPORTS EXERC, V24, P68##WILLETT WC, 1997, AM J CLIN NUTR, V65, P1220, DOI 10.1093/AJCN/65.4.1220S##ZUNG WWK, 1969, AM J PSYCHIAT, V126, P116, DOI 10.1176/AJP.126.1.116##ZUNG WWK, 1965, ARCH GEN PSYCHIAT, V13, P508, DOI 10.1001/ARCHPSYC.1965.01730060026004##ZUNG WWK, 1965, ARCH GEN PSYCHIAT, V12, P63, DOI 10.1001/ARCHPSYC.1965.01720310065008",41,2020-11-20,NA,"UNIV UTRECHT#NATL INST PUBL HLTH ENVIRONM#UNIV WAGENINGEN RES CTR","NETHERLANDS#NETHERLANDS#NETHERLANDS"
"J","WOS:000242245000009",2006,"ETHANOL INTAKE AND RISK OF LUNG CANCER IN THE EUROPEAN PROSPECTIVE INVESTIGATION INTO CANCER AND NUTRITION (EPIC)","WITHIN THE EUROPEAN PROSPECTIVE INVESTIGATION INTO CANCER AND NUTRITION (EPIC), THE AUTHORS EXAMINED THE ASSOCIATION OF ETHANOL INTAKE AT RECRUITMENT (1,119 CASES) AND MEAN LIFELONG ETHANOL INTAKE (887 CASES) WITH LUNG CANCER. INFORMATION ON BASELINE AND PAST ALCOHOL CONSUMPTION, LIFETIME TOBACCO SMOKING, DIET, AND THE ANTHROPOMETRIC CHARACTERISTICS OF 478,590 PARTICIPANTS WAS COLLECTED BETWEEN 1992 AND 2000. COX PROPORTIONAL HAZARDS REGRESSION WAS USED TO CALCULATE MULTIVARIATE-ADJUSTED HAZARD RATIOS AND 95% CONFIDENCE INTERVALS. OVERALL, NEITHER ETHANOL INTAKE AT RECRUITMENT NOR MEAN LIFELONG ETHANOL INTAKE WAS SIGNIFICANTLY ASSOCIATED WITH LUNG CANCER. HOWEVER, MODERATE INTAKE (5-14.9 G/DAY) AT RECRUITMENT (HAZARD RATIO (HR) = 0.76, 95% CONFIDENCE INTERVAL (CI): 0.63, 0.90) AND MODERATE MEAN LIFELONG INTAKE (HR = 0.80, 95% CI: 0.66, 0.97) WERE ASSOCIATED WITH A LOWER LUNG CANCER RISK IN COMPARISON WITH LOW CONSUMPTION (0.1-4.9 G/DAY). COMPARED WITH LOW INTAKE, A HIGH (>= 60 G/DAY) MEAN LIFELONG ETHANOL INTAKE TENDED TO BE RELATED TO A HIGHER RISK OF LUNG CANCER (HR = 1.29, 95% CI: 0.93, 1.74), BUT HIGH INTAKE AT RECRUITMENT WAS NOT. ALTHOUGH THERE WAS NO OVERALL ASSOCIATION BETWEEN ETHANOL INTAKE AND RISK OF LUNG CANCER, THE AUTHORS CANNOT RULE OUT A LOWER RISK FOR MODERATE CONSUMPTION AND A POSSIBLY INCREASED RISK FOR HIGH LIFELONG CONSUMPTION.","ALCOHOLIC BEVERAGE CONSUMPTION; MORTALITY; COHORT; TOBACCO; 8-HYDROXYDEOXYGUANOSINE; DRINKING; SMOKING; BOWEL; BEER; DIET","ALCOHOL DRINKING; COHORT STUDIES; ETHANOL; LUNG NEOPLASMS","AMERICAN JOURNAL OF EPIDEMIOLOGY","ROHRMANN, S##LINSEISEN, J##BOSHUIZEN, HC##WHITTAKER, J##AGUDO, A##VINEIS, P##BOFFETTA, P##JENSEN, MK##OLSEN, A##OVERVAD, K##TJONNELAND, A##BOUTRON-RUAULT, MC##CLAVEL-CHAPELON, F##BERGMANN, MM##BOEING, H##ALLEN, N##KEY, T##BINGHAM, S##KHAW, KT##KYRIAZI, G##SOUKARA, S##TRICHOPOULOU, A##PANICO, S##PALLI, D##SIERI, S##TUMINO, R##PEETERS, PHM##BUENO-DE-MESQUITA, HB##BUCHNER, FL##GRAM, IT##LUND, E##ARDANAZ, E##CHIRLAQUE, MD##DORRONSORO, M##PEREZ, MJS##QUIROS, JR##BERGLUND, G##JANZON, L##RASMUSON, T##WEINEHALL, L##FERRARI, P##JENAB, M##NORAT, T##RIBOLI, E","DEUTSCH KREBSFORSCHUNGSZENTRUM, DIV CLIN EPIDEMIOL, GERMAN CANC RES CTR, D-69120 HEIDELBERG, GERMANY. NATL INST PUBL HLTH & ENVIRONM, CTR INFORMAT TECHNOL & METHODOL, NL-3720 BA BILTHOVEN, NETHERLANDS. LONDON SCH HYG & TROP MED, DEPT EPIDEMIOL & POPULAT HLTH, LONDON WC1, ENGLAND. CATALAN INST ONCOL, DEPT EPIDEMIOL, BARCELONA, SPAIN. UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, LONDON SW7 2AY, ENGLAND. INT AGCY RES CANC, UNIT NUTR, LYON, FRANCE. AARHUS UNIV HOSP, AALBORG HOSP, DEPT CLIN EPIDEMIOL, DK-8000 AARHUS, DENMARK. DANISH CANC SOC, INST CANC EPIDEMIOL, COPENHAGEN, DENMARK. INST GUSTAVE ROUSSY, INSERM, E3N EPIC GRP, F-94805 VILLEJUIF, FRANCE. GERMAN INST HUMAN NUTR, DEPT EPIDEMIOL, POTSDAM, GERMANY. UNIV OXFORD, CANC RES UK EPIDEMIOL UNIT, OXFORD OX1 2JD, ENGLAND. UNIV CAMBRIDGE, INST PUBL HLTH, STRANGEWAYS RES LAB, CAMBRIDGE CB2 1TN, ENGLAND. UNIV ATHENS, SCH MED, DEPT HYG & EPIDEMIOL, GR-10679 ATHENS, GREECE. UNIV NAPLES FEDERICO II, DEPT CLIN & EXPT MED, NAPLES, ITALY. GSPO SCI INST TUSCANY, MOL & NUTR EPIDEMIOL UNIT, FLORENCE, ITALY. ITALIAN NATL CANC INST, EPIDEMIOL UNIT, MILAN, ITALY. AZIENDA OSPED CIVILE MP AREZZO, CANC REGISTRY, RAGUSA, ITALY. UNIV UTRECHT, MED CTR, JULIUS CTR HLTH SCI & PRIMARY CARE, NL-3508 TA UTRECHT, NETHERLANDS. NATL INST PUBL HLTH & ENVIRONM, CTR NUTR & HLTH, NL-3720 BA BILTHOVEN, NETHERLANDS. UNIV TROMSO, INST COMMUNITY MED, N-9001 TROMSO, NORWAY. INST PUBL HLTH, PAMPLONA, SPAIN. MURCIA HLTH COUNCIL, DEPT EPIDEMIOL, MURCIA, SPAIN. PUBL HLTH DIV GIPUZKOA, SAN SEBASTIAN, SPAIN. ANDALUSIAN SCH PUBL HLTH, GRANADA, SPAIN. PUBL HLTH & HLTH PLANNING DIRECTORATE, ASTURIAS, SPAIN. LUND UNIV, DEPT CLIN SCI MALMO, S-22100 LUND, SWEDEN. UMEA UNIV, DEPT RADIAT SCI, S-90187 UMEA, SWEDEN. UMEA UNIV, DEPT PUBL HLTH & CLIN MED, S-90187 UMEA, SWEDEN. UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, DEPT EPIDEMIOL & PUBL HLTH, LONDON SW7 2AZ, ENGLAND.","PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","ALBERG AJ, 2003, CHEST S1, V123, P21##BALDER HF, 2005, CANCER EPIDEM BIOMAR, V14, P483, DOI 10.1158/1055-9965.EPI-04-0353##BANDERA EV, 1997, CANCER CAUSE CONTROL, V8, P828, DOI 10.1023/A:1018456127018##BANDERA EV, 2001, CANCER EPIDEM BIOMAR, V10, P813##BIANCHINI F, 2003, EUR J CANCER PREV, V12, P417, DOI 10.1097/00008469-200310000-00011##BIANCHINI F, 2001, CARCINOGENESIS, V22, P885, DOI 10.1093/CARCIN/22.6.885##BRESLOW RA, 2000, CANCER CAUSE CONTROL, V11, P419, DOI 10.1023/A:1008996208313##CARPENTER CL, 1998, J NUTR, V128, P694##DJOUSSE L, 2002, J NATL CANCER I, V94, P1877, DOI 10.1093/JNCI/94.24.1877##DOLL R, 1994, BRIT MED J, V309, P911, DOI 10.1136/BMJ.309.6959.911##DOSEMECI M, 1997, CANCER CAUSE CONTROL, V8, P729, DOI 10.1023/A:1018479304728##FREUDENHEIM JL, 2005, AM J CLIN NUTR, V82, P657##FREUDENHEIM JL, 2003, J NUTR, V133, P3619##FRIESEMA IHM, 2004, AM J EPIDEMIOL, V159, P809, DOI 10.1093/AJE/KWH102##GORDON T, 1984, AM J EPIDEMIOL, V120, P97, DOI 10.1093/OXFORDJOURNALS.AJE.A113879##HEINZL H, 1997, COMPUT METH PROG BIO, V54, P201, DOI 10.1016/S0169-2607(97)00043-6##IMHOF A, 2004, EUR HEART J, V25, P2092, DOI 10.1016/J.EHJ.2004.09.032##*INT AG RES CANC, 1999, IARC MON EV CARC RIS, V71##KLATSKY AL, 1981, ANN INTERN MED, V95, P139, DOI 10.7326/0003-4819-95-2-139##KLIPSTEIN-GROBUSCHL K, 2002, PUBLIC HEALTH NUTR, V5, P1297, DOI 10.1079/PHN2002406##KONO S, 1986, INT J EPIDEMIOL, V15, P527, DOI 10.1093/IJE/15.4.527##KORTE JE, 2002, AM J EPIDEMIOL, V155, P496, DOI 10.1093/AJE/155.6.496##KVALE G, 1983, INT J CANCER, V31, P397, DOI 10.1002/IJC.2910310402##LIEBER CS, 2004, DRUG METAB REV, V36, P511, DOI 10.1081/DMR-200033441##MURATA M, 1996, CANCER DETECT PREV, V20, P557##NACHIAPPAN V, 1994, ALCOHOL ALCOHOLISM, V29, P565##POLLACK ES, 1984, NEW ENGL J MED, V310, P617, DOI 10.1056/NEJM198403083101003##POTTER J D, 1992, ANN EPIDEMIOL, V2, P587, DOI 10.1016/1047-2797(92)90003-9##POTTER JD, 1982, J CHRON DIS, V35, P833, DOI 10.1016/0021-9681(82)90048-0##PRESCOTT E, 1999, AM J EPIDEMIOL, V149, P463, DOI 10.1093/OXFORDJOURNALS.AJE.A009834##RIBOLI E, 2002, PUBLIC HEALTH NUTR, V5, P1113, DOI 10.1079/PHN2002394##SEITZ HK, 1981, EUR J CLIN INVEST, V11, P33, DOI 10.1111/J.1365-2362.1981.TB01762.X##STEENLAND K, 2004, EPIDEMIOLOGY, V15, P63, DOI 10.1097/01.EDE.0000100287.45004.E7##STEMMERMANN GN, 1990, DIGEST DIS SCI, V35, P1414, DOI 10.1007/BF01536750##WHITE IR, 1999, J CLIN EPIDEMIOL, V52, P967, DOI 10.1016/S0895-4356(99)00076-1##*WHO FAO EXP CONS, 2001, DIET NUTR PREV CHR D##WOODSON K, 1999, JNCI-J NATL CANCER I, V91, P1738, DOI 10.1093/JNCI/91.20.1738##YONG LC, 1997, AM J EPIDEMIOL, V146, P231, DOI 10.1093/OXFORDJOURNALS.AJE.A009258##YOSHIDA R, 2001, IND HEALTH, V39, P322, DOI 10.2486/INDHEALTH.39.322##ZANG EA, 2001, PREV MED, V32, P359, DOI 10.1006/PMED.2000.0818",25,2020-11-20,"MEDICAL RESEARCH COUNCILMEDICAL RESEARCH COUNCIL UK (MRC) [G0401527] FUNDING SOURCE: MEDLINE; WELLCOME TRUSTWELLCOME TRUST FUNDING SOURCE: MEDLINE","DEUTSCH KREBSFORSCHUNGSZENTRUM#NATL INST PUBL HLTH ENVIRONM#LONDON SCH HYG TROP MED#CATALAN INST ONCOL#UNIV LONDON IMPERIAL COLL SCI TECHNOL MED#INT AGCY RES CANC#AARHUS UNIV HOSP#DANISH CANC SOC#INST GUSTAVE ROUSSY#GERMAN INST HUMAN NUTR#UNIV OXFORD#UNIV CAMBRIDGE#UNIV ATHENS#UNIV NAPLES FEDERICO II#GSPO SCI INST TUSCANY#ITALIAN NATL CANC INST#AZIENDA OSPED CIVILE MP AREZZO#UNIV UTRECHT#NATL INST PUBL HLTH ENVIRONM#UNIV TROMSO#INST PUBL HLTH#MURCIA HLTH COUNCIL#PUBL HLTH DIV GIPUZKOA#ANDALUSIAN SCH PUBL HLTH#PUBL HLTH HLTH PLANNING DIRECTORATE#LUND UNIV#UMEA UNIV#UMEA UNIV#UNIV LONDON IMPERIAL COLL SCI TECHNOL MED","GERMANY#NETHERLANDS#ENGLAND#SPAIN#ENGLAND#FRANCE#DENMARK#DENMARK#FRANCE#GERMANY#ENGLAND#ENGLAND#GREECE#ITALY#ITALY#ITALY#ITALY#NETHERLANDS#NETHERLANDS#NORWAY#SPAIN#SPAIN#SPAIN#SPAIN#SPAIN#SWEDEN#SWEDEN#SWEDEN#ENGLAND"
"J","WOS:000242372800018",2006,"PSYCHOLOGICAL FACTORS AFFECT THE FREQUENCY OF BELCHING IN PATIENTS WITH AEROPHAGIA","BACKGROUND: IN PATIENTS WITH AEROPHAGIA AND EXCESSIVE BELCHING AN ORGANIC CAUSE IS SELDOM FOUND AND A PSYCHOGENIC CAUSE IS OFTEN SUSPECTED. AIM: TO INVESTIGATE THE EFFECTS OF ATTENTION AND DISTRACTION ON THE FREQUENCY OF BELCHING IN PATIENTS WITH AEROPHAGIA. METHODS: IN 10 PATIENTS WITH AEROPHAGIA, COMBINED ESOPHAGEAL MANOMETRY AND IMPEDANCE MONITORING WAS PERFORMED FOR 2 H, CONSISTING OF FOUR 30-MINUTE RECORDING PERIODS. PERIOD I: PATIENT UNAWARE THAT RECORDING HAD COMMENCED. PERIOD II: PATIENT INFORMED OF RECORDING IN PROGRESS. PERIOD III: DISTRACTION BY FILLING IN QUESTIONNAIRES. PERIOD IV: NO DISTRACTION. RESULTS: A TOTAL OF 1,258 BELCHES WAS MEASURED, 51 OF WHICH WERE THE RESULT OF AIR THAT ESCAPED FROM THE STOMACH (GASTRIC BELCHES). A TOTAL OF 1,207 BELCHES (96%) WERE EVENTS DURING WHICH AIR WAS EXPELLED IN THE ORAL DIRECTION ALMOST IMMEDIATELY AFTER ENTERING THE ESOPHAGUS FROM THERE (SUPRAGASTRIC BELCHES). GASTRIC BELCHES WERE DISTRIBUTED EQUALLY OVER THE FIRST (1.5 [0.5-2.0]), SECOND (1.5 [0.5-2.0]), THIRD (1.0 [0-2.0]), AND FOURTH (1.0 [0-2.0]) RECORDING PERIODS. IN CONTRAST, THE INCIDENCE OF SUPRAGASTRIC BELCHES INCREASED SIGNIFICANTLY FROM 0 (0-32) IN PERIOD 1 TO 30 (18-60) IN PERIOD II, AFTER PATIENTS WERE TOLD THAT RECORDING WAS STARTED. DURING PERIOD III (QUESTIONNAIRES) THE INCIDENCE OF SUPRAGASTRIC BELCHES DECREASED TO 14 (4-30). IN PERIOD IV THE INCIDENCE OF SUPRAGASTRIC BELCHES INCREASED TO 21 (10-49). CONCLUSIONS: WHEN PATIENTS WITH EXCESSIVE BELCHING ARE UNAWARE THAT THEY ARE BEING STUDIED OR WHEN THEY ARE DISTRACTED, THE INCIDENCE OF BELCHING IS SIGNIFICANTLY REDUCED. THESE FINDINGS UNDERLINE THE IMPORTANCE OF PSYCHOLOGICAL FACTORS AND PROVIDE RATIONALE FOR BEHAVIORAL THERAPY.","INTRALUMINAL ELECTRICAL-IMPEDANCE; DISORDERS; DYSPEPSIA; THERAPY; DISEASE; REFLUX",NA,"AMERICAN JOURNAL OF GASTROENTEROLOGY","BREDENOORD, AJ##WEUSTEN, BLAM##TIMMER, R##SMOUT, AJPM","ST ANTONIUS HOSP, DEPT GASTROENTEROL, NL-3430 EM NIEUWEGEIN, NETHERLANDS. UNIV UTRECHT, MED CTR, DEPT GASTROENTEROL, GASTROINTESTINAL RES UNIT, NL-3508 TA UTRECHT, NETHERLANDS.","GASTROENTEROLOGY & HEPATOLOGY","GASTROENTEROLOGY & HEPATOLOGY","BREDENOORD AJ, 2004, NEUROGASTROENT MOTIL, V16, P713, DOI 10.1111/J.1365-2982.2004.00575.X##BREDENOORD AJ, 2004, GUT, V53, P1561, DOI 10.1136/GUT.2004.042945##CAMILLERI M, 2005, CLIN GASTROENTEROL H, V3, P543, DOI 10.1016/S1542-3565(05)00153-9##CHITKARA DK, 2005, ALIMENT PHARM THER, V22, P855, DOI 10.1111/J.1365-2036.2005.02651.X##DAMSTE PH, 1975, LARYNGOSCOPE, V85, P649, DOI 10.1288/00005537-197504000-00006##DMELLO D, 1983, J CLIN PSYCHIAT, V44, P387##DROSSMAN DA, 2003, GASTROENTEROLOGY, V125, P19, DOI 10.1016/S0016-5085(03)00669-3##HU MTM, 1998, MOVEMENT DISORD, V13, P363, DOI 10.1002/MDS.870130232##KENNEDY T, 2005, BRIT MED J, V331, P435, DOI 10.1136/BMJ.38545.505764.06##LIN M, 2003, AM J GASTROENTEROL, V98, P2139, DOI 10.1016/S0002-9270(03)00538-0##ROTH JLA, 1973, EMOTIONAL FACTORS GA, P16##SIFRIM D, 1999, GUT, V44, P47, DOI 10.1136/GUT.44.1.47##ZELLA SJ, 1998, PSYCHOSOMATICS, V39, P299, DOI 10.1016/S0033-3182(98)71352-0",42,2020-11-20,NA,"ST ANTONIUS HOSP#UNIV UTRECHT","NETHERLANDS#NETHERLANDS"
"J","WOS:000242819400014",2006,"WATER IMMERSION IN PREECLAMPSIA","OBJECTIVE: PREECLAMPSIA IS ASSOCIATED WITH PROFOUND VASOCONSTRICTION IN MOST ORGAN SYSTEMS AND REDUCED PLASMA VOLUME. BECAUSE WATER IMMERSION PRODUCES A MARKED CENTRAL REDISTRIBUTION OF BLOOD VOLUME AND SUPPRESSES THE RENIN-ANGIOTENSIN SYSTEM RESPONSE AND SYMPATHETIC ACTIVITY, WE HYPOTHESIZED THAT WATER IMMERSION MIGHT BE USEFUL IN THE TREATMENT OF PREECLAMPSIA. STUDY DESIGN: THE EFFECTS OF THERMONEUTRAL WATER IMMERSION FOR 3 HOURS ON CENTRAL AND PERIPHERAL HEMODYNAMICS WERE EVALUATED IN 7 PREECLAMPTIC PATIENTS, 7 NORMAL PREGNANT CONTROL PATIENTS, AND 7 NONPREGNANT WOMEN. FINGER PLETHYSMOGRAPHY WAS USED TO DETERMINE HEMODYNAMIC MEASUREMENTS (CARDIAC OUTPUT AND TOTAL PERIPHERAL RESISTANCE), AND FOREARM BLOOD FLOW WAS MEASURED BY STRAIN GAUGE PLETHYSMOGRAPHY. POSTISCHEMIC HYPEREMIA WAS USED TO DETERMINE ENDOTHELIUM-DEPENDENT VASODILATION. ANALYSIS WAS BY ANALYSIS OF VARIANCE FOR REPEATED MEASUREMENTS. RESULTS: DURING WATER IMMERSION CARDIAC OUTPUT INCREASED WHILE DIASTOLIC BLOOD PRESSURE AND HEART RATE DECREASED, ALTHOUGH SYSTOLIC BLOOD PRESSURE REMAINED UNCHANGED IN EACH GROUP. FOREARM BLOOD FLOW INCREASED SIGNIFICANTLY IN THE NORMAL PREGNANT AND PREECLAMPTIC SUBJECTS. TOTAL PERIPHERAL RESISTANCE DECREASED IN ALL GROUPS, BUT VALUES IN PREECLAMPTIC PATIENTS REMAINED ABOVE THOSE. OF NORMOTENSIVE PREGNANT WOMEN. WATER IMMERSION HAD NO EFFECT ON ENDOTHELIUM-DEPENDENT VASODILATION IN THE PREECLAMPTIC GROUP, AND MOST HEMODYNAMIC CHANGES THAT WERE OBSERVED REVERSED TO BASELINE WITHIN 2 HOURS OF COMPLETION OF THE PROCEDURE. CONCLUSION: ALTHOUGH WATER IMMERSION RESULTS IN HEMODYNAMIC ALTERATIONS IN A MANNER THAT IS THEORETICALLY THERAPEUTIC FOR WOMEN WITH PREECLAMPSIA, THE EFFECT WAS LIMITED AND SHORT-LIVED. IN ADDITION WATER IMMERSION HAD NO EFFECT ON ENDOTHELIUM-DEPENDENT VASODILATION IN WOMEN WITH PREECLAMPSIA. THE THERAPEUTIC POTENTIAL FOR WATER IMMERSION IN PREECLAMPSIA APPEARS TO BE LIMITED. (C) 2006 MOSBY, INC. ALL RIGHTS RESERVED.","BLOOD-PRESSURE MONITOR; NITRIC-OXIDE; PREGNANCY; FLOW; HUMANS; PLASMA; VASODILATION; ALDOSTERONE; VALIDATION; FOREARM","WATER IMMERSION; PREECLAMPSIA; VASODILATION","AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY","ELVAN-TASPINAR, A##FRANX, A##DELPRAT, CC##BRUINSE, HW##KOOMANS, HA","UNIV UTRECHT, MED CTR, DEPT PERINATOL & GYNECOL, NL-3508 AB UTRECHT, NETHERLANDS. SINT ELISABETH HOSP, DEPT OBSTET & GYNECOL, TILBURG, NETHERLANDS. UNIV UTRECHT, MED CTR, DEPT HYPERTENS & NEPHROL, NL-3508 AB UTRECHT, NETHERLANDS.","OBSTETRICS & GYNECOLOGY","OBSTETRICS & GYNECOLOGY","BARDEN A, 2001, HYPERTENSION, V38, P803, DOI 10.1161/HY1101.092969##BOWYER L, 2003, BJOG-INT J OBSTET GY, V110, P383, DOI 10.1016/S1470-0328(02)02930-0##BROWN MA, 1994, CLIN SCI, V86, P575, DOI 10.1042/CS0860575##COCKELL AP, 1997, HYPERTENSION, V30, P247, DOI 10.1161/01.HYP.30.2.247##DAWES GS, 1991, J PERINAT MED, V19, P47, DOI 10.1515/JPME.1991.19.1-2.47##DIJKHORST-OEI LT, 2000, J AM SOC NEPHROL, V11, P1293##ELSHEIKH A, 2001, ARCH GYNECOL OBSTET, V264, P182, DOI 10.1007/S004040000104##ELVAN-TASPINAR A, 2003, J HYPERTENS, V21, P2053, DOI 10.1097/01.HJH.0000098138.70956.68##EPSTEIN M, 1992, PHYSIOL REV, V72, P563##FISCHER T, 2000, AM J OBSTET GYNECOL, V183, P1489, DOI 10.1067/MOB.2000.107323##FRANX A, 1997, HYPERTENS PREGNANCY, V16, P187, DOI 10.3109/10641959709031636##GANT NF, 1973, J CLIN INVEST, V52, P2682, DOI 10.1172/JCI107462##HARMS MPM, 1999, CLIN SCI, V97, P291, DOI 10.1042/CS19990061##JOANNIDES R, 1995, CIRCULATION, V91, P1314, DOI 10.1161/01.CIR.91.5.1314##KATZ VL, 1990, OBSTET GYNECOL, V75, P147##KOKOT F, 1983, P EUR DIAL TRANS, V20, P557##KWEE A, 2000, BRIT J OBSTET GYNAEC, V107, P663, DOI 10.1111/J.1471-0528.2000.TB13310.X##LINDHEIMER MD, 1999, CHESLEYS HYPERTENSIV##MCKINNEY ET, 2000, AM J OBSTET GYNECOL, V183, P874, DOI 10.1067/MOB.2000.108877##MEREDITH IT, 1996, AM J PHYSIOL-HEART C, V270, PH1435##NIJHUIS IJM, 1998, PRENAT NEONAT MED, V3, P314##PENAZ J, INT C MED BIOL ENG D, P104##RABELINK AJ, 1989, AM J PHYSIOL, V257, PF375##ROBERTS JM, 2003, HYPERTENSION, V41, P437, DOI 10.1161/01.HYP.0000054981.03589.E9##ROBERTS JM, 2002, PLACENTA, V23, P359, DOI 10.1053/PLAC.2002.0819##ROBERTS JM, 1989, AM J OBSTET GYNECOL, V161, P1200, DOI 10.1016/0002-9378(89)90665-0##SHENNAN AH, 1993, BRIT J OBSTET GYNAEC, V100, P904, DOI 10.1111/J.1471-0528.1993.TB15104.X##STROES ESG, 1995, LANCET, V346, P467, DOI 10.1016/S0140-6736(95)91322-X##WESSELING KH, 1995, HOMEOSTASIS HLTH DIS, V36, P67##WESSELING KH, 1993, J APPL PHYSIOL, V74, P2566##WILLIAMS DJ, 1997, AM J PHYSIOL, V272, P748##YOSHIDA A, 2000, HYPERTENSION, V36, P400, DOI 10.1161/01.HYP.36.3.400",7,2020-11-20,NA,"UNIV UTRECHT#SINT ELISABETH HOSP#UNIV UTRECHT","NETHERLANDS#NETHERLANDS#NETHERLANDS"
"J","WOS:000242914200001",2006,"EFFECT OF NON-INVASIVE VENTILATION ON SURVIVAL, QUALITY OF LIFE, RESPIRATORY FUNCTION AND COGNITION: A REVIEW OF THE LITERATURE","SYMPTOMS OF NOCTURNAL HYPOVENTILATION MAY NEGATIVELY INFLUENCE THE QUALITY OF LIFE (QOL) OF ALS PATIENTS LONG BEFORE RESPIRATORY FAILURE ENSUES. NON-INVASIVE MECHANICAL VENTILATION (NIV) IS CONSIDERED A TREATMENT OPTION FOR NOCTURNAL HYPOVENTILATION. THE PRIMARY OBJECTIVE OF NIV IS IMPROVING QUALITY OF LIFE (QOL). IT MAY ALSO PROLONG LIFE BY SEVERAL MONTHS. A SYSTEMATIC REVIEW OF THE LITERATURE WAS PERFORMED TO ANALYSE WHAT IS KNOWN OF THE EFFECT OF NIV ON SURVIVAL, QOL AND OTHER OUTCOME MEASURES. A COMPUTERIZED LITERATURE SEARCH WAS PERFORMED TO IDENTIFY CONTROLLED CLINICAL TRIALS AND OBSERVATIONAL STUDIES OF TREATMENT OF ALS-ASSOCIATED NOCTURNAL HYPOVENTILATION. FROM 1985 UNTIL MAY 2005. TWELVE STUDIES FULFILLED THE INCLUSION CRITERIA. FOUR STUDIES WERE RETROSPECTIVE, SEVEN PROSPECTIVE AND IN ONE STUDY RANDOMIZATION WAS USED. ALL STUDIES REPORTED BENEFICIAL EFFECTS OF NIV ON ALL OUTCOME MEASURES. IN SEVEN STUDIES NIV WAS ASSOCIATED WITH PROLONGED SURVIVAL IN PATIENTS TOLERANT FOR NIV, AND FIVE STUDIES REPORTED AN IMPROVED QOL. IN CONCLUSION, STUDIES ON THE USE OF NIV IN ALS DIFFER IN STUDY DESIGN AND ENDPOINT DEFINITIONS. ALL STUDIES SUGGEST A BENEFICIAL EFFECT ON QOL AND OTHER OUTCOME MEASURES (EVIDENCE LEVEL CLASS II-III). WELL-DESIGNED RANDOMIZED CONTROLLED TRIALS COMPARING THE EFFECT ON QOL AND SURVIVAL HAVE NOT BEEN PERFORMED.","AMYOTROPHIC-LATERAL-SCLEROSIS; POSITIVE-PRESSURE VENTILATION; MECHANICAL VENTILATION; PRACTICE PARAMETER; PULMONARY-FUNCTION; HOME VENTILATION; ALS PATIENTS; PATIENT; POPULATION; MANAGEMENT","AMYOTROPHIC LATERAL SCLEROSIS; NON-INVASIVE VENTILATION; QUALITY OF LIFE","AMYOTROPHIC LATERAL SCLEROSIS","PIEPERS, S##VAN DEN BERG, JP##KALMIJN, S##VAN DER POL, WL##WOKKE, JHJ##LINDEMAN, E##VAN DEN BERG, LH","UNIV UTRECHT, MED CTR, DEPT NEUROL, RUDOLF MAGNUS INST NEUROSCI, UTRECHT, NETHERLANDS. UNIV UTRECHT, MED CTR, DEPT REHABIL, RUDOLF MAGNUS INST NEUROSCI, UTRECHT, NETHERLANDS. ST ELIZABETH HOSP, MEANDER MED CTR, DEPT REHABIL, AMERSFOORT, NETHERLANDS. UNIV UTRECHT, MED CTR, JULIUS CTR HLTH SCI & PRIMARY CARE, UTRECHT, NETHERLANDS.","CLINICAL NEUROLOGY","NEUROSCIENCES & NEUROLOGY","ABOUSSOUAN LS, 2001, MUSCLE NERVE, V24, P403, DOI 10.1002/1097-4598(200103)24:3<403::AID-MUS1013>3.3.CO;2-V##ABOUSSOUAN LS, 1997, ANN INTERN MED, V127, P450, DOI 10.7326/0003-4819-127-6-199709150-00006##ALBERT SM, 1999, NEUROLOGY, V53, P278, DOI 10.1212/WNL.53.2.278##BACH JR, 2002, CHEST, V122, P92, DOI 10.1378/CHEST.122.1.92##BORASIO GD, 1998, J NEUROL, V245, P717, DOI 10.1007/S004150050273##BOURKE SC, 2003, NEUROLOGY, V61, P171, DOI 10.1212/01.WNL.0000076182.13137.38##BRADLEY WG, 2004, AMYOTROPH LATERAL SC, V5, P240, DOI 10.1080/14660820410021249##BUHR-SCHINNER H, 1999, MED KLIN, V94, P102##CAZZOLLI PA, 1996, J NEUROL SCI, V139, P123, DOI 10.1016/0022-510X(96)00099-8##CHANCELLOR AM, 1992, J NEUROL NEUROSUR PS, V55, P1106, DOI 10.1136/JNNP.55.12.1106##DAVID WS, 1997, J NEUROL SCI, V152, PS29, DOI 10.1016/S0022-510X(97)00241-4##DEL AGUILA MA, 2003, NEUROLOGY, V60, P813, DOI 10.1212/01.WNL.0000049472.47709.3B##HARDIMAN O, 2000, J NEUROL, V247, P245, DOI 10.1007/S004150050578##HAVERKAMP LJ, 1995, BRAIN, V118, P707, DOI 10.1093/BRAIN/118.3.707##JACKSON CE, 2001, J NEUROL SCI, V191, P75, DOI 10.1016/S0022-510X(01)00617-7##KLEOPA KA, 1999, J NEUROL SCI, V164, P82, DOI 10.1016/S0022-510X(99)00045-3##LECHTZIN N, 2001, NEW ENGL J MED, V344, P533, DOI 10.1056/NEJM200102153440718##LYALL RA, 2001, NEUROLOGY, V57, P153, DOI 10.1212/WNL.57.1.153##MILLER RG, 1999, NEUROLOGY, V52, P1311, DOI 10.1212/WNL.52.7.1311##MILLER RG, 2001, AMYOTROPH LATERAL SC, V2, P3, DOI 10.1080/146608201300079355##MITSUMOTO H, 1999, NEUROLOGY, V53, P248, DOI 10.1212/WNL.53.2.248##MOSS AH, 1993, NEUROLOGY, V43, P438, DOI 10.1212/WNL.43.2.438##NEWSOM-DAVIS IC, 2001, J NEUROL NEUROSUR PS, V71, P482, DOI 10.1136/JNNP.71.4.482##OPPENHEIMER EDWARD ANTHONY, 1993, PALLIATIVE MEDICINE, V7, P49##PINTO AC, 1995, J NEUROL SCI, V129, P19, DOI 10.1016/0022-510X(95)00052-4##SIVAK ED, 2001, AMYOTROPH LATERAL SC, V2, P139, DOI 10.1080/146608201753275724##TANDAN R, 1985, ANN NEUROL, V18, P271, DOI 10.1002/ANA.410180302##WINTERHOLLER MGM, 2001, NERVENARZT, V72, P293, DOI 10.1007/S001150050753",25,2020-11-20,NA,"UNIV UTRECHT#UNIV UTRECHT#ST ELIZABETH HOSP#UNIV UTRECHT","NETHERLANDS#NETHERLANDS#NETHERLANDS#NETHERLANDS"
"J","WOS:000242289100047",2006,"PREDICTIVE PERFORMANCE OF THREE MULTIVARIATE DIFFICULT TRACHEAL INTUBATION MODELS: A DOUBLE-BLIND, CASE-CONTROL STUDY",NA,NA,NA,"ANESTHESIA AND ANALGESIA","VAN KLEI, WA##KALKMAN, CJ##MOONS, KGM","OTTAWA GEN HOSP, DEPT ANESTHESIA, OTTAWA, ON K1H 8L6, CANADA. UNIV UTRECHT, MED CTR, DEPT PERIOPERAT CARE & EMERGENCY MED, JULIUS CTR HLTH SCI & PRIMARY CARE, NL-3508 TA UTRECHT, NETHERLANDS.","ANESTHESIOLOGY","ANESTHESIOLOGY","DEL SOL AI, 2001, STROKE, V32, P1532, DOI 10.1161/01.STR.32.7.1532##MOONS KGM, 2003, ANESTH ANALG, V96, P1843, DOI 10.1213/01.ANE.0000063178.15467.D8##NAGUIB M, 2006, ANESTH ANALG, V102, P818, DOI 10.1213/01.ANE.0000196507.19771.B2##ROTHMAN KJ, 1998, MODERN EPIDEMIOLOGY##SHIGA T, 2005, ANESTHESIOLOGY, V103, P429, DOI 10.1097/00000542-200508000-00027##VAN KLEI WA, 2003, EUR J ANAESTH, V20, P612, DOI 10.1097/00003643-200308000-00004",1,2020-11-20,NA,"OTTAWA GEN HOSP#UNIV UTRECHT","CANADA#NETHERLANDS"
"J","WOS:000242713600002",2006,"THE RELATION BETWEEN SOCIAL RANK, NEOPHOBIA AND INDIVIDUAL LEARNING IN STARLINGS","RESEARCHERS WITH DIVERSE INTERESTS IN TOPICS RANGING FROM THE FORMATION OF DOMINANCE HIERARCHIES AND SOCIAL INTELLIGENCE TO ANIMAL PERSONALITIES HAVE PREDICTED SPECIFIC, AND OFTEN CONFLICTING, RELATIONS BETWEEN SOCIAL RANK, NEOPHOBIA AND LEARNING ABILITY. WE INVESTIGATED THE RELATIONS BETWEEN THESE VARIABLES IN CAPTIVE GROUPS OF WILD-CAUGHT STARLINGS, STURNUS VULGARIS, ADOPTING A MULTIDIMENSIONAL APPROACH TO SOCIAL RANK AND NEOPHOBIA. BOTH AGONISTIC AND COMPETITIVE RANK ORDERS WERE DETERMINED FOR EACH GROUP AND WE TESTED INDIVIDUALS IN THE ABSENCE OF THEIR GROUPMATES FOR OBJECT NEOPHOBIA, LATENCY TO FEED IN A NOVEL ENVIRONMENT AND PERFORMANCE ON AN EXTRACTIVE FORAGING TASK. IN EACH STARLING GROUP, THE FASTEST LEARNERS OCCUPIED THE HIGHEST COMPETITIVE RANKS, SUPPORTING THE HYPOTHESIS THAT COGNITIVE ABILITY IS POSITIVELY CORRELATED WITH SOCIAL DOMINANCE. COMPETITIVE RANK ORDERS, HOWEVER, DID NOT CORRELATE SIGNIFICANTLY WITH AGONISTIC RANK ORDERS. SITUATION-SPECIFIC FORAGING NEOPHOBIA WAS SUGGESTED: INDIVIDUALS SHOWED CONSISTENCY IN THEIR LATENCIES TO FEED NEAR A VARIETY OF NOVEL OBJECTS, BUT NO SIGNIFICANT CORRELATION WAS FOUND BETWEEN THIS MEASURE OF OBJECT NEOPHOBIA AND LATENCY TO FEED IN A NOVEL ENVIRONMENT. STARLINGS FASTEST TO FEED IN THE NOVEL ENVIRONMENT WERE FASTEST IN SOLVING THE FORAGING TASK. WE DISCUSS THE IMPLICATIONS OF THESE FINDINGS FOR RESEARCHERS STUDYING HIERARCHY FORMATION IN ANIMAL GROUPS, SOCIAL INTELLIGENCE AND ANIMAL PERSONALITIES. (C) 2006 THE ASSOCIATION FOR THE STUDY OF ANIMAL BEHAVIOUR. PUBLISHED BY ELSEVIER LTD. ALL RIGHTS RESERVED.","HIERARCHY FORMATION; STURNUS-VULGARIS; FLUCTUATING ASYMMETRIES; DOMINANCE HIERARCHIES; FEMALE STARLINGS; ZENAIDA DOVES; COMPETITION; INNOVATION; BEHAVIOR; FOOD",NA,"ANIMAL BEHAVIOUR","BOOGERT, NJ##READER, SM##LALAND, KN","UNIV UTRECHT, HELMHOLTZ INST, NL-3508 TB UTRECHT, NETHERLANDS. UNIV ST ANDREWS, SCH BIOL, CTR SOCIAL LEARNING & COGNIT EVOLUT, ST ANDREWS KY16 9TS, FIFE, SCOTLAND.","BEHAVIORAL SCIENCES; ZOOLOGY","BEHAVIORAL SCIENCES; ZOOLOGY","BARNARD CJ, 2002, BEHAV PROCESS, V60, P53, DOI 10.1016/S0376-6357(02)00121-3##BATESON M, 1995, ANIM BEHAV, V50, P431, DOI 10.1006/ANBE.1995.0257##BUGNYAR T, 2004, ANIM COGN, V7, P69, DOI 10.1007/S10071-003-0189-4##BUNNELL B N, 1980, PRIMATES, V21, P515, DOI 10.1007/BF02373840##BUNNELL B N, 1980, PRIMATES, V21, P376, DOI 10.1007/BF02390467##BYRNE R. W., 1988, MACHIAVELLIAN INTELL##CAMBEFORT JP, 1981, FOLIA PRIMATOL, V36, P243, DOI 10.1159/000156000##CAMPBELL FM, 1999, ANIM BEHAV, V58, P151, DOI 10.1006/ANBE.1999.1121##CARLIER P, 1996, BEHAVIOUR, V133, P1197, DOI 10.1163/156853996X00369##CHASE ID, 1974, BEHAV SCI, V19, P374, DOI 10.1002/BS.3830190604##CHASE ID, 2002, P NATL ACAD SCI USA, V99, P5744, DOI 10.1073/PNAS.082104199##CHASE ID, 1982, SCIENCE, V216, P439, DOI 10.1126/SCIENCE.216.4544.439##CHASE ID, 1980, AM SOCIOL REV, V45, P905, DOI 10.2307/2094909##CLOUTIER S, 2004, BEHAV PROCESS, V65, P79, DOI 10.1016/J.BEPROC.2003.07.001##COHEN J., 1988, STAT POWER ANAL BEHA##COLEMAN K, 1998, ANIM BEHAV, V56, P927, DOI 10.1006/ANBE.1998.0852##DE VRIES H, 2006, ANIM BEHAV, V71, P585, DOI 10.1016/J.ANBEHAV.2005.05.015##DE VRIES H, 1998, ANIM BEHAV, V55, P827, DOI 10.1006/ANBE.1997.0708##DI BITETTI MS, 2001, ANIM BEHAV, V62, P47, DOI 10.1006/ANBE.2000.1730##DREA CM, 1999, P NATL ACAD SCI USA, V96, P12965, DOI 10.1073/PNAS.96.22.12965##DRENT PJ, 2003, P ROY SOC B-BIOL SCI, V270, P45, DOI 10.1098/RSPB.2002.2168##DUNBAR RIM, 2003, ANNU REV ANTHROPOL, V32, P163, DOI 10.1146/ANNUREV.ANTHRO.32.061002.093158##FAWCETT TW, 2002, ANIM BEHAV, V64, P547, DOI 10.1006/ANBE.2002.3092##FEARE C. J., 1984, STARLING##FERNANDEZ-JURICIC E, 2005, ANIM BEHAV, V69, P73, DOI 10.1016/J.ANBEHAV.2004.01.019##GAMMELL MP, 2003, ANIM BEHAV, V66, P601, DOI 10.1006/ANBE.2003.2226##GIRALDEAU LA, 2000, SOCIAL FORAGING THEO##GREENBERG R, 1984, J COMP PSYCHOL, V98, P131, DOI 10.1037/0735-7036.98.2.131##GREENBERG R, 1983, AM NAT, V122, P444, DOI 10.1086/284148##GREENBERG RUSSELL, 2003, P175##HUMPHREY N. K, 1976, GROWING POINTS ETHOL, P303##KACELNIK A, 2002, ANIM BEHAV, V63, P245, DOI 10.1006/ANBE.2001.1900##KATZIR G, 1982, BEHAVIOUR, V81, P231, DOI 10.1163/156853982X00157##KING MG, 1965, ANIM BEHAV, V13, P504, DOI 10.1016/0003-3472(65)90113-2##KUMMER H, 1985, PHILOS T ROY SOC B, V308, P203, DOI 10.1098/RSTB.1985.0020##LALAND KN, 1999, ANIM BEHAV, V57, P331, DOI 10.1006/ANBE.1998.0967##LANGBEIN J, 2004, APPL ANIM BEHAV SCI, V87, P293, DOI 10.1016/J.APPLANIM.2004.01.007##LEFEBVRE LOUIS, 1996, P107, DOI 10.1016/B978-012273965-1/50007-8##LEHNER PN, 1996, HDB ETHOLOGICAL METH##MARTIN P., 1993, MEASURING BEHAV INTR##NICOL CJ, 1999, ANIM BEHAV, V57, P163, DOI 10.1006/ANBE.1998.0920##POWELL GVN, 1974, ANIM BEHAV, V22, P501, DOI 10.1016/S0003-3472(74)80049-7##READER SM, 2002, P NATL ACAD SCI USA, V99, P4436, DOI 10.1073/PNAS.062041299##READER SM, 2001, INT J PRIMATOL, V22, P787, DOI 10.1023/A:1012069500899##READER SM, 2003, ANIMAL INNOVATION, P3##RICE WR, 1989, EVOLUTION, V43, P223, DOI 10.1111/J.1558-5646.1989.TB04220.X##RICHARDS SM, 1974, ANIM BEHAV, V22, P914, DOI 10.1016/0003-3472(74)90015-3##SEFERTA A, 2001, ETHOLOGY, V107, P281, DOI 10.1046/J.1439-0310.2001.00658.X##SEYFARTH RM, 2002, P NATL ACAD SCI USA, V99, P4141, DOI 10.1073/PNAS.082105099##SIH A, 2004, TRENDS ECOL EVOL, V19, P372, DOI 10.1016/J.TREE.2004.04.009##SOKAL R, 1998, BIOMETRY PRINCIPLES##STAHL J, 2001, ANIM BEHAV, V61, P257, DOI 10.1006/ANBE.2000.1564##SUMMERS RW, 1987, IBIS, V129, P96, DOI 10.1111/J.1474-919X.1987.TB03164.X##SWADDLE JP, 1995, P ROY SOC B-BIOL SCI, V260, P219, DOI 10.1098/RSPB.1995.0083##SWADDLE JP, 1994, P ROY SOC B-BIOL SCI, V255, P147, DOI 10.1098/RSPB.1994.0021##SYME GJ, 1974, ANIM BEHAV, V22, P931, DOI 10.1016/0003-3472(74)90016-5##SYME GJ, 1974, ANIM BEHAV, V22, P486, DOI 10.1016/S0003-3472(74)80048-5##TEBBICH S, 1996, ANIM BEHAV, V52, P1, DOI 10.1006/ANBE.1996.0147##TEMPLETON JJ, 1998, ANIM BEHAV, V55, P79, DOI 10.1006/ANBE.1997.0587##TEMPLETON JJ, 1999, J COMP PSYCHOL, V113, P450, DOI 10.1037/0735-7036.113.4.450##TEMPLETON JJ, 1995, ANIM BEHAV, V49, P1617, DOI 10.1016/0003-3472(95)90084-5##VERVAECKE H, 2000, INT J PRIMATOL, V21, P47, DOI 10.1023/A:1005471512788##VERVAECKE H, 1999, BEHAVIOUR, V136, P423, DOI 10.1163/156853999501405##WEBSTER SJ, 2001, ANIM BEHAV, V62, P23, DOI 10.1006/ANBE.2000.1725##WILSON DS, 1994, TRENDS ECOL EVOL, V9, P442, DOI 10.1016/0169-5347(94)90134-1##WITTER MS, 1994, P ROY SOC B-BIOL SCI, V256, P299, DOI 10.1098/RSPB.1994.0084##WITTER MS, 1997, ANIM BEHAV, V54, P279, DOI 10.1006/ANBE.1996.0443##WITTIG RM, 2003, INT J PRIMATOL, V24, P847, DOI 10.1023/A:1024632923180",132,2020-11-20,NA,"UNIV UTRECHT#UNIV ST ANDREWS","NETHERLANDS#SCOTLAND"
"J","WOS:000241714500229",2006,"MULTISPECIES PROBIOTICS ABOLISH ACUTE PANCREATITIS-ASSOCIATED MUCOSAL BARRIER FAILURE IN MURINE ILEUM",NA,NA,NA,"PANCREAS","VAN MINNEN, LP##VERHEEM, A##LUTGENDORFF, F##TIMMERMAN, HM##RIJKERS, GT##RYCHTER, J##GOOSZEN, HG##AKKERMANS, LMA##KROESE, ABA","UNIV MED CTR, DEPT SURG, UTRECHT, NETHERLANDS. UNIV MED CTR, DEPT PEDIAT IMMUNOL, UTRECHT, NETHERLANDS. ST ANTONIUS HOSP, DEPT MED MICROBIOL & IMMUNOL, NIEUWEGEIN, NETHERLANDS. UNIV UTRECHT, INST RISK ASSESSMENT SCI, UTRECHT, NETHERLANDS.","GASTROENTEROLOGY & HEPATOLOGY","GASTROENTEROLOGY & HEPATOLOGY",NA,0,2020-11-20,NA,"UNIV MED CTR#UNIV MED CTR#ST ANTONIUS HOSP#UNIV UTRECHT","NETHERLANDS#NETHERLANDS#NETHERLANDS#NETHERLANDS"
"J","WOS:000242238100008",2006,"DISCREPANCIES BETWEEN MEDICATION RECORDS OF ANTICOAGULATION CLINICS AND PHARMACY RECORDS","PURPOSE TO DETERMINE WHETHER THERE WERE DISCREPANCIES BETWEEN WITH COUMARIN ANTICOAGULANTS INTERACTING MEDICATIONS RECORDED IN MEDICAL FILES OF ANTICOAGULATION CLINICS (AC-RECORDS) AND COMPUTERIZED RECORDS OF COMMUNITY PHARMACIES (PHARMACY RECORDS). METHODS A DESCRIPTIVE STUDY WAS CONDUCTED AT TWO DUTCH ANTICOAGULATION CLINICS (AC'S). RECORDS OF WITH COUMARIN ANTICOAGULANTS INTERACTING DRUGS AT THE AC'S WERE COMPARED WITH THE PHARMACY RECORDS. A DRUG REGISTERED IN THE PHARMACY RECORDS BUT NOT IN THE AC-RECORDS, WAS RECORDED AS A DISCREPANCY, WHILE A DRUG REGISTERED IN AC-RECORDS AS WELL AS IN PHARMACY RECORDS, WAS RECORDED AS A MATCH. RESULTS OF THE 117 IDENTIFIED INTERACTING DRUGS REGISTERED IN PHARMACY RECORDS 32 (27%) WERE NOT REGISTERED IN THE AC-RECORDS. IN FOUR OUT OF SEVEN PATIENTS OF WHOM THE USE OF A PHARMACOKINETICALLY INTERACTING DRUG WAS NOT REGISTERED IN THE AC-RECORDS, SEVERAL INR-VALUES EXCEEDED THE UPPER THERAPEUTIC RANGE. CONCLUSION THIS STUDY DEMONSTRATES THAT A SUBSTANTIAL PERCENTAGE OF DRUGS OF WHICH AN INTERACTION WITH COUMARIN ANTICOAGULANTS CAN BE EXPECTED, IS NOT REGISTERED IN THE MEDICAL FILES OF ANTICOAGULATION CLINICS. COPYRIGHT (C) 2006 JOHN WILEY & SONS, LTD.","ACENOCOUMAROL; WARFARIN; DRUGS","ACENOCOUMAROL; DRUG-INTERACTION; PHARMACY RECORDS","PHARMACOEPIDEMIOLOGY AND DRUG SAFETY","SCHALEKAMP, T##SMIT, C##VAN GEEST-DAALDEROP, JHH##DE VRIES-GOLDSCHMEDING, H##DE BOER, A","UNIV UTRECHT, FAC PHARMACEUT SCI, DEPT PHARMACOEPIDEMIOL & PHARMACOTHERAPY, UIPS, NL-3508 TB UTRECHT, NETHERLANDS. JEROEN BOSCH HOSP, THROMBOSIS SERV, DEPT LAB CLIN CHEM & HEAMATOL, SHERTOGENBOSCH, NETHERLANDS. SALTRO, GP LAB & THROMBOSIS SERV, UTRECHT, NETHERLANDS.","PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH; PHARMACOLOGY & PHARMACY","PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH; PHARMACOLOGY & PHARMACY","CHAN TYK, 1995, ANN PHARMACOTHER, V29, P1274, DOI 10.1177/106002809502901214##CHRISTENSEN DB, 1994, ANN PHARMACOTHER, V28, P99, DOI 10.1177/106002809402800119##HARDER S, 1996, CLIN PHARMACOKINET, V30, P416, DOI 10.2165/00003088-199630060-00002##HIRSH J, 2001, CHEST, V119, P8S, DOI 10.1378/CHEST.119.1_SUPPL.8S##LAU HS, 1997, J CLIN EPIDEMIOL, V50, P619, DOI 10.1016/S0895-4356(97)00040-1##LEISTER KA, 1981, MED CARE, V19, P658, DOI 10.1097/00005650-198106000-00008##MAAT DM, 2002, ANN PHARMACOTHER, V36, P410##PENNING-VAN BEEST FJA, 2001, THROMB HAEMOSTASIS, V86, P569##SCHALEKAMP T, 2004, CLIN PHARMACOL THER, V75, P394, DOI 10.1016/J.CLPT.2003.12.017##TURPIE AGG, 1993, NEW ENGL J MED, V329, P524, DOI 10.1056/NEJM199308193290802##VISSER LE, 2002, THROMB HAEMOSTASIS, V88, P705##WEN X, 2002, DRUG METAB DISPOS, V30, P631, DOI 10.1124/DMD.30.6.631##2003, STANDARD AFHANDELING",1,2020-11-20,NA,"UNIV UTRECHT#JEROEN BOSCH HOSP#SALTRO","NETHERLANDS#NETHERLANDS#NETHERLANDS"
"J","WOS:000242408900133",2006,"BOGOLIUBOV THEORY OF FESHBACH MOLECULES IN THE BEC-BCS CROSSOVER","WE PRESENT THE BOGOLIUBOV THEORY FOR THE BOSE-EINSTEIN CONDENSATION OF FESHBACH MOLECULES IN A BALANCED FERMI MIXTURE. BECAUSE THE BOGOLIUBOV THEORY INCLUDES (GAUSSIAN) FLUCTUATIONS, WE CAN IN THIS MANNER ACCURATELY INCORPORATE BOTH THE TWO-BODY AND MANY-BODY ASPECTS OF THE BEC-BCS CROSSOVER THAT OCCURS NEAR A FESHBACH RESONANCE. WE APPLY THE THEORY IN PARTICULAR TO THE VERY BROAD FESHBACH RESONANCE IN ATOMIC LI-6 AT A MAGNETIC FIELD OF B-0=834 G AND FIND GOOD AGREEMENT WITH EXPERIMENTS IN THAT CASE. THE BEC-BCS CROSSOVER FOR MORE NARROW FESHBACH RESONANCES IS ALSO DISCUSSED.","BOSE-EINSTEIN CONDENSATION; GINZBURG-LANDAU THEORY; NUCLEAR REACTIONS; UNIFIED THEORY; ATOMIC GAS; SUPERCONDUCTIVITY; RESONANCES; WEAK",NA,"PHYSICAL REVIEW A","ROMANS, MWJ##STOOF, HTC","UNIV UTRECHT, INST THEORET PHYS, NL-3584 CE UTRECHT, NETHERLANDS.","OPTICS; PHYSICS, ATOMIC, MOLECULAR & CHEMICAL","OPTICS; PHYSICS","ANDERSON MH, 1995, SCIENCE, V269, P198, DOI 10.1126/SCIENCE.269.5221.198##ANDERSON PW, 1958, PHYS REV, V112, P1900, DOI 10.1103/PHYSREV.112.1900##ASTRAKHARCHIK GE, 2005, PHYS REV LETT, V95, DOI 10.1103/PHYSREVLETT.95.030404##ASTRAKHARCHIK GE, 2004, PHYS REV LETT, V93, DOI 10.1103/PHYSREVLETT.93.200404##BARTENSTEIN M, 2004, PHYS REV LETT, V92, DOI 10.1103/PHYSREVLETT.92.120401##BOGOLIUBOV N. N., 1959, NEW METHOD THEORY SU##BOGOLUROV N.F., 1947, JOURNAL OF PHYSICS, V11, P23##BOURDEL T, 2004, PHYS REV LETT, V93, DOI 10.1103/PHYSREVLETT.93.050401##BRADLEY CC, 1995, PHYS REV LETT, V75, P1687, DOI 10.1103/PHYSREVLETT.75.1687##CARLSON J, 2005, PHYS REV LETT, V95, DOI 10.1103/PHYSREVLETT.95.060401##DAVIS KB, 1995, PHYS REV LETT, V75, P3969, DOI 10.1103/PHYSREVLETT.75.3969##DEMARCO B, 1999, SCIENCE, V285, P1703, DOI 10.1126/SCIENCE.285.5434.1703##DEMELO CARS, 1993, PHYS REV LETT, V71, P3202, DOI 10.1103/PHYSREVLETT.71.3202##DIEHL S, 2006, PHYS REV A, V73, DOI 10.1103/PHYSREVA.73.033615##DIENER RB, CONDMAT0404517, P53401##DRUMMOND PD, 1998, PHYS REV LETT, V81, P3055, DOI 10.1103/PHYSREVLETT.81.3055##DUINE RA, 2004, PHYS REP, V396, P115, DOI 10.1016/J.PHYSREP.2004.03.003##EAGLES DM, 1969, PHYS REV, V186, P456, DOI 10.1103/PHYSREV.186.456##FALCO GM, 2005, PHYS REV A, V71, DOI 10.1103/PHYSREVA.71.063614##FALCO GM, 2004, PHYS REV LETT, V92, DOI 10.1103/PHYSREVLETT.92.130401##FESHBACH H, 1962, ANN PHYS-NEW YORK, V19, P287, DOI 10.1016/0003-4916(62)90221-X##FESHBACH H, 1958, ANN PHYS-NEW YORK, V5, P357, DOI 10.1016/0003-4916(58)90007-1##GALITSKII VM, 1958, SOV PHYS JETP-USSR, V7, P698##GHOSH TK, 2006, PHYS REV A, V73, DOI 10.1103/PHYSREVA.73.013613##HUGENHOLTZ NM, 1959, PHYS REV, V116, P489, DOI 10.1103/PHYSREV.116.489##JAVANAINEN J, 2005, PHYS REV LETT, V95, DOI 10.1103/PHYSREVLETT.95.110408##JOCHIM S, 2003, PHYS REV LETT, V91, DOI 10.1103/PHYSREVLETT.91.240402##KINAST J, 2005, SCIENCE, V307, P1296, DOI 10.1126/SCIENCE.1109220##KINAST J, 2004, PHYS REV LETT, V92, DOI 10.1103/PHYSREVLETT.92.150402##LEGGETT A. J., 1980, MODERN TRENDS IN THE THEORY OF CONDENSED MATTER. PROCEEDINGS OF THE XVITH KARPACZ WINTER SCHOOL OF THEORETICAL PHYSICS, P13##MACKIE M, 2005, PHYS REV LETT, V94, DOI 10.1103/PHYSREVLETT.94.060403##MORITZ H, 2005, PHYS REV LETT, V94, DOI 10.1103/PHYSREVLETT.94.210401##NOZIERES P, 1985, J LOW TEMP PHYS, V59, P195, DOI 10.1007/BF00683774##NYGAARD N, 2006, PHYS REV A, V73, DOI 10.1103/PHYSREVA.73.042705##OHASHI Y, 2005, PHYS REV A, V72, DOI 10.1103/PHYSREVA.72.013601##PARTRIDGE GB, 2005, PHYS REV LETT, V95, DOI 10.1103/PHYSREVLETT.95.020404##PERALI A, 2004, PHYS REV LETT, V92, DOI 10.1103/PHYSREVLETT.92.220404##REGAL CA, 2004, PHYS REV LETT, V92, DOI 10.1103/PHYSREVLETT.92.040403##ROMANS MWJ, 2005, PHYS REV LETT, V95, DOI [10.1103/PHYSREVLETT.95.260407, 10.1103/PHYSREVLETT.260407]##STAJIC J, 2005, PHYS REV LETT, V94, DOI 10.1103/PHYSREVLETT.94.060401##STOOF HTC, 1993, PHYS REV B, V47, P7979, DOI 10.1103/PHYSREVB.47.7979##STWALLEY WC, 1976, PHYS REV LETT, V37, P1628, DOI 10.1103/PHYSREVLETT.37.1628##SZYMANSKA MH, 2005, PHYS REV A, V72, DOI 10.1103/PHYSREVA.72.013610##TIESINGA E, 1993, PHYS REV A, V47, P4114, DOI 10.1103/PHYSREVA.47.4114##TIMMERMANS E, 1999, PHYS REP, V315, P199, DOI 10.1016/S0370-1573(99)00025-3##ZHONG F, 2005, PHYS REV LETT, V95, DOI 10.1103/PHYSREVLETT.95.175701##ZWIERLEIN MW, 2004, PHYS REV LETT, V92, DOI 10.1103/PHYSREVLETT.92.120403",10,2020-11-20,NA,"UNIV UTRECHT","NETHERLANDS"
"J","WOS:000242408900117",2006,"FULDE-FERRELL-LARKIN-OVCHINNIKOV VORTEX LATTICE STATES IN FERMIONIC COLD-ATOM SYSTEMS","CONDENSATION OF ATOM PAIRS WITH FINITE TOTAL MOMENTUM IS EXPECTED IN A PORTION OF THE PHASE DIAGRAM OF A TWO-COMPONENT FERMIONIC COLD-ATOM SYSTEM. THIS UNUSUAL CONDENSATE CAN BE IDENTIFIED BY DETECTING THE EXOTIC HIGHER-LANDAU-LEVEL (HLL) VORTEX LATTICE STATES IT CAN FORM WHEN ROTATED. WITH THIS MOTIVATION, WE HAVE SOLVED THE LINEARIZED GAP EQUATIONS OF A POLARIZED COLD-ATOM SYSTEM IN A LANDAU-LEVEL BASIS TO PREDICT EXPERIMENTAL CIRCUMSTANCES UNDER WHICH HLL VORTEX LATTICE STATES OCCUR.","MAGNETIC-FIELDS; EXCHANGE FIELD; SUPERCONDUCTIVITY; GAS; SUPERFLUIDITY; TEMPERATURES",NA,"PHYSICAL REVIEW A","SHIM, YP##DUINE, RA##MACDONALD, AH","UNIV TEXAS, DEPT PHYS, AUSTIN, TX 78712 USA. UNIV UTRECHT, INST THEORET PHYS, NL-3584 CE UTRECHT, NETHERLANDS.","OPTICS; PHYSICS, ATOMIC, MOLECULAR & CHEMICAL","OPTICS; PHYSICS","AKERA H, 1991, PHYS REV LETT, V67, P2375, DOI 10.1103/PHYSREVLETT.67.2375##BARANOV M, 2002, PHYS SCRIPTA, VT102, P74, DOI 10.1238/PHYSICA.TOPICAL.102A00074##BULGAC A, CONDMAT0606043##BUROVSKI E, 2006, NEW J PHYS, V8, DOI 10.1088/1367-2630/8/8/153##CHEVY F, 2006, PHYS REV LETT, V96, DOI 10.1103/PHYSREVLETT.96.130401##CHEVY F, CONDMAT0605751, P63405##CHIEN CC, 2006, PHYS REV A, V74, DOI 10.1103/PHYSREVA.74.021602##CHIEN CC, 2006, PHYS REV LETT, V97, DOI 10.1103/PHYSREVLETT.97.090402##CLOGSTON AM, 1962, PHYS REV LETT, V9, P266, DOI 10.1103/PHYSREVLETT.9.266##CUI QH, 2006, PHYS REV B, V73, DOI 10.1103/PHYSREVB.73.214514##DE SILVA TN, 2006, PHYS REV A, V73, DOI 10.1103/PHYSREVA.73.051602##DE SILVA TN, 2006, PHYS REV LETT, V97, DOI 10.1103/PHYSREVLETT.97.070402##EAGLES DM, 1969, PHYS REV, V186, P456, DOI 10.1103/PHYSREV.186.456##FEDER DL, 2004, PHYS REV LETT, V93, DOI 10.1103/PHYSREVLETT.93.200406##FULDE P, 1964, PHYS REV, V135, PA550, DOI 10.1103/PHYSREV.135.A550##GORKOV LP, 1961, SOV PHYS JETP-USSR, V13, P1018##GUBBELS KB, CONDMAT0606330##HAQUE M, 2006, PHYS REV A, V74, DOI 10.1103/PHYSREVA.74.011602##HO TL, CONDMAT0602568, P53401##IMAMBEKOV A, CONDMAT0604423##KAKUYANAGI K, 2005, PHYS REV LETT, V94, DOI 10.1103/PHYSREVLETT.94.047602##KINNUNEN J, 2006, PHYS REV LETT, V96, DOI 10.1103/PHYSREVLETT.96.110403##KLEIN U, 2004, PHYS REV B, V69, DOI 10.1103/PHYSREVB.69.134518##LARKIN AI, 1965, ZH EKSP TEOR FIZ, V20, P762##LEGGETT AJ, 1980, J PHYS C SOLID STATE, V41, P7##MACDONALD AH, 1992, PHYS REV B, V45, P10147, DOI 10.1103/PHYSREVB.45.10147##MACHIDA K, 2006, PHYS REV LETT, V97, DOI 10.1103/PHYSREVLETT.97.120407##MARINESCU M, 1998, PHYS REV LETT, V81, P4596, DOI 10.1103/PHYSREVLETT.81.4596##MARTIKAINEN JP, 2006, PHYS REV A, V74, DOI 10.1103/PHYSREVA.74.013602##NORMAN MR, 1995, PHYS REV B, V51, P5927, DOI 10.1103/PHYSREVB.51.5927##NOZIERES P, 1985, J LOW TEMP PHYS, V59, P195, DOI 10.1007/BF00683774##PARISH MM, CONDMAT0605744##PARTRIDGE GB, 2006, SCIENCE, V311, P503, DOI 10.1126/SCIENCE.1122876##PIERI P, 2006, PHYS REV LETT, V96, DOI 10.1103/PHYSREVLETT.96.150404##RADOVAN HA, 2003, NATURE, V425, P51, DOI 10.1038/NATURE01842##REGNAULT N, 2004, PHYS REV B, V70, DOI 10.1103/PHYSREVB.70.241307##SARMA G, 1963, J PHYS CHEM SOLIDS, V24, P1029, DOI 10.1016/0022-3697(63)90007-6##SCHRIEFFER J R, 1999, THEORY SUPERCONDUCTI##SCHWEIKHARD V, 2004, PHYS REV LETT, V92, DOI 10.1103/PHYSREVLETT.92.040404##SHEEHY DE, 2006, PHYS REV LETT, V96, DOI 10.1103/PHYSREVLETT.96.060401##SHIMAHARA H, 1997, J PHYS SOC JPN, V66, P3591, DOI 10.1143/JPSJ.66.3591##STOOF HTC, 1996, J RES NATL INST STAN, V101, P443, DOI 10.6028/JRES.101.047##STWALLEY WC, 1976, PHYS REV LETT, V37, P1628, DOI 10.1103/PHYSREVLETT.37.1628##TIESINGA E, 1993, PHYS REV A, V47, P4114, DOI 10.1103/PHYSREVA.47.4114##YANG K, 2004, PHYS REV B, V70, DOI 10.1103/PHYSREVB.70.094512##YI W, 2006, PHYS REV A, V73, DOI 10.1103/PHYSREVA.73.031604##ZWIERLEIN MW, 2006, NATURE, V442, P54, DOI 10.1038/NATURE04936##ZWIERLEIN MW, 2006, SCIENCE, V311, P492, DOI 10.1126/SCIENCE.1122318##ZWIERLEIN MW, 2005, NATURE, V435, P1047, DOI 10.1038/NATURE03858",14,2020-11-20,NA,"UNIV TEXAS#UNIV UTRECHT","TX USA#NETHERLANDS"
"J","WOS:000242409100041",2006,"OPTICAL CONDUCTIVITY OF CHARGE CARRIERS INTERACTING WITH A TWO-LEVEL SYSTEMS RESERVOIR","USING THE FUNCTIONAL-INTEGRAL METHOD WE INVESTIGATE THE EFFECTIVE DYNAMICS OF A CHARGED PARTICLE COUPLED TO A SET OF TWO-LEVEL SYSTEMS AS A FUNCTION OF TEMPERATURE AND EXTERNAL ELECTRIC FIELD. THE OPTICAL CONDUCTIVITY AND THE DIRECT CURRENT (DC) RESISTIVITY INDUCED BY THE RESERVOIR ARE COMPUTED. THREE DIFFERENT REGIMES ARE FOUND DEPENDING ON THE TWO-LEVEL SYSTEM SPECTRAL FUNCTION, WHICH MAY LEAD TO A NON-DRUDE OPTICAL CONDUCTIVITY IN A CERTAIN RANGE OF PARAMETERS. OUR RESULTS CONTRAST TO THE BEHAVIOR FOUND WHEN CONSIDERING THE USUAL BATH OF HARMONIC OSCILLATORS WHICH WE ARE ABLE TO RECOVER IN THE LIMIT OF VERY LOW TEMPERATURES.","QUANTUM; DYNAMICS",NA,"PHYSICAL REVIEW B","FERRER, AV##CALDEIRA, AO##SMITH, CM","UNIV FED FLUMINENSE, INST FIS, BR-24210346 RIO DE JANEIRO, BRAZIL. UNIV ESTADUAL CAMPINAS, INST FIS GLEB WATAGHIN, DEPT FIS MAT CONDENSADA, BR-13083970 CAMPINAS, SP, BRAZIL. UNIV UTRECHT, INST THEORET PHYS, NL-3584 CE UTRECHT, NETHERLANDS.","MATERIALS SCIENCE, MULTIDISCIPLINARY; PHYSICS, APPLIED; PHYSICS, CONDENSED MATTER","MATERIALS SCIENCE; PHYSICS","BARONE PMVB, 1991, PHYS REV A, V43, P57, DOI 10.1103/PHYSREVA.43.57##CALDEIRA AO, 1983, PHYSICA A, V121, P587, DOI 10.1016/0378-4371(83)90013-4##CALDEIRA AO, 1993, PHYS REV B, V48, P13974, DOI 10.1103/PHYSREVB.48.13974##CALDEIRA AO, 1983, ANN PHYS-NEW YORK, V149, P374, DOI 10.1016/0003-4916(83)90202-6##CASTRO NETO AH, 1993, PHYS REV E, V48, P4037, DOI 10.1103/PHYSREVE.48.4037##DORSEY AT, 1986, PHYS REV A, V33, P1117, DOI 10.1103/PHYSREVA.33.1117##FERRER AV, 2000, PHYS REV B, V61, P2755, DOI 10.1103/PHYSREVB.61.2755##FERRER AV, 2001, PHYS REV B, V64, DOI 10.1103/PHYSREVB.64.104425##FEYNMAN RP, 1963, ANN PHYS-NEW YORK, V24, P118, DOI 10.1016/0003-4916(63)90068-X##GRADSHTEYN I S, 2000, TABLE INTEGRALS PROD##HEDEGARD P, 1987, PHYS SCRIPTA, V35, P609, DOI 10.1088/0031-8949/35/5/001##KATO T, 1998, J PHYS SOC JPN, V67, P2828, DOI 10.1143/JPSJ.67.2828##LEGGETT AJ, 1987, REV MOD PHYS, V59, P1, DOI 10.1103/REVMODPHYS.59.1##MAKRI N, 1999, J PHYS CHEM B, V103, P2823, DOI 10.1021/JP9847540##PROKOF'EV NV, 2000, REP PROG PHYS, V63, P669, DOI 10.1088/0034-4885/63/4/204##WEISS U, 1999, SERIES MODERN CONDEN, V10##ZOTOS X., 2004, STRONG INTERACTIONS",12,2020-11-20,NA,"UNIV FED FLUMINENSE#UNIV ESTADUAL CAMPINAS#UNIV UTRECHT","BRAZIL#BRAZIL#NETHERLANDS"
"J","WOS:000242409500042",2006,"NEUTRAL KAON INTERFEROMETRY IN AU PLUS AU COLLISIONS AT ROOT(S)(NN) =200GEV","WE PRESENT THE FIRST STATISTICALLY MEANINGFUL RESULTS FROM TWO-K-S(0) INTERFEROMETRY IN HEAVY-ION COLLISIONS AT ROOT S(NN)=200 GEV. A MODEL THAT TAKES THE EFFECT OF THE STRONG INTERACTION INTO ACCOUNT HAS BEEN USED TO FIT THE MEASURED CORRELATION FUNCTION. THE EFFECTS OF SINGLE AND COUPLED CHANNELS WERE EXPLORED. AT THE MEAN TRANSVERSE MASS < M(T)>=1.07 GEV, WE OBTAIN THE VALUES R=4.09 +/- 0.46(STAT)+/- 0.31(SYS) FM AND LAMBDA=0.92 +/- 0.23(STAT)+/- 0.13(SYS), WHERE R AND LAMBDA ARE THE INVARIANT RADIUS AND CHAOTICITY PARAMETERS, RESPECTIVELY. THE RESULTS ARE QUALITATIVELY CONSISTENT WITH M(T) SYSTEMATICS ESTABLISHED WITH PIONS IN A SCENARIO CHARACTERIZED BY A STRONG COLLECTIVE FLOW.","BOSE-EINSTEIN CORRELATIONS; STRANGE QUARK MATTER; PION INTERFEROMETRY; LATTICE QCD; STAR TPC; PAIRS; MULTIPLICITY; TEMPERATURE; FEMTOSCOPY; PARTICLES",NA,"PHYSICAL REVIEW C","ABELEV, BI##AGGARWAL, MM##AHAMMED, Z##AMONETT, J##ANDERSON, BD##ANDERSON, M##ARKHIPKIN, D##AVERICHEV, GS##BAI, Y##BALEWSKI, J##BARANNIKOVA, O##BARNBY, LS##BAUDOT, J##BEKELE, S##BELAGA, VV##BELLINGERI-LAURIKAINEN, A##BELLWIED, R##BENEDOSSO, F##BHARDWAJ, S##BHASIN, A##BHATI, AK##BICHSEL, H##BIELCIK, J##BIELCIKOVA, J##BLAND, LC##BLYTH, SL##BONNER, BE##BOTJE, M##BOUCHET, J##BRANDIN, AV##BRAVAR, A##BURTON, TP##BYSTERSKY, M##CADMAN, RV##CAI, XZ##CAINES, H##SANCHEZ, MCD##CASTILLO, J##CATU, O##CEBRA, D##CHAJECKI, Z##CHALOUPKA, P##CHATTOPADHYAY, S##CHEN, HF##CHEN, JH##CHENG, J##CHERNEY, M##CHIKANIAN, A##CHRISTIE, W##COFFIN, JP##CORMIER, TM##COSENTINO, MR##CRAMER, JG##CRAWFORD, HJ##DAS, D##DAS, S##DASH, S##DAUGHERITY, M##DE MOURA, MM##DEDOVICH, TG##DEPHILLIPS, M##DEREVSCHIKOV, AA##DIDENKO, L##DIETEL, T##DJAWOTHO, P##DOGRA, SM##DONG, WJ##DONG, X##DRAPER, JE##DU, F##DUNIN, VB##DUNLOP, JC##MAZUMDAR, MRD##ECKARDT, V##EDWARDS, WR##EFIMOV, LG##EMELIANOV, V##ENGELAGE, J##EPPLEY, G##ERAZMUS, B##ESTIENNE, M##FACHINI, P##FATEMI, R##FEDORISIN, J##FILIMONOV, K##FILIP, P##FINCH, E##FINE, V##FISYAK, Y##FU, J##GAGLIARDI, CA##GAILLARD, L##GANTI, MS##GHAZIKHANIAN, V##GHOSH, P##GONZALEZ, JE##GORBUNOV, YG##GOS, H##GREBENYUK, O##GROSNICK, D##GUERTIN, SM##GUIMARAES, KSFF##GUPTA, N##GUTIERREZ, TD##HAAG, B##HALLMAN, TJ##HAMED, A##HARRIS, JW##HE, W##HEINZ, M##HENRY, TW##HEPPLEMANN, S##HIPPOLYTE, B##HIRSCH, A##HJORT, E##HOFFMAN, AM##HOFFMANN, GW##HORNER, MJ##HUANG, HZ##HUANG, SL##HUGHES, EW##HUMANIC, TJ##IGO, G##JACOBS, P##JACOBS, WW##JAKL, P##JIA, F##JIANG, H##JONES, PG##JUDD, EG##KABANA, S##KANG, K##KAPITAN, J##KAPLAN, M##KEANE, D##KECHECHYAN, A##KHODYREV, VY##KIM, BC##KIRYLUK, J##KISIEL, A##KISLOV, EM##KLEIN, SR##KOCOLOSKI, A##KOETKE, DD##KOLLEGGER, T##KOPYTINE, M##KOTCHENDA, L##KOUCHPIL, V##KOWALIK, KL##KRAMER, M##KRAVTSOV, P##KRAVTSOV, VI##KRUEGER, K##KUHN, C##KULIKOV, AI##KUMAR, A##KUZNETSOV, AA##LAMONT, MAC##LANDGRAF, JM##LANGE, S##LAPOINTE, S##LAUE, F##LAURET, J##LEBEDEV, A##LEDNICKY, R##LEE, CH##LEHOCKA, S##LEVINE, MJ##LI, C##LI, Q##LI, Y##LIN, G##LIN, X##LINDENBAUM, SJ##LISA, MA##LIU, F##LIU, H##LIU, J##LIU, L##LIU, Z##LJUBICIC, T##LLOPE, WJ##LONG, H##LONGACRE, RS##LOVE, WA##LU, Y##LUDLAM, T##LYNN, D##MA, GL##MA, JG##MA, YG##MAGESTRO, D##MAHAPATRA, DP##MAJKA, R##MANGOTRA, LK##MANWEILER, R##MARGETIS, S##MARKERT, C##MARTIN, L##MATIS, HS##MATULENKO, YA##MCCLAIN, CJ##MCSHANE, TS##MELNICK, Y##MESCHANIN, A##MILLANE, J##MILLER, ML##MINAEV, NG##MIODUSZEWSKI, S##MIRONOV, C##MISCHKE, A##MISHRA, DK##MITCHELL, J##MOHANTY, B##MOLNAR, L##MOORE, CF##MOROZOV, DA##MUNHOZ, MG##NANDI, BK##NATTRASS, C##NAYAK, TK##NELSON, JM##NETRAKANTI, PK##NOGACH, LV##NURUSHEV, SB##ODYNIEC, G##OGAWA, A##OKOROKOV, V##OLDENBURG, M##OLSON, D##PACHR, M##PAL, SK##PANEBRATSEV, Y##PANITKIN, SY##PAVLINOV, AI##PAWLAK, T##PEITZMANN, T##PEREVOZTCHIKOV, V##PERKINS, C##PERYT, W##PHATAK, SC##PICHA, R##PLANINIC, M##PLUTA, J##POLJAK, N##PORILE, N##PORTER, J##POSKANZER, AM##POTEKHIN, M##POTREBENIKOVA, E##POTUKUCHI, BVKS##PRINDLE, D##PRUNEAU, C##PUTSCHKE, J##RAKNESS, G##RANIWALA, R##RANIWALA, S##RAY, RL##RAZIN, SV##REINNARTH, J##RELYEA, D##RETIERE, F##RIDIGER, A##RITTER, HG##ROBERTS, JB##ROGACHEVSKIY, OV##ROMERO, JL##ROSE, A##ROY, C##RUAN, L##RUSSCHER, MJ##SAHOO, R##SAKUMA, T##SALUR, S##SANDWEISS, J##SARSOUR, M##SAZHIN, PS##SCHAMBACH, J##SCHARENBERG, RP##SCHMITZ, N##SCHWEDA, K##SEGER, J##SELYUZHENKOV, I##SEYBOTH, P##SHABETAI, A##SHAHALIEV, E##SHAO, M##SHARMA, M##SHEN, WQ##SHIMANSKIY, SS##SICHTERMANN, EP##SIMON, F##SINGARAJU, RN##SMIRNOV, N##SNELLINGS, R##SOOD, G##SORENSEN, P##SOWINSKI, J##SPELTZ, J##SPINKA, HM##SRIVASTAVA, B##STADNIK, A##STANISLAUS, TDS##STOCK, R##STOLPOVSKY, A##STRIKHANOV, M##STRINGFELLOW, B##SUAIDE, AAP##SUGARBAKER, E##SUMBERA, M##SUN, Z##SURROW, B##SWANGER, M##SYMONS, TJM##DE TOLEDO, AS##TAI, A##TAKAHASHI, J##TANG, AH##TARNOWSKY, T##THEIN, D##THOMAS, JH##TIMMINS, AR##TIMOSHENKO, S##TOKAREV, M##TRAINOR, TA##TRENTALANGE, S##TRIBBLE, RE##TSAI, OD##ULERY, J##ULLRICH, T##UNDERWOOD, DG##VAN BUREN, G##VAN DER KOLK, N##VAN LEEUWEN, M##MOLEN, AMV##VARMA, R##VASILEVSKI, IM##VASILIEV, AN##VERNET, R##VIGDOR, SE##VIYOGI, YP##VOKAL, S##VOLOSHIN, SA##WAGGONER, WT##WANG, F##WANG, G##WANG, JS##WANG, XL##WANG, Y##WATSON, JW##WEBB, JC##WESTFALL, GD##WETZLER, A##WHITTEN, C##WIEMAN, H##WISSINK, SW##WITT, R##WOOD, J##WU, J##XU, N##XU, QH##XU, Z##YEPES, P##YOO, IK##YUREVICH, VI##ZHAN, W##ZHANG, H##ZHANG, WM##ZHANG, Y##ZHANG, ZP##ZHAO, Y##ZOULKARNEEV, R##ZOULKARNEEVA, Y##ZUBAREV, AN##ZUO, JX","ARGONNE NATL LAB, 9700 S CASS AVE, ARGONNE, IL 60439 USA. UNIV BIRMINGHAM, BIRMINGHAM, W MIDLANDS, ENGLAND. BROOKHAVEN NATL LAB, UPTON, NY 11973 USA. CALTECH, PASADENA, CA 91125 USA. UNIV CALIF BERKELEY, BERKELEY, CA 94720 USA. UNIV CALIF DAVIS, DAVIS, CA 95616 USA. UNIV CALIF LOS ANGELES, LOS ANGELES, CA 90095 USA. CARNEGIE MELLON UNIV, PITTSBURGH, PA 15213 USA. UNIV ILLINOIS, CHICAGO, IL USA. CREIGHTON UNIV, OMAHA, NE 68178 USA. NUCL PHYS INST AS CR, PRAGUE 25068, CZECH REPUBLIC. LAB HIGH ENERGY JINR, DUBNA, RUSSIA. PARTICLE PHYS LAB JINR, DUBNA, RUSSIA. GOETHE UNIV FRANKFURT, FRANKFURT, GERMANY. INST PHYS, BHUBANESWAR 751005, ORISSA, INDIA. INDIAN INST TECHNOL, BOMBAY, MAHARASHTRA, INDIA. INDIANA UNIV, BLOOMINGTON, IN 47408 USA. INST RECH SUBATOM, STRASBOURG, FRANCE. UNIV JAMMU, JAMMU 180001, INDIA. KENT STATE UNIV, KENT, OH 44242 USA. INST MODERN PHYS, LANZHOU, PEOPLES R CHINA. LAWRENCE BERKELEY NATL LAB, BERKELEY, CA 94720 USA. MIT, CAMBRIDGE, MA 02139 USA. MAX PLANCK INST PHYS & ASTROPHYS, MUNICH, GERMANY. MICHIGAN STATE UNIV, E LANSING, MI 48824 USA. MOSCOW ENGN PHYS INST, MOSCOW, RUSSIA. CUNY CITY COLL, NEW YORK, NY 10031 USA. NIKHEF, AMSTERDAM, NETHERLANDS. UNIV UTRECHT, AMSTERDAM, NETHERLANDS. OHIO STATE UNIV, COLUMBUS, OH 43210 USA. PANJAB UNIV, CHANDIGARH 160014, INDIA. PENN STATE UNIV, UNIVERSITY PK, PA 16802 USA. INST HIGH ENERGY PHYS, PROTVINO, RUSSIA. PURDUE UNIV, W LAFAYETTE, IN 47907 USA. PUSAN NATL UNIV, PUSAN, SOUTH KOREA. UNIV RAJASTHAN, JAIPUR 302004, RAJASTHAN, INDIA. RICE UNIV, HOUSTON, TX 77251 USA. UNIV SAO PAULO, SAO PAULO, BRAZIL. UNIV SCI & TECHNOL CHINA, HEFEI 230026, PEOPLES R CHINA. SHANGHAI INST APPL PHYS, SHANGHAI 201800, PEOPLES R CHINA. SUBATECH, NANTES, FRANCE. TEXAS A&M UNIV, COLLEGE STN, TX 77843 USA. UNIV TEXAS AUSTIN, AUSTIN, TX 78712 USA. TSINGHUA UNIV, BEIJING 100084, PEOPLES R CHINA. VALPARAISO UNIV, VALPARAISO, IN 46383 USA. VARIABLE ENERGY CYCLOTRON CTR, KOLKATA 700064, INDIA. WARSAW UNIV TECHNOL, WARSAW, POLAND. UNIV WASHINGTON, SEATTLE, WA 98195 USA. WAYNE STATE UNIV, DETROIT, MI 48201 USA. CCNU HZNU, INST PARTICLE PHYS, WUHAN 430079, PEOPLES R CHINA. YALE UNIV, NEW HAVEN, CT 06520 USA. UNIV ZAGREB, HR-10002 ZAGREB, CROATIA.","PHYSICS, NUCLEAR","PHYSICS","ABBIENDI G, 2001, EUR PHYS J C, V21, P23, DOI 10.1007/S100520100715##ACHASOV NN, 2003, PHYS REV D, V68, DOI 10.1103/PHYSREVD.68.014006##ACHASOV NN, 2001, PHYS REV D, V63, DOI 10.1103/PHYSREVD.63.094007##ACKERMAN KH, 1999, NUCL PHYS A, V661, P681C, DOI 10.1016/S0375-9474(99)00549-7##ADAMS J, 2004, PHYS REV LETT, V92, DOI 10.1103/PHYSREVLETT.92.112301##ADAMS J, 2003, PHYS REV LETT, V91, DOI 10.1103/PHYSREVLETT.91.262301##ADAMS J, 2005, PHYS REV C, V71, DOI 10.1103/PHYSREVC.71.044906##ADAMS J, NUCLEX0511003##ADAMS JA, IN PRESS##ADLER C, 2004, PHYS LETT B, V595, P143, DOI 10.1016/J.PHYSLETB.2004.06.044##ADLER C, 2001, PHYS REV LETT, V87, DOI [10.1103/PHYSREVLETT.87.182301, 10.1103/PHYSREVLETT.87.262301, 10.1103/PHYSREVLETT.262301]##ADLER C, 2001, NUCL INSTRUM METH A, V461, P337, DOI 10.1016/S0168-9002(00)01238-9##ALEXANDER G, 2003, REP PROG PHYS, V66, P481, DOI 10.1088/0034-4885/66/4/202##ALEXANDER G, 1999, PHYS LETT B, V456, P270, DOI 10.1016/S0370-2693(99)00496-7##ANANTHANARAYAN B, 2001, PHYS REP, V353, P207, DOI 10.1016/S0370-1573(01)00009-6##ANDERSON M, 2003, NUCL INSTRUM METH A, V499, P659, DOI 10.1016/S0168-9002(02)01964-2##ANTINORI F, 1999, NUCL PHYS A, V661, P130C, DOI 10.1016/S0375-9474(99)85015-5##ANTONELLI A, 2002, ECONF C##ARDOUIN D, 1999, PHYS LETT B, V446, P191, DOI 10.1016/S0370-2693(98)01566-4##BACK BB, 2000, PHYS REV LETT, V85, P3100, DOI 10.1103/PHYSREVLETT.85.3100##BACK BB, 2002, PHYS REV LETT, V88, DOI 10.1103/PHYSREVLETT.88.022302##BARU V, 2005, EUR PHYS J A, V23, P523, DOI 10.1140/EPJA/I2004-10105-X##BEKELE S, 2004, THESIS OHIO STATE U##BETTS W, 1997, IEEE T NUCL SCI, V44, P592, DOI 10.1109/23.603717##BUSKULIC D, 1994, Z PHYS C PART FIELDS, V64, P361, DOI 10.1007/BF01560099##EIDELMAN S, 2004, PHYS LETT B, V592, P1, DOI 10.1016/J.PHYSLETB.2004.06.001##GELLMANN M, 1955, PHYS REV, V97, P1387, DOI 10.1103/PHYSREV.97.1387##GREINER C, 1987, PHYS REV LETT, V58, P1825, DOI 10.1103/PHYSREVLETT.58.1825##GYULASSY M, 1992, PHYS LETT B, V286, P211, DOI 10.1016/0370-2693(92)91763-Y##GYULASSY M, 1990, PHYS REV C, V41, PR21, DOI 10.1103/PHYSREVC.41.R21##GYULASSY M, 1989, PHYS LETT B, V217, P181, DOI 10.1016/0370-2693(89)91539-6##HEINZ U, 1996, NUCL PHYS A, V610, PC264, DOI 10.1016/S0375-9474(96)00361-2##JOHNSON SC, 2002, NUCL PHYS A, V698, P603C##KARSCH F, 2002, LECT NOTES PHYS, V583, P209, DOI 10.1007/3-540-45792-5_6##KARSCH F, 1988, Z PHYS C PART FIELDS, V38, P147, DOI 10.1007/BF01574529##KLEIN SR, 1996, IEEE T NUCL SCI, V43, P1768, DOI 10.1109/23.507219##LEDNICKY R, 2004, PHYS ATOM NUCL+, V67, P72, DOI 10.1134/1.1644010##LEDNICKY R, 1982, SOV J NUCL PHYS+, V35, P770##LEDNICKY R, 1998, PHYS ATOM NUCL+, V61, P2050##LEDNICKY R, NUCLTH0501065##LISA MA, 2005, ANNU REV NUCL PART S, V55, P357, DOI 10.1146/ANNUREV.NUCL.55.090704.151533##LYUBOSHITS VL, 1979, SOV J NUCL PHYS+, V30, P407##MARTIN AD, 1977, NUCL PHYS B, V121, P514, DOI 10.1016/0550-3213(77)90169-9##PODGORETSKII M. I., 1989, SOVIET JOURNAL OF PARTICLES AND NUCLEI, V20, P266##PRATT S, 1990, PHYS REV C, V42, P2646, DOI 10.1103/PHYSREVC.42.2646##SOFF S, 1997, J PHYS G NUCL PARTIC, V23, P2095, DOI 10.1088/0954-3899/23/12/035##SPIELES C, 1996, PHYS REV LETT, V76, P1776, DOI 10.1103/PHYSREVLETT.76.1776##SULLIVAN JP, 1993, PHYS REV LETT, V70, P3000, DOI 10.1103/PHYSREVLETT.70.3000##WIEDEMANN UA, 1999, PHYS REP, V319, P145, DOI 10.1016/S0370-1573(99)00032-0##WIEMAN H, 1997, IEEE T NUCL SCI, V44, P671, DOI 10.1109/23.603731##ZAJC WA, 2002, NUCL PHYS A, V698, P39C",38,2020-11-20,NA,"ARGONNE NATL LAB#UNIV BIRMINGHAM#BROOKHAVEN NATL LAB#CALTECH#UNIV CALIF BERKELEY#UNIV CALIF DAVIS#UNIV CALIF LOS ANGELES#CARNEGIE MELLON UNIV#UNIV ILLINOIS#CREIGHTON UNIV#NUCL PHYS INST AS CR#LAB HIGH ENERGY JINR#PARTICLE PHYS LAB JINR#GOETHE UNIV FRANKFURT#INST PHYS#INDIAN INST TECHNOL#INDIANA UNIV#INST RECH SUBATOM#UNIV JAMMU#KENT STATE UNIV#INST MODERN PHYS#LAWRENCE BERKELEY NATL LAB#MIT#MAX PLANCK INST PHYS ASTROPHYS#MICHIGAN STATE UNIV#MOSCOW ENGN PHYS INST#CUNY CITY COLL#NIKHEF#UNIV UTRECHT#OHIO STATE UNIV#PANJAB UNIV#PENN STATE UNIV#INST HIGH ENERGY PHYS#PURDUE UNIV#PUSAN NATL UNIV#UNIV RAJASTHAN#RICE UNIV#UNIV SAO PAULO#UNIV SCI TECHNOL CHINA#SHANGHAI INST APPL PHYS#SUBATECH#TEXAS A M UNIV#UNIV TEXAS AUSTIN#TSINGHUA UNIV#VALPARAISO UNIV#VARIABLE ENERGY CYCLOTRON CTR#WARSAW UNIV TECHNOL#UNIV WASHINGTON#WAYNE STATE UNIV#CCNU HZNU#YALE UNIV#UNIV ZAGREB","IL USA#ENGLAND#NY USA#CA USA#CA USA#CA USA#CA USA#PA USA#IL USA#NE USA#CZECH REPUBLIC#RUSSIA#RUSSIA#GERMANY#INDIA#INDIA#IN USA#FRANCE#INDIA#OH USA#PEOPLES R CHINA#CA USA#MA USA#GERMANY#MI USA#RUSSIA#NY USA#NETHERLANDS#NETHERLANDS#OH USA#INDIA#PA USA#RUSSIA#IN USA#SOUTH KOREA#INDIA#TX USA#BRAZIL#PEOPLES R CHINA#PEOPLES R CHINA#FRANCE#TX USA#TX USA#PEOPLES R CHINA#IN USA#INDIA#POLAND#WA USA#MI USA#PEOPLES R CHINA#CT USA#CROATIA"
"J","WOS:000241678400012",2006,"TIME-LAPSE ANALYSIS OF STEM-CELL DIVISIONS IN THE ARABIDOPSIS THALIANA ROOT MERISTEM","IN THE ARABIDOPSIS ROOT, ASYMMETRIC STEM-CELL DIVISIONS PRODUCE DAUGHTERS THAT FORM THE DIFFERENT ROOT CELL TYPES. HERE WE REPORT THE ESTABLISHMENT OF A CONFOCAL TRACKING SYSTEM THAT ALLOWS THE ANALYSIS OF NUMBERS AND ORIENTATIONS OF CELL DIVISIONS IN ROOT STEM CELLS. THE SYSTEM PROVIDES DIRECT EVIDENCE THAT STEM CELLS HAVE LOWER DIVISION RATES THAN CELLS IN THE PROXIMAL MERISTEM. IT ALSO ALLOWS TRACKING OF CELL DIVISION TIMING, WHICH WE HAVE USED TO ANALYSE THE SYNCHRONIZATION OF ROOT CAP DIVISIONS. FINALLY, IT GIVES NEW INSIGHTS INTO LATERAL ROOT CAP FORMATION: EPIDERMAL STEM-CELL DAUGHTERS CAN ROTATE THE ORIENTATION OF THE DIVISION PLANE LIKE THE STEM CELL.","SHOOT APICAL MERISTEM; CAENORHABDITIS-ELEGANS; VISUALIZATION; LINEAGE; NICHE; FATE","CELL CYCLE; GROWTH; PLANT; DEVELOPMENT; IMAGE ANALYSIS; REAL-TIME","PLANT JOURNAL","CAMPILHO, A##GARCIA, B##VAN DER TOORN, H##VAN WIJK, H##CAMPILHO, A##SCHERES, B","UNIV UTRECHT, DEPT MOL GENET, NL-3508 TA UTRECHT, NETHERLANDS. UNIV PORTO, LAB SINAL IMAGEM BIOMED, INEB, P-4100 OPORTO, PORTUGAL. UNIV UTRECHT, CTR BIOSTAT, NL-3508 TC UTRECHT, NETHERLANDS. UNIV PORTO, FAC ENGN, DEPT ENGN ELECTROTEC COMP, P-4100 OPORTO, PORTUGAL.","PLANT SCIENCES","PLANT SCIENCES","AIDA M, 2004, CELL, V119, P109, DOI 10.1016/J.CELL.2004.09.018##BASKIN TI, 2000, PLANT MOL BIOL, V43, P545, DOI 10.1023/A:1006383921517##BOISNARD-LORIG C, 2001, PLANT CELL, V13, P495, DOI 10.1105/TPC.13.3.495##BUVAT R., 1952, ANN SCI NAT BOT 11E SER, V13, P199##CLOUGH SJ, 1998, PLANT J, V16, P735, DOI 10.1046/J.1365-313X.1998.00343.X##CLOWES F. A. L., 1956, NEW PHYTOL, V55, P29, DOI 10.1111/J.1469-8137.1956.TB05264.X##CUTLER SR, 2000, P NATL ACAD SCI USA, V97, P3718, DOI 10.1073/PNAS.97.7.3718##DOLAN L, 1994, DEVELOPMENT, V120, P2465##DOLAN L, 1993, DEVELOPMENT, V119, P71##DOLZNIG H, 2004, NAT CELL BIOL, V6, P899, DOI 10.1038/NCB1166##FURNER IJ, 1992, DEVELOPMENT, V115, P755##GARCIA B, 2004, LECT NOTES COMPUT SC, V3212, P166##IRISH VF, 1992, DEVELOPMENT, V115, P745##JORGENSEN P, 2002, SCIENCE, V297, P395, DOI 10.1126/SCIENCE.1070850##NANCE J, 2002, DEVELOPMENT, V129, P387##O'CONNELL KF, 1998, GENETICS, V149, P1303##OTSU N, 1979, IEEE T SYST MAN CYB, V9, P62, DOI 10.1109/TSMC.1979.4310076##PERONA P, 1990, IEEE T PATTERN ANAL, V12, P629, DOI 10.1109/34.56205##REDDY GV, 2004, DEVELOPMENT, V131, P4225, DOI 10.1242/DEV.01261##SABATINI S, 2003, GENE DEV, V17, P354, DOI 10.1101/GAD.252503##SCHERES B, 1994, DEVELOPMENT, V120, P2475##SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4##THOMAS C, 1996, SCIENCE, V273, P603, DOI 10.1126/SCIENCE.273.5275.603##VAN DEN BERG C, 1998, NATO ADV SCI I H-CEL, V104, P237##VANDENBERG C, 1997, NATURE, V390, P287, DOI 10.1038/36856##WATT FM, 2000, SCIENCE, V287, P1427, DOI 10.1126/SCIENCE.287.5457.1427##WILDWATER M, 2005, CELL, V123, P1337, DOI 10.1016/J.CELL.2005.09.042",74,2020-11-20,NA,"UNIV UTRECHT#UNIV PORTO#UNIV UTRECHT#UNIV PORTO","NETHERLANDS#PORTUGAL#NETHERLANDS#PORTUGAL"
"J","WOS:000242649200011",2006,"ASSEMBLY FACTOR OMP85 RECOGNIZES ITS OUTER MEMBRANE PROTEIN SUBSTRATES BY A SPECIES-SPECIFIC C-TERMINAL MOTIF","INTEGRAL BETA-BARREL PROTEINS ARE FOUND IN THE OUTER MEMBRANES OF GRAM-NEGATIVE BACTERIA, MITOCHONDRIA, AND CHLOROPLASTS. THE ASSEMBLY OF THESE PROTEINS REQUIRES A PROTEINACEOUS APPARATUS OF WHICH OMP85 IS AN EVOLUTIONARY CONSERVED CENTRAL COMPONENT. TO STUDY ITS MOLECULAR MECHANISM, WE HAVE PRODUCED OMP85 FROM ESCHERICHIA COLI IN INCLUSION BODIES AND REFOLDED IT IN VITRO. THE INTERACTION OF OMP85 WITH ITS SUBSTRATE PROTEINS WAS STUDIED IN LIPID-BILAYER EXPERIMENTS, WHERE IT FORMED CHANNELS. THE PROPERTIES OF THESE CHANNELS WERE AFFECTED UPON ADDITION OF UNFOLDED OUTER-MEMBRANE PROTEINS ( OMPS) OR SYNTHETIC PEPTIDES CORRESPONDING TO THEIR C-TERMINAL SIGNATURE SEQUENCES. THE INTERACTION EXHIBITED SPECIES SPECIFICITY, EXPLAINING THE INEFFICIENT ASSEMBLY OF OMPS FROM NEISSERIA IN E. COLI. ACCORDINGLY, THE IN VIVO ASSEMBLY OF THE NEISSERIAL PORIN PORA INTO THE E. COLI OUTER MEMBRANE WAS ACCOMPLISHED AFTER ADAPTING ITS SIGNATURE SEQUENCE. THESE RESULTS DEMONSTRATE THAT THE OMP85 ASSEMBLY MACHINERY RECOGNIZES OMPS BY VIRTUE OF THEIR C-TERMINAL SIGNATURE SEQUENCE.","ESCHERICHIA-COLI K-12; CONSERVED BACTERIAL PROTEIN; PERIPLASMIC CHAPERONE SKP; NEISSERIA-MENINGITIDIS; LEVEL EXPRESSION; BIOGENESIS; PORINS; IDENTIFICATION; TRANSLOCATION; ENVELOPE",NA,"PLOS BIOLOGY","ROBERT, V##VOLOKHINA, EB##SENF, F##BOS, MP##VAN GELDER, P##TOMMASSEN, J","UNIV UTRECHT, DEPT MOL MICROBIOL, UTRECHT, NETHERLANDS. UNIV UTRECHT, INST BIOMEMBRANES, UTRECHT, NETHERLANDS. VRIJE UNIV BRUSSEL VIB, DEPT MOL & CELLULAR INTERACT, B-1050 BRUSSELS, BELGIUM.","BIOCHEMISTRY & MOLECULAR BIOLOGY; BIOLOGY","BIOCHEMISTRY & MOLECULAR BIOLOGY; LIFE SCIENCES & BIOMEDICINE - OTHER TOPICS","BAYAN N, 2006, MOL MICROBIOL, V60, P1, DOI 10.1111/J.1365-2958.2006.05084.X##BEUCHER M, 1995, J BACTERIOL, V177, P2041, DOI 10.1128/JB.177.8.2041-2049.1995##BOLTER B, 1998, P NATL ACAD SCI USA, V95, P15831, DOI 10.1073/PNAS.95.26.15831##BOS MP, 2005, INFECT IMMUN, V73, P6194, DOI 10.1128/IAI.73.9.6194-6197.2005##BOS MP, 2004, CURR OPIN MICROBIOL, V7, P610, DOI 10.1016/J.MIB.2004.10.011##BOS MP, 2004, P NATL ACAD SCI USA, V101, P9417, DOI 10.1073/PNAS.0402340101##COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727A0##DE COCK H, 1999, EUR J BIOCHEM, V259, P96, DOI 10.1046/J.1432-1327.1999.00010.X##DECOCK H, 1997, J MOL BIOL, V269, P473, DOI 10.1006/JMBI.1997.1069##DOERRLER WT, 2005, J BIOL CHEM, V280, P27679, DOI 10.1074/JBC.M504796200##EPPENS EF, 1997, EMBO J, V16, P4295, DOI 10.1093/EMBOJ/16.14.4295##GENTLE I, 2004, J CELL BIOL, V164, P19, DOI 10.1083/JCB.200310092##GOTSCHLICH EC, 1987, P NATL ACAD SCI USA, V84, P8135, DOI 10.1073/PNAS.84.22.8135##HARMS N, 2001, J BIOL CHEM, V276, P18804, DOI 10.1074/JBC.M011194200##HOEKSTRA WPM, 1976, MOL GEN GENET, V145, P109, DOI 10.1007/BF00331565##INOUE K, 2004, PLANT J, V39, P354, DOI 10.1111/J.1365-313X.2004.02135.X##JANSEN C, 2000, EUR J BIOCHEM, V267, P3792, DOI 10.1046/J.1432-1327.2000.01417.X##JANSEN C, 2000, BBA-BIOMEMBRANES, V1464, P284, DOI 10.1016/S0005-2736(00)00155-3##KLOSE M, 1988, J BIOL CHEM, V263, P13291##KOEBNIK R, 2000, MOL MICROBIOL, V37, P239, DOI 10.1046/J.1365-2958.2000.01983.X##KOZJAK V, 2003, J BIOL CHEM, V278, P48520, DOI 10.1074/JBC.C300442200##LAZAR SW, 1996, J BACTERIOL, V178, P1770, DOI 10.1128/JB.178.6.1770-1773.1996##LERNER CG, 1990, NUCLEIC ACIDS RES, V18, P4631, DOI 10.1093/NAR/18.15.4631##LUGTENBERG B, 1975, FEBS LETT, V58, P254, DOI 10.1016/0014-5793(75)80272-9##NAKAMURA K, 1976, J BIOCHEM, V80, P1411, DOI 10.1093/OXFORDJOURNALS.JBCHEM.A131414##NIKAIDO H, 1991, J BIOL CHEM, V266, P770##NOUWEN N, 1999, P NATL ACAD SCI USA, V96, P8173, DOI 10.1073/PNAS.96.14.8173##OOMEN CJ, 2004, EMBO J, V23, P1257, DOI 10.1038/SJ.EMBOJ.7600148##OSBORNE AR, 2005, ANNU REV CELL DEV BI, V21, P529, DOI 10.1146/ANNUREV.CELLBIO.21.012704.133214##PASCHEN SA, 2003, NATURE, V426, P862, DOI 10.1038/NATURE02208##PETTERSSON A, 1995, INFECT IMMUN, V63, P4181, DOI 10.1128/IAI.63.10.4181-4184.1995##PRILIPOV A, 1998, FEMS MICROBIOL LETT, V163, P65, DOI 10.1016/S0378-1097(98)00151-7##REUMANN S, 1999, TRENDS PLANT SCI, V4, P302, DOI 10.1016/S1360-1385(99)01449-1##RUIZ N, 2005, CELL, V121, P307, DOI 10.1016/J.CELL.2005.02.014##SANCHEZ-PULIDO L, 2003, TRENDS BIOCHEM SCI, V28, P523, DOI 10.1016/J.TIBS.2003.08.003##SCHAGGER H, 2001, METHOD CELL BIOL, V65, P231, DOI 10.1016/S0091-679X(01)65014-3##SEN K, 1988, J BIOL CHEM, V263, P1182##STRUYVE M, 1991, J MOL BIOL, V218, P141, DOI 10.1016/0022-2836(91)90880-F##SUGAWARA E, 1992, J BIOL CHEM, V267, P2507##SURANA NK, 2004, P NATL ACAD SCI USA, V101, P14497, DOI 10.1073/PNAS.0404679101##TOMMASSEN J, 1983, EMBO J, V2, P1275, DOI 10.1002/J.1460-2075.1983.TB01581.X##TU SL, 2004, PLANT CELL, V16, P2078, DOI 10.1105/TPC.104.023952##VAN GELDER P, 2000, EUR J BIOCHEM, V267, P79, DOI 10.1046/J.1432-1327.2000.00960.X##VOULHOUX R, 2004, RES MICROBIOL, V155, P129, DOI 10.1016/J.RESMIC.2003.11.007##VOULHOUX R, 2003, SCIENCE, V299, P262, DOI 10.1126/SCIENCE.1078973##WALSH NP, 2003, CELL, V113, P61, DOI 10.1016/S0092-8674(03)00203-4##WALTON TA, 2004, MOL CELL, V15, P367, DOI 10.1016/J.MOLCEL.2004.07.023##WERNER J, 2005, MOL MICROBIOL, V57, P1450, DOI 10.1111/J.1365-2958.2005.04775.X##WHITE DA, 1990, MOL MICROBIOL, V4, P769, DOI 10.1111/J.1365-2958.1990.TB00647.X##WU T, 2005, CELL, V121, P235, DOI 10.1016/J.CELL.2005.02.015##YEN MR, 2002, BBA-BIOMEMBRANES, V1562, P6, DOI 10.1016/S0005-2736(02)00359-0",230,2020-11-20,NA,"UNIV UTRECHT#UNIV UTRECHT#VRIJE UNIV BRUSSEL VIB","NETHERLANDS#NETHERLANDS#BELGIUM"
"J","WOS:000242374800007",2006,"CRITERIA FOR DRUGS USED IN PRE-EXPOSURE PROPHYLAXIS TRIALS AGAINST HIV INFECTION",NA,"IMMUNODEFICIENCY-VIRUS TYPE-1; REVERSE-TRANSCRIPTASE; RESISTANT HIV-1; TRANSMISSION; MACAQUES; MUTATIONS; PERSISTENCE; DIDANOSINE; PREVENTION; PROTECTION",NA,"PLOS MEDICINE","DERDELINCKX, I##WAINBERG, MA##LANGE, JMA##HILL, A##HALIMA, Y##BOUCHER, CAB","UNIV UTRECHT, MED CTR, EIJKMAN WINKLER INST, DEPT VIROL, UTRECHT, NETHERLANDS. MCGILL UNIV, JEWISH GEN HOSP, LADY DAVIS INST MED RES, AIDS CTR, MONTREAL, PQ H3T 1E2, CANADA. UNIV AMSTERDAM, ACAD MED CTR, IATEC, NL-1012 WX AMSTERDAM, NETHERLANDS. UNIV AMSTERDAM, ACAD MED CTR, CTR POVERTY RELATED COMMUNICABLE DIS, NL-1105 AZ AMSTERDAM, NETHERLANDS. UNIV LIVERPOOL, PHARMACOL RES LABS, LIVERPOOL L69 3BX, MERSEYSIDE, ENGLAND. INT AIDS SOC, GENEVA, SWITZERLAND.","MEDICINE, GENERAL & INTERNAL","GENERAL & INTERNAL MEDICINE",NA,36,2020-11-20,NA,"UNIV UTRECHT#MCGILL UNIV#UNIV AMSTERDAM#UNIV AMSTERDAM#UNIV LIVERPOOL#INT AIDS SOC","NETHERLANDS#CANADA#NETHERLANDS#NETHERLANDS#ENGLAND#SWITZERLAND"
"J","WOS:000241062700001",2006,"VENTRICULAR REPOLARIZATION: AN OVERVIEW OF (PATHO)PHYSIOLOGY, SYMPATHETIC EFFECTS AND GENETIC ASPECTS","MOST TEXTBOOK KNOWLEDGE ON VENTRICULAR REPOLARIZATION IS BASED ON ANIMAL DATA RATHER THAN ON DATA FROM THE IN VIVO HUMAN HEART. YET, THESE DATA HAVE BEEN EXTRAPOLATED TO THE HUMAN HEART, OFTEN WITHOUT AN APPROPRIATE CAVEAT. HERE, WE REVIEW MULTIPLE ASPECTS OF REPOLARIZATION, FROM BASIC MEMBRANE CURRENTS TO CELLULAR ASPECTS INCLUDING EXTRINSIC FACTORS SUCH AS THE EFFECTS OF THE SYMPATHETIC NERVOUS SYSTEM. WE CRITICALLY DISCUSS SOME MECHANISTIC ASPECTS OF THE GENESIS OF THE T-WAVE OF THE ECG IN THE HUMAN HEART. OBVIOUSLY, THE T-WAVE RESULTS FROM THE SUMMATION OF REPOLARIZATION ALL OVER THE HEART. THE T-WAVE IN A LOCAL ELECTROGRAM IDEALLY REFLECTS LOCAL REPOLARIZATION. THE REPOLARIZATION MOMENT IS COMPOSED OF THE MOMENT OF LOCAL ACTIVATION PLUS LOCAL ACTION POTENTIAL DURATION (APD) AT 90% REPOLARIZATION (APD(90)). THE DURATION OF THE LATTER LARGELY DEPENDS ON THE BALANCE BETWEEN L-TYPE CA2+ CURRENT AND THE DELAYED RECTIFIER CURRENTS. GENERALLY SPEAKING, THERE IS AN INVERSE RELATIONSHIP BETWEEN LOCAL ACTIVATION TIME AND LOCAL APD90, LEADING TO LESS DISPERSION IN REPOLARIZATION MOMENTS THAN IN ACTIVATION MOMENTS OR IN APD90. IN TRANSMURAL DIRECTION, THE TIME NEEDED FOR ACTIVATION FROM ENDOCARDIUM TOWARD EPICARDIUM HAS BEEN CONSIDERED TO BE OVERCOMPENSATED BY SHORTER APD90 AT THE EPICARDIUM, LEADING TO THE EARLIEST REPOLARIZATION AT THE SUBEPICARDIUM. IN ADDITION, MID-MYOCARDIAL CELLS WOULD DISPLAY THE LATEST REPOLARIZATION MOMENTS. THE SPARSE HUMAN DATA AVAILABLE, HOWEVER, DO NOT SHOW ANY TRANSMURAL DISPERSION IN REPOLARIZATION MOMENT. ALSO, THE EFFECT OF ADRENERGIC STIMULATION ON APD90 HAS BEEN STUDIED MAINLY IN ANIMALS. AGAIN, SPARSE HUMAN DATA SUGGEST THAT THE EFFECT OF ADRENERGIC STIMULATION IS DIFFERENT IN THE HUMAN HEART COMPARED TO MANY OTHER MAMMALIAN HEARTS. FINALLY, ASPECTS OF THE LONG QT SYNDROME ARE DISCUSSED, BECAUSE THIS INTRINSIC GENETIC DISEASE RESULTS FROM REPOLARIZATION DISORDERS WITH EXTRINSIC ASPECTS. (C) 2005 PUBLISHED BY ELSEVIER LTD.","LONG-QT-SYNDROME; ACTION-POTENTIAL PROLONGATION; CALCIUM-CHANNEL MODULATION; AUTONOMIC NERVOUS-SYSTEM; T-WAVE; EARLY AFTERDEPOLARIZATIONS; CARDIAC-ARRHYTHMIA; REFRACTORY PERIODS; GUINEA-PIG; HEART-RATE","T-WAVE; ACTION POTENTIAL; DISPERSION; BETA-ADRENOCEPTOR BLOCKADE; LONG QT SYNDROME","PROGRESS IN BIOPHYSICS & MOLECULAR BIOLOGY","CONRATH, CE##OPTHOF, T","UNIV UTRECHT, MED CTR, DEPT CARDIOL, UTRECHT, NETHERLANDS. UNIV UTRECHT, MED CTR, DEPT MED PHYSIOL, UTRECHT, NETHERLANDS. UNIV AMSTERDAM, ACAD MED CTR, EXPT & MOL CARDIOL GRP, NL-1105 AZ AMSTERDAM, NETHERLANDS.","BIOCHEMISTRY & MOLECULAR BIOLOGY; BIOPHYSICS","BIOCHEMISTRY & MOLECULAR BIOLOGY; BIOPHYSICS","ABBOTT GW, 1999, CELL, V97, P175, DOI 10.1016/S0092-8674(00)80728-X##ABILDSKOV J. A., 1991, J CARDIOVASC ELECTR, V2, P355, DOI 10.1111/J.1540-8167.1991.TB01332.X##ABILDSKOV JA, 1976, AM HEART J, V92, P210, DOI 10.1016/S0002-8703(76)80256-6##ABILDSKOV JA, 1962, CIRC RES, V11, P247, DOI 10.1161/01.RES.11.2.247##ALLESSIE MA, 1976, CIRC RES, V39, P168, DOI 10.1161/01.RES.39.2.168##[ANONYMOUS], 1989, NEW ENGL J MED, V321, P406##ANTZELEVITCH C, 1999, J CARDIOVASC ELECTR, V10, P1124, DOI 10.1111/J.1540-8167.1999.TB00287.X##ANYUKHOVSKY EP, 1999, J CARDIOVASC ELECTR, V10, P244, DOI 10.1111/J.1540-8167.1999.TB00667.X##ANYUKHOVSKY EP, 1996, CIRCULATION, V94, P1981, DOI 10.1161/01.CIR.94.8.1981##ATTWELL D, 1988, LANCET, V1, P1136##BATCHVAROV VN, 2002, AM J PHYSIOL-HEART C, V282, PH2356, DOI 10.1152/AJPHEART.00860.2001##BAZETT HC, 1920, HEART-J STUD CIRC, V7, P353##BENSON DW, 2003, J CLIN INVEST, V112, P1019, DOI 10.1172/JCI200318062##BOYLE NG, 2001, J CARDIOVASC ELECTR, V12, P421, DOI 10.1046/J.1540-8167.2001.00421.X##BROOKS CM, 1955, EXCITABILITY HEART, P188##BURGESS M J, 1969, J ELECTROCARDIOL, V2, P101##BURGESS MJ, 1982, J ELECTROCARDIOL, V15, P1##BURTON FL, 2001, CARDIOVASC RES, V50, P10, DOI 10.1016/S0008-6363(01)00197-3##CARMELIET E, 1999, PHYSIOL REV, V79, P917##CHATTERJEE K, 1969, BRIT HEART J, V31, P770##CHEN QY, 1998, NATURE, V392, P293##CHENG JH, 1999, CARDIOVASC RES, V43, P135, DOI 10.1016/S0008-6363(99)00061-9##CLAYTON RH, 2004, PROG BIOPHYS MOL BIO, V85, P473, DOI 10.1016/J.PBIOMOLBIO.2003.12.002##CONRATH CE, 2004, CIRCULATION, V110, P365##CONRATH CE, 2004, CARDIOVASC RES, V62, P407, DOI 10.1016/J.CARDIORES.2004.02.016##CONRATH CE, 2002, CARDIOVASC RES, V53, P770, DOI 10.1016/S0008-6363(01)00477-1##CONRATH CE, 2005, THESIS U UTRECHT THE, PCH3##CORONEL R, 2005, HEART RHYTHM, V2, P170, DOI 10.1016/J.HRTHM.2004.11.024##CORONEL R, 2002, CARDIOVASC RES, V54, P11, DOI 10.1016/S0008-6363(02)00249-3##CORR PB, 1986, HEART CARDIOVASCULAR, P1343##COSTARDJACKLE A, 1989, CIRCULATION, V80, P1412, DOI 10.1161/01.CIR.80.5.1412##COWAN JC, 1988, BRIT HEART J, V60, P424##CRANEFIELD PF, 1975, CONDUCTION CARDIAC I##CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5##DANIK S, 2002, AM J PHYSIOL-HEART C, V283, PH372, DOI 10.1152/AJPHEART.01091.2001##DE BAKKER JMT, 2002, J CARDIOVASC PHARM, V39, P328, DOI 10.1097/00005344-200203000-00002##DEAN JW, 1990, J PHYSIOL-LONDON, V429, P387, DOI 10.1113/JPHYSIOL.1990.SP018263##DROUIN E, 1995, J AM COLL CARDIOL, V26, P185, DOI 10.1016/0735-1097(95)00167-X##DUKES ID, 1984, J PHYSIOL-LONDON, V355, P523, DOI 10.1113/JPHYSIOL.1984.SP015436##DURRER D, 1970, CIRCULATION, V41, P899, DOI 10.1161/01.CIR.41.6.899##ELSON JJ, 1981, AM J PHYSIOL, V240, PH738##FRANZ MR, 1988, J CLIN INVEST, V82, P972, DOI 10.1172/JCI113706##FRANZ MR, 2003, J CARDIOVASC ELECTR, V14, PS140, DOI 10.1046/J.1540.8167.90303.X##FRANZ MR, 1991, PROG CARDIOVASC DIS, V33, P369, DOI 10.1016/0033-0620(91)90003-5##FRANZ MR, 1994, J AM COLL CARDIOL, V23, P1554, DOI 10.1016/0735-1097(94)90655-6##FRANZ MR, 1987, CIRCULATION, V75, P379, DOI 10.1161/01.CIR.75.2.379##FUNCKBRENTANO C, 1993, AM J CARDIOL, V72, PB17, DOI 10.1016/0002-9149(93)90035-B##GAIDE MS, 1984, EXPERIENTIA, V40, P694, DOI 10.1007/BF01949727##GARCIACALVO R, 1992, PACE, V15, P1492, DOI 10.1111/J.1540-8159.1992.TB02923.X##HAN J, 1964, CIRC RES, V14, P516, DOI 10.1161/01.RES.14.6.516##HAN J, 1964, CIRC RES, V14, P44, DOI 10.1161/01.RES.14.1.44##HANDA Y, 1982, N-S ARCH PHARMACOL, V318, P330, DOI 10.1007/BF00501173##HARTZELL HC, 1992, J CARDIOVASC ELECTR, V3, P567, DOI 10.1111/J.1540-8167.1992.TB01937.X##HARTZELL HC, 1988, PROG BIOPHYS MOL BIO, V52, P165, DOI 10.1016/0079-6107(88)90014-4##HOFFMAN B.F., 1960, ELECTROPHYSIOLOGY HE##HORAN LG, 1978, CIRC RES, V42, P750, DOI 10.1161/01.RES.42.6.750##INOUE H, 1987, CIRC RES, V60, P942, DOI 10.1161/01.RES.60.6.942##ITOH T, 2001, J HUM GENET, V46, P38, DOI 10.1007/S100380170123##JAKOB H, 1988, BRIT J PHARMACOL, V94, P584, DOI 10.1111/J.1476-5381.1988.TB11564.X##JANSE MJ, 1985, CIRCULATION, V72, P585, DOI 10.1161/01.CIR.72.3.585##JANSE MJ, 1969, CIRC RES, V24, P251, DOI 10.1161/01.RES.24.2.251##JANSE MJ, 1989, PHYSIOL REV, V69, P1049##JANSE MJ, 1998, CARDIOVASC RES, V39, P165, DOI 10.1016/S0008-6363(97)00313-1##JANSE MJ, 2005, IN PRESS CIRCULATION##KASS RS, 1982, J PHYSIOL-LONDON, V322, P541, DOI 10.1113/JPHYSIOL.1982.SP014054##KIMURA S, 1984, ARCH INT PHARMACOD T, V268, P46##KLEBER AG, 1986, CIRCULATION, V73, P189, DOI 10.1161/01.CIR.73.1.189##KODAMA I, 1984, J MOL CELL CARDIOL, V16, P247, DOI 10.1016/S0022-2828(84)80591-X##KORS JA, 1999, CIRCULATION, V99, P1458, DOI 10.1161/01.CIR.99.11.1458##KRALIOS FA, 1975, AM J PHYSIOL, V228, P1621##KUO CS, 1983, CIRCULATION, V67, P1356, DOI 10.1161/01.CIR.67.6.1356##LEE JH, 1991, J PHARMACOL EXP THER, V258, P681##LEPESCHKIN E, 1952, CIRCULATION, V6, P378, DOI 10.1161/01.CIR.6.3.378##LERICHE R, 1931, CR SOC BIOL, V108, P547##LI Q, 1990, PROG CLIN BIOL RES, V327, P743##LIU DW, 1995, CIRC RES, V76, P351, DOI 10.1161/01.RES.76.3.351##LOCATI EH, 1998, CIRCULATION, V97, P2237, DOI 10.1161/01.CIR.97.22.2237##LU ZB, 2001, CIRCULATION, V104, P951, DOI 10.1161/HC3401.093151##MALIK M, 2000, J CARDIOVASC ELECTR, V11, P835, DOI 10.1111/J.1540-8167.2000.TB00061.X##MALIK M, 2001, J CARDIOVASC ELECTR, V12, P411, DOI 10.1046/J.1540-8167.2001.00411.X##MALIK M, 2000, EUR HEART J, V21, P955, DOI 10.1053/EUHJ.2000.2070##MCDONALD TF, 1994, PHYSIOL REV, V74, P365##MILLAR CK, 1985, CIRCULATION, V72, P1372, DOI 10.1161/01.CIR.72.6.1372##MIRVIS DM, 2005, BRAUNWALDS HEART DIS, P107##MISIER ARR, 1995, CIRCULATION, V91, P2566, DOI 10.1161/01.CIR.91.10.2566##MISIER ARR, 1992, J AM COLL CARDIOL, V19, P1531##MOHLER PJ, 2003, NATURE, V421, P634, DOI 10.1038/NATURE01335##MOSS AJ, 1999, AM J CARDIOL, V84, P876, DOI 10.1016/S0002-9149(99)00458-0##MOSS AJ, 2000, CIRCULATION, V101, P616, DOI 10.1161/01.CIR.101.6.616##MOSS AJ, 1995, CIRCULATION, V92, P2929, DOI 10.1161/01.CIR.92.10.2929##MOSS AJ, 1971, NEW ENGL J MED, V285, P903, DOI 10.1056/NEJM197110142851607##MUBAGWA K, 1994, J CARDIOVASC ELECTR, V5, P659, DOI 10.1111/J.1540-8167.1994.TB01189.X##OPTHOF T, 1991, CIRC RES, V68, P1204, DOI 10.1161/01.RES.68.5.1204##OPTHOF T, 1993, CARDIOVASC RES, V27, P1954, DOI 10.1093/CVR/27.11.1954##PRIORI SG, 1994, CIRCULATION, V89, P1681, DOI 10.1161/01.CIR.89.4.1681##PUDDU PE, 1988, CIRCULATION, V77, P935, DOI 10.1161/01.CIR.77.4.935##RANDALL WC, 1963, AM J PHYSIOL, V205, P1227##RAUTAHARJU PM, 2002, J CARDIOVASC ELECTR, V13, P1211, DOI 10.1046/J.1540-8167.2002.01211.X##RENSMA PL, 1988, CIRC RES, V62, P395, DOI 10.1161/01.RES.62.2.395##REUTER H, 1983, NATURE, V301, P569, DOI 10.1038/301569A0##RODEN DM, 1985, CIRC RES, V56, P857, DOI 10.1161/01.RES.56.6.857##ROGERS MC, 1973, ANESTHESIOLOGY, V39, P525, DOI 10.1097/00000542-197311000-00013##ROSEN MR, 1998, CARDIOVASC RES, V40, P469, DOI 10.1016/S0008-6363(98)00208-9##ROSEN MR, 2002, CIRCULATION, V106, P2173, DOI 10.1161/01.CIR.0000036741.27574.CE##ROSENBAUM MB, 1982, AM J CARDIOL, V50, P213, DOI 10.1016/0002-9149(82)90169-2##SAFFITZ JE, 1999, CARDIOVASC RES, V42, P309, DOI 10.1016/S0008-6363(99)00023-1##SANGUINETTI MC, 1991, CIRC RES, V68, P77, DOI 10.1161/01.RES.68.1.77##SAVARD P, 1991, J AUTONOM NERV SYST, V34, P47, DOI 10.1016/0165-1838(91)90007-P##SCHOTT JJ, 1999, NAT GENET, V23, P20, DOI 10.1038/12618##SCHWARTZ PJ, 1995, CIRCULATION, V92, P3381, DOI 10.1161/01.CIR.92.12.3381##SCHWARTZ PJ, 2001, CIRCULATION, V103, P89##SCHWARTZ PJ, 1982, ANN NY ACAD SCI, V382, P162, DOI 10.1111/J.1749-6632.1982.TB55214.X##SCHWARTZ PJ, 1991, CIRCULATION, V84, P503, DOI 10.1161/01.CIR.84.2.503##SCHWARTZ PJ, 1990, CARDIAC ELECTROPHYSI, P589##SCHWARTZ PJ, 1988, NERVOUS CONTROL CARD, P225##SHIMIZU W, 1994, J CARDIOVASC ELECTR, V5, P438, DOI 10.1111/J.1540-8167.1994.TB01183.X##SHIMIZU W, 1991, CIRCULATION, V84, P1915, DOI 10.1161/01.CIR.84.5.1915##SHVILKIN A, 1998, CIRCULATION, V97, P1810, DOI 10.1161/01.CIR.97.18.1810##SICOURI S, 1991, CIRC RES, V68, P1729, DOI 10.1161/01.RES.68.6.1729##SPLAWSKI I, 1997, NAT GENET, V17, P338, DOI 10.1038/NG1197-338##SZENTADRASSY N, 2005, CARDIOVASC RES, V65, P851, DOI 10.1016/J.CARDIORES.2004.11.022##TAGGART P, 2000, J MOL CELL CARDIOL, V32, P621, DOI 10.1006/JMCC.2000.1105##TAGGART P, 2003, CIRCULATION, V107, P285, DOI 10.1161/01.CIR.0000044941.13346.74##TAGGART P, 2001, CARDIOVASC RES, V50, P454, DOI 10.1016/S0008-6363(01)00223-1##TILL JA, 1988, AM J CARDIOL, V62, P1319, DOI 10.1016/0002-9149(88)90289-5##TSIEN RW, 1986, J MOL CELL CARDIOL, V18, P691, DOI 10.1016/S0022-2828(86)80941-5##TSUJI Y, 2002, CIRCULATION, V106, P2012, DOI 10.1161/01.CIR.0000031160.86313.24##VELDKAMP MW, 2001, EUR HEART J, V22, P955, DOI 10.1053/EUHJ.2000.2499##VERKERK AO, 2000, CARDIOVASC RES, V47, P124, DOI 10.1016/S0008-6363(00)00064-X##VOLDERS PGA, 1999, CIRCULATION, V99, P206, DOI 10.1161/01.CIR.99.2.206##VOS MA, 1998, CIRCULATION, V98, P1125, DOI 10.1161/01.CIR.98.11.1125##WANG Q, 1995, CELL, V80, P805, DOI 10.1016/0092-8674(95)90359-3##WANG Q, 1996, NAT GENET, V12, P17, DOI 10.1038/NG0196-17##WEISS JN, 1999, CIRCULATION, V99, P2819, DOI 10.1161/01.CIR.99.21.2819##WIENER N, 1946, ARCH INST CARDIOL MEX, V16, P205##WILDE AAM, 1999, J AM COLL CARDIOL, V33, P327, DOI 10.1016/S0735-1097(98)00578-6##WILLIAMS EMV, 1984, J CLIN PHARMACOL, V24, P129, DOI 10.1002/J.1552-4604.1984.TB01822.X##WILLIAMS EMV, 1975, PHARMACOL THER   B, V1, P115##WILSON FN, 1935, AM HEART J, V10, P46##WILSON FN, 1931, T ASSOC AM PHYSICIAN, V46, P29##XIA YL, 2005, HEART RHYTHM, V2, P162, DOI 10.1016/J.HRTHM.2004.11.011##YAN GX, 1998, CIRCULATION, V98, P1928, DOI 10.1161/01.CIR.98.18.1928##YAN GX, 1998, CIRCULATION, V98, P1921, DOI 10.1161/01.CIR.98.18.1921##YANOWITZ F, 1966, CIRC RES, V18, P416, DOI 10.1161/01.RES.18.4.416##ZABEL M, 2000, J AM COLL CARDIOL, V36, P1654, DOI 10.1016/S0735-1097(00)00921-9##ZABEL M, 1998, J CARDIOVASC ELECTR, V9, P1279, DOI 10.1111/J.1540-8167.1998.TB00103.X##ZABEL M, 1995, J AM COLL CARDIOL, V25, P746, DOI 10.1016/0735-1097(94)00446-W##ZAREBA W, 1998, NEW ENGL J MED, V339, P960, DOI 10.1056/NEJM199810013391404##ZAZA A, 1991, CIRC RES, V68, P1191, DOI 10.1161/01.RES.68.5.1191",74,2020-11-20,NA,"UNIV UTRECHT#UNIV UTRECHT#UNIV AMSTERDAM","NETHERLANDS#NETHERLANDS#NETHERLANDS"
"J","WOS:000242939600009",2006,"FROM AFFECTIVE VALENCE TO MOTIVATIONAL DIRECTION - THE FRONTAL ASYMMETRY OF EMOTION REVISED",NA,"PREFRONTAL CORTEX; BRAIN",NA,"PSYCHOLOGICAL SCIENCE","VAN HONK, J##SCHUTTER, DJLG","UNIV UTRECHT, DEPT PSYCHOL, HELMHOLTZ RES INST, NL-3584 CS UTRECHT, NETHERLANDS.","PSYCHOLOGY, MULTIDISCIPLINARY","PSYCHOLOGY","ALEMAN A, 2002, COGNITIVE BRAIN RES, V14, P300, DOI 10.1016/S0926-6410(02)00109-X##D'ALFONSO AAL, 2000, NEUROSCI LETT, V280, P195, DOI 10.1016/S0304-3940(00)00781-3##DAVIDSON R. J, 1984, EMOTIONS COGNITION B, P320##DAVIDSON RJ, 2004, BIOL PSYCHOL, V67, P219, DOI 10.1016/J.BIOPSYCHO.2004.03.008##FOX NA, 1991, AM PSYCHOL, V46, P863, DOI 10.1037/0003-066X.46.8.863##HARMON-JONES E, 2006, PSYCHOL SCI, V17, P434, DOI 10.1111/J.1467-9280.2006.01724.X##HARMON-JONES E, 2004, BIOL PSYCHOL, V67, P51, DOI 10.1016/J.BIOPSYCHO.2004.03.003##JAY SCHULKIN, 2003, RETHINKING HOMEOSTAS##VAN HONK J, 2003, PSYCHONEUROENDOCRINO, V28, P941, DOI 10.1016/S0306-4530(02)00116-6##VAN HONK JACK, 2006, COGN NEUROPSYCHIATRY, V11, P285, DOI 10.1080/13546800500233728##WEGNER D. M., 1993, HDB MENTAL CONTROL",83,2020-11-20,NA,"UNIV UTRECHT","NETHERLANDS"
"J","WOS:000242259300010",2006,"IMMUNE AND ENDOCRINE FUNCTION IN BURNOUT SYNDROME","OBJECTIVE: BURNOUT IS A STRESS-INDUCED WORK-RELATED SYNDROME. IT IS ASSOCIATED WITH A HIGHER INCIDENCE OF INFECTIONS POSSIBLY POINTING TO A COMPROMISED IMMUNE SYSTEM. IN THE PRESENT STUDY, ENDOCRINE AND EX VIVO IMMUNE FUNCTION OF SEVERE CASES OF BURNOUT WERE INVESTIGATED. METHODS: ENDOCRINE AND IMMUNE VARIABLES WERE COMPARED IN 56 PERSONS WITH BURNOUT AND 38 HEALTHY CONTROL SUBJECTS. CORTISOL AFTER AWAKENING, AFTER A LOW-DOSE DEXAMETHASONE, AND DEHYDROEPIANDROSTERONE-SULPHATE (DHEAS) WERE ANALYZED FROM SALIVA. PERIPHERAL BLOOD WAS ANALYZED FOR T, B, AND NK CELL NUMBER AND IN VITRO MITOGEN-INDUCED PRO- AND ANTIINFLAMMATORY CYTOKINE RELEASE. THE CAPACITY OF DEXAMETHASONE TO REGULATE CYTOKINE RELEASE WAS COMPARED BETWEEN THE GROUPS. RESULTS: THE BURNOUT GROUP SHOWED AN INCREASED PRODUCTION OF THE ANTIINFLAMMATORY CYTOKINE INTERLEUKIN-10 (IL-10) BY MONOCYTES AFTER LIPOPOLYSACCHARIDE STIMULATION. NO DIFFERENCES WERE OBSERVED IN IL-10 RELEASE INDUCED BY THE T-CELL MITOGEN PHA NOR IN THE PROINFLAMMATORY CYTOKINES GAMMA INTERFERON AND TUMOR NECROSIS FACTOR ALPHA. THE CAPACITY OF DEXAMETHASONE TO REGULATE CYTOKINE RELEASE DID NOT DIFFER BETWEEN THE GROUPS. THE NUMBER OF PERIPHERAL BLOOD T CELLS, B CELLS, OR NK CELLS WAS NOT DIFFERENT EITHER. THE BURNOUT GROUP SHOWED HIGHER DHEAS LEVELS BUT NO DIFFERENCE IN CORTISOL LEVELS AFTER AWAKENING OR AFTER DEXAMETHASONE INTAKE IN COMPARISON TO CONTROLS. CONCLUSION: PRODUCTION OF THE ANTIINFLAMMATORY CYTOKINE IL-10 BY MONOCYTES WAS INCREASED IN INDIVIDUALS WITH BURNOUT SYNDROME. IT SEEMS UNLIKELY THAT GLUCOCORTICOIDS OR CHANGES IN GLUCOCORTICOID RECEPTOR FUNCTION PLAY A ROLE IN THIS HIGHER IL-10 PRODUCTION.","CHRONIC-FATIGUE-SYNDROME; DEXAMETHASONE-SUPPRESSION; CYTOKINE PRODUCTION; CORTISOL-LEVELS; DEHYDROEPIANDROSTERONE; SENSITIVITY; HORMONES; SULFATE; SAMPLE; CURVE","BURNOUT; CYTOKINES; IL-10; MONOCYTE; GLUCOCORTICOIDS; DHEAS","PSYCHOSOMATIC MEDICINE","MOMMERSTEEG, PMC##HEIJNEN, CJ##KAVELAARS, A##VAN DOORNEN, LJP","UNIV UTRECHT, DEPT HLTH PSYCHOL, NL-3508 TC UTRECHT, NETHERLANDS. UNIV UTRECHT, MED CTR, LAB PSYCHONEUROIMMUNOL, NL-3508 TC UTRECHT, NETHERLANDS.","PSYCHIATRY; PSYCHOLOGY; PSYCHOLOGY, MULTIDISCIPLINARY","PSYCHIATRY; PSYCHOLOGY","AMERICAN PSYCHIATRIC ASSOCIATION, 1994, DIAGN STAT MAN MENT##APPELS A, 1989, J PSYCHOSOM RES, V33, P727, DOI 10.1016/0022-3999(89)90088-3##ARRINDELL WA, 1981, NEDERLANDS TIJDSCHRI, V36, P77##ASSIES J, 2004, PSYCHIAT RES, V128, P117, DOI 10.1016/J.PSYCHRES.2004.05.016##BARGELLINI A, 2000, OCCUP ENVIRON MED, V57, P453, DOI 10.1136/OEM.57.7.453##BOUMA J, 1995, METEN SYMPTOMEN DEPR, P1##BULTMANN U, 2000, J OCCUP HEALTH PSYCHOL, V5, P411, DOI 10.1037/1076-8998.5.4.411##CANALS J, 1997, PERS INDIV DIFFER, V23, P593, DOI 10.1016/S0191-8869(97)00093-7##CHEN CCG, 2004, SEMIN REPROD MED, V22, P369, DOI 10.1055/S-2004-861553##CHENG CF, 2000, J INTERF CYTOK RES, V20, P471, DOI 10.1089/10799900050023889##COHEN J., 1988, STAT POWER ANAL BEHA##COHEN S, 1998, HEALTH PSYCHOL, V17, P214, DOI 10.1037/0278-6133.17.3.214##COLE MA, 2000, PSYCHONEUROENDOCRINO, V25, P151, DOI 10.1016/S0306-4530(99)00045-1##ELENKOV IJ, 2002, ANN NY ACAD SCI, V966, P290, DOI 10.1111/J.1749-6632.2002.TB04229.X##GAAB J, 2005, PSYCHONEUROENDOCRINO, V30, P188, DOI 10.1016/J.PSYNEUEN.2004.06.008##GLASER R, 2005, BRAIN BEHAV IMMUN, V19, P91, DOI 10.1016/J.BBI.2004.09.001##GROSSI G, 2003, J PSYCHOSOM RES, V55, P309, DOI 10.1016/S0022-3999(02)00633-5##GUPTA S, 1997, J PSYCHIAT RES, V31, P149, DOI 10.1016/S0022-3956(96)00063-5##GWALTNEY JM, 2002, AM J MED, V112, P13S##KAVELAARS A, 2000, J CLIN ENDOCR METAB, V85, P692, DOI 10.1210/JC.85.2.692##KIECOLT-GLASER JK, 2002, PSYCHOSOM MED, V64, P15, DOI 10.1097/00006842-200201000-00004##KIRSCHBAUM C, 1999, PSYCHOSOM MED, V61, P154, DOI 10.1097/00006842-199903000-00006##KROBOTH PD, 1999, J CLIN PHARMACOL, V39, P327, DOI 10.1177/00912709922007903##KUDIELKA BM, 2003, PSYCHOSOM MED, V65, P313, DOI 10.1097/01.PSY.0000058374.50240.BF##LYALL M, 2003, J PSYCHOSOM RES, V55, P79, DOI 10.1016/S0022-3999(02)00515-9##MAIER SF, 1998, PSYCHOL REV, V105, P83, DOI 10.1037/0033-295X.105.1.83##MASLACH C, 2001, ANNU REV PSYCHOL, V52, P397, DOI 10.1146/ANNUREV.PSYCH.52.1.397##MEIJMAN TF, 1990, WORK STRESS, V4, P65, DOI 10.1080/02678379008256965##MOCH SL, 2003, ENDOCRINE, V21, P267, DOI 10.1385/ENDO:21:3:267##MOHREN DCL, 2003, J PSYCHOSOM RES, V55, P201, DOI 10.1016/S0022-3999(02)00517-2##MOMMERSTEEG PMC, 2006, HEALTH PSYCHOL, V25, P243, DOI 10.1037/0278-6133.25.2.243##MOMMERSTEEG PMC, 2006, PSYCHONEUROENDOCRINO, V31, P216, DOI 10.1016/J.PSYNEUEN.2005.07.003##NAKAMURA H, 1999, J PSYCHOSOM RES, V46, P569, DOI 10.1016/S0022-3999(99)00009-4##PATARCA R, 2001, ANN NY ACAD SCI, V933, P185##PRUESSNER JC, 2003, PSYCHONEUROENDOCRINO, V28, P916, DOI 10.1016/S0306-4530(02)00108-7##PRUESSNER JC, 1997, LIFE SCI, V61, P2539, DOI 10.1016/S0024-3205(97)01008-4##REEVES WC, 2003, BMC HEALTH SERV RES, V3, DOI 10.1186/1472-6963-3-25##SCHAUFELI W, 1998, BURNOUT COMPANION ST##SCHAUFELI WB, 2001, PSYCHOL HEALTH, V16, P565, DOI 10.1080/08870440108405527##SHIROM A, 2005, WORK STRESS, V19, P263, DOI 10.1080/02678370500376649##SHIRTCLIFF EA, 2001, PSYCHONEUROENDOCRINO, V26, P165, DOI 10.1016/S0306-4530(00)00042-1##STOCKL J, 1999, J CLIN INVEST, V104, P957, DOI 10.1172/JCI7255##VAN DER VEN A, 2003, PSYCHOSOM MED, V65, P194, DOI 10.1097/01.PSY.0000058378.50240.80##VAN DIERENDONCK D., 2000, UBOS UTRECHTSE BURNO##VERCOULEN JHMM AM, 1999, GEDRAGSTHERAPIE, P131##VISSER J, 1998, J INFECT DIS, V177, P451, DOI 10.1086/517373##VISSER J, 2001, J NEUROIMMUNOL, V119, P343, DOI 10.1016/S0165-5728(01)00400-3##*WHO, 1994, ICD10 INT STAT CLASS##WIRTZ PH, 2003, PSYCHOSOM MED, V65, P672, DOI 10.1097/01.PSY.0000062529.39901.C7##WOLF OT, 1999, BRAIN RES REV, V30, P264, DOI 10.1016/S0165-0173(99)00021-1##YOUNG AH, 2002, AM J PSYCHIAT, V159, P1237, DOI 10.1176/APPI.AJP.159.7.1237",58,2020-11-20,NA,"UNIV UTRECHT#UNIV UTRECHT","NETHERLANDS#NETHERLANDS"
"J","WOS:000242698700009",2006,"INFLUENCE OF NEEDLE POSITION ON LUMBAR SEGMENTAL NERVE ROOT BLOCK SELECTIVITY","BACKGROUND AND OBJECTIVES: IN PATIENTS WITH CHRONIC LOW BACK PAIN RADIATING TO THE LEG, SEGMENTAL NERVE ROOT BLOCKS (SNRBS) ARE PERFORMED TO PREDICT SURGICAL OUTCOME AND IDENTIFY THE PUTATIVE SYMPTOMATIC SPINAL NERVE. EPIDURAL SPREAD MAY LEAD TO FALSE INTERPRETATION, AFFECTING CLINICAL DECISION MAKING. SYSTEMATIC FLUOROSCOPIC ANALYSIS OF EPIDURAL LOCAL ANESTHETIC SPREAD AND ITS RELATIONSHIP TO NEEDLE TIP LOCATION HAS NOT BEEN PUBLISHED TO DATE. STUDY AIMS INCLUDE ASSESSMENT OF EPIDURAL LOCAL ANESTHETIC SPREAD AND ITS RELATIONSHIP TO NEEDLE POSITION DURING FLUOROSCOPY-ASSISTED BLOCKS. METHODS: PATIENTS SCHEDULED FOR L4, L5, AND S1 BLOCKS WERE INCLUDED IN THIS PROSPECTIVE OBSERVATIONAL STUDY. UNDER FLUOROSCOPY AND ELECTROSTIMULATION, THEY RECEIVED 0.5 ML OF A MIXTURE CONTAINING LIDOCAINE 5 MG AND IOHEXOL 75 MG. X-RAYS WITH NEEDLE TIP AND CONTRAST WERE SCORED FOR NO EPIDURAL SPREAD (GRADE 0), LOCAL SPREAD EPIDURALLY (GRADE 1), OR TO ADJACENT NERVE ROOTS (GRADE 2). RESULTS: SIXTY-FIVE PATIENTS WERE ANALYZED FOR EPIDURAL SPREAD, 62 FOR NEEDLE POSITION. GRADE I EPIDURAL SPREAD OCCURRED IN 47% OF L4 AND 28% OF L5 BLOCKS AND GRADE 2 SPREAD IN 3 BLOCKS (5%; L5 N = 1, S1 N = 2). FOR LUMBAR BLOCKS, THE NEEDLE WAS MOST FREQUENTLY FOUND IN THE LATERAL UPPER HALF OF THE INTERVERTEBRAL FORAMEN. EPIDURAL SPREAD OCCURRED MORE FREQUENTLY WITH MEDIAL NEEDLE POSITIONS (P=.06). CONCLUSION: THE FINDINGS SUGGEST (P=.06) THAT THE RISK OF GRADE 1 AND 2 LUMBAR EPIDURAL SPREAD, WHICH RESULTS IN DECREASED SNRB SELECTIVITY, IS GREATER WITH MEDIAL NEEDLE POSITIONS IN THE INTERVERTEBRAL FORAMEN. THE VARIABILITY IN ANATOMIC POSITION OF THE DORSAL ROOT GANGLION NECESSITATES ELECTROSTIMULATION TO GUIDE SNRB IN ADDITION TO FLUOROSCOPY.","LOW-BACK-PAIN; RADICULAR PAIN; DOUBLE-BLIND; LOCAL-ANESTHETICS; SCIATICA; INFILTRATION; DIAGNOSIS; RADICULOGRAPHY; INJECTION; GANGLIA","SEGMENTAL NERVE ROOT BLOCK; CHRONIC LOW BACK PAIN; SELECTIVITY","REGIONAL ANESTHESIA AND PAIN MEDICINE","WOLFF, AP##GROEN, GJ##WILDER-SMITH, OH","RADBOUD UNIV NIJMEGEN, NIJMEGEN MED CTR, DEPT ANESTHESIOL, PAIN CTR, NL-6500 HB NIJMEGEN, NETHERLANDS. UNIV UTRECHT, MED CTR, DIV PERIOPERAT MED & EMERGENCY CARE, DEPT ANESTHESIOL, UTRECHT, NETHERLANDS. BERNHOVEN HOSP, DEPT ANESTHESIOL, PAIN CTR, OSS, NETHERLANDS.","ANESTHESIOLOGY","ANESTHESIOLOGY","AKKERVEEKEN PF, 1993, NEURO-ORTHOPEDICS, V14, P81##CASTRO W H, 1994, EUR SPINE J, V3, P255, DOI 10.1007/BF02226574##DERBY R, 1992, SPINE, V17, PS176, DOI 10.1097/00007632-199206001-00020##DOOLEY JF, 1988, SPINE, V13, P79, DOI 10.1097/00007632-198801000-00019##EVERETT CLIFFORD R, 2005, PAIN PHYSICIAN, V8, P225##FURMAN MB, 2000, PAIN, V85, P526, DOI 10.1016/S0304-3959(99)00293-6##GAJRAJ NM, 2004, REGION ANESTH PAIN M, V29, P243, DOI 10.1016/J.RAPM.2003.12.025##GAUCI A, 2004, MANUAL RF TECHNIQUES, P7##GEURTS JWM, 2003, LANCET, V361, P21, DOI 10.1016/S0140-6736(03)12115-0##GROEN GJ, 1990, AM J ANAT, V188, P282, DOI 10.1002/AJA.1001880307##HASUE M, 1989, SPINE, V14, P1261##HAUEISEN DC, 1985, CLIN ORTHOP RELAT R, P179##HAYNSWORTH ROBERT F JR, 2003, PAIN PHYSICIAN, V6, P517##HERRON L D, 1989, J SPINAL DISORD, V2, P75##HOGAN QH, 1997, ANESTHESIOLOGY, V86, P216, DOI 10.1097/00000542-199701000-00026##HUSTON CW, 2005, ARCH PHYS MED REHAB, V86, P277, DOI 10.1016/J.APMR.2004.02.018##KREMPEN JF, 1974, J BONE JOINT SURG AM, VA 56, P1435, DOI 10.2106/00004623-197456070-00011##KREMPEN JF, 1975, ORTHOP CLIN N AM, V6, P311##KUSLICH SD, 1991, ORTHOP CLIN N AM, V22, P181##MACADAEG K, 2001, PAIN MED, V2, P245##MANCHIKANTI L, 2001, PAIN PHYSICIAN, V4, P308##NITTA H, 1993, SPINE, V18, P1782, DOI 10.1097/00007632-199310000-00011##NORTH RB, 1996, PAIN, V65, P77, DOI 10.1016/0304-3959(95)00170-0##PORTER DG, 1999, BRIT J NEUROSURG, V13, P290##QUINN SF, 1988, AM J ROENTGENOL, V151, P1213, DOI 10.2214/AJR.151.6.1213##SCHUTZ H, 1973, CAN J SURG, V16, P217##STANLEY D, 1990, SPINE, V15, P540, DOI 10.1097/00007632-199006000-00020##STOLKER RJ, 1994, PAIN, V58, P1, DOI 10.1016/0304-3959(94)90180-5##TAJIMA T, 1980, SPINE, V5, P68, DOI 10.1097/00007632-198001000-00013##WOLFF AP, 2001, REGION ANESTH PAIN M, V26, P147, DOI 10.1053/RAPM.2001.21436##WOLFF AP, 2004, ANESTH ANALG, V99, P496",18,2020-11-20,NA,"RADBOUD UNIV NIJMEGEN#UNIV UTRECHT#BERNHOVEN HOSP","NETHERLANDS#NETHERLANDS#NETHERLANDS"
"J","WOS:000242168700011",2006,"EFFECT OF CUMULUS MORPHOLOGY AND MATURATION STAGE ON THE CRYOPRESERVABILITY OF EQUINE OOCYTES","OOCYTE CRYOPRESERVATION IS A POTENTIALLY VALUABLE WAY OF PRESERVING THE FEMALE GERM LINE. HOWEVER, THE DEVELOPMENTAL COMPETENCE OF CRYOPRESERVED OOCYTES IS PRESENTLY POOR. THIS STUDY INVESTIGATED WHETHER THE MORPHOLOGY OF THE CUMULUS COMPLEX SURROUNDING AN IMMATURE EQUINE OOCYTE AND/OR THE OOCYTE'S STAGE OF MATURATION AFFECT ITS CRYOPRESERVABILITY. COMPACT (CP) AND EXPANDED (EX) CUMULUS OOCYTE COMPLEXES (COCS) WERE VITRIFIED EITHER SHORTLY AFTER RECOVERY (GERMINAL VESICLE STAGE, GV) OR AFTER MATURATION IN VITRO (IVM); CRYOPROTECTANT-TREATED AND -UNTREATED NON-FROZEN OOCYTES SERVED AS CONTROLS. IN EXPERIMENT 1, OOCYTES MATURED IN VITRO AND THEN VITRIFIED, OR VICE VERSA, WERE EXAMINED FOR MATURATION STAGE AND MEIOTIC SPINDLE QUALITY. CP AND EX COCS VITRIFIED AT THE GV STAGE MATURED AT SIMILAR RATES DURING SUBSEQUENT IVM (41 VS 46% MIL), BUT MEIOTIC SPINDLE QUALITY WAS BETTER FOR CP THAN EX (63 VS 33% NORMAL SPINDLES). VITRIFYING OOCYTES AFTER IVM RESULTED IN DISAPPOINTING POST-WARMING SPINDLE QUALITY (32 VS 28% NORMAL FOR CP VS EX). IN EXPERIMENT 11, OOCYTES FROM CP AND EX COCS VITRIFIED AT THE GV OR MIL STAGES WERE FERTILIZED BY INTRACYTOPLASMIC SPERM INJECTION (ICSI) AND MONITORED FOR CLEAVAGE AND BLASTOCYST FORMATION. OOCYTES VITRIFIED PRIOR TO IVM YIELDED HIGHER CLEAVAGE RATES (34 AND 27% FOR CP AND EX CCICS) THAN THOSE VITRIFIED AFTER IVM (16 AND 4%). HOWEVER, ONLY ONE BLASTOCYST WAS PRODUCED FROM A SPERM-INJECTED VITRIFIED-WARMED OOCYTE (0.4 VS 9.3% AND 13% BLASTOCYSTS FOR CRYOPROTECTANT-EXPOSED AND -UNTREATED CONTROLS). IT IS CONCLUDED THAT, WHEN VITRIFICATION IS THE CHOSEN METHOD OF CRYOPRESERVATION, CP EQUINE CCICS AT THE GV STAGE OFFER THE BEST CHANCE OF AN MII OOCYTE WITH A NORMAL SPINDLE AND THE POTENTIAL FOR FERTILIZATION; HOWEVER, DEVELOPMENTAL COMPETENCE IS STILL REDUCED DRAMATICALLY.","INTRACYTOPLASMIC SPERM INJECTION; IN-VITRO MATURATION; INITIAL CHROMATIN CONFIGURATION; II HUMAN OOCYTES; BOVINE OOCYTES; DEVELOPMENTAL COMPETENCE; HORSE OOCYTES; MEIOTIC COMPETENCE; INVITRO MATURATION; GERMINAL VESICLE",NA,"REPRODUCTION","THARASANIT, T##COLLEONI, S##LAZZARI, G##COLENBRANDER, B##GALLI, C##STOUT, TAE","UNIV UTRECHT, FAC MED VET, DEPT EQUINE SCI, NL-3584 CM UTRECHT, NETHERLANDS. IST SPERIMENTALE ITALIANO LAZZARO SPALLANZANI, LAB TECNOL RIPROD, CIZ, I-26100 CREMONA, ITALY. UNIV BOLOGNA, DIPARTIMENTO CLIN VET, BOLOGNA, ITALY.","DEVELOPMENTAL BIOLOGY; REPRODUCTIVE BIOLOGY","DEVELOPMENTAL BIOLOGY; REPRODUCTIVE BIOLOGY","AGCA Y, 1998, MOL REPROD DEV, V49, P408, DOI 10.1002/(SICI)1098-2795(199804)49:4&LT;408::AID-MRD8&GT;3.0.CO;2-R##ALM H, 1996, J REPROD FERTIL, V107, P215, DOI 10.1530/JRF.0.1070215##ARAV A, 1996, CRYOBIOLOGY, V33, P589, DOI 10.1006/CRYO.1996.0062##ATABAY EC, 2004, THERIOGENOLOGY, V61, P15, DOI 10.1016/S0093-691X(03)00179-1##BLONDIN P, 1995, MOL REPROD DEV, V41, P54, DOI 10.1002/MRD.1080410109##BOISO I, 2002, HUM REPROD, V17, P1885, DOI 10.1093/HUMREP/17.7.1885##CARROLL J, 1990, J REPROD FERTIL, V90, P547, DOI 10.1530/JRF.0.0900547##CHEN C, 1986, LANCET, V1, P884, DOI 10.1016/S0140-6736(86)90989-X##CHEN SU, 2003, MOL CELL ENDOCRINOL, V202, P101, DOI 10.1016/S0303-7207(03)00070-4##CHOI YH, 2004, REPRODUCTION, V127, P187, DOI 10.1530/REP.1.00087##COMIZZOLI P, 2004, BIOL REPROD, V71, P598, DOI 10.1095/BIOLREPROD.104.027920##DELCAMPO MR, 1995, THERIOGENOLOGY, V43, P1141, DOI 10.1016/0093-691X(95)00086-N##DELL'AQUILA ME, 1997, HUM REPROD, V12, P2766, DOI 10.1093/HUMREP/12.12.2766##DELL'AQUILA ME, 2001, MOL REPROD DEV, V60, P79, DOI 10.1002/MRD.1064##DIEZ C, 2005, THERIOGENOLOGY, V64, P317, DOI 10.1016/J.THERIOGENOLOGY.2004.11.023##FAN HY, 2004, BIOL REPROD, V70, P535, DOI 10.1095/BIOLREPROD.103.022830##GALLI C, 2001, THERIOGENOLOGY, V55, P1341, DOI 10.1016/S0093-691X(01)00486-1##HINRICHS K, 1993, BIOL REPROD, V48, P363, DOI 10.1095/BIOLREPROD48.2.363##HINRICHS K, 1997, BIOL REPROD, V57, P377, DOI 10.1095/BIOLREPROD57.2.377##HINRICHS K, 2000, BIOL REPROD, V62, P1402, DOI 10.1095/BIOLREPROD62.5.1402##HINRICHS K, 1997, EQUINE VET J SUPPL, P43##HOCHI S, 1996, CRYOBIOLOGY, V33, P300, DOI 10.1006/CRYO.1996.0030##HOCHI S, 1994, THERIOGENOLOGY, V42, P1085, DOI 10.1016/0093-691X(94)90856-7##HOCHI S, 1998, THERIOGENOLOGY, V49, P787, DOI 10.1016/S0093-691X(98)00028-4##HURTT AE, 2000, THERIOGENOLOGY, V54, P119, DOI 10.1016/S0093-691X(00)00330-7##IMOEDEMHE DG, 1992, J ASSIST REPROD GEN, V9, P323, DOI 10.1007/BF01203954##ISACHENKO EF, 1999, HUM REPROD, V14, P400, DOI 10.1093/HUMREP/14.2.400##JONES A, 2004, HUM REPROD, V19, P1861, DOI 10.1093/HUMREP/DEH313##KIMURA Y, 1995, BIOL REPROD, V52, P709, DOI 10.1095/BIOLREPROD52.4.709##LAZZARI G, 2002, BIOL REPROD, V67, P767, DOI 10.1095/BIOLREPROD.102.004481##LEIBO SP, 1980, J MEMBRANE BIOL, V53, P179, DOI 10.1007/BF01868823##LIM JM, 1992, THERIOGENOLOGY, V37, P351, DOI 10.1016/0093-691X(92)90193-U##LIM JM, 1991, THERIOGENOLOGY, V35, P1225, DOI 10.1016/0093-691X(91)90368-N##LONERGAN P, 1994, MOL REPROD DEV, V37, P48, DOI 10.1002/MRD.1080370107##MACLELLAN LJ, 2002, THERIOGENOLOGY, V58, P911, DOI 10.1016/S0093-691X(02)00920-2##MACULLAGH P, 1989, BINARY DATA, P98##MARTINO A, 1996, BIOL REPROD, V54, P1059, DOI 10.1095/BIOLREPROD54.5.1059##MEN HS, 2002, THERIOGENOLOGY, V57, P1095, DOI 10.1016/S0093-691X(01)00679-3##OTOI T, 1995, CRYOBIOLOGY, V32, P455, DOI 10.1006/CRYO.1995.1045##PARK SE, 1997, FERTIL STERIL, V68, P920, DOI 10.1016/S0015-0282(97)00365-8##PARKS JE, 1992, THERIOGENOLOGY, V37, P59, DOI 10.1016/0093-691X(92)90247-O##PARRISH JJ, 1988, BIOL REPROD, V38, P1171, DOI 10.1095/BIOLREPROD38.5.1171##PELLICER A, 1988, FERTIL STERIL, V50, P805##POMAR FJR, 2005, THERIOGENOLOGY, V63, P2254, DOI 10.1016/J.THERIOGENOLOGY.2004.10.015##PORCU E, 2001, SEMIN REPROD MED, V19, P221, DOI 10.1055/S-2001-18041##RHO GJ, 2002, MOL REPROD DEV, V63, P464, DOI 10.1002/MRD.10196##RIENZI L, 2004, HUM REPROD, V19, P655, DOI 10.1093/HUMREP/DEH101##RUFFING NA, 1993, CRYOBIOLOGY, V30, P562, DOI 10.1006/CRYO.1993.1059##SATHANANTHAN AH, 1988, GAMETE RES, V21, P385, DOI 10.1002/MRD.1120210407##SAUNDERS KM, 1999, BIOL REPROD, V61, P178, DOI 10.1095/BIOLREPROD61.1.178##SCOTT TJ, 2001, THERIOGENOLOGY, V55, P705, DOI 10.1016/S0093-691X(01)00438-1##SIMERLY C, 1993, METHOD ENZYMOL, V225, P516##SUN QY, 2003, J REPROD DEVELOP, V49, P347, DOI 10.1262/JRD.49.347##THARASANIT T, 2006, MOL REPROD DEV, V73, P627, DOI 10.1002/MRD.20432##TREMOLEDA JL, 2001, MOL REPROD DEV, V60, P260, DOI 10.1002/MRD.1086##TREMOLEDA JL, 2003, BIOL REPROD, V69, P1895, DOI 10.1095/BIOLREPROD.103.018515##TREMOLEDA JL, 2003, BIOL REPROD, V69, P186, DOI 10.1095/BIOLREPROD.102.012823##VAJTA G, 1998, MOL REPROD DEV, V51, P53, DOI 10.1002/(SICI)1098-2795(199809)51:1&LT;53::AID-MRD6&GT;3.0.CO;2-V##VANBLERKOM J, 1994, MICROSC RES TECHNIQ, V27, P165, DOI 10.1002/JEMT.1070270209##VERLHAC MH, 1994, DEVELOPMENT, V120, P1017",35,2020-11-20,NA,"UNIV UTRECHT#IST SPERIMENTALE ITALIANO LAZZARO SPALLANZANI#UNIV BOLOGNA","NETHERLANDS#ITALY#ITALY"
"J","WOS:000242184800005",2006,"OPTIMISING WASTE TREATMENT SYSTEMS - PART A: METHODOLOGY AND TECHNOLOGICAL DATA FOR OPTIMISING ENERGY PRODUCTION AND ECONOMIC PERFORMANCE","THE TREATMENT AND UTILISATION OF BIOMASS RESIDUES AND WASTE FOR ENERGY AND RECYCLING CAN CONTRIBUTE SIGNIFICANTLY TO GREENHOUSE GAS EMISSION REDUCTION. THEREFORE, A WASTE TREATMENT STRUCTURE SHOULD BE DESIGNED FOR AN EFFICIENT SAVING OF FOSSIL PRIMARY ENERGY IN TERMS OF MAXIMAL PRIMARY ENERGY SAVINGS OR MINIMAL COSTS PER UNIT OF PRIMARY ENERGY SAVINGS. HOWEVER, THIS IS A COMPLEX TASK, GIVEN THE LARGE NUMBER OF TECHNOLOGIES, RECYCLING OPTIONS AND THEIR LOGISTIC CONSEQUENCES, THAT NECESSITATE AN INTEGRATED ANALYSIS. ALSO, ON LONGER TERM VARIOUS NEW AND IMPROVED TECHNOLOGIES BECOME AVAILABLE WHICH CAN AFFECT PERFORMANCES FOR OPTIONS FROM AN ECONOMIC AND/OR ENERGY POINT OF VIEW. FOR THAT REASON, AN OPTIMISATION TOOL, THAT OPTIMISES A BIOMASS AND WASTE TREATMENT SYSTEM FOR A GIVEN AMOUNT OF BIOMASS AND WASTE, IS DEVELOPED IN THIS STUDY. THIS OPTIMAL BIOMASS AND WASTE TREATMENT SYSTEM IS COMPOSED OF SEVERAL TREATMENT INSTALLATIONS, THAT ARE CHARACTERISED BY SCALE, LOCATION AND KIND OF TECHNOLOGY. IMPORTANT ASPECTS THAT ARE TAKEN INTO ACCOUNT IN THE ANALYSIS ARE HEAT DISTRIBUTION, BIOMASS AND WASTE TRANSPORT AND ECONOMIES OF SCALE. A BROAD VARIETY OF TECHNOLOGIES FOR MATERIAL RECYCLING, CONVERSION OF BIOMASS AND/OR WASTE TO HEAT, ELECTRICITY OR TRANSPORTATION FUEL ARE INCLUDED IN THE OPTIMISATION TOOL. PERFORMANCE DATA OF THESE TECHNOLOGIES ARE BASED ON AN EXTENSIVE REVIEW. EXAMPLES OF INCLUDED TECHNOLOGIES COMPRISE: INTEGRATED GASIFICATION WITH COMBINED CYCLE, WASTE INCINERATION, PYROLYSIS, DIGESTION, CO-FIRING IN FOSSIL POWER PLANTS, BIOMASS INCINERATION, HYDRO-THERMAL UPGRADING, PAPER RECYCLING AND CHIPBOARD PRODUCTION. A COMPARISON OF THE DIFFERENT TECHNOLOGIES IN RELATION TO SCALE SHOWS THAT PRIMARY ENERGY SAVINGS AND COSTS PER UNIT OF PRIMARY ENERGY SAVINGS DIVERGE SIGNIFICANTLY. IN GENERAL, THE OPTIMISATION TOOL DEVELOPED HERE IS SUITABLE FOR ANALYSES OF OPTIMAL BIOMASS AND WASTE TREATMENT STRUCTURES IN DIFFERENT REGIONS WITH REGARD TO PRIMARY ENERGY SAVINGS AND THEIR COSTS. BY MEANS OF SCENARIO ANALYSIS, ROBUST OPTIMAL SOLUTIONS IN TERMS OF PRIMARY ENERGY SAVINGS AND THEIR COSTS CAN BE IDENTIFIED AND THE INFLUENCE OF IMPORTANT PARAMETERS CAN BE ANALYSED. A CASE STUDY OF THE DUTCH BIOMASS AND WASTE TREATMENT SYSTEMS HAS BEEN CARRIED OUT WITH THE OPTIMISATION TOOL AND IS PRESENTED IN PART TWO OF THIS ARTICLE. (C) 2006 ELSEVIER B.V. ALL RIGHTS RESERVED.","POWER; HEAT","SOLID WASTE; RECYCLING; PRIMARY ENERGY SAVINGS; OPTIMISATION; WASTE TREATMENT; BIOMASS","RESOURCES CONSERVATION AND RECYCLING","DORNBURG, V##FAAIJ, APC##MEULEMAN, B","UNIV UTRECHT, COPERNICUS INST, DEPT SCI TECHNOL & SOC, NL-3584 CS UTRECHT, NETHERLANDS.","ENGINEERING, ENVIRONMENTAL; ENVIRONMENTAL SCIENCES","ENGINEERING; ENVIRONMENTAL SCIENCES & ECOLOGY","*AOO, 1998, IN THERM VERW GEL HO##BERGER C, 1998, SYST ENG MOD WAST MA##BERGSMA GC, 1997, AFWEGING ENERGETISCH##BESTEBROER SJ, 1996, VGB KRAFTWERKSTECHN, V76, P570##BILITEWSKI B, 1994, ABFALLWIRTSCHAFT EIN##DEKANT HF, 2000, STUDIE VOORSCHAKELIN##DORNBURG V, 2001, BIOMASS BIOENERG, V21, P91, DOI 10.1016/S0961-9534(01)00030-7##DORNBURG V, 2001, SCENARIO ONTWIKKELIN##FAAIJ A, 1998, RESOUR CONSERV RECY, V22, P47, DOI 10.1016/S0921-3449(97)00043-8##FAAIJ A, 2000, 1 WORLD C BIOM EN IN##FAAIJ A, 1998, LONG TERM PERSPECTIV##*FBT, 1994, FLUID BED COMB GAS G##FEENSTRA F, 1995, LOGISTIEK BIJ INZAME##FOCKENS S, 1994, ONTWIKKELINGEN TOTAL##HARDTLEIN M, 1996, WANN RECHNEN GROSS 1##HENKES W, 1998, RECYCLINGMAGAZIN, V24, P8##HEUVEL EJM, 1994, 9414 BTG NOVEM EWAB##HOLMGREN K, 2004, RESOUR CONSERV RECY, V43, P51, DOI 10.1016/J.RESCONREC.2004.05.001##*IEA, 1998, ADV THERM CONV TECHN##ISING M, 1998, 1385 VDI##JAHRAUS B, 1993, BRENNST-WARME-KRAFT, V45, P438##KALTSCHMITT M, 1998, BIOMASS GASTIFICATIO##KALTSCHMITT M., 1997, NACHWACHSENDE ENERGI##KLOOTWIJK M, 1998, ENERGIE EFFICIENT DR##MEULEMAN B, 1998, OPTIMALISATIEMODEL O##*OK I, 1999, ER BAS EN UMW EN PRO##OSSEBAARD ME, 1994, WARMTEDISTRIBUTE TEC##PFEIFFER AE, 1992, OPTIMALISATIE OPBREN##*RECYCLENET, 2000, REC WORLD REC REC IN##ROSCH C, 1997, MONITORING NACHWACHS##ROSCH C, 1998, BIOMASS GASIFICATION, PCH6##SAS HJW, 1994, VERWIJDERING HUISHOU##SOLANTAUSTA Y, 1997, ELECT PRODUCTION ADV##SUNDBERG J, 1997, SYST ENG MOD WAST MA##TANSKANEN JH, 2000, RESOUR CONSERV RECY, V30, P111, DOI 10.1016/S0921-3449(00)00056-2##TIJMENSEN MJA, 2002, BIOMASS BIOENERG, V23, P129, DOI 10.1016/S0961-9534(02)00037-5##VANDENBROEK R, 1995, JOU2CT930397 EUR COM##VANHALEN CJG, 2000, BEDRIJFSECONOMISCHE##VANHEIJNINGEN RJJ, 1992, MEER ENERGIEKENTALLE##VEENENDAAL R, 1994, GASIFICATION WASTE E##VROONHOF JTT, 1994, BIJLAGEN BIJ RAPPORT##WANG FS, 1998, SYST ENG MOD WAST MA##WIEGEL U, 1997, MULLMAGAZIN, P64##RESOUR CONSERV RECY, DOI DOI 10.1016/J.RESCONREC.2006.02.002",34,2020-11-20,NA,"UNIV UTRECHT","NETHERLANDS"
"J","WOS:000242325200007",2006,"REGIONAL DIFFERENCES IN NUTRIENT LIMITATION IN FLOODPLAINS OF SELECTED EUROPEAN RIVERS: IMPLICATIONS FOR REHABILITATION OF CHARACTERISTIC FLOODPLAIN VEGETATION","EXTREMELY HIGH RIVER DISCHARGES IN 1993 AND 1995 ALONG THE DUTCH RIVERS RHINE AND MEUSE HAVE INCREASED THE PUBLIC AWARENESS OF POSSIBLE SAFETY THREATS. AS A RESULT THE 'SPACE FOR RIVERS' PROGRAM WAS IMPLEMENTED, AIMING AT RESTORING PHYSICAL SPACE FOR THE RIVERS IN COMBINATION WITH ECOLOGICAL REHABILITATION. HOWEVER, THE DEVELOPMENT OF SPECIES-RICH VEGETATION TYPES IN THESE FLOODPLAIN AREAS IS LAGGING BEHIND RESTORATION TARGETS AND BIOGEOCHEMICAL CONSTRAINTS MAY PLAY A VITAL ROLE IN THIS. BIOGEOCHEMICAL, HYDROLOGICAL AND VEGETATION DATA WERE COLLECTED IN I I I PLOTS IN BOTH REHABILITATED AND ORIGINAL FLOODPLAINS IN REGULATED AND MORE PRISTINE RIVER SYSTEMS IN THE NETHERLANDS AND POLAND. SOIL NUTRIENT AND SOIL PORE WATER DATA WERE SUMMARIZED BY FACTOR ANALYSIS AND THE SUBSEQUENT PRINCIPAL COMPONENTS WERE COMPARED TO VEGETATION AND HYDROLOGICAL DATA BY CORRELATION ANALYSIS. THE CORRELATION ANALYSES BETWEEN VEGETATION PARAMETERS INCLUDING NUTRIENT STOICHIOMETRY AND THE BIOGEOCHEMICAL SOIL VARIABLES RESULTED IN A REMARKABLE DIFFERENCE BETWEEN PRISTINE AND IMPACTED RIVER SYSTEMS. THE RESULTS SUGGEST A CLEAR N-LIMITATION OF PLANT GROWTH IN PRISTINE FLOODPLAINS, AND APPARENT ABSENCE OF LIMITATION IN REGULATED, IMPACTED FLOODPLAINS. IN ADDITION, RESULTS INDICATE THAT FLOODING EVENTS DO NOT LEAD TO ONE-WAY TRANSPORT OF SEDIMENT AND NUTRIENTS FROM THE RIVER INTO THE FLOODPLAINS; RATHER THEY INDICATE THAT HIGHLY DYNAMIC HYDROLOGICAL CONDITIONS PREVENT SOILS FROM ACCUMULATING ORGANIC MATTER AND NUTRIENTS. THIS STUDY SHOWS THAT NUTRIENT LIMITATION IN REGULATED FLOODPLAINS SHIFTED FROM DISTINCTLY N-LIMITED PLANT GROWTH TO NO NUTRIENT LIMITATION AT ALL, PROBABLY DUE TO DECADES OF HIGH FERTILIZER AND MANURE APPLICATION AND NUTRIENT INPUT BY THE RIVERS DURING FLOODING. THE CONSEQUENCE OF OUR FINDINGS FOR REHABILITATION ACTIVITIES IS THAT IT MIGHT BE NECESSARY TO RESTORE NITROGEN LIMITATION IN FLOODPLAIN SYSTEMS IN ORDER TO CREATE OPPORTUNITIES FOR A SPECIES-RICH FLOODPLAIN VEGETATION, THROUGH NUTRIENT REMOVAL BY HAYMAKING. COPYRIGHT (C) 2006 JOHN WILEY & SONS, LTD.","N-P RATIOS; ECOLOGICAL REHABILITATION; LOWLAND RIVERS; PRESENT STATE; LAND-USE; RHINE; PLANT; RESTORATION; DYNAMICS; MEUSE","ECOLOGICAL REHABILITATION; FLOODPLAIN; HERBACEOUS VEGETATION; NUTRIENT LIMITATION; POLAND; REGULATED RIVER; THE NETHERLANDS","RIVER RESEARCH AND APPLICATIONS","ANTHEUNISSE, AM##LOEB, R##LAMERS, LPM##VERHOEVEN, JTA","UNIV UTRECHT, INST ENVIRONM BIOL, NL-3508 TD UTRECHT, NETHERLANDS. RADBOUD UNIV NIJMEGEN, DEPT AQUAT ECOL & ENVIRONM BIOL, INST WATER & WETLAND RES, NL-6525 ED NIJMEGEN, NETHERLANDS.","ENVIRONMENTAL SCIENCES; WATER RESOURCES","ENVIRONMENTAL SCIENCES & ECOLOGY; WATER RESOURCES","ADMIRAAL W, 1993, HYDROBIOLOGIA, V265, P97, DOI 10.1007/BF00007264##BAL D, 1995, HDB NATUURDOELTYPEN##BALDWIN DS, 2000, REGUL RIVER, V16, P457, DOI 10.1002/1099-1646(200009/10)16:5&LT;457::AID-RRR597&GT;3.0.CO;2-B##BARKMAN J. J., 1964, ACTA BOT NEER, V13, P394##BISCHOFF A, 2002, BIOL CONSERV, V104, P25, DOI 10.1016/S0006-3207(01)00151-3##BISCHOFF A, 2001, REGUL RIVER, V17, P171, DOI 10.1002/RRR.612##BISSELS S, 2004, BIOL CONSERV, V118, P641, DOI 10.1016/J.BIOCON.2003.10.013##BOEYE D, 1997, J VEG SCI, V8, P415, DOI 10.2307/3237333##BREMNER JM, 1982, AGRON MONOGR, V9, P621##BUIJSE AD, 2002, FRESHWATER BIOL, V47, P889, DOI 10.1046/J.1365-2427.2002.00915.X##CALS MJR, 1998, AQUAT CONSERV, V8, P61, DOI 10.1002/(SICI)1099-0755(199801/02)8:1<61::AID-AQC267>3.0.CO;2-8##CASANOVA MT, 2000, PLANT ECOL, V147, P237, DOI 10.1023/A:1009875226637##CHBAB EH, 1995, PHYS CHEM EARTH, V20, P455, DOI DOI 10.1016/S0079-1946(96)00005-5##DOMBROWSKI A, 2002, BUG RIVER VALLEY ECO##DYNESIUS M, 1994, SCIENCE, V266, P753, DOI 10.1126/SCIENCE.266.5186.753##ENGELHARDT C, 1999, ACTA HYDROCH HYDROB, V27, P325, DOI 10.1002/(SICI)1521-401X(199911)27:5&LT;325::AID-AHEH325&GT;3.0.CO;2-A##*EUR UN, 2000, WAT FRAM WORK DIR ES##GIELCZEWSKI M, 2003, NAREW RIVER BASIN MO##GLASBY GP, 2004, SCI TOTAL ENVIRON, V330, P249, DOI 10.1016/J.SCITOTENV.2004.04.004##GUSEWELL S, 2004, NEW PHYTOL, V164, P243, DOI 10.1111/J.1469-8137.2004.01192.X##GUSEWELL S, 2003, ECOL APPL, V13, P372, DOI 10.1890/1051-0761(2003)013[0372:BNRAIO]2.0.CO;2##HEILER G, 1995, REGUL RIVER, V11, P351, DOI 10.1002/RRR.3450110309##HOHENSINNER S, 2004, RIVER RES APPL, V20, P25, DOI 10.1002/RRA.719##HOOIJER A, 2004, RIVER RES APPL, V20, P343, DOI 10.1002/RRA.781##HOUBA VJG, 1989, SOIL PLANT ANAL SERI##JONGMAN RHG, 1992, REGUL RIVER, V7, P279, DOI 10.1002/RRR.3450070306##JUNK W J, 1989, CANADIAN SPECIAL PUBLICATION OF FISHERIES AND AQUATIC SCIENCES, V106, P110##KOERSELMAN W, 1996, J APPL ECOL, V33, P1441, DOI 10.2307/2404783##LAMERS LPM, 2006, HYDROBIOLOGIA, V565, P165, DOI 10.1007/S10750-005-1912-8##LAMERS LPM, 1998, ENVIRON SCI TECHNOL, V32, P199, DOI 10.1021/ES970362F##LORENZ CM, 1997, REGUL RIVER, V13, P501##MALISAUSKAS AP, 2001, LANDBAUFORSCH VOLK, V51, P87##*MIN VOLKSH RUIMT, 1996, BEL RUIMT RIV##NIENHUIS PH, 2001, HYDROBIOLOGIA, V444, P85, DOI 10.1023/A:1017509410951##OETKEN M, 2005, ENVIRON POLLUT, V134, P87, DOI 10.1016/J.ENVPOL.2004.08.001##OGDEN RW, 2002, HYDROBIOLOGIA, V489, P277, DOI 10.1023/A:1023293925854##PEDROLI B, 2001, LANDSCAPE ECOL, V17, P5, DOI 10.1023/A:1015221425315##PFISTER L, 2004, RIVER RES APPL, V20, P229, DOI 10.1002/RRA.775##PRACH K, 1996, ACTA BOT GALLICA, V143, P441, DOI 10.1080/12538078.1996.10515740##SCHILDERMAN PAEL, 1999, ECOTOX ENVIRON SAFE, V44, P241, DOI 10.1006/EESA.1999.1827##SCHROPP MHI, 1998, AQUAT CONSERV, V8, P53, DOI 10.1002/(SICI)1099-0755(199801/02)8:1<53::AID-AQC260>3.0.CO;2-O##SPINK A, 1998, REGUL RIVER, V14, P203, DOI 10.1002/(SICI)1099-1646(199803/04)14:2&LT;203::AID-RRR498&GT;3.0.CO;2-7##THOMS MC, 2003, GEOMORPHOLOGY, V56, P335, DOI 10.1016/S0169-555X(03)00160-0##TOCKNER K, 2002, ENVIRON CONSERV, V29, P308, DOI 10.1017/S037689290200022X##TOCKNER K, 2000, HYDROL PROCESS, V14, P2861, DOI 10.1002/1099-1085(200011/12)14:16/17&LT;2861::AID-HYP124&GT;3.0.CO;2-F##VAN DER MEIJDEN R., 1996, HEUKELS FLORA NEDERL##VAN GEEST GJ, 2005, HYDROBIOLOGIA, V539, P239, DOI 10.1007/S10750-004-4879-Y##VAN OORSCHOT M, 1998, REGUL RIVER, V14, P313, DOI 10.1002/(SICI)1099-1646(199807/08)14:4&LT;313::AID-RRR506&GT;3.0.CO;2-U##VAN OORSCHOT M, 2000, ACTA OECOL, V21, P49, DOI 10.1016/S1146-609X(00)00116-8##VAN OORSCHOT MMP, 1994, GLOBAL WETLANDS OLD, P133##VANDERPOORTEN A, 1999, ENVIRON POLLUT, V104, P401, DOI 10.1016/S0269-7491(98)00170-5##VANDIJK GM, 1995, REGUL RIVER, V11, P377, DOI 10.1002/RRR.3450110311##VANECK W, 2004, FLOODING TOLERANCE D##VANOORSCHOT M, 1997, J ECOL, V85, P167, DOI 10.2307/2960649##VENTERINK HO, 2002, PLANT SOIL, V243, P119, DOI 10.1023/A:1019993510737##VERHOEVEN JTA, 1996, TRENDS ECOL EVOL, V11, P494, DOI 10.1016/S0169-5347(96)10055-0##VERHOEVEN JTA, 1998, NEW CONCEPTS FOR SUSTAINABLE MANAGEMENT OF RIVER BASINS, P229##VERVUREN PJA, 2003, J ECOL, V91, P135, DOI 10.1046/J.1365-2745.2003.00749.X##WASSEN MJ, 1998, ACTA BOT NEERL, V47, P241##WILLBY NJ, 2001, NEW PHYTOL, V152, P463, DOI 10.1046/J.0028-646X.2001.00274.X##WINTER HV, 2003, J FISH BIOL, V63, P871, DOI 10.1046/J.1095-8649.2003.00193.X##WOLFERT HP, 2001, GEOMORPHOLOGICAL CHA, P153##WOLFF W. J., 1978, THE BREAKDOWN AND RESTORATION OF ECOSYSTEMS., P169",23,2020-11-20,NA,"UNIV UTRECHT#RADBOUD UNIV NIJMEGEN","NETHERLANDS#NETHERLANDS"
"J","WOS:000241780900014",2006,"DO DUTCH DOCTORS COMMUNICATE DIFFERENTLY WITH IMMIGRANT PATIENTS THAN WITH DUTCH PATIENTS?","THE AIM OF THIS STUDY WAS TO GAIN DEEPER INSIGHT INTO RELATIONAL ASPECTS OF THE MEDICAL COMMUNICATION PATTERN IN INTERCULTURAL CONSULTATIONS AT GP PRACTICES IN THE NETHERLANDS. WE ASK WHETHER THERE ARE DIFFERENCES IN THE VERBAL INTERACTION OF DUTCH GPS WITH IMMIGRANT AND DUTCH PATIENTS. DATA WERE DRAWN FROM 144 ADULT PATIENT INTERVIEWS AND VIDEO OBSERVATIONS OF CONSULTATIONS BETWEEN THE PATIENTS AND 31 DUTCH GPS. THE PATIENT GROUP CONSISTED OF 61 NON-WESTERN IMMIGRANTS (TURKISH, MOROCCAN, SURINAMESE, ANTILLEAN, CAPE VERDIAN) AND 83 DUTCH PARTICIPANTS. AFFECTIVE AND INSTRUMENTAL ASPECTS OF VERBAL COMMUNICATION WERE ASSESSED USING ROTER'S INTERACTION ANALYSIS SYSTEM (RIAS). PATIENTS' CULTURAL BACKGROUND WAS ASSESSED BY ETHNICITY, LANGUAGE PROFICIENCY, LEVEL OF EDUCATION, RELIGIOSITY AND CULTURAL VIEWS (IN TERMS OF BEING MORE TRADITIONAL OR MORE MODERN). CONSULTATIONS WITH THE NON-WESTERN IMMIGRANT PATIENTS (ESPECIALLY THOSE FROM TURKEY AND MOROCCO) WERE WELL OVER 2 MIN SHORTER, AND THE POWER DISTANCE BETWEEN GPS AND THESE PATIENTS WAS GREATER WHEN COMPARED TO THE DUTCH PATIENTS. MAJOR DIFFERENCES IN VERBAL INTERACTION WERE OBSERVED ON THE AFFECTIVE BEHAVIOR DIMENSIONS, BUT NOT ON THE INSTRUMENTAL DIMENSIONS. DOCTORS INVESTED MORE IN TRYING TO UNDERSTAND THE IMMIGRANT PATIENTS, WHILE IN THE CASE OF DUTCH PATIENTS THEY SHOWED MORE INVOLVEMENT AND EMPATHY. DUTCH PATIENTS SEEMED TO BE MORE ASSERTIVE IN THE MEDICAL CONVERSATION. THE DIFFERENCES ARE DISCUSSED IN TERMS OF PATIENTS' ETHNIC BACKGROUND, CULTURAL VIEWS (E.G. PRACTICING A RELIGION) AND LINGUISTIC BARRIERS. IT IS CONCLUDED THAT ATTENTION TO CULTURAL DIVERSITY DOES MATTER, AS THIS LEADS TO DIFFERENT MEDICAL COMMUNICATION PATTERNS. A TWO-WAY STRATEGY IS RECOMMENDED FOR IMPROVING MEDICAL COMMUNICATION, WITH IMPLICATIONS FOR BOTH DOCTOR AND PATIENT BEHAVIOR. (C) 2006 ELSEVIER LTD. ALL RIGHTS RESERVED.","HEALTH-CARE; INTERCULTURAL COMMUNICATION; GENERAL-PRACTICE; PHYSICIAN; QUALITY; INTERPRETER; DISPARITIES; RACE; RACE/ETHNICITY; PERCEPTIONS","MEDICAL COMMUNICATION; INTERCULTURAL COMMUNICATION; GENERAL PRACTICE; INTERETHNIC DIFFERENCES; IMMIGRANTS; HEALTH CARE; THE NETHERLANDS","SOCIAL SCIENCE & MEDICINE","MEEUWESEN, L##HARMSEN, JAM##BERNSEN, RMD##BRUIJNZEELS, MA","UNIV UTRECHT, RES SCH PSYCHOL & HLTH, INTERDISCIPLINARY SOCIAL SCI DEPT, NL-3508 TC UTRECHT, NETHERLANDS. ERASMUS MC ROTTERDAM, DEPT GEN PRACTICE, ROTTERDAM, NETHERLANDS. UNITED ARAB EMIRATES UNIV, DEPT COMMUNITY MED, AL AIN, U ARAB EMIRATES. ERASMUS MC ROTTERDAM, DEPT HLTH POLICY & MANAGEMENT, ROTTERDAM, NETHERLANDS.","PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH; SOCIAL SCIENCES, BIOMEDICAL","PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH; BIOMEDICAL SOCIAL SCIENCES","BOT H, 2005, DIALOGUE INTERPRETIN##BRAMAN AC, 2004, PERS INDIV DIFFER, V37, P815, DOI 10.1016/J.PAID.2003.10.009##CASS A, 2002, MED J AUSTRALIA, V176, P466, DOI 10.5694/J.1326-5377.2002.TB04517.X##COOPER LA, 2003, ANN INTERN MED, V139, P907, DOI 10.7326/0003-4819-139-11-200312020-00009##COOPER-PATRICK L, 1999, JAMA-J AM MED ASSOC, V282, P583, DOI 10.1001/JAMA.282.6.583##DOESCHER MP, 2000, ARCH FAM MED, V9, P1156, DOI 10.1001/ARCHFAMI.9.10.1156##EDWARDS A, 2003, PATIENT EDUC COUNS, V50, P33, DOI 10.1016/S0738-3991(03)00077-6##FERGUSON WJ, 2002, FAM MED, V34, P353##FLORES G, 2005, MED CARE RES REV, V62, P255, DOI 10.1177/1077558705275416##GASS SM, 1991, MISCOMMUNICATION PRO, P121##GERITS YC, 2001, TIJDSCHRIFT GEZONDHE, V79, P15##GUDYKUNST WB, 1994, BRIDGING DIFFERENCES##HARMSEN H, 2005, BRIT J GEN PRACT, V55, P343##HARMSEN J A M, 2006, J IMMIGR MINOR HEALTH, V8, P115, DOI 10.1007/S10903-006-8520-6##HARMSEN JAM, 2005, PATIENT EDUC COUNS, V59, P171, DOI 10.1016/J.PEC.2004.11.003##HARMSEN JAM, 2003, WHEN CULTURES M MED##HOFSTEDE G., 1991, CULTURE ORG SOFTWARE##HOFSTEDE G, 2001, CULTURES CONSEQUENCE##*ISEO, 1987, BET MET, V1##JACOBS EA, 2003, LANGUAGE BARRIERS HL##JOHNSON RL, 2004, AM J PUBLIC HEALTH, V94, P2084, DOI 10.2105/AJPH.94.12.2084##KIESLER DJ, 2003, SOC SCI MED, V57, P1707, DOI 10.1016/S0277-9536(02)00558-0##KIRMAYER LJ, 2003, CAN J PSYCHIAT, V48, P145##KLEINMAN MA, 1980, PATIENTS HEALERS CON##LEMAN P, 1997, J ACCID EMERG MED, V14, P98##LILLIEBLANTON M, 1996, SOC SCI MED, V43, P83, DOI 10.1016/0277-9536(95)00337-1##LINELL PER, 1991, ASYMMETRIES DIALOGUE, P1##LUIJTEN MCG, 1995, HUISARTSEN ACHTERSTA##MEEUWESEN L, 1991, SOC SCI MED, V32, P1143, DOI 10.1016/0277-9536(91)90091-P##NIERKENS V, 2002, PATIENT EDUC COUNS, V46, P253, DOI 10.1016/S0738-3991(01)00161-6##PHINNEY JS, 1996, AM PSYCHOL, V51, P918, DOI 10.1037/0003-066X.51.9.918##RAMIREZ AG, 2003, PATIENT EDUC COUNS, V50, P51, DOI 10.1016/S0738-3991(03)00080-6##RIVADENEYRA R, 2000, AM J MED, V108, P470, DOI 10.1016/S0002-9343(99)00445-3##ROTER DL, 1993, ROTER METHOD INTERAC##SAHA S, 1999, ARCH INTERN MED, V159, P997, DOI 10.1001/ARCHINTE.159.9.997##SAHA S, 2003, AM J PUBLIC HEALTH, V93, P1713, DOI 10.2105/AJPH.93.10.1713##SCHELLEVIS FG, 2004, TWEEDE NATL STUDIE Z##SCHOUTEN BC, 2006, IN PRESS PATIENT ED##SEELEMAN C, 2005, EEN ARTS VANDEWERELD##SLEATH B, 2003, CLIN THER, V25, P1739, DOI 10.1016/S0149-2918(03)80166-2##TRIANDIS HC, 1995, INDIVIDUALISM COLLEC##VAN RYN M, 2000, SOC SCI MED, V50, P813, DOI 10.1016/S0277-9536(99)00338-X##VAN RYN M, 2003, AM J PUBLIC HEALTH, V93, P248, DOI 10.2105/AJPH.93.2.248##VAN WIERINGEN JCM, 2002, EUR J PUBLIC HEALTH, V12, P63, DOI 10.1093/EURPUB/12.1.63##VANDENBRINKMUIN.A, 2004, OOG COMMUNICATIE HUI##VANDERVLUGT MJ, 1992, BEHAV RES METH INSTR, V24, P147, DOI 10.3758/BF03203488##YOUNG M, 1996, HEALTH COMMUN, V8, P29, DOI 10.1207/S15327027HC0801_2",68,2020-11-20,NA,"UNIV UTRECHT#ERASMUS MC ROTTERDAM#UNITED ARAB EMIRATES UNIV#ERASMUS MC ROTTERDAM","NETHERLANDS#NETHERLANDS#U ARAB EMIRATES#NETHERLANDS"
"J","WOS:000241780900017",2006,"THE PREDICTION OF BEREAVEMENT OUTCOME: DEVELOPMENT OF AN INTEGRATIVE RISK FACTOR FRAMEWORK","WE PROPOSE AN INTEGRATIVE RISK FACTOR FRAMEWORK TO ENHANCE UNDERSTANDING OF INDIVIDUAL DIFFERENCES IN ADJUSTMENT TO BEREAVEMENT AND TO ENCOURAGE MORE SYSTEMATIC ANALYSIS OF FACTORS CONTRIBUTING TO BEREAVEMENT OUTCOME (E.G., EXAMINATION OF INTERACTIONS BETWEEN VARIABLES AND ESTABLISHING PATHWAYS IN THE ADAPTATION PROCESS). THE EXAMINATION OF INDIVIDUAL DIFFERENCES IN ADAPTATION TO BEREAVEMENT IS ESSENTIAL FOR PRACTICAL (E.G. TARGETING HIGH RISK INDIVIDUALS FOR INTERVENTION) AND THEORETICAL (E.G. TESTING THE VALIDITY OF THEORETICAL CLAIMS ABOUT SOURCES OF DIFFERENCES) PURPOSES. AND YET, EXISTING THEORETICAL APPROACHES HAVE NOT LED TO SYSTEMATIC EMPIRICAL EXAMINATION AND EMPIRICAL STUDIES IN THE CURRENT LITERATURE ARE FRAUGHT WITH SHORTCOMINGS. DERIVED FROM COGNITIVE STRESS THEORY [LAZARUS, R. S. & FOLKMAN, S. (1984). STRESS, APPRAISAL, AND COPING. NEW YORK: SPRINGER] AND THE STRESSOR-SPECIFIC DUAL PROCESS MODEL OF COPING WITH BEREAVEMENT [STROEBE, M. S., & SCHUT, H. A. W. (1999). THE DUAL PROCESS MODEL OF COPING WITH BEREAVEMENT: RATIONALE AND DESCRIPTION. DEATH STUDIES, 23, 197-224], THE FRAMEWORK INCORPORATES AN ANALYSIS OF STRESSORS, INTRAFINTERPERSONAL RISK/PROTECTIVE FACTORS, AND APPRAISAL AND COPING PROCESSES THAT ARE POSTULATED TO IMPACT ON OUTCOME. ADVANTAGES OF USING THE APPROACH ARE OUTLINED. CHALLENGES IN UNDERTAKING SUCH RESEARCH ARE ADDRESSED. (C) 2006 ELSEVIER LTD. ALL RIGHTS RESERVED.","DEATH; ADJUSTMENT; ADAPTATION; WIDOWHOOD; SUICIDE; SPOUSE; GRIEF; RECOVERY; ANXIETY; PARENTS","GRIEF; COPING; HEALTH; BEREAVEMENT; FACTOR FRAMEWORK","SOCIAL SCIENCE & MEDICINE","STROEBE, MS##FOLKMAN, S##HANSSON, RO##SCHUT, H","UNIV UTRECHT, DEPT CLIN PSYCHOL, NL-3508 TC UTRECHT, NETHERLANDS. UNIV CALIF SAN FRANCISCO, OSHER CTR INTEGRAT MED, SAN FRANCISCO, CA 94143 USA. UNIV TULSA, DEPT PSYCHOL, TULSA, OK 74104 USA.","PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH; SOCIAL SCIENCES, BIOMEDICAL","PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH; BIOMEDICAL SOCIAL SCIENCES","AARTSEN MJ, 2004, PSYCHOL MED, V34, P1##AGERBO E, 2005, J EPIDEMIOL COMMUN H, V59, P407, DOI 10.1136/JECH.2004.024950##ARCHER J., 1999, NATURE GRIEF EVOLUTI##BOELEN PA, 2005, COMPLICATED GRIEF AS##BOERNER K, 2004, PSYCHOL AGING, V19, P668, DOI 10.1037/0882-7974.19.4.668##BONANNO G.A., 2001, HDB BEREAVEMENT RES, P493, DOI [10.1037/10436-021, DOI 10.1037/10436-021]##BONANNO GA, 1999, PSYCHOL BULL, V125, P760, DOI 10.1037/0033-2909.125.6.760##BONANNO GA, 2004, PSYCHOL AGING, V19, P260, DOI 10.1037/0882-7974.19.2.260##BOWLBY J, 1980, ATTACHMENT LOSS, V3##CARR D, 2000, J GERONTOL B-PSYCHOL, V55, PS197, DOI 10.1093/GERONB/55.4.S197##CARR D, 2005, LATE LIFE WIDOWHOOD##CEREL J, 1999, J AM ACAD CHILD PSY, V38, P672, DOI 10.1097/00004583-199906000-00013##CLEIREN MPH, 1993, BEREAVEMENT ADAPTATI##DAVIS CG, 1998, J PERS SOC PSYCHOL, V75, P561, DOI 10.1037/0022-3514.75.2.561##DYREGROV K, 2003, DEATH STUD, V27, P143, DOI 10.1080/07481180302892##EYETSEMITAN F, 1998, DEATH STUD, V22, P469, DOI 10.1080/074811898201461##FARBEROW NL, 1992, J GERONTOL, V47, PP357, DOI 10.1093/GERONJ/47.6.P357##FIELD NP, 2003, J CONSULT CLIN PSYCH, V71, P110, DOI 10.1037/0022-006X.71.1.110##FOLKMAN S., 2001, HDB BEREAVEMENT RES, P563, DOI DOI 10.1037/10436-024##FRISTAD MA, 2001, OMEGA-J DEATH DYING, V42, P321, DOI 10.2190/MC87-GQMC-VCDV-UL3U##HAINE RA, 2003, DEATH STUD, V27, P619, DOI 10.1080/07481180302894##HANSSON RO, 1994, RELATIONSHIPS OLD AG##HANSSON RO, IN PRESS BEREAVEMENT##JORDAN JR, 2003, DEATH STUD, V27, P765, DOI 10.1080/713842360##KLASS D., 1996, CONTINUING BONDS NEW##KREICBERGS U, 2004, PSYCHOL MED, V34, P1431, DOI 10.1017/S0033291704002740##LAST JM, 1995, DICT EPIDEMIOLOGY##LAZARUS R.S., 1984, STRESS APPRAISAL COP##LEE GR, 2001, J GERONTOL B-PSYCHOL, V56, PS56, DOI 10.1093/GERONB/56.1.S56##LI J, 2004, NEUROLOGY, V62, P726, DOI 10.1212/01.WNL.0000113766.21896.B1##LOPATA H. Z., 1996, CURRENT WIDOWHOOD MY##LUCAS RE, 2003, J PERS SOC PSYCHOL, V84, P527, DOI 10.1037/0022-3514.84.3.527##LUECKEN LJ, 2006, DEV PSYCHOPATHOL, V18, P295, DOI 10.1017/S0954579406060160##MARTIKAINEN P, 1998, EPIDEMIOLOGY, V9, P530, DOI 10.1097/00001648-199809000-00010##MEIJ LWD, 2005, J CONSULT CLIN PSYCH, V73, P617, DOI 10.1037/0022-006X.73.4.617##MOSKOWITZ JT, 2003, DEATH STUD, V27, P471, DOI 10.1080/07481180390197624##NADEAU J. W., 2001, HDB BEREAVEMENT RES, DOI DOI 10.1037/10436-014##NEIMEYER RA, 1995, CONSTRUCTIVISM PSYCH##NOLENHOEKSEMA SK, 1999, COPING LOSS##O'CONNOR MF, 2002, J PSYCHOSOM RES, V52, P183, DOI 10.1016/S0022-3999(02)00292-1##ONG AD, 2005, PERS INDIV DIFFER, V38, P1057, DOI 10.1016/J.PAID.2004.07.004##PARGAMENT KENNETH I., 1997, PSYCHOL RELIG COPING##PARKES C. M., 1983, RECOVERY BEREAVEMENT##PARKES C. M., 1972, BEREAVEMENT STUDIES##PARKES C.M., 1996, BEREAVEMENT STUDIES##PARKES CM, 1986, BEREAVEMENT STUDIES##PARKES CM, 2001, HDB BEREAVEMENT RES, P25, DOI DOI 10.1037/10436-001##PENNEBAKER J. W., 2001, HDB BEREAVEMENT RES, P517, DOI DOI 10.1037/10436-022##PRIGERSON HG, 2000, GERONTOLOGIST, V40, P349, DOI 10.1093/GERONT/40.3.349##RAPHAEL B, 2001, HDB BEREAVEMENT RES, P587##RAPHAEL BEVERLEY, 1997, P373##ROSENBLATT P, 2004, ETHNIC VARIATIONS DY, P13##SANDERS CM, 1999, GRIEF MOURNING DEALI##SCHAEFER J. A., 2001, HDB BEREAVEMENT RES, P145##SCHULZ R, 2001, JAMA-J AM MED ASSOC, V285, P3123, DOI 10.1001/JAMA.285.24.3123##SCHUT H., 2001, HDB BEREAVEMENT RES, P705, DOI DOI 10.1037/10436-029##SCHWARZER R., 1989, PSYCHOL HEALTH, V3, P1, DOI DOI 10.1080/08870448908400361##SHAVER PR, 2001, HDB BEREAVEMENT RES, P63, DOI DOI 10.1037/10436-003##STROEBE M, 1999, DEATH STUD, V23, P197, DOI 10.1080/074811899201046##STROEBE M, 2005, REV GEN PSYCHOL, V9, P48, DOI 10.1037/1089-2680.9.1.48##STROEBE M., 2001, REV GEN PSYCHOL, V5, P62, DOI [10.1037//1089-2680.5.1.62, DOI 10.1037/1089-2680.5.1.62]##STROEBE M. S., 2004, INT J PSYCHOL RELIG, V14, P23, DOI [10.1207/S15327582IJPR1401_2, DOI 10.1207/S15327582IJPR1401_2]##STROEBE MARGARET S., 1993, P175, DOI 10.1017/CBO9780511664076.013##STROEBE W, 2005, CLIN PSYCHOL REV, V25, P395, DOI 10.1016/J.CPR.2005.01.004##STROEBE W, 1988, J SOC ISSUES, V44, P143, DOI 10.1111/J.1540-4560.1988.TB02082.X##STROEBE W., 2001, HDB BEREAVEMENT RES, P349, DOI DOI 10.1037/10436-015##STROEBE W, 1987, BEREAVEMENT HLTH PSY##VACHON MLS, 1982, AM J PSYCHIAT, V139, P998##WALTER T., 1999, BEREAVEMENT CULTURE##WIJNGAARDS L, UNPUB PATTERNS ATTAC##WORTMAN CB, 2001, HDB BEREAVEMENT RES, P405, DOI DOI 10.1037/10436-017##ZISOOK S, 1994, PSYCHIAT RES, V52, P1, DOI 10.1016/0165-1781(94)90114-7",139,2020-11-20,NA,"UNIV UTRECHT#UNIV CALIF SAN FRANCISCO#UNIV TULSA","NETHERLANDS#CA USA#OK USA"
"J","WOS:000242163300008",2006,"BIOLOGICALLY EFFECTIVE DOSE IN TOTAL-BODY IRRADIATION AND HEMATOPOIETIC STEM CELL TRANSPLANTATION","BACKGROUND AND PURPOSE: TOTAL-BODY IRRADIATION (TBI) IS AN IMPORTANT PART OF THE CONDITIONING REGIMEN FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES. THE RESULTS AFTER TREATMENT WITH VARIOUS TBI REGIMENS WERE COMPARED, AND DOSE-EFFECT RELATIONSHIPS FOR THE ENDPOINTS RELAPSE INCIDENCE, DISEASE-FREE SURVIVAL, TREATMENT-RELATED MORTALITY, AND OVERALL SURVIVAL WERE DERIVED. THE AIM WAS TO DEFINE REQUIREMENTS FOR AN OPTIMAL TREATMENT SCHEDULE WITH RESPECT TO LEUKEMIC CELL KILL AND LATE NORMAL-TISSUE MORBIDITY. MATERIAL AND METHODS: A LITERATURE SEARCH WAS PERFORMED. THREE RANDOMIZED STUDIES, FOUR STUDIES COMPARING RESULTS OF TWO OR THREE TBI REGIMENS, AND NINE REPORTS WITH RESULTS OF ONE SPECIFIC TBI REGIMEN WERE IDENTIFIED. BIOLOGICALLY EFFECTIVE DOSES (BEDS) WERE CALCULATED. THE RESULTS OF THE RANDOMIZED STUDIES AND THE STUDIES COMPARING RESULTS OF TWO OR THREE TBI REGIMENS WERE POOLED, AND THE POOLED RELATIVE RISK (RR) WAS CALCULATED FOR THE TREATMENTS WITH HIGH BED VALUES VERSUS TREATMENTS WITH A LOW BED. BED-EFFECT RELATIONSHIPS WERE OBTAINED. RESULTS: RRS FOR THE HIGH BED TREATMENTS WERE SIGNIFICANTLY LOWER FOR RELAPSE INCIDENCE, NOT SIGNIFICANTLY DIFFERENT FOR DISEASE-FREE SURVIVAL AND TREATMENT-RELATED MORTALITY, AND SIGNIFICANTLY HIGHER FOR OVERALL SURVIVAL. BED-EFFECT RELATIONSHIPS INDICATE A DECREASE IN RELAPSE INCIDENCE AND TREATMENT-RELATED MORTALITY AND AN INCREASE IN DISEASE-FREE AND OVERALL SURVIVAL WITH HIGHER BED VALUES. CONCLUSION: """"MORE DOSE IS BETTER"""", PROVIDED THAT A TBI SETTING IS USED LIMITING THE BEDS OF LUNGS, KIDNEYS, AND EYE LENSES.","BONE-MARROW-TRANSPLANTATION; ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE NONLYMPHOBLASTIC LEUKEMIA; 1ST COMPLETE REMISSION; VERSUS-HOST-DISEASE; TERM-FOLLOW-UP; RENAL DYSFUNCTION; AFFECTS PROGNOSIS; IN-VIVO; TOXICITY","ALLOGENEIC HSCT; BED; EUKEMIA; ORGAN SHIELDING; TBI","STRAHLENTHERAPIE UND ONKOLOGIE","KAL, HB##VAN KEMPEN-HARTEVELD, ML##HEIJENBROK-KAL, MH##STRUIKMANS, H","UNIV UTRECHT, MED CTR, DEPT RADIOTHERAPY, NL-3584 CX UTRECHT, NETHERLANDS. UNIV MED CTR ROTTERDAM, ERASMUS MC, DEPT EPIDEMIOL & BIOSTAT, ROTTERDAM, NETHERLANDS. LEIDEN UNIV, MED CTR, DEPT RADIOTHERAPY, LEIDEN, NETHERLANDS.","ONCOLOGY; RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","ONCOLOGY; RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","ALTSCHULER C, 1990, INT J RADIAT ONCOL, V19, P1151, DOI 10.1016/0360-3016(90)90220-E##BARENDSEN GW, 1982, INT J RADIAT ONCOL, V8, P1981, DOI 10.1016/0360-3016(82)90459-X##BELKACEMI Y, 1998, STRAHLENTHER ONKOL, V174, P92, DOI 10.1007/BF03038482##BIERI S, 2001, INT J RADIAT ONCOL, V49, P1071, DOI 10.1016/S0360-3016(00)01491-7##BORG M, 2002, INT J RADIAT ONCOL, V54, P1165, DOI 10.1016/S0360-3016(02)03039-0##CHAO NJ, 1991, BLOOD, V78, P1923##CLIFT RA, 1990, BLOOD, V76, P1867##CLIFT RA, 1998, BLOOD, V92, P1455, DOI 10.1182/BLOOD.V92.4.1455##COOPERMAN J, 2004, STEM CELLS, V22, P1111, DOI 10.1634/STEMCELLS.22-6-1111##CORVO R, 2002, BONE MARROW TRANSPL, V30, P717, DOI 10.1038/SJ.BMT.1703701##CORVO R, 1999, INT J RADIAT ONCOL, V43, P497, DOI 10.1016/S0360-3016(98)00441-6##DALE RG, 1989, BRIT J RADIOL, V62, P241, DOI 10.1259/0007-1285-62-735-241##DAVIS HP, 1988, BONE MARROW TRANSPL, V3, P349##DEEG HJ, 1986, BONE MARROW TRANSPL, V1, P151##DIMOPOULOS MA, 1994, AM J HEMATOL, V46, P82, DOI 10.1002/AJH.2830460205##DU W, 1998, BONE MARROW TRANSPL, V21, P1043, DOI 10.1038/SJ.BMT.1701210##FRASSONI F, 1989, BRIT J HAEMATOL, V73, P211, DOI 10.1111/J.1365-2141.1989.TB00254.X##FYLES GM, 1991, BONE MARROW TRANSPL, V8, P453##GALE RP, 1991, INT J RADIAT ONCOL, V20, P631, DOI 10.1016/0360-3016(91)90081-E##GIRINSKY T, 2000, J CLIN ONCOL, V18, P981, DOI 10.1200/JCO.2000.18.5.981##GONZALEZ-VILA V, 1990, RADIOTHER ONCOL, V18 SUPPL 1, P110, DOI 10.1016/0167-8140(90)90187-2##HEINZELMANN F, 2006, STRAHLENTHER ONKOL, V182, P222, DOI 10.1007/S00066-006-1468-1##IGAKI H, 2005, STRAHLENTHER ONKOL, V181, P704, DOI 10.1007/S00066-005-1405-8##JUCKETT MB, 2001, BONE MARROW TRANSPL, V27, P451, DOI 10.1038/SJ.BMT.1702797##KAL HB, 2005, STRAHLENTHER ONKOL, V181, P717, DOI 10.1007/S00066-005-1407-6##KAL HB, 2004, STRAHLENTHER ONKOL, V180, P798, DOI 10.1007/S00066-004-1276-4##KAL HB, 2006, INT J RADIAT ONCOL, V65, P1228, DOI 10.1016/J.IJROBP.2006.02.021##KIM TH, 1990, INT J RADIAT ONCOL, V19, P889, DOI 10.1016/0360-3016(90)90009-9##LAWTON CA, 1997, BONE MARROW TRANSPL, V20, P1069, DOI 10.1038/SJ.BMT.1701022##LONG G D, 1997, BIOL BLOOD MARROW TRANSPLANT, V3, P324##MIRALBELL R, 1996, J CLIN ONCOL, V14, P579, DOI 10.1200/JCO.1996.14.2.579##NIETO Y, 2006, BIOL BLOOD MARROW TR, V12, P217, DOI 10.1016/J.BBMT.2005.10.012##OZSAHIN M, 1992, CANCER, V69, P2853, DOI 10.1002/1097-0142(19920601)69:11<2853::AID-CNCR2820691135>3.0.CO;2-2##PREISLER HD, 1992, BLOOD, V80, P2600##REGNIER R, 1990, RADIOTHER ONCOL, V18 SUPPL 1, P128, DOI 10.1016/0167-8140(90)90192-Y##RESBEUT M, 1995, INT J RADIAT ONCOL, V31, P509, DOI 10.1016/0360-3016(94)00446-R##SCARPATI D, 1990, RADIOTHER ONCOL, V18 SUPPL 1, P135, DOI 10.1016/0167-8140(90)90194-2##SHANK B, 1993, RADIOTHER ONCOL, V27, P30, DOI 10.1016/0167-8140(93)90041-6##SHAPIRA MY, 2004, BONE MARROW TRANSPL, V34, P155, DOI 10.1038/SJ.BMT.1704540##STEEL GG, 2002, BASIC CLIN RADIOBIOL##SUTTON L, 1993, BONE MARROW TRANSPL, V12, P583##THAMES HD, 1987, FRACTIONATION RADIOT##VALLS A, 1990, RADIOTHER ONCOL, V18 SUPPL 1, P151, DOI 10.1016/0167-8140(90)90198-6##VAN KEMPEN-HARTEVELD ML, 2002, INT J RADIAT ONCOL, V52, P1367, DOI 10.1016/S0360-3016(01)02758-4##VRIESENDORP HM, 1991, INT J RADIAT ONCOL, V20, P635, DOI 10.1016/0360-3016(91)90082-F",31,2020-11-20,NA,"UNIV UTRECHT#UNIV MED CTR ROTTERDAM#LEIDEN UNIV","NETHERLANDS#NETHERLANDS#NETHERLANDS"
"J","WOS:000241798800031",2006,"MEDIUM-TERM VARIABILITY OF BLOOD PRESSURE AND POTENTIAL UNDERDIAGNOSIS OF HYPERTENSION IN PATIENTS WITH PREVIOUS TRANSIENT ISCHEMIC ATTACK OR MINOR STROKE","BACKGROUND AND PURPOSE-BLOOD PRESSURE (BP) IS A MAJOR RISK FACTOR FOR STROKE. HOWEVER, THE VARIABILITY OF SYSTOLIC AND DIASTOLIC BP (SBP AND DBP) MEANS THAT SINGLE MEASUREMENTS DO NOT PROVIDE A RELIABLE MEASURE OF USUAL BP. ALTHOUGH 24-HOUR AMBULATORY BP MONITORING CAN CORRECT FOR THE EFFECTS OF SHORT-TERM VARIATION, THERE IS ALSO IMPORTANT MEDIUM-TERM VARIABILITY. THE EXTENT OF MEDIUM-TERM VARIABILITY IN BP IS MOST MARKED IN PATIENTS WITH A PREVIOUS TRANSIENT ISCHEMIC ATTACK (TIA) OR STROKE. WE STUDIED THE POTENTIAL IMPACT OF THIS VARIABILITY ON THE LIKELY RECOGNITION OF HYPERTENSION. METHODS-WE ANALYZED MULTIPLE REPEATED MEASUREMENTS OF BP IN 3 LARGE COHORTS WITH A TIA OR MINOR STROKE: THE UK-TIA TRIAL (N=2098), THE DUTCH TIA TRIAL (N=2953), AND THE EUROPEAN CAROTID SURGERY TRIAL (ECST; N=2646). REGRESSION DILUTION RATIOS AND COEFFICIENTS OF VARIATION WERE CALCULATED FOR SBP AND DBP FROM BASELINE AND REPEATED MEASUREMENTS DURING THE SUBSEQUENT 12 MONTHS. CATEGORIZATION BASED ON SINGLE BASELINE MEASUREMENTS WAS ALSO COMPARED WITH CATEGORIZATION BASED ON THE SUBSEQUENT """"USUAL"""" BP. RESULTS-THE CORRELATION BETWEEN MEASUREMENTS OF BP AT BASELINE AND 3 TO 5 MONTHS LATER WAS POOR (R-2 FROM 0.17 TO 0.31 FOR SBP AND FROM 0.10 TO 0.20 FOR DBP). CATEGORIZATION OF PATIENTS BY BASELINE VALUES RESULTED IN SUBSTANTIAL MISCLASSIFICATION IN RELATION TO USUAL BP. FOR EXAMPLE, OF PATIENTS WITH AN SBP < 140 MM HG AT BASELINE, THE PERCENTAGE WITH A USUAL SBP >= 140 MM HG WAS 31.6% IN THE UK-TIA TRIAL, 48.2% IN THE DUTCH TIA TRIAL, AND 57.7% IN THE ECST. AT LEAST 3 CONSECUTIVE MEASUREMENTS OF SBP < 120 MM HG WERE REQUIRED TO BE > 90% CERTAIN THAT SUBSEQUENT USUAL SBP WOULD NOT BE >= 140 MM HG. CONCLUSIONS-GIVEN THE GREATER MEDIUM-TERM VARIABILITY OF BP IN PATIENTS WITH A PREVIOUS TIA OR STROKE THAN IN THE GENERAL POPULATION, SINGLE MEASUREMENTS OF """"NORMAL"""" OR """"LOW"""" BP WILL SUBSTANTIALLY UNDERESTIMATE THE TRUE PREVALENCE OF HYPERTENSION.","WITHIN-PERSON VARIABILITY; REGRESSION DILUTION; WHITE-COAT; FOLLOW-UP; RISK","HYPERTENSION; PREVENTION; RISK FACTORS; STROKE","STROKE","CUFFE, RL##HOWARD, SC##ALGRA, A##WARLOW, CP##ROTHWELL, PM","UNIV OXFORD, DEPT CLIN NEUROL, STROKE PREVENT RES UNIT, OXFORD, ENGLAND. UNIV UTRECHT, MED CTR, RUDOLF MAGNUS INST NEUROSCI, DEPT NEUROL, UTRECHT, NETHERLANDS. UNIV UTRECHT, MED CTR, JULIUS CTR HLTH SCI & PRIMARY CARE, UTRECHT, NETHERLANDS. UNIV EDINBURGH, DEPT CLIN NUTR, EDINBURGH, MIDLOTHIAN, SCOTLAND.","CLINICAL NEUROLOGY; PERIPHERAL VASCULAR DISEASE","NEUROSCIENCES & NEUROLOGY; CARDIOVASCULAR SYSTEM & CARDIOLOGY","CELIS H, 2002, BLOOD PRESSURE, V11, P352, DOI 10.1080/080370502321095311##CICCONETTI P, 2000, ARCH GERONTOL GERIAT, V30, P225, DOI 10.1016/S0167-4943(00)00052-2##CLARKE R, 1999, AM J EPIDEMIOL, V150, P341##DONNAN GA, 2003, J HYPERTENS, V21, PS25, DOI 10.1097/00004872-200306005-00006##ESPOSTI LD, 2004, PHARMACOECONOMICS, V22, P907##FARRELL B, 1991, J NEUROL NEUROSUR PS, V54, P1044, DOI 10.1136/JNNP.54.12.1044##FARRELL B, 1998, LANCET, V351, P1379, DOI 10.1016/S0140-6736(97)09292-1##*GUID SUBC, 1999, BLOOD PRESSURE, V8, P1##HATA Y, 2000, HYPERTENS RES, V23, P553, DOI 10.1291/HYPRES.23.553##HEBEL JR, 1980, J CHRON DIS, V33, P745, DOI 10.1016/0021-9681(80)90062-4##HOWARD SC, 2003, J CLIN EPIDEMIOL, V56, P1084, DOI 10.1016/S0895-4356(03)00267-1##IMAI Y, 1997, AM J HYPERTENS, V10, P1281, DOI 10.1016/S0895-7061(97)00277-X##KLUNGEL OH, 2000, J CLIN EPIDEMIOL, V53, P1158, DOI 10.1016/S0895-4356(00)00228-6##KLUNGEL OH, 1999, STROKE, V30, P1312, DOI 10.1161/01.STR.30.7.1312##LEWINGTON S, 2002, LANCET, V360, P1903##MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9##MACMAHON S, 2001, LANCET, V358, P1033, DOI 10.1016/S0140-6736(01)06178-5##OHKUBO T, 2005, J AM COLL CARDIOL, V46, P508, DOI 10.1016/J.JACC.2005.03.070##PICKERING TG, 2005, CIRCULATION, V111, P697, DOI [10.1161/01.CIR.0000154900.76284.F6, 10.1161/01.HYP.0000150859.47929.8E]##RAMSAY LE, 1999, J HUM HYPERTENS, V13, P569, DOI 10.1038/SJ.JHH.1000917##ROBINSON T, 1997, CEREBROVASC DIS, V7, P214, DOI 10.1159/000108194##RODGERS A, 1998, LANCET, V352, P1801##RODGERS A, 1996, BRIT MED J, V313, P147, DOI 10.1136/BMJ.313.7050.147##ROMAN MJ, 2001, ARTERIOSCL THROM VAS, V21, P1507, DOI 10.1161/HQ0901.095149##ROSNER B, 1979, J CHRON DIS, V32, P451, DOI 10.1016/0021-9681(79)90105-X##ROSNER B, 1983, AM J EPIDEMIOL, V117, P429, DOI 10.1093/OXFORDJOURNALS.AJE.A113561##ROTHWELL PM, 2004, LANCET, V363, P1925, DOI 10.1016/S0140-6736(04)16405-2##SHEPARD DS, 1981, J CHRON DIS, V34, P191, DOI 10.1016/0021-9681(81)90064-3##STRAESSEN J, 1990, J HYPERTENS, V8, P393##TURNBULL F, 2003, LANCET, V362, P1527##VANGIJN J, 1991, NEW ENGL J MED, V325, P1261, DOI 10.1056/NEJM199110313251801##VERDECCHIA P, 2005, HYPERTENSION, V45, P203, DOI 10.1161/01.HYP.0000151623.49780.89##1997, ARCH INTERN MED, V157, P2413",24,2020-11-20,NA,"UNIV OXFORD#UNIV UTRECHT#UNIV UTRECHT#UNIV EDINBURGH","ENGLAND#NETHERLANDS#NETHERLANDS#SCOTLAND"
"J","WOS:000242522300006",2006,"DEVELOPING FUNDAMENTAL PRINCIPLES FOR TEACHER EDUCATION PROGRAMS AND PRACTICES","TRADITIONAL APPROACHES TO TEACHER EDUCATION ARE INCREASINGLY CRITIQUED FOR THEIR LIMITED RELATIONSHIP TO STUDENT TEACHERS' NEEDS AND FOR THEIR MEAGER IMPACT ON PRACTICE; MANY PLEAS ARE HEARD FOR A RADICAL NEW AND EFFECTIVE PEDAGOGY OF TEACHER EDUCATION IN WHICH THEORY AND PRACTICE ARE LINKED EFFECTIVELY. ALTHOUGH VARIOUS ATTEMPTS TO RESTRUCTURE TEACHER EDUCATION HAVE BEEN PUBLISHED, NO COHERENT BODY OF KNOWLEDGE EXISTS ABOUT CENTRAL PRINCIPLES UNDERLYING TEACHER EDUCATION PROGRAMS THAT ARE RESPONSIVE TO THE EXPECTATIONS, NEEDS AND PRACTICES OF STUDENT TEACHERS. BY ANALYZING EFFECTIVE FEATURES OF PROGRAMS IN AUSTRALIA, CANADA, AND THE NETHERLANDS, THIS STUDY CONTRIBUTES AN INITIAL FRAMEWORK OF SEVEN FUNDAMENTAL PRINCIPLES TO GUIDE THE DEVELOPMENT OF RESPONSIVE TEACHER EDUCATION PROGRAMS THAT MAKE A DIFFERENCE. (C) 2006 ELSEVIER LTD. ALL RIGHTS RESERVED.","EXPERIENCE","PEDAGOGY OF TEACHER EDUCATION; THEORY-PRACTICE-RELATIONSHIP; TEACHER EDUCATORS","TEACHING AND TEACHER EDUCATION","KOTTHAGEN, F##LOUGHRAN, J##RUSSELL, T","VRIJE UNIV AMSTERDAM, AMSTERDAM, NETHERLANDS. UNIV UTRECHT, NL-3508 TC UTRECHT, NETHERLANDS. MONASH UNIV, CLAYTON, VIC 3168, AUSTRALIA. QUEENS UNIV, KINGSTON, ON, CANADA.","EDUCATION & EDUCATIONAL RESEARCH","EDUCATION & EDUCATIONAL RESEARCH","ADMIRAAL W. F., 1998, LEARNING ENV RES, V1, P59, DOI DOI 10.1023/A:1009936715640##ANDERSON G, 1994, STUDYING YOUR OWN SC##ASHTON PT, 1996, ED RES, V25, P21##BAIRD JR, 1992, LEARNING PEEL EXPERI##BARNES D, 1975, COMMUNICATION CURRIC##BARONE T., 1996, HDB RES TEACHER ED, P1108##BEN-PERETZ M., 1995, INT ENCY TEACHING TE, P543##BERRY A, 2004, INT HDB SELF STUDY T, P1295, DOI DOI 10.1007/978-1-4020-6545-3##BERRY A, 2002, IMPROVING TEACHER ED, P13##BODE BOYD H., 1940, WE LEARN##BOUD D., 1985, REFLECTION TURNING E##BROOKFIELD S., 1995, BECOMING CRITICALLY##BROUWER N, 2005, AM EDUC RES J, V42, P153, DOI 10.3102/00028312042001153##BROWN J. S., 1989, ED RES, V18, P32, DOI DOI 10.3102/0013189X018001032##BULLOUGH R., 2001, BECOMING STUDENT TEA##BULLOUGH RV, 1997, J EDUC TEACHING, V23, P215, DOI DOI 10.1080/02607479719972##CALDERHEAD J, 1993, CONCEPTUALIZING REFL##CARLSON HL, 1999, TEACH TEACH, V5, P203, DOI DOI 10.1080/1354060990050205##CLANDININ D. J., 1995, TEACHERS WHO TEACH T, P25##CLIFT RT, 1990, ENCOURAGING REFLECTI##COBB P, 1999, ED RES, V28, P4, DOI DOI 10.3102/0013189X028002004##COCHRAN-SMITH M., 1993, INSIDE OUTSIDE TEACH##COCHRAN-SMITH M., 2005, STUDYING TEACHER ED##COLE AL, 1993, AM EDUC RES J, V30, P473, DOI 10.2307/1163298##COLE AL, 1997, TEACH TEACH, V3, P7, DOI DOI 10.1080/1354060970030102##COOK-SATHER A., 2002, ED RES, V31, P3, DOI DOI 10.3102/0013189X031004003##DAMASIO AR, 1994, DESCARTES ERROR EMOT##DARLING-HAMMOND L., 1994, PROFESSIONAL DEV SCH##DEWEY J., 1933, WE THINK##DUCHARME ER, 1993, LIVES TEACHERS ED##ELLIOT J, 1991, ACTION RES ED CHANGE##FEIMAN-NEMSER S., 1986, HDB RES TEACHING, P505##FENSTERMACHER GD, 1997, TEACHING TEACHING PU, PR8##FOSNOT CATHERINE T., 1996, CONSTRUCTIVISM THEOR##FREUDENTHAL H, 1978, WEEDING SOWING PREFA##GALESLOOT L. J., 1997, PEDAGOGISCHE STUDIEN, V74, P249##GOODLAD J, 1990, TEACHERS OUR NATIONS##GRIMMETT PP, 1988, REFLECTION TEACHER E##HAMILTON ML, 1998, RECONCEPTUALISING TE##HERMANS J. J., 1993, TEACHER ED, V9, P111##KESSELS J. P. A. M., 1996, ED RES, V25, P17, DOI DOI 10.3102/0013189X025003017##KOETSIER C., 1997, TEACHER ED SCH PARTN, P113##KOETSIER CP, 1995, J EDUC TEACHING, V21, P333, DOI 10.1080/02607479550038545##KORTHAGEN F, 2001, LINKING PRACTICE THE##KORTHAGEN F. A. J., 1999, ED RES, V28, P4, DOI DOI 10.3102/0013189X028004004##KORTHAGEN FAJ, 1985, J TEACH EDUC, V36, P11, DOI 10.1177/002248718503600502##LABOSKEY V. K., 1994, DEV REFLECTIVE PRACT##LABOSKEY V. L., 2004, INT HDB SELF STUDY T, P817, DOI DOI 10.1007/978-1-4020-6545-3_21##LANIER J., 1986, HDB RES TEACHING, P527##LATHER P. A., 1991, GETTING SMART FEMINI##LORTIE D. C., 1975, SCHOOLTEACHER##LOUGHRAN J., 2006, DEV PEDAGOGY TEACHER##LOUGHRAN J., 1997, TEACHING TEACHING PU, P57##LOUGHRAN J. J., 1996, DEVELOPING REFLECTIV##LOUGHRAN JJ, 2002, J TEACH EDUC, V53, P33, DOI 10.1177/0022487102053001004##MARTIN AK, 2001, M CAN SOC STUD ED QU##MCINTYRE D, 1992, BRIT J EDUC STUD, V40, P264, DOI 10.2307/3120894##MERRIAM S. B., 1998, QUALITATIVE RES CASE##MULLER-FOHRBRODT G., 1978, PRAXISSCHOCK BEI JUN##MYERS C. B., 2002, IMPROVING TEACHER ED, P130##NORTHFIELD J., 1983, RES SCI EDUC, V13, P185##NORTHFIELD J. R., 1997, TEACHING TEACHING PU, P48##OSTERMAN K., 1993, REFLECTIVE PRACTICE##PUTNAM RT, 1997, INT HDB TEACHERS TEA, V2, P1223##RICHARDSON V., 1997, CONSTRUCTIVIST TEACH##RUSSELL T., 1997, PURPOSE PASSION PEDA##RUSSELL T., 1999, REFLECTING TEACHING, P219##RUSSELL T, 2002, IMPROVING TEACHER ED, P73##RUSSELL T, 1995, TEACHERS WHO TEACH T, P95##RUSSELL T., 1995, TEACHERS WHO TEACH T, P187##SANDLIN RA, 1992, ACTION TEACHER ED, V14, P16, DOI DOI 10.1080/01626620.1993.10463137##SCHON DA, 1987, ED REFLECTIVE PRACTI##SCHON DA, 1983, REFLECTIVE PRACTITIO##SEGALL A., 2002, DISTURBING PRACTICE##SIGEL I, 1977, COGNITIVE DEV BIRTH##STAKE R.E., 1982, REV J PHILOS SOCIAL, V7, P1##STEVENSON R, 1996, ETHN ED RES FOR PHIL##STOFFLETT RT, 1994, J RES SCI TEACH, V31, P31, DOI 10.1002/TEA.3660310105##TIGCHELAAR A., 2000, TRENDS DUTCH TEACHER, P185##TOM AR, 1997, REDESIGNING TEACHER##UPITIS R. B, 2000, WHO WILL TEACH CASE##VAN MANEN M., 1999, RES TEACHING METHODO, P13##VEDDER J, 1984, ORIENTATIE BEROEP LE##VEDDER J, 1987, M ASS TEACH ED EUR B##VEENMAN S, 1984, REV EDUC RES, V54, P143, DOI 10.3102/00346543054002143##WIDEEN M, 1998, REV EDUC RES, V68, P130, DOI 10.2307/1170752##ZEICHNER K.M., 2001, HDB RES TEACHING, P298##ZEICHNER K. M., 1995, ED ACTION RES BECOMI, P13##ZEICHNER KM, 1981, J TEACH EDUC, V32, P7, DOI 10.1177/002248718103200302",378,2020-11-20,NA,"VRIJE UNIV AMSTERDAM#UNIV UTRECHT#MONASH UNIV#QUEENS UNIV","NETHERLANDS#NETHERLANDS#AUSTRALIA#CANADA"
"J","WOS:000241546900003",2006,"ACID-BASE BALANCE OF UMBILICAL ARTERY BLOOD OF LIVEBORN PIGLETS AT BIRTH AND ITS RELATION WITH FACTORS AFFECTING DELIVERY OF INDIVIDUAL PIGLETS","IN THE LIMITED NUMBER OF STUDIES THAT REPORTED ON THE RELATION BETWEEN FACTORS AFFECTING BIRTH OF INDIVIDUAL PIGLETS AND ACID-BASE BALANCE VALUES AT BIRTH, PREDOMINANTLY SIMPLE CORRELATION COEFFICIENTS HAVE BEEN USED. THE AIM OF THE PRESENT STUDY WAS TO ANALYSE THE RELATION BETWEEN FACTORS AFFECTING DELIVERY OF INDIVIDUAL LIVEBORN PIGLETS AND ACID-BASE BALANCE VALUES (PH, P-CO2, HCO3- AND BEECF) AT BIRTH. IN TOTAL 201 PIGLETS ORIGINATING FROM 44 LITTERS WERE USED FOR THE COLLECTION OF BLOOD SAMPLES FROM THE UMBILICAL ARTERY IMMEDIATELY AFTER BIRTH, PREFERABLY IN THE PERIOD OF APNEA. BLOOD SAMPLES WERE ANALYSED WITH THE ISTAT (R) PORTABLE CLINICAL ANALYSER. SIGNIFICANTLY LOWER PH, HCO3-, BEECF AND SIGNIFICANTLY HIGHER P-CO2 LEVELS WERE FOUND IN POSTERIORLY PRESENTED PIGLETS, INDEPENDENTLY OF THE CONDITION OF THE UMBILICAL CORD, BIRTH WEIGHT AND CUMULATIVE BIRTH INTERVAL/RANK. INDEPENDENTLY OF PRESENTATION, BIRTH WEIGHT AND RANK, PIGLETS BORN WITH RUPTURED UMBILICAL CORDS SHOWED SIGNIFICANTLY LOWER PH VALUES. NEXT TO THAT, INCREASING BIRTH WEIGHTS RESULTED IN INCREASING HCO3- AND BEECF VALUES AT BIRTH, INDEPENDENTLY OF PRESENTATION, CONDITION OF THE UMBILICAL CORD AND CUMULATIVE BIRTH INTERVAL/RANK. BOTH AN INCREASE IN CUMULATIVE BIRTH INTERVAL AND IN RANK WAS ASSOCIATED WITH A SIGNIFICANT DECREASE OF PH, HCO3-, BEECF AND INCREASE OF P-CO2 LEVELS IN UMBILICAL CORD BLOOD AT BIRTH. TOGETHER THESE RESULTS DEMONSTRATE FOR THE FIRST TIME THAT A CLEAR RELATION EXISTS BETWEEN (FACTORS AFFECTING) THE PROGRESS OF DELIVERY AND ACID-BASE BALANCE VALUES IN A POLYTOCOUS SPECIES LIKE THE PIG. (C) 2006 ELSEVIER INC. ALL RIGHTS RESERVED.","NEWBORN PIGLETS; PERINATAL MORTALITY; PARTURITION; VIABILITY; GAS; PIG; ASPHYXIA; ANALYZER; PH; STILLBIRTH","PIGLET; PRESENTATION; BIRTH WEIGHT; BIRTH INTERVAL; ACID-BASE BALANCE","THERIOGENOLOGY","VAN DIJK, AJ##VAN DER LENDE, T##TAVERNE, MAM","UNIV UTRECHT, FAC VET MED, DEPT VET PHARMACOL PHARM & TOXICOL, NL-3508 TD UTRECHT, NETHERLANDS. UNIV WAGENINGEN & RES CTR, ANIM SCI GRP, DIV ANIM RESOURCES, NL-8200 AB LELYSTAD, NETHERLANDS. UNIV UTRECHT, FAC VET MED, DEPT FARM ANIM HLTH, NL-3584 CL UTRECHT, NETHERLANDS.","REPRODUCTIVE BIOLOGY; VETERINARY SCIENCES","REPRODUCTIVE BIOLOGY; VETERINARY SCIENCES","ANDREN B, 1982, ACTA VET SCAND, V23, P581##BRENNER KV, 1977, MONATSH VETERINARMED, V32, P850##CHAN WW, 1993, ANIM REPROD SCI, V34, P43, DOI 10.1016/0378-4320(93)90048-V##CHIANG FE, 1997, RES VET SCI, V63, P107, DOI 10.1016/S0034-5288(97)90001-1##CHRISTIANSON WT, 1992, VET CLIN N AM-FOOD A, V8, P623, DOI 10.1016/S0749-0720(15)30708-8##DZIUK P, 1979, ANIM REPROD SCI, V2, P335, DOI 10.1016/0378-4320(79)90057-5##GLAWISCHNIG E, 1980, COMMUNICATION, V87, P441##GROSENBAUGH DA, 1998, J AM VET MED ASSOC, V213, P691##HERPIN P, 1996, J ANIM SCI, V74, P2067##HERPIN P, 2001, J ANIM SCI, V79, P5##LAUTERBACH K, 1987, ARCH EXP VET MED, V41, P522##LEENHOUWERS JI, 1999, LIVEST PROD SCI, V57, P243, DOI 10.1016/S0301-6226(98)00171-7##LINDERKAMP O, 1981, PEDIATR RES, V15, P53, DOI 10.1203/00006450-198101000-00013##LOW JA, 1994, AM J OBSTET GYNECOL, V170, P1081, DOI 10.1016/S0002-9378(94)70101-6##RANDALL GCB, 1971, CAN J COMPARAT MED, V35, P141##RANDALL GCB, 1992, ANIM REPROD SCI, V28, P309, DOI 10.1016/0378-4320(92)90117-V##RANDALL GCB, 1972, BIOL NEONATE, V20, P68, DOI 10.1159/000240447##RANDALL GCB, 1972, VET REC, V90, P183, DOI 10.1136/VR.90.7.183##RANDALL GCB, 1982, RES VET SCI, V32, P278, DOI 10.1016/S0034-5288(18)32380-4##ROSS MG, 2002, AM J OBSTET GYNECOL, V187, P1, DOI 10.1067/MOB.2002.123204##*SAS I, 1990, SAS STAT US GUID##SCHUIJT G, 1992, THESIS UTRECHT U, P57##SEDIAME S, 1999, EUR RESPIR J, V14, P214, DOI 10.1034/J.1399-3003.1999.14A36.X##SILVERMAN S C, 2002, EQUINE VET J SUPPL, P551##STANTON HC, 1974, J ANIM SCI, V38, P1037##SVENDSEN LS, 1991, ACTA VET SCAND, V32, P287##SZENCI O, 1985, ACTA VET HUNG, V33, P199##SZENCI O, 1988, J VET MED A, V35, P572##TAVERNE MAM, 1979, BIOL REPROD, V21, P1125, DOI 10.1095/BIOLREPROD21.5.1125##VAN DIJK AJ, 2005, THERIOGENOLOGY, V64, P1573, DOI 10.1016/J.THERIOGENOLOGY.2005.03.017##VAN RENS BTTM, 2004, THERIOGENOLOGY, V62, P331, DOI 10.1016/J.THERIOGENOLOGY.2003.10.008##VERWAERDE P, 2002, RES VET SCI, V73, P71, DOI 10.1016/S0034-5288(02)00065-6##WILHELM VU, 1997, BERL MUNCH TIERARZTL, V90, P92##ZALESKI HM, 1993, CAN J ANIM SCI, V73, P649, DOI 10.4141/CJAS93-069##ZALESKI HM, 1993, J ANIM SCI, V71, P298, DOI 10.2527/1993.712298X",21,2020-11-20,NA,"UNIV UTRECHT#UNIV WAGENINGEN RES CTR#UNIV UTRECHT","NETHERLANDS#NETHERLANDS#NETHERLANDS"
"J","WOS:000241628400010",2006,"STATIN TREATMENT AND REDUCED RISK OF PNEUMONIA IN PATIENTS WITH DIABETES","BACKGROUND: RECENT PROGNOSTIC STUDIES HAVE SHOWN THAT PREVIOUS TREATMENT WITH STATINS IS ASSOCIATED WITH A BETTER OUTCOME IN PATIENTS ADMITTED TO HOSPITAL WITH PNEUMONIA. BECAUSE OF AN INCREASED RISK OF PNEUMONIA IN PATIENTS WITH DIABETES, WE ASSESSED THE EFFECTS OF STATIN USE ON THE OCCURRENCE OF PNEUMONIA IN ADULT DIABETIC PATIENTS. METHODS: ALL PATIENTS WITH A DIAGNOSIS OF DIABETES ( TYPES 1 AND 2) ENLISTED IN THE UK GENERAL PRACTICE RESEARCH DATABASE BETWEEN 1 JUNE 1987 AND 21 JANUARY 2001 WERE INCLUDED. A CASE-CONTROL STUDY WAS PERFORMED WITH CASES DEFINED AS PATIENTS WITH A FIRST RECORDED DIAGNOSIS OF PNEUMONIA. FOR EACH CASE UP TO FOUR CONTROLS WERE MATCHED BY AGE, SEX, PRACTICE, AND INDEX DATE. PATIENTS WERE CLASSIFIED AS CURRENT USERS WHEN THE INDEX DATE WAS BETWEEN THE START AND END DATE OF STATIN TREATMENT. CONDITIONAL MULTIPLE LOGISTIC REGRESSION ANALYSIS WAS USED TO ESTIMATE THE STRENGTH OF THE ASSOCIATION BETWEEN STATIN TREATMENT AND THE OCCURRENCE OF PNEUMONIA. RESULTS: STATINS WERE USED IN 1.1% OF 4719 CASES AND IN 2.1% OF 15 322 MATCHED CONTROLS ( CRUDE ODDS RATIO ( OR) 0.51, 95% CI 0.37 TO 0.68). AFTER ADJUSTING FOR POTENTIAL CONFOUNDERS, TREATMENT WITH STATINS WAS ASSOCIATED WITH A SIGNIFICANT REDUCTION IN THE RISK OF PNEUMONIA ( ADJUSTED OR 0.49, 95% CI 0.35 TO 0.69). THE ASSOCIATION WAS CONSISTENT AMONG RELEVANT SUBGROUPS ( CARDIOVASCULAR DISEASES, PULMONARY DISEASES) AND INDEPENDENT OF THE USE OF OTHER PRESCRIPTION DRUGS. CONCLUSIONS: THE USE OF STATINS IS ASSOCIATED WITH A CONSIDERABLE REDUCTION IN THE RISK OF PNEUMONIA IN DIABETIC PATIENTS. IN ADDITION TO LOWERING THE RISK OF CARDIOVASCULAR DISEASE, STATINS MAY BE USEFUL IN PREVENTING RESPIRATORY INFECTIONS.","COMMUNITY-ACQUIRED PNEUMONIA; POPULATION-BASED COHORT; INFLUENZA VACCINES; SOCIAL-CLASS; MORTALITY; SEPSIS; DRUGS; INFLAMMATION; POSTCODES; ACCURACY",NA,"THORAX","VAN DE GARDE, EMW##HAK, E##SOUVEREIN, PC##HOES, AW##VAN DEN BOSCH, JMM##LEUFKENS, HGM","UIPS, DEPT PHARMACOEPIDEMIOL & PHARMACOTHERAPY, NL-3583 CA UTRECHT, NETHERLANDS. ST ANTONIUS HOSP, DEPT CLIN PHARM, NIEUWEGEIN, NETHERLANDS. UNIV UTRECHT, MED CTR, JULIUS CTR HLTH SCI & PRIMARY CARE, UTRECHT, NETHERLANDS. ST ANTONIUS HOSP, DEPT PULM DIS, NIEUWEGEIN, NETHERLANDS.","RESPIRATORY SYSTEM","RESPIRATORY SYSTEM","ALMIRALL J, 1999, EUR RESPIR J, V13, P349, DOI 10.1183/09031936.99.13234999##ALMOG Y, 2003, CHEST, V124, P740, DOI 10.1378/CHEST.124.2.740##ALMOG Y, 2004, CIRCULATION, V110, P880, DOI 10.1161/01.CIR.0000138932.17956.F1##ARONSKY D, 2005, AM J MED QUAL, V20, P319, DOI 10.1177/1062860605280358##DANESH J, 1999, BRIT MED J, V318, P843, DOI 10.1136/BMJ.318.7187.843##DE BRUIN ML, 2005, DIABETES CARE, V28, P440, DOI 10.2337/DIACARE.28.2.440##FESSLER MB, 2005, AM J RESP CRIT CARE, V171, P606, DOI 10.1164/RCCM.200406-729OC##FINE MJ, 1996, JAMA-J AM MED ASSOC, V275, P134, DOI 10.1001/JAMA.275.2.134##FRY AM, 2005, JAMA-J AM MED ASSOC, V294, P2712, DOI 10.1001/JAMA.294.21.2712##GUEVARA RE, 1999, AM J EPIDEMIOL, V149, P282, DOI 10.1093/OXFORDJOURNALS.AJE.A009804##HACKAM DG, 2006, LANCET, V367, P413, DOI 10.1016/S0140-6736(06)68041-0##JEFFERSON T, 2005, LANCET, V366, P1165, DOI 10.1016/S0140-6736(05)67339-4##JICK H, 1991, BRIT MED J, V302, P766, DOI 10.1136/BMJ.302.6779.766##JICK SS, 2003, PHARMACOTHERAPY, V23, P686, DOI 10.1592/PHCO.23.5.686.32205##KOIVULA I, 1994, AM J MED, V96, P313, DOI 10.1016/0002-9343(94)90060-4##KWAK B, 2000, NAT MED, V6, P1399##LAHEIJ RJF, 2004, JAMA-J AM MED ASSOC, V292, P1955, DOI 10.1001/JAMA.292.16.1955##MCLOONE P, 1999, BRIT MED J, V319, P1003, DOI 10.1136/BMJ.319.7215.1003##MORTENSEN EM, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-82##MORTENSEN EM, 2002, ARCH INTERN MED, V162, P1059, DOI 10.1001/ARCHINTE.162.9.1059##MOUTSCHEN M, 2005, REV MED LIEGE, V60, P541##MULLER LMAJ, 2005, CLIN INFECT DIS, V41, P281, DOI 10.1086/431587##NAKAGAWA T, 1997, ARCH INTERN MED, V157, P321, DOI 10.1001/ARCHINTE.157.3.321##RUIZ M, 1999, AM J RESP CRIT CARE, V160, P397, DOI 10.1164/AJRCCM.160.2.9808045##SHORR AF, 2005, CLIN CHEST MED, V26, P123, DOI 10.1016/J.CCM.2004.10.003##THOMSEN RW, 2006, CRIT CARE MED, V34, P1080, DOI 10.1097/01.CCM.0000207345.92928.E4##VALDEZ R, 1999, AM J PUBLIC HEALTH, V89, P1715, DOI 10.2105/AJPH.89.11.1715##VERDEL BM, 2006, ANN PHARMACOTHER, V40, P1040, DOI 10.1345/APH.1G642##WHITE DA, 2004, CLIN CHEST MED, V25, P179, DOI 10.1016/S0272-5231(03)00134-5",100,2020-11-20,NA,"UIPS#ST ANTONIUS HOSP#UNIV UTRECHT#ST ANTONIUS HOSP","NETHERLANDS#NETHERLANDS#NETHERLANDS#NETHERLANDS"
"J","WOS:000241999300002",2006,"UNSUCCESSFUL LAPAROSCOPIC CASTRATION IN A CRYPTORCHID FRISIAN STALLION","A 2-YEAR-OLD UNILATERAL INGUINAL CRYPTORCHID FRISIAN STALLION WAS CASTRATED BY BILATERAL LAPAROSCOPIC INTRA-ABDOMINAL SPERMATIC CORD TRANSECTION. BECAUSE BLOOD TESTOSTERONE LEVELS WERE STILL HIGH ON POSTOPERATIVE DAY 7, BOTH TESTICLES WERE REMOVED USING AN OPEN APPROACH. PATHOLOGY REVEALED THE PRESENCE OF VITAL LEYDIG-CELLS IN BOTH TESTES. FAILURE OF THE LAPAROSCOPIC CASTRATION IN THIS HORSE WAS ATTRIBUTED TO AN ALTERNATE BLOOD SUPPLY TO THE TESTES BY VESSELS DERIVED FROM THE CREMASTER AND/OR EXTERNAL PUDENDAL ARTERY.","TESTIS; TRANSECTION; DIVISION; VESSELS",NA,"TIJDSCHRIFT VOOR DIERGENEESKUNDE","VOERMANS, M##VAN DER VELDEN, MA","UNIV UTRECHT, FAC DIERGENEESKUNDE, DEPT GEZONDHEIDSZORG PAARD, NL-3508 TC UTRECHT, NETHERLANDS.","VETERINARY SCIENCES","VETERINARY SCIENCES","COLLIN B, 1973, ANAT HISTOL EMBRYOL, V2, P46##DAVIS EW, 1997, VET SURG, V26, P326, DOI 10.1111/J.1532-950X.1997.TB01505.X##DELAHUNTA A, 1986, APPL VET ANATOMY, P287##FISCHER AT, 1998, EQUINE VET J, V30, P105, DOI 10.1111/J.2042-3306.1998.TB04468.X##FISCHER AT, 1992, J AM VET MED ASSOC, V201, P1705##HENDRICKSON DA, 1997, VET SURG, V26, P335, DOI 10.1111/J.1532-950X.1997.TB01507.X##JANTOSOVICOVA J, 1983, GEGENBAURS MORPHOL JAHRB, V129, P467##KING LR, 1998, J UROLOGY, V160, P2457, DOI 10.1016/S0022-5347(01)62210-9##NOORDHUIZENSTASSEN EN, 1986, INT J ANDROL, V9, P141, DOI 10.1111/J.1365-2605.1986.TB00877.X##NOORDHUIZENSTASSEN EN, 1983, INT J ANDROL, V6, P509, DOI 10.1111/J.1365-2605.1983.TB00342.X##RAVASSE P, 1992, ANN CHIR, V46, P497##RIJKENHUIZEN ABM, 2002, PFERDEHEILKUNDE, V18, P12##RIJKENHUIZEN ABM, 1999, PFERDEHEILKUNDE, V15, P425, DOI 10.21836/PEM19990504##RUTGERS LJE, 1989, TIJDSCHR DIERGENEESK, V114, P493##SENGER PL, 1999, PATHWAYS PREGNANCY P, P101##VAN DER VELDEN MA, 2005, TIJDSCHR DIERGENEESK, V130, P312##VOERMANS M, 2006, EQUINE VET J, V38, P35, DOI 10.2746/042516406775374234##WILSON DG, 1996, J AM VET MED ASSOC, V209, P112",2,2020-11-20,NA,"UNIV UTRECHT","NETHERLANDS"
"J","WOS:000241999300005",2006,"ANALYSIS OF THE REPORT """"HOMEOPATHY, A SOLUTION FOR CALF DIARRHOEA!""""",NA,NA,NA,"TIJDSCHRIFT VOOR DIERGENEESKUNDE","LUMEIJ, JT##TESKE, E##PELLICAAN, CHP","UNIV UTRECHT, FAC DIERGENEESKUNDE, DEPT GEZELSCHAPSDIEREN, NL-3508 TC UTRECHT, NETHERLANDS.","VETERINARY SCIENCES","VETERINARY SCIENCES",NA,0,2020-11-20,NA,"UNIV UTRECHT","NETHERLANDS"
"J","WOS:000240963800002",2006,"COMPOSITE TISSUE ALLOTRANSPLANTATION OF THE HAND AND FACE: A NEW FRONTIER IN TRANSPLANT AND RECONSTRUCTIVE SURGERY","EACH YEAR AN ESTIMATED 7-MILLION PEOPLE IN THE USA NEED COMPOSITE TISSUE RECONSTRUCTION BECAUSE OF SURGICAL EXCISION OF TUMORS, ACCIDENTS AND CONGENITAL MALFORMATIONS. LIMB AMPUTEES ALONE COMPRISE OVER 1.2 MILLION OF THESE. THIS FIGURE IS MORE THAN DOUBLE THE NUMBER OF SOLID ORGANS NEEDED FOR TRANSPLANTATION. COMPOSITE TISSUE ALLOTRANSPLANTATION IN THE FORM OF HAND AND FACIAL TISSUE TRANSPLANTATION ARE NOW A CLINICAL REALITY. THE DISCOVERY, IN THE LATE 1990S, THAT THE SAME IMMUNOTHERAPY USED ROUTINELY IN KIDNEY TRANSPLANTATION WAS ALSO EFFECTIVE IN PREVENTING SKIN REJECTION MADE THIS POSSIBLE. WHILE THESE NEW TREATMENTS SEEM LIKE MAJOR ADVANCEMENTS MOST OF THE SURGICAL, IMMUNOLOGICAL AND ETHICAL METHODS USED ARE NOT NEW AT ALL AND HAVE BEEN AROUND AND ROUTINELY USED IN CLINICAL PRACTICE FOR SOME TIME. IN THIS REVIEW OF COMPOSITE TISSUE ALLOTRANSPLANTATION, WE: (I) OUTLINE THE LIMITATIONS OF CONVENTIONAL RECONSTRUCTIVE METHODS FOR TREATING SEVERE FACIAL DISFIGUREMENT, (II) REVIEW THE HISTORY OF COMPOSITE TISSUE ALLOTRANSPLANTATION, (III) DISCUSS THE CHRONOLOGICAL SCIENTIFIC ADVANCES THAT HAVE MADE IT POSSIBLE, (IV) FOCUS ON THE TWO UNIQUE CLINICAL SCENARIOS OF HAND AND FACE TRANSPLANTATION, AND (V) REFLECT ON THE CRITICAL ISSUES THAT MUST BE ADDRESSED AS WE MOVE THIS NEW FRONTIER TOWARD BECOMING A TREATMENT IN MAINSTREAM MEDICINE.","ISOLATED RABBIT FORELIMB; CYCLOSPORINE-A DELIVERY; LONG-TERM SURVIVAL; FACIAL TRANSPLANTATION; LIMB ALLOGRAFTS; PHARMACOKINETIC ADVANTAGE; SUBCLINICAL REJECTION; MANDIBULAR ALLOGRAFTS; INDEFINITE SURVIVAL; PERIPHERAL-NERVE","COMPOSITE TISSUE ALLOTRANSPLANTATION; ETHICS; FACE TRANSPLANT; HAND TRANSPLANT; IMMUNOSUPPRESSION","TRANSPLANT INTERNATIONAL","GANDER, B##BROWN, CS##VASILIC, D##FURR, A##BANIS, JC##CUNNINGHAM, M##WIGGINS, O##MALDONADO, C##WHITAKER, I##PEREZ-ABADIA, G##FRANK, JM##BARKER, JH","UNIV LOUISVILLE, DEPT SURG, LOUISVILLE, KY 40202 USA. UNIV UTRECHT, DEPT PLAST RECONSTRUCT & HAND SURG, UTRECHT, NETHERLANDS. UNIV LOUISVILLE, DEPT SOCIOL, LOUISVILLE, KY 40292 USA. UNIV LOUISVILLE, DEPT COMMUN, LOUISVILLE, KY 40292 USA. UNIV LOUISVILLE, DEPT PHILOSOPHY, LOUISVILLE, KY 40292 USA. UNIV LOUISVILLE, SCH MED, HLTH SCI CTR, DEPT PHYSIOL & BIOPHYS, LOUISVILLE, KY 40292 USA. MORRISTON HOSP, WELSH NATL PLAST SURG UNIT, DEPT PLAST RECONSTRUCT & BURNS SURG, SWANSEA, W GLAM, WALES. GOETHE UNIV FRANKFURT, DEPT TRAUMA SURG, D-6000 FRANKFURT, GERMANY.","SURGERY; TRANSPLANTATION","SURGERY; TRANSPLANTATION","AGICH GJ, 2004, AM J BIOETHICS, V4, P25, DOI 10.1080/15265160490496921##*AM SOC REC MICR F, 2006, POS AM SOC REC MICR##ANKENY RA, 2004, AM J BIOETHICS, V4, P35, DOI 10.1080/15265160490496750##*ASRM, 2006, FAC TRANSPL ASRM ASP##BAIN JR, 2000, MICROSURG, V20, P384, DOI 10.1002/1098-2752(2000)20:8<384::AID-MICR7>3.0.CO;2-W##BANIS JC, 2004, AM J BIOETHICS, V4, PW23, DOI 10.1080/15265160490508945##BARKER J, 2004, INT J SURG, V2, P8##BARKER J, 2003, NAKED SCI FACE FUTUR##BARKER JH, 2002, TRANSPLANTATION, V73, P832, DOI 10.1097/00007890-200203150-00033##BARKER JH, 2000, MICROSURG, V20, P359, DOI 10.1002/1098-2752(2000)20:8<359::AID-MICR3>3.0.CO;2-B##BARKER JH, 1998, TRANSPLANT P, V30, P2691##BARKER JH, 2006, IN PRESS PLAST RECON##BAYLIS F, 2004, AM J BIOETHICS, V4, P30, DOI 10.1080/15265160490496804##BLACK K, 1991, COMPOSITE TISSUE TRA##BLACK KS, 1982, NEW ENGL J MED, V306, P368##BLACK KS, 1985, TRANSPLANTATION, V39, P365, DOI 10.1097/00007890-198504000-00005##BOREL JF, 1994, AGENTS ACTIONS, V43, P179, DOI 10.1007/BF01986686##BROUHA P, 2006, MICROSURG, V26, P144, DOI 10.1002/MICR.20227##BROUHA PCR, 2004, TRANSPL INT, V17, P341, DOI 10.1111/J.1432-2277.2004.TB00453.X##BUNGER C, 1823, J CHIR AUGENHEILK, V4, P569##BUTLER PEM, 2006, J PLAST RECONSTR AES, V59, P211, DOI 10.1016/J.BJPS.2006.01.001##BUTLER PEM, 2004, AM J BIOETHICS, V4, P16, DOI 10.1080/15265160490496589##CALNE RY, 1979, LANCET, V2, P1033##CAPLAN A, 2004, AM J BIOETHICS, V4, P18, DOI 10.1080/15265160490496930##CARREL A, 1983, JAMA-J AM MED ASSOC, V250, P944, DOI 10.1001/JAMA.250.7.944##CHAMBERS T, 2004, AM J BIOETHICS, V4, P20, DOI 10.1080/15265160490496769##CUNNINGHAM M, 2004, EUR J TRAUMA, V30, P12##DANIEL RK, 1986, J HAND SURG-AM, V11A, P1##DAVARAGINE J, 1952, LEGGENDA AUREA, P648##DOI K, 1979, PLAST RECONSTR SURG, V64, P613, DOI 10.1097/00006534-197964050-00003##DOUGHERTY H, 2003, BURNS GIRL TO HAVE 1##DUBERNARD JM, 1999, LANCET, V353, P1315, DOI 10.1016/S0140-6736(99)02062-0##FAGEEH W, 2002, INT J GYNECOL OBSTET, V76, P245, DOI 10.1016/S0020-7292(01)00597-5##FRANCOIS CG, 2000, MICROSURG, V20, P360, DOI 10.1002/1098-2752(2000)20:8<360::AID-MICR4>3.3.CO;2-5##FRANCOIS CG, 2006, IN PRESS TRANSPLANTA##FRITZ WD, 1984, ANN SURG, V199, P211, DOI 10.1097/00000658-198402000-00014##FURNAS DW, 1983, TRANSPL P, V15, P3063##GILBERT R, 1964, MED TRIB MED NEWS, V5, P20##GNUDI MT, 1976, LIFE TIMES GASPARE T, P285##GOERING S, 2004, AM J BIOETHICS, V4, P37, DOI 10.1080/15265160490906583##GOLD ME, 1991, ANN PLAS SURG, V26, P125, DOI 10.1097/00000637-199102000-00004##GOLDBERG VM, 1980, J BONE JOINT SURG AM, V62, P414, DOI 10.2106/00004623-198062030-00011##GOLDWYN RM, 1966, PLAST RECONSTR SURG, V37, P184, DOI 10.1097/00006534-196603000-00002##GORANTLA V, 2001, EUR J TRAUMA, V7, P267##GORANTLA V, 2000, SURG FORUM, V51, P578##GORANTLA VS, 2003, TRANSPLANTATION, V75, P922, DOI 10.1097/01.TP.0000058302.45424.03##GRATWOHL A, 1986, LAB ANIM, V20, P213, DOI 10.1258/002367786780865692##GRUBER SA, 2000, MICROSURG, V20, P407, DOI 10.1002/1098-2752(2000)20:8<407::AID-MICR11>3.0.CO;2-B##GUIMBERTEAU JC, 1992, PLAST RECONSTR SURG, V89, P1135, DOI 10.1097/00006534-199206000-00023##GUTHRIE C., 1912, BLOOD VESSEL SURG, P37##HEWITT CW, 1985, TRANSPLANTATION, V39, P360, DOI 10.1097/00007890-198504000-00004##HOFMANN GO, 2000, MICROSURG, V20, P375##HOVIUS SER, 1992, PLAST RECONSTR SURG, V89, P700, DOI 10.1097/00006534-199204000-00020##JIANG HQ, 2005, PLAST RECONSTR SURG, V115, P31E, DOI 10.1097/01.PRS.0000153038.31865.02##JONES JW, 1999, SURGERY, V126, P384, DOI 10.1067/MSY.1999.99166##JONES JW, 2000, NEW ENGL J MED, V343, P468, DOI 10.1056/NEJM200008173430704##JONES TR, 1998, TRANSPLANT P, V30, P2746, DOI 10.1016/S0041-1345(98)00802-1##KANITAKIS J, 2005, EUR J DERMATOL, V15, P235##KANITAKIS J, 2003, TRANSPLANTATION, V76, P688, DOI 10.1097/01.TP.0000079458.81970.9A##KANITAKIS J, 2001, TRANSPLANT P, V33, P1722, DOI 10.1016/S0041-1345(00)02657-9##KNIHA H, 1989, ANN PLAS SURG, V22, P135, DOI 10.1097/00000637-198902000-00008##LANCE EM, 1971, J BONE JOINT SURG AM, VA 53, P1137, DOI 10.2106/00004623-197153060-00010##LANGER R, 1993, SCIENCE, V260, P920, DOI 10.1126/SCIENCE.8493529##LANZETTA M, 2005, TRANSPLANTATION, V79, P1210, DOI 10.1097/01.TP.0000157118.28394.FA##LANZETTA M, 2004, TRANSPLANT P, V36, P675, DOI 10.1016/J.TRANSPROCEED.2004.03.008##LEE WPA, 1991, PLAST RECONSTR SURG, V87, P401, DOI 10.1097/00006534-199103000-00001##LEVI DM, 2003, LANCET, V361, P2173, DOI 10.1016/S0140-6736(03)13769-5##LEVINE E, 2005, ANN PLAS SURG, V54, P502, DOI 10.1097/01.SAP.0000155282.48465.94##LUBBE AS, 1996, CANCER RES, V56, P4694##LUBBE AS, 1996, CANCER RES, V56, P4686##MACKINNON SE, 1992, PLAST RECONSTR SURG, V90, P695, DOI 10.1097/00006534-199210000-00024##MACKINNON SE, 1996, J NEUROSURG, V84, P671, DOI 10.3171/JNS.1996.84.4.0671##MACKINNON SE, 2001, PLAST RECONSTR SURG, V107, P1419, DOI 10.1097/00006534-200105000-00016##MAJZOUB RK, 2006, J HAND SURG-AM, V31A, P295, DOI 10.1016/J.JHSA.2005.09.013##MASCHKE KJ, 2004, AM J BIOETHICS, V4, P33, DOI 10.1080/15265160490496796##MCCABE S, 1998, TRANSPLANT P, V30, P2783, DOI 10.1016/S0041-1345(98)00808-2##MILES SH, 2004, AM J BIOETHICS, V4, P39, DOI 10.1080/15265160490496741##MIYAGI M, 2005, CLIN TRANSPLANT, V19, P456, DOI 10.1111/J.1399-0012.2005.00303.X##MORREIM EH, 2004, AM J BIOETHICS, V4, P27, DOI 10.1080/15265160490496697##MORRIS P, 2003, FACIAL TRANSPLANTATI##MORRIS PJ, 1981, TRANSPLANTATION, V32, P349##MURRAY JE, 1955, SURG FORUM, V6, P432##NANKIVELL BRIAN J., 2003, NEW ENGLAND JOURNAL OF MEDICINE, V349, P2326, DOI 10.1056/NEJMOA020009##OKIE S, 2006, NEW ENGL J MED, V354, P889, DOI 10.1056/NEJMP068005##OLESEN A, 2006, CHINESE FACE TRANSPL##PASCUAL M, 2002, NEW ENGL J MED, V346, P580, DOI 10.1056/NEJMRA011295##PEREZ-ABADIA G, 2003, TRANSPL INT, V16, P835, DOI 10.1111/J.1432-2277.2003.TB00251.X##PETIT F, 2004, AM J BIOETHICS, V4, P14, DOI 10.1080/15265160490496868##PRABHUNE KA, 2003, TRANSPLANTATION, V76, P1548, DOI 10.1097/01.TP.0000085288.12571.65##PRABHUNE KA, 2000, MICROSURG, V20, P441, DOI 10.1002/1098-2752(2000)20:8<441::AID-MICR16>3.0.CO;2-A##PRESS BHJ, 1986, ANN PLAS SURG, V16, P313, DOI 10.1097/00000637-198604000-00007##PRUZINSKY T, 2006, FACIAL TRAUMA FACIAL##RANDZIO J, 1991, ANN PLAS SURG, V26, P140, DOI 10.1097/00000637-199102000-00006##REN XP, 2000, MICROSURG, V20, P143, DOI 10.1002/(SICI)1098-2752(2000)20:3<143::AID-MICR9>3.0.CO;2-9##REYNOLDS C, 2006, IN PRESS LARYNGOSCOP##ROBERTSON JA, 2004, AM J BIOETHICS, V4, P32, DOI 10.1080/15265160490496840##ROBINSON E, 1996, BRIT J PLAST SURG, V49, P281, DOI 10.1016/S0007-1226(96)90156-3##RUMSEY N, 2004, AM J BIOETHICS, V4, P22, DOI 10.1080/15265160490496903##RUSH D, 1998, J AM SOC NEPHROL, V9, P2129##SHIRBACHEH MV, 1999, J PHARMACOL EXP THER, V289, P1196##SHIRBACHEH MV, 1999, J PHARMACOL EXP THER, V289, P1191##SHIRBACHEH MV, 1998, TRANSPLANT P, V30, P2739, DOI 10.1016/S0041-1345(98)00800-8##SHIRBACHEH MV, 1999, J PHARMACOL EXP THER, V289, P1185##SHISHIDO S, 2003, J AM SOC NEPHROL, V14, P1046, DOI 10.1097/01.ASN.0000056189.02819.32##SHRIBACHEH M, 1998, 7 IFSSH C 24 27 MAY##SILISKI JM, 1984, ARCH ORTHOP TRAUM SU, V103, P26, DOI 10.1007/BF00451315##STARK GB, 1987, TRANSPLANT P, V19, P3968##STEVENAGE SV, 1999, BRIT J PSYCHOL, V90, P221, DOI 10.1348/000712699161369##STROME M, 2001, NEW ENGL J MED, V344, P1676, DOI 10.1056/NEJM200105313442204##STRONG C, 2004, AM J BIOETHICS, V4, P13, DOI 10.1080/15265160490496985##TOLEDO-PEREYRA LH, 2003, J INVEST SURG, V16, P243, DOI 10.1080/08941930390230883##TRACHTMAN H, 2004, AM J BIOETHICS, V4, PW33, DOI 10.1080/15265160490508963##USTUNER ET, 2000, MICROSURG, V20, P400, DOI 10.1002/1098-2752(2000)20:8<400::AID-MICR10>3.0.CO;2-Z##WAMKE P, 2005, LANCET, V366, P1984##WIGGINS OP, 2004, AM J BIOETHICS, V4, P1, DOI 10.1080/15265160490496507##*WORK GROUP CCNE, 2006, COMP TISS ALL FAC FU##YE EM, 1998, BURNS, V24, P646, DOI 10.1016/S0305-4179(98)00081-3##ZIMMERMANN KW, 1998, 1 LEG GRAVE MIRACLE##2006, DOCTORS CHINESE FACE##1964, MED TRIB MED NEWS, V5, P23##2003, L M MURPHY APOLOGY##1997, 1 INT S COMP TISS AL##2006, CHINAS 1 FACE TRANSP##2006, CHINESE FACE OP MAN##2000, 2 INT S COMP TISS AL",72,2020-11-20,NA,"UNIV LOUISVILLE#UNIV UTRECHT#UNIV LOUISVILLE#UNIV LOUISVILLE#UNIV LOUISVILLE#UNIV LOUISVILLE#MORRISTON HOSP#GOETHE UNIV FRANKFURT","KY USA#NETHERLANDS#KY USA#KY USA#KY USA#KY USA#WALES#GERMANY"
"J","WOS:000242296600005",2006,"THE ARCHITECTURE OF PICEA SITCHENSIS STRUCTURAL ROOT SYSTEMS ON HORIZONTAL AND SLOPING TERRAIN","THE COARSE ROOT SYSTEMS OF 24 SITKA SPRUCE (PICEA SITCHENSIS (BONG.) CARR.) TREES, FROM A 40-YEAR-OLD PLANTATION IN WEST SCOTLAND, WERE EXTRACTED, DIGITISED IN THREE DIMENSIONS, AND ROOT TOPOLOGY WAS RECORDED. ROOTS WERE FROM TREES GROWN ON A STEEP (CA. 30 DEGREES) NORTH-FACING SLOPE, AND FROM AN ADJACENT HORIZONTAL AREA WITH SIMILAR GLEYED MINERAL SOIL. THE PREVAILING WIND WAS ACROSS-SLOPE FROM THE WEST. ANALYSIS OF BELOW-GROUND PARTS OF THE TREES IN COMPARISON WITH THOSE ABOVE-GROUND REVEALED A POSITIVE LINEAR RELATIONSHIP BETWEEN COARSE ROOT VOLUME AND STEM VOLUME. MOST NON-DIRECTIONAL CHARACTERISTICS OF THE ROOT SYSTEMS WERE SIMILAR BETWEEN TREES ON THE SLOPE AND ON FLAT TERRAIN. ALLOCATION OF ROOT MASS AROUND TREES WAS EXAMINED IN RELATION TO THE SLOPE AND THE PREVAILING WIND DIRECTION. TREES ON THE HORIZONTAL AREA HAD MORE ROOT MASS IN LEEWARD SECTORS THAN OTHER SECTORS, BUT TREES ON THE SLOPES HAD MORE ROOT MASS IN THE WINDWARD SECTORS THAN OTHER SECTORS. CENTRES OF MASS OF THE ROOT SYSTEMS FROM THE HORIZONTAL PART OF THE SITE WERE NOT SIGNIFICANTLY CLUSTERED IN ANY DIRECTION, BUT ROOT SYSTEMS OF TREES ON THE SLOPE HAD CENTRES OF MASS SIGNIFICANTLY CLUSTERED ACROSS THE SLOPE IN THE WINDWARD DIRECTION. FOR TREES ON THE SLOPE, THE MEAN DIRECTION OF THE LARGEST SECTOR WITHOUT STRUCTURAL ROOTS WAS 4 DEGREES FROM NORTH, I.E. DOWNSLOPE. THE RESULTS ARE DISCUSSED IN RELATION TO SOIL CHARACTERISTICS AND THE BIOMECHANICAL BEHAVIOUR OF TREES ON SLOPES.","SITKA SPRUCE; LATERAL ROOTS; TREE STABILITY; DOUGLAS-FIR; BIOMASS; WIND; RESPONSES; GROWTH; ORIENTATION; WINDTHROW","ROOT ARCHITECTURE; STRUCTURE; ANCHORAGE; SLOPE; WIND ACTION","TREES-STRUCTURE AND FUNCTION","NICOLL, BC##BERTHIER, S##ACHIM, A##GOUSKOU, K##DANJON, F##VAN BEEK, LPH","FORESTRY COMMISS ROSLIN, NO RES STN, ROSLIN EH25 9SY, MIDLOTHIAN, SCOTLAND. INRA, EPHYSE, F-33611 GAZINET, FRANCE. UNIV UTRECHT, DEPT PHYS GEOG, UTRECHT CTR GEOSCI, UTRECHT, NETHERLANDS.","FORESTRY","FORESTRY","ACHIM A., 2003, P INT C WIND EFF TRE, P231##ARMSTRONG W, 1976, J APPL ECOL, V13, P585, DOI 10.2307/2401805##COUTTS MP, 1989, ANN SCI FOREST, V46, PS277, DOI 10.1051/FOREST:19890565##COUTTS MP, 1986, FORESTRY, V59, P173, DOI 10.1093/FORESTRY/59.2.173##COUTTS MP, 1991, NEW PHYTOL, V119, P227, DOI 10.1111/J.1469-8137.1991.TB01025.X##COUTTS MP, 1983, FORESTRY, V56, P1, DOI 10.1093/FORESTRY/56.1.1##COUTTS MP, 1993, NEW PHYTOL, V124, P277, DOI 10.1111/J.1469-8137.1993.TB03817.X##COUTTS MP, 1990, FORESTRY, V63, P143, DOI 10.1093/FORESTRY/63.2.143##COUTTS MP, 1999, PLANT SOIL, V217, P1, DOI 10.1023/A:1004578032481##DANJON F, 2005, NEW PHYTOL, V168, P387, DOI 10.1111/J.1469-8137.2005.01497.X##DANJON F, 1999, PLANT SOIL, V211, P241, DOI 10.1023/A:1004680824612##DEANS JD, 1983, PLANT SOIL, V71, P189, DOI 10.1007/BF02182654##DI IORIO A, 2005, ANN BOT-LONDON, V95, P351, DOI 10.1093/AOB/MCI033##DREXHAGE M, 2001, FORESTRY, V74, P491, DOI 10.1093/FORESTRY/74.5.491##DREXHAGE M, 1998, CAN J FOREST RES, V28, P13, DOI 10.1139/CJFR-28-1-13##EKANAYAKE JAGATH C., 1997, NEW ZEALAND JOURNAL OF FORESTRY SCIENCE, V27, P216##FAYLE D.C.F., 1968, RADIAL GROWTH TREE R##FAYLE DCF, 1980, ENV ROOT BEHAV GEOBI, P93##FRASER AI, 1967, FORESTRY COMMISSION, V40##GARDINER B. A., 1995, P41, DOI 10.1017/CBO9780511600425.003##GODIN C, 2000, ANN FOREST SCI, V57, P413##GRUBER F, 1999, ALLG FORST JAGDZTG, V170, P213##HENDERSON R, 1983, FORESTRY, V56, P121, DOI 10.1093/FORESTRY/56.2.121##HINTIKKA V, 1972, METSANTUTKIMUSLAITOK, V76, P1##HOFFMANN CW, 2001, FOREST ECOL MANAG, V149, P103, DOI 10.1016/S0378-1127(00)00548-X##KENNEDY F, 2002, IDENTIFICATION SOILS##KRAMER MG, 2004, ECOLOGY, V85, P2230, DOI 10.1890/02-4098##LAING EV, 1932, FORESTRY COMMISSION, V13##LEVY PE, 2004, FORESTRY, V77, P421, DOI 10.1093/FORESTRY/77.5.421##MARDIA KV, 2000, STAT DIRECTIONAL DAT##MARLER TE, 1997, PLANT SOIL, V195, P37, DOI 10.1023/A:1004231009366##MAYER H, 1987, TREES-STRUCT FUNCT, V1, P195, DOI 10.1007/BF01816816##MCMICHAEL BL, 1993, ENVIRON EXP BOT, V33, P53, DOI 10.1016/0098-8472(93)90055-K##MCMINN R. G., 1963, CANADIAN JOUR BOT, V41, P105, DOI 10.1139/B63-010##MOFFAT AJ, 1998, 14198ERB ARB ADV INF##MOU P, 1997, J APPL ECOL, V34, P645, DOI 10.2307/2404913##NICOLL B. C., 1995, P276, DOI 10.1017/CBO9780511600425.017##NICOLL BC, 2005, CAN J FOREST RES, V35, P2360, DOI 10.1139/X05-157##NICOLL BC, 1996, TREE PHYSIOL, V16, P891##PARR A, 2004, FOREST ECOL MANAG, V195, P97, DOI 10.1016/J.FORECO.2004.02.033##QUINE C P, 1991, SCOTTISH FORESTRY, V45, P175##QUINE CP, 1991, FORESTRY, V64, P385, DOI 10.1093/FORESTRY/64.4.385##RUFELT H, 1965, ENCY PLANT PHYSL, P322##SAINJU UM, 1993, PLANT SOIL, V150, P87, DOI 10.1007/BF00779179##SAKALS ME, 2004, CAN J FOREST RES, V34, P950, DOI [10.1139/X03-268, 10.1139/X03-268]##SAVILL PS, 1976, FORESTRY, V49, P133, DOI 10.1093/FORESTRY/49.2.133##SINOQUET H, 1997, TREES-STRUCT FUNCT, V11, P265, DOI 10.1007/S004680050084##SINOQUET HERVE, 1997, SILVA FENNICA, V31, P265##STOKES A, 1995, J EXP BOT, V46, P1139, DOI 10.1093/JXB/46.9.1139##STOKES A, 1997, CAN J FOREST RES, V27, P1049, DOI 10.1139/CJFR-27-7-1049##STOKES A, 1996, J EXP BOT, V47, P693, DOI 10.1093/JXB/47.5.693##STOKES A., 1995, P264, DOI 10.1017/CBO9780511600425.016##SUNDSTROM E, 1999, PLANT SOIL, V217, P65, DOI 10.1023/A:1004693031375##TAMASI E, 2005, TREES-STRUCT FUNCT, V19, P374, DOI 10.1007/S00468-004-0396-X##THIES WG, 1996, CAN J FOREST RES, V26, P237, DOI 10.1139/X26-027##WAGG JWB, 1967, DEP PUBLICATION NUMB, V1192##WATSON A, 1995, VEGETATION AND SLOPES, P161##WATSON ALEX, 1997, NEW ZEALAND JOURNAL OF FORESTRY SCIENCE, V27, P205##WU TH, 1988, FOREST SCI, V34, P980##YEATMAN CW, 1955, FORESTRY COMMISSION, V21##ZHOU Y, 1997, PLANT SOIL, V190, P77, DOI 10.1023/A:1004263205165##2000, 3SPACE FASTRAK USERS",36,2020-11-20,NA,"FORESTRY COMMISS ROSLIN#INRA#UNIV UTRECHT","SCOTLAND#FRANCE#NETHERLANDS"
"J","WOS:000240922000526",2006,"COSTS ASSOCIATED WITH DRUG USE IN THE NONADHERENCE TO CHOLESTEROL MANAGEMENT GUIDELINES FOR PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE IN AN ELDERLY POPULATION: THE ROTTERDAM STUDY",NA,NA,NA,"VALUE IN HEALTH","GUMBS, PD##VERSCHUREN, WMM##MANTEL-TEEUWISSE, AK##DE WIT, GA##HOFMAN, A##TRIENEKENS, PH##STRICKER, BHC##DE, BA##KLUNGEL, OH","UNIV UTRECHT, UTRECHT, NETHERLANDS. NATL INST PUBL HLTH & ENVIRONM, NL-3720 BA BILTHOVEN, NETHERLANDS. ERASMUS UNIV, ROTTERDAM, NETHERLANDS. STICHTING TROMBOSEDIENST ARTSENLAB RIJNMOND, ROTTERDAM, NETHERLANDS.","ECONOMICS; HEALTH CARE SCIENCES & SERVICES; HEALTH POLICY & SERVICES","BUSINESS & ECONOMICS; HEALTH CARE SCIENCES & SERVICES",NA,0,2020-11-20,NA,"UNIV UTRECHT#NATL INST PUBL HLTH ENVIRONM#ERASMUS UNIV#STICHTING TROMBOSEDIENST ARTSENLAB RIJNMOND","NETHERLANDS#NETHERLANDS#NETHERLANDS#NETHERLANDS"
"J","WOS:000240922000060",2006,"CRITICAL APPRAISAL OF ECONOMIC EVALUATIONS OF CHOLESTEROL LOWERING DRUGS: A SYSTEMATIC REVIEW",NA,NA,NA,"VALUE IN HEALTH","GUMBS, PD##VERSCHUREN, WMM##MANTEL-TEEUWISSE, AK##DE WIT, GA##DE BOER, A##KLUNGEL, OH","UNIV UTRECHT, UTRECHT, NETHERLANDS. NATL INST PUBL HLTH & ENVIRONM, NL-3720 BA BILTHOVEN, NETHERLANDS.","ECONOMICS; HEALTH CARE SCIENCES & SERVICES; HEALTH POLICY & SERVICES","BUSINESS & ECONOMICS; HEALTH CARE SCIENCES & SERVICES",NA,0,2020-11-20,NA,"UNIV UTRECHT#NATL INST PUBL HLTH ENVIRONM","NETHERLANDS#NETHERLANDS"
"J","WOS:000240922000614",2006,"THE ESTIMATION OF COST-EFFECTIVENESS THRESHOLDS PRIOR TO THE START OF LARGE CLINICAL STUDIES",NA,NA,NA,"VALUE IN HEALTH","VAN STAA, TP##COOPER, C##LEUFKENS, HG","GEN PRACTICE RES DATABASE, LONDON, ENGLAND. UNIV SOUTHAMPTON, SOUTHAMPTON, HANTS, ENGLAND. UNIV UTRECHT, UTRECHT, NETHERLANDS.","ECONOMICS; HEALTH CARE SCIENCES & SERVICES; HEALTH POLICY & SERVICES","BUSINESS & ECONOMICS; HEALTH CARE SCIENCES & SERVICES",NA,0,2020-11-20,NA,"GEN PRACTICE RES DATABASE#UNIV SOUTHAMPTON#UNIV UTRECHT","ENGLAND#ENGLAND#NETHERLANDS"
"J","WOS:000242844400006",2006,"MURINE MODELS OF MYOCARDIAL AND LIMB ISCHEMIA: DIAGNOSTIC END-POINTS AND RELEVANCE TO CLINICAL PROBLEMS","ISCHEMIC DISEASE REPRESENTS THE NEW EPIDEMIC WORLDWIDE. ANIMAL MODELS OF ISCHEMIC DISEASE ARE USEFUL BECAUSE THEY CAN HELP US TO UNDERSTAND THE UNDERLYING PATHOGENETIC MECHANISMS AND DEVELOP NEW THERAPIES. THE PRESENT REVIEW ARTICLE SUMMARIZES THE RESULTS OF A CONSENSUS CONFERENCE ON THE STATUS AND FUTURE DEVELOPMENT OF EXPERIMENTATION IN THE FIELD OF CARDIOVASCULAR MEDICINE USING MURINE MODELS OF PERIPHERAL AND MYOCARDIAL ISCHEMIA. THE STARTING POINT WAS TO RECOGNIZE THE LIMITS OF THE APPROACH, WHICH MAINLY DERIVE FROM SPECIES- AND DISEASE-RELATED DIFFERENCES IN CARDIOVASCULAR PHYSIOLOGY. FOR INSTANCE, THE MOUSE HEART BEATS AT A RATE 10 TIMES FASTER THAN THE HUMAN HEART. FURTHERMORE, HEALING PROCESSES ARE MORE RAPID IN ANIMALS, AS THEY RELY ON MECHANISMS THAT MAY HAVE LOST RELEVANCE IN MAN. THE MAIN OBJECTIVE OF THE AUTHORS WAS TO PROPOSE GENERAL GUIDELINES, DIAGNOSTIC END POINTS AND RELEVANCE TO CLINICAL PROBLEMS. (C) 2006 ELSEVIER INC. ALL RIGHTS RESERVED.","ENDOTHELIAL GROWTH-FACTOR; COLLATERAL VESSEL DEVELOPMENT; APOLIPOPROTEIN-E-DEFICIENT; VEIN BYPASS GRAFTS; GENE-TRANSFER; MOUSE MODEL; INFARCT SIZE; HISTOLOGICAL CLASSIFICATION; ATHEROSCLEROTIC LESIONS; NEOINTIMA HYPERPLASIA","ISCHEMIA; MOUSE MODELS; MYOCARDIAL INFARCTION; WOUND HEALING; BLOOD FLOW","VASCULAR PHARMACOLOGY","MADEDDU, P##EMANUELI, C##SPILLMANN, F##MELONI, M##BOUBY, N##RICHER, C##ALHENC-GELAS, F##VAN WEEL, V##EEFTING, D##QUAX, PHA##HU, Y##XU, Q##HEMDAHL, AL##VAN GOLDE, J##HUIJBERTS, M##DE LUSSANET, Q##BOUDIER, HS##COUFFINHAL, T##DUPLAA, C##CHIMENTI, S##STASZEWSKY, L##LATINI, R##BAUMANS, V##LEVY, BI","UNIV BRISTOL, BRISTOL ROYAL INFIRM, BRISTOL HEART INST, BRISTOL BS2 8HW, AVON, ENGLAND. INSERM, U652367, PARIS, FRANCE. LEIDEN UNIV, MED CTR, DEPT SURG, LEIDEN, NETHERLANDS. TNO, PG, LEIDEN, NETHERLANDS. UNIV LONDON ST GEORGES HOSP, DEPT CARDIAC & VASC SCI, LONDON, ENGLAND. KAROLINSKA INST, S-10401 STOCKHOLM, SWEDEN. MASTRICHT UNIV HOSP, DEPT INTERNAL MED, MAASTRICHT, NETHERLANDS. MASTRICHT UNIV HOSP, DEPT RADIOL, MAASTRICHT, NETHERLANDS. CARDIOVASC RES INST MAASTRICHT, MAASTRICHT, NETHERLANDS. UNIV BORDEAUX, BORDEAUX, FRANCE. INSERM, U441, PESSAC, FRANCE. MARIO NEGRI INST PHARMACOL RES, DEPT CARDIOVASC RES, I-20157 MILAN, ITALY. UNIV UTRECHT, DEPT LAB ANIM SCI, NL-3508 TC UTRECHT, NETHERLANDS. INSERM, U689, PARIS, FRANCE.","PHARMACOLOGY & PHARMACY","PHARMACOLOGY & PHARMACY","ANVERSA P, 1986, CIRC RES, V58, P26, DOI 10.1161/01.RES.58.1.26##ANVERSA P, 1985, AM J PATHOL, V118, P484##ARRAS M, 1998, J CLIN INVEST, V101, P40, DOI 10.1172/JCI119877##AZIZI M, 2005, J CLIN INVEST, V115, P780, DOI 10.1172/JCI200523669##BAUMANS V, 2004, GENE THER, V11, PS64, DOI 10.1038/SJ.GT.3302371##BERGAYA S, 2001, CIRC RES, V88, P593, DOI 10.1161/01.RES.88.6.593##BREITENEDER-GELEFF S, 1999, AM J PATHOL, V154, P385, DOI 10.1016/S0002-9440(10)65285-6##BRULL D, 2001, LANCET, V358, P1155, DOI 10.1016/S0140-6736(01)06273-0##CALARA F, 2001, J PATHOL, V195, P257, DOI 10.1002/PATH.915##CALIGIURI G, 1999, P NATL ACAD SCI USA, V96, P6920, DOI 10.1073/PNAS.96.12.6920##CALIGIURI G, 2003, MOL MED, V9, P10, DOI 10.1007/BF03402102##CARMELIET P, 2000, NAT MED, V6, P389, DOI 10.1038/74651##CHERWEK DH, 2003, AM J PHYSIOL-HEART C, V279, PH932##CHEVAL L, 2000, PRACT APPROACH SER, P139##COHEN M, 1986, CIRCULATION, V74, P469, DOI 10.1161/01.CIR.74.3.469##COUFFINHAL T, 1998, AM J PATHOL, V152, P1667##COUFFINHAL T, 1999, CIRCULATION, V99, P3188, DOI 10.1161/01.CIR.99.24.3188##*COUNC EUR, 1985, 123 ETS COUNC EUR##CRAWLEY JN, 1998, WHATS WRONG MY MOUSE##DEINDL E, 2001, CIRC RES, V89, P779, DOI 10.1161/HH2101.098613##DUVALL CL, 2004, AM J PHYSIOL-HEART C, V287, PH302, DOI 10.1152/AJPHEART.00928.2003##EMANUELI C, 2004, DIABETES, V53, P1096, DOI 10.2337/DIABETES.53.4.1096##EMANUELI C, 2004, CIRCULATION, V110, P1638, DOI 10.1161/01.CIR.0000142051.36244.83##EMANUELI C, 2002, CIRCULATION, V106, P993, DOI 10.1161/01.CIR.0000027104.33206.C8##EMANUELI C, 2001, CIRCULATION, V103, P125##EMANUELI C, 1999, CIRCULATION, V100, P2359, DOI 10.1161/01.CIR.100.23.2359##ENTMAN ML, 2000, AM J PHYSIOL-HEART C, V278, PH1017##ENTMAN ML, 1991, FASEB J, V5, P2529##*EUR COUNC DIR, 1986, 86609EEC EUR COUNC D##EZAN J, 2004, CARDIOVASC RES, V63, P731, DOI 10.1016/J.CARDIORES.2004.05.006##FARREHI PM, 1998, CIRCULATION, V97, P1002##FIORDALISO F, 2000, LAB INVEST, V80, P513, DOI 10.1038/LABINVEST.3780057##FRANGOGIANNIS NG, 2002, CARDIOVASC RES, V53, P31, DOI 10.1016/S0008-6363(01)00434-5##GOROG DA, 2003, J MOL CELL CARDIOL, V35, P705, DOI 10.1016/S0022-2828(03)00082-8##GRAIANI G, 2005, HYPERTENSION, V46, P433, DOI 10.1161/01.HYP.0000174986.73346.BA##GRAIANI G, 2004, DIABETOLOGIA, V47, P1047, DOI 10.1007/S00125-004-1414-7##HANSEN PR, 1995, CIRCULATION, V91, P1872, DOI 10.1161/01.CIR.91.6.1872##HEIL M, 2004, CIRC RES, V95, P449, DOI 10.1161/01.RES.0000141145.78900.44##HEIL M, 2004, CIRC RES, V94, P671, DOI 10.1161/01.RES.0000122041.73808.B5##HEMDAHL AL, 2004, AM J PHYSIOL-HEART C, V287, PH872, DOI 10.1152/AJPHEART.01083.2003##HERSHEY JC, 2001, CARDIOVASC RES, V49, P618, DOI 10.1016/S0008-6363(00)00232-7##HIMORI N, 1989, AM J PHYSIOL, V256, PH1719##HO HKV, 2004, CIRCULATION, V109, P1314, DOI 10.1161/01.CIR.0000118465.36018.2D##HOEFER IE, 2004, CIRC RES, V94, P1179, DOI 10.1161/01.RES.0000126922.18222.F0##HU YH, 2004, J CLIN INVEST, V113, P1258, DOI 10.1172/JCI200419628##HU YH, 2002, CIRC RES, V91, PE13, DOI 10.1161/01.RES.0000037090.34760.EE##HU YH, 1999, CIRCULATION, V100, P861, DOI 10.1161/01.CIR.100.8.861##HUANG W, 2001, P NATL ACAD SCI USA, V98, P13330, DOI 10.1073/PNAS.231476798##ISHIBASHI S, 1994, P NATL ACAD SCI USA, V91, P4431, DOI 10.1073/PNAS.91.10.4431##IWAGURO H, 2002, CIRCULATION, V105, P732, DOI 10.1161/HC0602.103673##JACOBI J, 2004, CIRCULATION, V110, P2424, DOI 10.1161/01.CIR.0000145142.85645.EA##JORDAN BF, 2004, MAGNET RESON MED, V52, P391, DOI 10.1002/MRM.20155##KAJSTURA J, 2001, DIABETES, V50, P1414, DOI 10.2337/DIABETES.50.6.1414##KAJSTURA J, 2005, CIRC RES, V96, P127, DOI 10.1161/01.RES.0000151843.79801.60##KURZ KD, 1990, THROMB RES, V60, P269, DOI 10.1016/0049-3848(90)90106-M##LAMFERS MLM, 2001, GENE THER, V8, P534, DOI 10.1038/SJ.GT.3301437##LARDENOYE JHP, 2002, CIRC RES, V91, P577, DOI 10.1161/01.RES.0000036901.58329.D7##LEITGES M, 2001, J CLIN INVEST, V108, P1505##LIBBY P, 2002, NATURE, V420, P868, DOI 10.1038/NATURE01323##LINDBERG T, 2000, ACTA PAEDIATR, V89, P1, DOI 10.1080/080352500750028933##MADEDDU P, 2004, FASEB J, V18, P1737, DOI 10.1096/FJ.04-2192FJE##MAESTRI R, 2003, HYPERTENSION, V41, P1151, DOI 10.1161/01.HYP.0000064180.55222.DF##MASAKI I, 2002, CIRC RES, V90, P966, DOI 10.1161/01.RES.0000019540.41697.60##MAYR U, 2002, CIRC RES, V90, P197, DOI 10.1161/HH0202.103715##MEDVEDEV OS, 1993, AM HEART J, V126, P764, DOI 10.1016/0002-8703(93)90927-2##MENETON P, 2001, P NATL ACAD SCI USA, V98, P2634, DOI 10.1073/PNAS.051619598##MERTENS C, 2000, ALTEX-ALTERN TIEREXP, V17, P15##MOTWANI JG, 1998, CIRCULATION, V97, P916, DOI 10.1161/01.CIR.97.9.916##NOSSULI TO, 2000, AM J PHYSIOL-HEART C, V278, PH1049##PFEFFER JM, 1991, AM J PHYSIOL, V260, PH1406, DOI 10.1152/AJPHEART.1991.260.5.H1406##PFEFFER MA, 1979, CIRC RES, V44, P503, DOI 10.1161/01.RES.44.4.503##QUAX PHA, 2001, CIRCULATION, V103, P562, DOI 10.1161/01.CIR.103.4.562##REDDICK RL, 1998, ATHEROSCLEROSIS, V140, P297, DOI 10.1016/S0021-9150(98)00133-6##RIVARD A, 1999, AM J PATHOL, V154, P355, DOI 10.1016/S0002-9440(10)65282-0##RONA G, 1959, ARCH PATHOL, V67, P443##ROSENFELD MICHAEL E, 2002, CURR ATHEROSCLER REP, V4, P238, DOI 10.1007/S11883-002-0025-3##ROTH DM, 2002, AM J PHYSIOL-HEART C, V282, PH2134, DOI 10.1152/AJPHEART.00845.2001##RUSSINOFF D. M., 1992, JOURNAL OF AUTOMATED REASONING, V8, P3##SCHATTEMAN GC, 2000, J CLIN INVEST, V106, P571, DOI 10.1172/JCI9087##SCHOLZ D, 2002, J MOL CELL CARDIOL, V34, P775, DOI 10.1006/JMCC.2002.2013##SELYE H., 1960, ANGIOLOGY, V11, P398, DOI 10.1177/000331976001100505##SILVESTRE JS, 2002, CIRC RES, V90, P1072, DOI 10.1161/01.RES.0000019892.41157.24##SILVESTRE JS, 2000, CIRC RES, V87, P448##SMANUELI C, 2003, DIABETOLOGIA, V46, P67##SMANUELI C, 2002, CIRCULATION, V106, P2257##SMITHIES O, 2000, KIDNEY INT, V58, P2265, DOI 10.1046/J.1523-1755.2000.00411.X##SPILLMAN F, 2006, LOCAL GENE TRANSFER##STARY HC, 2000, ARTERIOSCL THROM VAS, V20, P1177, DOI 10.1161/01.ATV.20.5.1177##STARY HC, 1995, ARTERIOSCL THROM VAS, V15, P1512, DOI 10.1161/01.ATV.15.9.1512##STEPANOVIC V, 2003, CIRC RES, V92, P1247, DOI 10.1161/01.RES.0000074906.98021.55##TORSNEY E, 2004, CIRC RES, V94, P1466, DOI 10.1161/01.RES.0000129570.06647.00##TRABOLD F, 2002, HYPERTENSION, V40, P90, DOI 10.1161/01.HYP.0000021747.43346.95##VAN DER MEER M, 2001, LAB ANIM-UK, V35, P379, DOI 10.1258/0023677011911859##VAN WEEL V, 2004, CIRC RES, V95, P58, DOI 10.1161/01.RES.0000133247.69803.C3##VANHERCK H, 1994, AUTOIMMUNE DIS MODEL, P303##VIRMANI R, 2000, ARTERIOSCL THROM VAS, V20, P1262, DOI 10.1161/01.ATV.20.5.1262##VON DER THUSEN JH, 2002, CIRCULATION, V105, P2064, DOI 10.1161/01.CIR.0000015502.97828.93##WILLIAMS H, 2002, ARTERIOSCL THROM VAS, V22, P788, DOI 10.1161/01.ATV.0000014587.66321.B4##WRIGHT MJ, 2001, GENE THER, V8, P1833, DOI 10.1038/SJ.GT.3301614##XU QB, 2004, AM J PATHOL, V165, P1, DOI 10.1016/S0002-9440(10)63270-1##XU QB, 2003, CIRC RES, V93, PE76, DOI 10.1161/01.RES.0000097864.24725.60##YANG XP, 1999, AM J PHYSIOL-HEART C, V277, PH1967##YIN H, 2005, J BIOL CHEM, V280, P8022, DOI 10.1074/JBC.M407179200##YLA-HERTTUALA S, 2004, TRENDS CARDIOVAS MED, V14, P295, DOI 10.1016/J.TCM.2004.09.001##YOUNG JL, 2002, MICROCIRCULATION, V9, P35, DOI 10.1038/SJ.MN.7800120##ZHONG JP, 2003, J CLIN INVEST, V112, P30, DOI 10.1172/JCI200317034##ZOU YP, 2000, CIRC RES, V86, P434, DOI 10.1161/01.RES.86.4.434##ZOU YP, 1998, AM J PATHOL, V153, P1301, DOI 10.1016/S0002-9440(10)65675-1##ZURAW B, 2001, LANCET, V358, P1116, DOI 10.1016/S0140-6736(01)06300-0",42,2020-11-20,NA,"UNIV BRISTOL#INSERM#LEIDEN UNIV#TNO#UNIV LONDON ST GEORGES HOSP#KAROLINSKA INST#MASTRICHT UNIV HOSP#MASTRICHT UNIV HOSP#CARDIOVASC RES INST MAASTRICHT#UNIV BORDEAUX#INSERM#MARIO NEGRI INST PHARMACOL RES#UNIV UTRECHT#INSERM","ENGLAND#FRANCE#NETHERLANDS#NETHERLANDS#ENGLAND#SWEDEN#NETHERLANDS#NETHERLANDS#NETHERLANDS#FRANCE#FRANCE#ITALY#NETHERLANDS#FRANCE"
"J","WOS:000241776700008",2006,"INVESTIGATION OF THE INTERACTION BETWEEN BUPRENORPHINE AND SUFENTANIL DURING ANAESTHESIA FOR OVARIECTOMY IN DOGS","OBJECTIVE: TO INVESTIGATE THE EFFECT OF BUPRENORPHINE PRE-TREATMENT ON SUFENTANIL REQUIREMENTS IN FEMALE DOGS UNDERGOING OVARIECTOMY. STUDY DESIGN: RANDOMIZED, 'BLINDED', PROSPECTIVE CLINICAL STUDY. ANIMALS: THIRTY HEALTHY FEMALE DOGS REFERRED FOR OVARIECTOMY. MATERIALS AND METHODS: DOGS WERE RANDOMLY ASSIGNED TO ONE OF TWO PRE-ANAESTHETIC TREATMENT GROUPS. THOSE IN THE BUPRENORPHINE GROUP (B) RECEIVED BUPRENORPHINE 20 MU G KG(-1) AND ACEPROMAZINE 0.03 MG KG(-1) IM. CONTROL GROUP (C) ANIMALS RECEIVED AN EQUAL VOLUME OF NACL 0.9% AND ACEPROMAZINE 0.03 MG KG(-1) IM. THE ANAESTHETIC TECHNIQUE WAS IDENTICAL IN BOTH GROUPS. PRE-ANAESTHETIC MEDICATION CONSISTED OF INTRAVENOUS (IV) SUFENTANIL (1.0 MU G KG(-1)) AND MIDAZOLAM (0.05 MG KG(-1)) AND INTRAMUSCULAR ATROPINE (0.03 MG KG(-1)). ANAESTHESIA WAS INDUCED WITH PROPOFOL AND MAINTAINED WITH A CONSTANT RATE INFUSION OF SUFENTANIL (1.0 MU G KG(-1) HOUR(-1)) AND WITH OXYGEN-ISOFLURANE. VENTILATION WAS CONTROLLED MECHANICALLY. OVARIECTOMY WAS PERFORMED USING A STANDARD TECHNIQUE. BASELINE HEART RATE (HR) AND DIRECT MEAN ARTERIAL BLOOD PRESSURE (MAP) WERE RECORDED BEFORE THE FIRST INCISION. INCREASES IN HR AND MAP OF >= 20% OVER BASELINE AND, OR SPONTANEOUS VENTILATION WERE CONTROLLED USING IV SUFENTANIL (1.0 MU G KG(-1)) REPEATED AFTER 5 MINUTES IF HAEMODYNAMIC VARIABLES REMAINED ELEVATED OR ATTEMPTS AT SPONTANEOUS VENTILATION PERSISTED. ANALYSIS OF VARIANCE WAS USED TO DETERMINE GROUP DIFFERENCES IN MEAN AND MEDIAN HR AND MAP AND TO COMPARE THE MAXIMUM HR AND MAP ATTAINED DURING SURGERY. POISSON REGRESSION WAS USED TO COMPARE THE NUMBER OF SUFENTANIL INJECTIONS REQUIRED IN BOTH GROUPS. RESULTS: GROUP B REQUIRED 2.46 TIMES MORE SUFENTANIL INJECTIONS (P = 0.00487) THAN DOGS IN GROUP C TO MAINTAIN HAEMODYNAMIC STABILITY AND PREVENT SPONTANEOUS VENTILATION DURING SURGERY. GROUP B DOGS ALSO HAD A SIGNIFICANTLY HIGHER (P = 0.034) MARGINAL MEAN OF THE LOG MAXIMUM MAP (4.756 +/- 0.036) COMPARED WITH GROUP C (4.642 +/- 0.036). CONCLUSIONS: PRE-TREATMENT WITH BUPRENORPHINE APPEARS TO NEGATIVELY INFLUENCE THE ANTINOCICEPTIVE EFFICACY OF INTRA-OPERATIVE SUFENTANIL. CLINICAL RELEVANCE: WITHHOLDING BUPRENORPHINE THERAPY 6-8 HOURS BEFORE ANAESTHESIA INCORPORATING PURE MU RECEPTOR AGONISTS IS PROBABLY ADVISABLE. ALTERNATIVE METHODS OF ANALGESIA SHOULD BE PROVIDED IN THIS PERIOD.","OPIOID RECEPTOR ANTAGONIST; MIXED AGONIST-ANTAGONIST; POSTOPERATIVE ANALGESIA; RESPIRATORY DEPRESSION; MU-OPIOIDS; MORPHINE; FENTANYL; ANTINOCICEPTION; BRADYCARDIA; RESPONSES","ANAESTHESIA; ANTINOCICEPTION; BUPRENORPHINE; DOGS; OPIOID; SUFENTANIL","VETERINARY ANAESTHESIA AND ANALGESIA","JARAMILLO, LAG##MURRELL, JC##HELLEBREKERS, LJ","UNIV UTRECHT, FAC VET MED, DEPT EQUINE SCI, NL-3508 GA UTRECHT, NETHERLANDS. UNIV UTRECHT, FAC VET MED, DEPT CLIN SCI & COMPAN ANIM, NL-3508 GA UTRECHT, NETHERLANDS.","VETERINARY SCIENCES","VETERINARY SCIENCES","BOAS RA, 1985, BRIT J ANAESTH, V57, P192, DOI 10.1093/BJA/57.2.192##BRODBELT DC, 1997, J VET PHARMACOL THER, V20, P284, DOI 10.1046/J.1365-2885.1997.00060.X##CARDINAL V, 2004, CAN J ANAESTH, V51, P806, DOI 10.1007/BF03018453##COWAN A, 1977, BRIT J PHARMACOL, V60, P547, DOI 10.1111/J.1476-5381.1977.TB07533.X##COWAN A, 1977, BRIT J PHARMACOL, V60, P537, DOI 10.1111/J.1476-5381.1977.TB07532.X##COWAN A, 2003, INT J CLIN PRACT, P3##DOBBINS S, 2002, J AM ANIM HOSP ASSOC, V38, P507, DOI 10.5326/0380507##DOMINO KB, 1999, ANESTHESIOLOGY, V90, P1053, DOI 10.1097/00000542-199904000-00019##DUM JE, 1981, BRIT J PHARMACOL, V74, P627, DOI 10.1111/J.1476-5381.1981.TB10473.X##EVANS J. M., 1984, CLIN ANAESTHESIOL, V2, P243##FLECKNELL PA, 1989, LAB ANIM, V23, P147, DOI 10.1258/002367789780863655##FREYE E, 2000, ANESTH ANALG, V90, P1359, DOI 10.1097/00000539-200006000-00018##GARRETT ER, 1990, BIOPHARM DRUG DISPOS, V11, P311, DOI 10.1002/BDD.2510110403##GREEN DW, 1985, ANAESTHESIA, V40, P371##HUG CC, 1990, ANESTHESIOLOGY, V73, P1, DOI 10.1097/00000542-199007000-00001##JOUBERT KE, 2001, J S AFR VET ASSOC, V72, P57##KAZAMA T, 1998, ANESTHESIOLOGY, V89, P894, DOI 10.1097/00000542-199810000-00014##LASCELLES BDX, 2003, VET ANAESTH ANALG, V30, P108, DOI 10.1046/J.1467-2995.2003.00133_19.X##LASCELLES BDX, 2000, ANIMAL PAIN PRACTICE, P85##LATASCH L, 2002, ARZNEIMITTEL-FORSCH, V52, P870##LEANDER JD, 1987, NEUROPHARMACOLOGY, V26, P1445, DOI 10.1016/0028-3908(87)90112-2##LEANDER JD, 1988, EUR J PHARMACOL, V151, P457, DOI 10.1016/0014-2999(88)90543-2##LIZASOAIN I, 1991, GEN PHARMACOL, V22, P297, DOI 10.1016/0306-3623(91)90452-C##MARTIN WR, 1976, J PHARMACOL EXP THER, V197, P517##MOENIRALAM HS, 1998, AM J PHYSIOL, V275, P440##MORGAN D, 1999, ANESTH ANALG, V88, P407, DOI 10.1097/00000539-199902000-00035##NOLAN A, 1987, BRIT J PHARMACOL, V92, P527, DOI 10.1111/J.1476-5381.1987.TB11353.X##OTTO KA, 2003, RES VET SCI, V75, P103, DOI 10.1016/S0034-5288(03)00077-8##OTTO KA, 2001, VET REC, V149, P80, DOI 10.1136/VR.149.3.80##PASCOE P, 2000, VET CLIN N AM-SMALL, P85##PICK CG, 1997, BRAIN RES, V744, P41, DOI 10.1016/S0006-8993(96)01069-4##PRAKANRATTANA U, 2002, J MED ASS THAI, V85, P807##ROUGHAN JV, 2004, BEHAV PHARMACOL, V15, P461, DOI 10.1097/00008877-200411000-00002##ROUGHAN JV, 2002, LAB ANIM-UK, V36, P322, DOI 10.1258/002367702320162423##ROVATI LC, 1987, MED SCI RES-BIOCHEM, V15, P659##SADEE W, 1982, J PHARMACOL EXP THER, V223, P157##STEPHENSON RP, 1956, BRIT J PHARM CHEMOTH, V11, P379, DOI 10.1111/J.1476-5381.1956.TB00006.X##STEWART LSA, 2003, CONTEMP TOP LAB ANIM, V42, P28##TAYLOR PM, 2001, J VET PHARMACOL THER, V24, P391, DOI 10.1046/J.1365-2885.2001.368GOBLIN.X##TAYLOR PM, 2003, VET ANAESTH ANALG, V30, P51##TYERS MB, 1980, BRIT J PHARMACOL, V69, P503, DOI 10.1111/J.1476-5381.1980.TB07041.X##WALKER EA, 1995, J PHARMACOL EXP THER, V273, P1345##WHITE PF, 1989, ANESTH ANALG, V68, P177, DOI 10.1213/00000539-198902000-00020##YEOMANS DC, 1996, PAIN, V68, P141, DOI 10.1016/S0304-3959(96)03177-6##YEOMANS DC, 1994, PAIN, V59, P85, DOI 10.1016/0304-3959(94)90051-5##ZBINDEN AM, 1994, ANESTHESIOLOGY, V80, P261, DOI 10.1097/00000542-199402000-00005",10,2020-11-20,NA,"UNIV UTRECHT#UNIV UTRECHT","NETHERLANDS#NETHERLANDS"
"J","WOS:000241942200019",2006,"EFFECTS OF GROWTH HORMONE SECRETAGOGUES ON THE RELEASE OF ADENOHYPOPHYSEAL HORMONES IN YOUNG AND OLD HEALTHY DOGS","THE EFFECTS OF THREE GROWTH HORMONE SECRETAGOGUES (GHSS), GHRELIN, GROWTH HORMONE-RELEASING PEPTIDE-6 (GHRP-6), AND GROWTH HORMONE-RELEASING HORMONE (GHRH), ON THE RELEASE OF ADENOHYPOPHYSEAL HORMONES, GROWTH HORMONE (GH), ADRENOCORTICOTROPIC HORMONE (ACTH), THYROID-STIMULATING HORMONE (TSH), LUTEINISING HORMONE (LH), PROLACTIN (PRL) AND ON CORTISOL WERE INVESTIGATED IN YOUNG AND OLD HEALTHY BEAGLE DOGS. GHRELIN PROVED TO BE THE MOST POTENT GHS IN YOUNG DOGS, WHEREAS IN OLD DOGS GHRH ADMINISTRATION WAS ASSOCIATED WITH THE HIGHEST PLASMA GH CONCENTRATIONS. THE MEAN PLASMA GH RESPONSE AFTER ADMINISTRATION OF GHRELIN WAS SIGNIFICANTLY LOWER IN THE OLD DOGS COMPARED WITH THE YOUNG DOGS. THE MEAN PLASMA GH CONCENTRATION AFTER GHRH AND GHRP-6 ADMINISTRATION WAS LOWER IN THE OLD DOGS COMPARED WITH THE YOUNG DOGS, BUT THIS DIFFERENCE DID NOT REACH STATISTICAL SIGNIFICANCE. IN BOTH AGE GROUPS, THE GHSS WERE SPECIFIC FOR GH RELEASE AS THEY DID NOT CAUSE SIGNIFICANT ELEVATIONS IN THE PLASMA CONCENTRATIONS OF ACTH, CORTISOL, TSH, LH, AND PRL. IT IS CONCLUDED THAT IN YOUNG DOGS, GHRELIN IS A MORE POWERFUL STIMULATOR OF GH RELEASE THAN EITHER GHRH OR GHRP-6. AGEING IS ASSOCIATED WITH A DECREASE IN GH-RELEASING CAPACITY OF GHRELIN, WHEREAS THIS DECLINE IS CONSIDERABLY LOWER FOR GHRH OR GHRP-6. (C) 2005 ELSEVIER LTD. ALL RIGHTS RESERVED.","MESSENGER-RIBONUCLEIC-ACID; PITUITARY-ADRENAL AXIS; FACTOR-I; GH SECRETAGOGUE; SYNTHETIC HEXAPEPTIDE; ACYLATED PEPTIDE; GHRELIN; SECRETION; HEXARELIN; AGE","AGEING; CANINE; GHRELIN; GROWTH HORMONE-RELEASING HORMONE; GROWTH HORMONE-RELEASING PEPTIDE-6","VETERINARY JOURNAL","BHATTI, SFM##DUCHATEAU, L##VAN HAM, LML##DE VLIEGHER, SP##MOL, JA##RIJNBERK, A##KOOISTRA, HS","UNIV GHENT, FAC MED VET, DEPT SMALL ANIM MED & CLIN BIOL, B-9820 MERELBEKE, BELGIUM. UNIV GHENT, FAC MED VET, DEPT PHYSIOL BIOCHEM & BIOMETR, B-9820 MERELBEKE, BELGIUM. UNIV GHENT, FAC MED VET, DEPT OBSTET REPROD & HERD HLTH, B-9820 MERELBEKE, BELGIUM. UNIV UTRECHT, FAC VET MED, DEPT CLIN SCI COMPAN ANIM, NL-3508 TD UTRECHT, NETHERLANDS.","VETERINARY SCIENCES","VETERINARY SCIENCES","ALOI JA, 1994, J CLIN ENDOCRINOLOGY, V81, P4249##ARVAT E, 1997, PEPTIDES, V18, P885, DOI 10.1016/S0196-9781(97)00016-8##ARVAT E, 2001, J CLIN ENDOCR METAB, V86, P1169, DOI 10.1210/JC.86.3.1169##ARVAT E, 1998, PITUITARY, V1, P51, DOI 10.1023/A:1009970909015##BHATTI SFM, 2002, MOL CELL ENDOCRINOL, V197, P97, DOI 10.1016/S0303-7207(02)00293-9##BORST SE, 1994, J AM GERIATR SOC, V42, P528, DOI 10.1111/J.1532-5415.1994.TB04976.X##BOWERS C.Y., 1977, MOL ENDOCRINOL, P287##BOWERS CY, 1984, ENDOCRINOLOGY, V114, P1537, DOI 10.1210/ENDO-114-5-1537##BOWERS CY, 2001, J CLIN ENDOCR METAB, V86, P1464, DOI 10.1210/JC.86.4.1464##BOWERS CY, 1993, J CLIN ENDOCR METAB, V76, P817, DOI 10.1210/JC.76.4.817##BOWERS CY, 1992, P 74 ANN M END SOC, P172##BROGLIO F, 2003, J CLIN ENDOCR METAB, V88, P1537, DOI 10.1210/JC.2002-021504##CARPINO PA, 2003, BIOORGAN MED CHEM, V11, P581, DOI 10.1016/S0968-0896(02)00433-9##CASANUEVA FF, 1999, TRENDS ENDOCRIN MET, V10, P30, DOI 10.1016/S1043-2760(98)00116-7##CEDA GP, 1986, ENDOCRINOLOGY, V118, P2109, DOI 10.1210/ENDO-118-5-2109##CELLA SG, 1993, NEUROENDOCRINOLOGY, V57, P432, DOI 10.1159/000126389##CELLA SG, 1995, PEPTIDES, V16, P81, DOI 10.1016/0196-9781(94)00149-Z##CELLA SG, 1989, ACTA ENDOCRINOL-COP, V121, P177, DOI 10.1530/ACTA.0.1210177##CHAPMAN IM, 1996, J CLIN ENDOCR METAB, V81, P4249, DOI 10.1210/JC.81.12.4249##COLONNA VD, 1994, NEUROCHEM INT, V25, P5##CORPAS E, 1992, J CLIN ENDOCR METAB, V75, P530, DOI 10.1210/JC.75.2.530##DATE Y, 2000, ENDOCRINOLOGY, V141, P4255, DOI 10.1210/EN.141.11.4255##DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/EDRV-10-1-68##DICKSON SL, 1997, ENDOCRINOLOGY, V138, P771, DOI 10.1210/EN.138.2.771##EIGENMANN JE, 1981, ACTA ENDOCRINOL-COP, V98, P514, DOI 10.1530/ACTA.0.0980514##EVERITT A, 1989, J GERONTOL, V44, PB139, DOI 10.1093/GERONJ/44.6.B139##FINKELSTEIN JW, 1972, J CLIN ENDOCR METAB, V35, P665, DOI 10.1210/JCEM-35-5-665##FRANCHIMONT P, 1989, ACTA ENDOCRINOL-COP, V120, P121, DOI 10.1530/ACTA.0.1200121##FRAWLEY LS, 1991, ENDOCR REV, V12, P337, DOI 10.1210/EDRV-12-4-337##GHIGO E, 1994, J CLIN ENDOCR METAB, V78, P693, DOI 10.1210/JC.78.3.693##GHIGO E, 1999, ENDOCRINE RESPONSE A, P152##GIUSTINA A, 1998, ENDOCR REV, V19, P717, DOI 10.1210/ER.19.6.717##HAYASHIDA T, 2001, DOMEST ANIM ENDOCRIN, V21, P17, DOI 10.1016/S0739-7240(01)00104-7##HICKEY G, 1994, ENDOCRINOLOGY, V134, P695, DOI 10.1210/EN.134.2.695##JACKS T, 1996, ENDOCRINOLOGY, V137, P5284, DOI 10.1210/EN.137.12.5284##KELIJMAN M, 1991, J AM GERIATR SOC, V39, P295, DOI 10.1111/J.1532-5415.1991.TB01654.X##KOJIMA M, 1999, NATURE, V402, P656, DOI 10.1038/45230##KORBONITS M, 1999, J CLIN ENDOCR METAB, V84, P2489, DOI 10.1210/JC.84.7.2489##LAMBERTS SWJ, 1999, GROWTH HORMONE SECRE, P1##LOCHE S, 1995, J CLIN ENDOCR METAB, V80, P674, DOI 10.1210/JC.80.2.674##MASSOUD AF, 1996, J CLIN ENDOCR METAB, V81, P4338, DOI 10.1210/JC.81.12.4338##MOMANY FA, 1981, ENDOCRINOLOGY, V108, P31, DOI 10.1210/ENDO-108-1-31##MUCCIOLI G, 2002, EUR J PHARMACOL, V440, P235, DOI 10.1016/S0014-2999(02)01432-2##MULLER EE, 1999, PHYSIOL REV, V79, P511##MULLER EE, 2002, NEUROBIOL AGING, V23, P907, DOI 10.1016/S0197-4580(02)00026-X##NETT TM, 1975, P SOC EXP BIOL MED, V148, P134, DOI 10.3181/00379727-148-38491##NICOLAS V, 1994, J CLIN ENDOCR METAB, V78, P1011, DOI 10.1210/JC.78.5.1011##OKKENS AC, 1985, VET QUART, V7, P169, DOI 10.1080/01652176.1985.9693978##PATCHETT AA, 1995, P NATL ACAD SCI USA, V92, P7001, DOI 10.1073/PNAS.92.15.7001##PONG SS, 1996, MOL ENDOCRINOL, V10, P57, DOI 10.1210/ME.10.1.57##RAUN K, 1998, EUR J ENDOCRINOL, V139, P552, DOI 10.1530/EJE.0.1390552##RENNER U, 1994, J CLIN ENDOCR METAB, V78, P1090, DOI 10.1210/JC.78.5.1090##RIGAMONTI AE, 1999, EUR J ENDOCRINOL, V141, P313, DOI 10.1530/EJE.0.1410313##RINDI G, 2002, HISTOCHEM CELL BIOL, V117, P511, DOI 10.1007/S00418-002-0415-1##RUDMAN D, 1985, J AM GERIATR SOC, V33, P800, DOI 10.1111/J.1532-5415.1985.TB04195.X##SEOANE LM, 2000, EUR J ENDOCRINOL, V143, PR7, DOI 10.1530/EJE.0.143R007##SMITH RG, 1997, ENDOCR REV, V18, P621, DOI 10.1210/ER.18.5.621##SONNTAG WE, 1980, ENDOCRINOLOGY, V107, P1875, DOI 10.1210/ENDO-107-6-1875##SVENSSON J, 1998, J CLIN ENDOCR METAB, V83, P362, DOI 10.1210/JC.83.2.362##TAKAYA K, 2000, J CLIN ENDOCR METAB, V85, P4908, DOI 10.1210/JC.85.12.4908##THOMAS GB, 1997, ENDOCRINOLOGY, V138, P1585, DOI 10.1210/EN.138.4.1585##TOMASETTO C, 2001, PEPTIDES, V22, P2055, DOI 10.1016/S0196-9781(01)00557-5##VANEEKELEN JA, 1995, BIOL SCI MED SCI, V50, P83##WALKER RF, 1990, LIFE SCI, V47, P29, DOI 10.1016/0024-3205(90)90563-7##WALKER RF, 1991, LIFE SCI, V49, P1499, DOI 10.1016/0024-3205(91)90050-L##WILSHIRE GB, 1995, J CLIN ENDOCR METAB, V80, P608, DOI 10.1210/JC.80.2.608##ZADIK Z, 1985, J CLIN ENDOCR METAB, V60, P513, DOI 10.1210/JCEM-60-3-513",11,2020-11-20,NA,"UNIV GHENT#UNIV GHENT#UNIV GHENT#UNIV UTRECHT","BELGIUM#BELGIUM#BELGIUM#NETHERLANDS"
"J","WOS:000240539000002",2006,"TRANSMISSION OF ENCEPHALOMYOCARDITIS VIRUS IN PIGS ESTIMATED FROM FIELD DATA IN BELGIUM BY MEANS OF R-0","TRANSMISSION OF ENCEPHALOMYOCARDITIS-VIRUS ( EMCV) HAS BEEN ESTIMATED IN EXPERIMENTS, BUT NEVER USING FIELD DATA. IN THIS FIELD STUDY, A FARM IN BELGIUM WAS SELECTED WHERE THE PRESENCE OF EMCV WAS CONFIRMED BY NECROPSY AND VIRUS ISOLATION. SEROLOGY WAS USED TO ESTIMATE THE TRANSMISSION PARAMETER R-0. IN ONE COMPARTMENT WITH 630 PIGS, 6 PENS WERE FULLY SAMPLED, IN THE REMAINING 38 PENS, 2 RANDOMLY SELECTED PIGS WERE BLED. THE 151 PIGS WERE BLED TWICE AND THEIR SERUM WAS TESTED IN A VIRUS NEUTRALISATION TEST. SEROPREVALENCE AT THE FIRST AND SECOND SAMPLING WAS 41 AND 43% RESPECTIVELY, WITH A CUT OFF VALUE OF 1: 40. R-0 WAS ESTIMATED FOR 2 SCENARIOS, IN- AND EXCLUDING MORTALITY BASED ON THE FINAL SIZES FROM THE SEROLOGICAL RESULTS OF THE SECOND SAMPLING. THE R-0 FOR THE FULLY SAMPLED PENS WAS ESTIMATED BETWEEN 0.6 AND 1.7, THE COMBINED ESTIMATED R-0 OF THESE 6 PENS WAS 1.36 (95%-CI 0.93-2.23). THE MEDIAN OF THE ESTIMATED R-0 OF THE PARTIALLY SAMPLED PENS WAS 1.3 AND 1.4. SAMPLING TWO PIGS PER PEN PROVIDED INSIGHT INTO THE SPREAD OF THE VIRUS IN THE COMPARTMENT, WHILE THE FULLY SAMPLED PENS PROVIDED AN ACCURATE ESTIMATION OF R-0. THE LOW R-0 STRONGLY SUGGESTS THAT EMCV IS NOT VERY EFFECTIVELY TRANSMITTED BETWEEN PIGS. THE NUMBER OF SEROPOSITIVE PIGS IN A PEN AND THE SPREAD IN THE COMPARTMENT SUGGESTS THAT OTHER ROUTES OF INFECTION ARE MORE IMPORTANT, IN THIS CASE MOST LIKELY RODENTS. PREVENTING VIRAL SPREAD SHOULD THEREFORE BE FOCUSSED ON RODENT CONTROL INSTEAD OF REDUCTION OF CONTACT BETWEEN PIGS.","INFECTION; EMCV; QUANTIFICATION; SWINE","ENCEPHALOMYOCARDITIS VIRUS; PIGS; TRANSMISSION; R-0; FIELD DATA","VETERINARY RESEARCH","KLUIVERS, M##MAURICE, H##VYT, P##KOENEN, F##NIELEN, M","UNIV UTRECHT, FAC VET MED, DEPT FARM ANIM HLTH, NL-3584 CL UTRECHT, NETHERLANDS. UNIV WAGENINGEN & RES CTR, DEPT SOCIAL SCI, BUSINESS ECON GRP, NL-6706 KN WAGENINGEN, NETHERLANDS. ANIM HLTH CARE FLANDERS, TORHOUT, BELGIUM. CODA, CERVA, VAR, SECT EPIZOOT DIS,DEPT VIROL, B-1180 BRUSSELS, BELGIUM.","VETERINARY SCIENCES","VETERINARY SCIENCES","ACLAND H. M., 1989, VIRUS INFECTIONS OF PORCINES., P259##AUGUSTIJN M, 2006, TIJDSCHR DIERGENEESK, V131, P40##BILLINIS C, 2004, VET MICROBIOL, V99, P187, DOI 10.1016/J.VETMIC.2004.01.002##DEJONG MCM, 1994, VACCINE, V12, P761, DOI 10.1016/0264-410X(94)90229-1##DEJONG MCM, 1995, PREV VET MED, V25, P183, DOI 10.1016/0167-5877(95)00538-2##DIEKMANN O, 1990, J MATH BIOL, V28, P365##FONI E, 1993, J VET MED B, V40, P347, DOI 10.1111/J.1439-0450.1993.TB00149.X##GUALANDI GL, 1989, MICROBIOLOGICA, V12, P129##JOO H.S, 1999, DIS SWINE, P139##JUNGEBLUT CW, 1943, AM J PUBLIC HEALTH N, V33, P169, DOI 10.2105/AJPH.33.2.169##JUNGEBLUT CW, 1940, J EXP MED, V72, P407, DOI 10.1084/JEM.72.4.407##KLINKENBERG D, 2002, EPIDEMIOL INFECT, V128, P293, DOI 10.1017/S0950268801006537##KOENEN F, 1999, J VET MED B, V46, P217##KOENEN F, 2002, CT984146 CODASERVAVA##KROESE AH, 2001, SOCIETY FOR VETERINARY EPIDEMIOLOGY AND PREVENTIVE MEDICINE, PROCEEDINGS, PXXI##LITTLEJOHNS IR, 1975, AUST VET J, V51, P416, DOI 10.1111/J.1751-0813.1975.TB15790.X##MAURICE H, 2005, EPIDEMIOL INFECT, V133, P547, DOI 10.1017/S0950268804003668##MAURICE H, 2002, VET MICROBIOL, V88, P301, DOI 10.1016/S0378-1135(02)00127-X##PAPADOPOULOU EP, 1992, INT PIG VET SOC HAG, P106##PASCHALERIPAPADOPOULOU E, 1990, VET REC, V126, P364##SANGAR DV, 1977, VET REC, V100, P240, DOI 10.1136/VR.100.12.240##SEAMAN JT, 1986, AUST VET J, V63, P292, DOI 10.1111/J.1751-0813.1986.TB08069.X##SHIBATA I, 1993, J VET MED SCI, V55, P117, DOI 10.1292/JVMS.55.117##SPYROU V, 2004, VET RES, V35, P113, DOI 10.1051/VETRES:2003044##VANDERHALLEN H, 1997, J VIROL METHODS, V66, P83, DOI 10.1016/S0166-0934(97)02214-3##VANREGENMORTEL M, 2000, VIRUS TAXONOMY, P667##VELTHUIS AGJ, 2002, EPIDEMIOL INFECT, V128, P193, DOI 10.1017/S0950268801006707##ZIMMERMAN J, 1993, J VET DIAGN INVEST, V5, P317, DOI 10.1177/104063879300500302##ZIMMERMAN J J, 1990, J VET DIAGN INVEST, V2, P347##ZIMMERMAN JJ, 1994, HDB ZOONOSES B, P423",13,2020-11-20,NA,"UNIV UTRECHT#UNIV WAGENINGEN RES CTR#ANIM HLTH CARE FLANDERS#CODA","NETHERLANDS#NETHERLANDS#BELGIUM#BELGIUM"
"J","WOS:000242628300012",2006,"THE IMPACT OF BIOTURBATION BY SMALL MAMMALS ON HEAVY METAL REDISTRIBUTION IN AN EMBANKED FLOODPLAIN OF THE RIVER RHINE","FLOODPLAINS ALONG LARGE EUROPEAN RIVERS ARE DIFFUSELY POLLUTED WITH HEAVY METALS DUE TO EMISSIONS IN THE PAST. BECAUSE OF LOW MOBILITY OF HEAVY METALS IN FLOODPLAIN SOILS AND IMPROVEMENTS OF WATER QUALITY, THESE POLLUTANTS WILL REMAIN IN PLACE, AND CAN GRADUALLY BECOME COVERED WITH LESS CONTAMINATED SEDIMENTS. BIOTURBATORS, ESPECIALLY EARTHWORMS, CAN PLAY AN IMPORTANT ROLE IN THE MIXING AND SURFACING OF CONTAMINATED SUBSTRATE. SURFACED SUBSTRATE CAN BE REDISTRIBUTED BY RECURRENT FLOODING EVENTS, EVEN TO AREAS OUTSIDE THE FLOODPLAIN. THE QUESTION REMAINED TO WHAT EXTENT BIOTURBATION BY SMALL MAMMALS CONTRIBUTES TO THE REDISTRIBUTION OF HEAVY METALS FROM RIVER SEDIMENTS IN FLOODPLAINS. EXTENSIVE FIELDWORK ON BIOTURBATORS SUCH AS VOLES, MOLES AND EARTHWORMS AND THEIR DISTRIBUTION PATTERNS, AS WELL AS ON SEDIMENT DEPOSITION AND BIOTURBATION, WAS CONDUCTED AT THE 'AFFERDENSCHE EN DEESTSCHE WAARDEN' FLOODPLAIN OVER THE YEARS 2001-2003. FIELD DATA WERE COMBINED WITH DATA OF EXPERIMENTS IN FIELD ENCLOSURES AND SUBSTRATE COLUMNS TO CALCULATE THE AMOUNTS OF SEDIMENT AND HEAVY METALS (ZN, CU, PB AND CD) REDISTRIBUTED DURING THE FLOODS AS WELL AS ON AN ANNUAL BASIS. MOLES AND VOLES SURFACED CONSIDERABLE AMOUNTS OF SUBSTRATE AND HEAVY METALS, BUT NOT AS MUCH AS EARTHWORMS WHICH CONTRIBUTE A SUBSTANTIAL PROPORTION OF THE TOTAL DEPOSITION AND REDISTRIBUTION DURING FLOODS. ALTHOUGH THE IMPACT OF MOLES AND VOLES ON THE REDISTRIBUTION DURING FLOODS WAS ONLY LOCALLY IMPORTANT, ON AN ANNUAL BASIS THE BIOTURBATION ACTIVITY OF ESPECIALLY MOLES IN FLOODPLAINS CANNOT BE NEGLECTED. THE ANNUAL AMOUNTS OF SUBSTRATE AND HEAVY METALS SURFACED BY ALL INVESTIGATED BIOTURBATORS WERE EVEN LARGER THAN THE TOTAL AMOUNTS OF SUBSTRATE AND HEAVY METALS DEPOSITED DURING FLOODS.","ECOLOGICAL RISK-ASSESSMENT; SPATIAL VARIABILITY; SEDIMENTATION; SOIL; EARTHWORMS","BIOTURBATION; EARTHWORMS; FLOODPLAINS; HEAVY METALS; MOLES; REDISTRIBUTION; SEDIMENT; SMALL MAMMALS; VOLES","WATER AIR AND SOIL POLLUTION","WIJNHOVEN, S##THONON, I##VAN DER VELDE, G##LEUVEN, R##ZORN, M##EIJSACKERS, H##SMITS, T","RADBOUD UNIV NIJMEGEN, FAC SCI, CTR WATER & SOC, NL-6500 GL NIJMEGEN, NETHERLANDS. UNIV UTRECHT, FAC GEOSCI, DEPT PHYS GEOG, NL-3508 TC UTRECHT, NETHERLANDS. RADBOUD UNIV NIJMEGEN, INST WETLAND & WATER RES, DEPT ANIM ECOL & ECOPHYSIOL, NL-6500 GL NIJMEGEN, NETHERLANDS. RADBOUD UNIV NIJMEGEN, INST WETLAND & WATER RES, DEPT ENVIRONM SCI, NL-6500 GL NIJMEGEN, NETHERLANDS. FREE UNIV AMSTERDAM, INST ECOL SCI, NL-1081 HV AMSTERDAM, NETHERLANDS. UNIV WAGENINGEN & RES CTR, NL-6700 HB WAGENINGEN, NETHERLANDS. ERASMUS UNIV, FAC SOCIAL SCI, NL-3000 DR ROTTERDAM, NETHERLANDS.","ENVIRONMENTAL SCIENCES; METEOROLOGY & ATMOSPHERIC SCIENCES; WATER RESOURCES","ENVIRONMENTAL SCIENCES & ECOLOGY; METEOROLOGY & ATMOSPHERIC SCIENCES; WATER RESOURCES","ANDERSEN DC, 2000, J MAMMAL, V81, P1087, DOI 10.1644/1545-1542(2000)081<1087:MPORSM>2.0.CO;2##BRAUN-BLANQUET J., 1932, PLANT SOCIOLOGY STUD##CISZEWSKI D, 2003, WATER AIR SOIL POLL, V143, P81, DOI 10.1023/A:1022825103974##EDWARDS GR, 1999, J APPL ECOL, V36, P434, DOI 10.1046/J.1365-2664.1999.00411.X##EIJSACKERS HJP, 2000, NEW APPROACHES TO RIVER MANAGEMENT, P307##GABLER HE, 1997, J GEOCHEM EXPLOR, V58, P185, DOI 10.1016/S0375-6742(96)00061-1##GODFREY G, 1969, LIFE MOLE, P152##HAECK J, 1969, NETHERLANDS JOURNAL OF ZOOLOGY, V19, P145##KOOISTRA L, 2005, ENVIRON SCI TECHNOL, V39, P2177, DOI 10.1021/ES049814W##KOOISTRA L, 2001, ENVIRON MANAGE, V28, P359, DOI 10.1007/S0026702433##KWADIJK J, 1994, CLIMATIC CHANGE, V27, P199, DOI 10.1007/BF01093591##LAMBERT CP, 1987, GEOGR ANN A, V69, P393, DOI 10.2307/521353##LANGE R, 1994, ZOOGDIEREN W EUROPA, P400##LEUVEN R. S. E. W., 2005, ARCHIV FUER HYDROBIOLOGIE SUPPLEMENT, V155, P657##MIDDELKOOP H, 2002, HYDROL PROCESS, V16, P47, DOI 10.1002/HYP.283##MIDDELKOOP H, 1998, EARTH SURF PROC LAND, V23, P561, DOI 10.1002/(SICI)1096-9837(199806)23:6&LT;561::AID-ESP870&GT;3.0.CO;2-5##MIDDELKOOP H, 2000, NETH J GEOSCI, V79, P411##MITCHELL P., 1988, P43##MULLERLEMANS H, 1996, J ENVIRON RADIOACTIV, V31, P7, DOI 10.1016/0265-931X(95)00029-A##NIENHUIS PH, 2002, HYDROBIOLOGIA, V478, P53, DOI 10.1023/A:1021070428566##PEBESMA EJ, 1998, COMPUT GEOSCI-UK, V24, P17, DOI 10.1016/S0098-3004(97)00082-4##ROBINSON CT, 2002, FRESHWATER BIOL, V47, P661, DOI 10.1046/J.1365-2427.2002.00921.X##SCHEU S, 1987, OECOLOGIA, V72, P192, DOI 10.1007/BF00379266##SCHRODER TJ, 2005, THESIS WAGENINGEN U, P172##SILVA W, 2001, 2001031 ARNH DELFT##THONON I, 2005, EARTH SURF PROC LAND, V30, P1327, DOI 10.1002/ESP.1239##THONON I, 2003, IAHS-AISH P, P37##THONON I, 2006, THESIS UTRECHT U UTR##TYLER AN, 2001, CATENA, V43, P81, DOI 10.1016/S0341-8162(00)00127-2##VAN VLIET PCJ, 2005, ENVIRON POLLUT, V138, P505, DOI 10.1016/J.ENVPOL.2005.04.010##VERBEKE A, 1997, THESIS ECOLE NATL VE##VINK R, 1999, WATER SCI TECHNOL, V39, P215, DOI 10.1016/S0273-1223(99)00338-8##WIJNHOVEN S, 2006, HYDROBIOLOGIA, V565, P135, DOI 10.1007/S10750-005-1910-X##WIJNHOVEN S, 2006, ENVIRON POLLUT, V140, P444, DOI 10.1016/J.ENVPOL.2005.08.011##WIJNHOVEN S, 2005, ACTA THERIOL, V50, P453, DOI 10.1007/BF03192639##WITTE GR, 1997, MAULWURF TALPA EUROP, P213##ZANDBERG B, 1999, 99001 DIR GEN PUBL W##ZORN MI, 2005, PEDOBIOLOGIA, V49, P189, DOI 10.1016/J.PEDOBI.2004.08.004##ZORN ML, 2004, THESIS VU AMSTERDAM, P121",21,2020-11-20,NA,"RADBOUD UNIV NIJMEGEN#UNIV UTRECHT#RADBOUD UNIV NIJMEGEN#RADBOUD UNIV NIJMEGEN#FREE UNIV AMSTERDAM#UNIV WAGENINGEN RES CTR#ERASMUS UNIV","NETHERLANDS#NETHERLANDS#NETHERLANDS#NETHERLANDS#NETHERLANDS#NETHERLANDS#NETHERLANDS"
"J","WOS:000241331900009",2006,"CROSSOVER OF BURNOUT AND ENGAGEMENT IN WORK TEAMS","THIS STUDY INVESTIGATES THE CROSSOVER OF BURNOUT AND WORK ENGAGEMENT AMONG 2,229 ROYAL DUTCH CONSTABULARY OFFICERS, WORKING IN ONE OF 85 TEAMS. THE AUTHORS HYPOTHESIZED THAT BOTH STATES MAY TRANSFER FROM TEAMS TO INDIVIDUAL TEAM MEMBERS. THE RESULTS OF MULTILEVEL ANALYSES CONFIRM THIS CROSSOVER PHENOMENON BY SHOWING THAT TEAM-LEVEL BURNOUT AND WORK ENGAGEMENT ARE RELATED TO INDIVIDUAL TEAM MEMBERS' BURNOUT (I.E., EXHAUSTION, CYNICISM, AND REDUCED PROFESSIONAL EFFICACY) AND WORK ENGAGEMENT (VIGOR, DEDICATION, AND ABSORPTION), AFTER CONTROLLING FOR INDIVIDUAL MEMBERS' JOB DEMANDS AND RESOURCES. THE IMPLICATIONS OF THESE FINDINGS FOR INTERVENTIONS AIMED AT THE PROMOTION OF EMPLOYEE WELL-BEING ARE DISCUSSED.","DEMANDS-RESOURCES MODEL; JOB DEMANDS; PERFORMANCE; SATISFACTION; CONTAGION; ABSENCE; LEVEL","BURNOUT; CROSSOVER; EMOTIONAL CONTAGION; WORK ENGAGEMENT","WORK AND OCCUPATIONS","BAKKER, AB##VAN EMMERIK, H##EUWEMA, MC","ERASMUS UNIV, ROTTERDAM, NETHERLANDS. UNIV UTRECHT, DEPT SOCIOL, NL-3508 TC UTRECHT, NETHERLANDS. UNIV UTRECHT, DEPT SOCIAL & ORG PSYCHOL, NL-3508 TC UTRECHT, NETHERLANDS.","INDUSTRIAL RELATIONS & LABOR; SOCIOLOGY","BUSINESS & ECONOMICS; SOCIOLOGY","BAKKER A. B., 2003, INT J STRESS MANAGE, V10, P16, DOI DOI 10.1037/1072-5245.10.1.16##BAKKER AB, 2005, J ADV NURS, V51, P276, DOI 10.1111/J.1365-2648.2005.03494.X##BAKKER AB, 2003, ADV PSY RES, V25, P13##BAKKER AB, 2004, HUM RESOUR MANAGE-US, V43, P83, DOI 10.1002/HRM.20004##BAKKER AB, 2003, J VOCAT BEHAV, V62, P341, DOI 10.1016/S0001-8791(02)00030-1##BAKKER AB, 2002, ANXIETY STRESS COPIN, V15, P245, DOI 10.1080/1061580021000020716##BAKKER AB, 2001, J SOC CLIN PSYCHOL, V20, P82, DOI 10.1521/JSCP.20.1.82.22251##BAKKER AB, 2000, J APPL SOC PSYCHOL, V30, P2289, DOI 10.1111/J.1559-1816.2000.TB02437.X##BAVELAS JB, 1987, EMPATHY ITS DEV, P317##BERNIERI FJ, 1988, J PERS SOC PSYCHOL, V54, P243, DOI 10.1037/0022-3514.54.2.243##BURKE RJ, 1995, HUM RELAT, V48, P187, DOI 10.1177/001872679504800205##BUUNK BP, 1993, S AP PSYC S, P53##CHANG A, 2001, SMALL GR RES, V32, P379, DOI 10.1177/104649640103200401##CHERNISS C., 1980, PROFESSIONAL BURNOUT##DEMEROUTI E, 2000, J ADV NURS, V32, P454, DOI 10.1046/J.1365-2648.2000.01496.X##DEMEROUTI E, 2001, J APPL PSYCHOL, V86, P499, DOI 10.1037//0021-9010.86.3.499##DEVINE DJ, 1999, SMALL GR RES, V30, P678, DOI 10.1177/104649649903000602##EDELWICH J., 1980, BURNOUT STAGES DISIL##FIRTH H, 1989, J OCCUP PSYCHOL, V62, P55, DOI 10.1111/J.2044-8325.1989.TB00477.X##FURDA J, 1995, THESIS UTRECHT U NET##GOLEMBIEWSKI RT, 1996, PUBLIC PRODUCTIVITY, V20, P56##GRAEN G. B., 1991, J MANAGEMENT SYSTEMS, V3, P25##GULLY SM, 2002, J APPL PSYCHOL, V87, P819, DOI 10.1037/0021-9010.87.5.819##HACKMAN J. R., 1980, WORK REDESIGN##HARTER JK, 2002, J APPL PSYCHOL, V87, P268, DOI 10.1037/0021-9010.87.2.268##HATFIELD E., 1994, EMOTIONAL CONTAGION##HOX J., 2002, MULTILEVEL ANAL TECH##HSEE CK, 1990, COGNITION EMOTION, V4, P327, DOI 10.1080/02699939008408081##JACKSON SE, 1986, J APPL PSYCHOL, V71, P630, DOI 10.1037/0021-9010.71.4.630##KAHILL S, 1988, CAN PSYCHOL, V29, P284, DOI 10.1037/H0079772##KARASEK R. A., 1985, JOB CONTENT QUESTION##LAIRD JD, 1984, J PERS SOC PSYCHOL, V47, P909, DOI 10.1037/0022-3514.47.4.909##LEBLANC P, 1994, THESIS AMSTERDAM##LEITER MP, 1996, ANXIETY STRESS COPIN, V9, P229, DOI 10.1080/10615809608249404##MASLACH C, 1996, MASLACH BURNOUT INVE##MASLACH C, 1997, TRUTH BURNOUT ORG CA##ORGAN DW, 1994, J MANAGE, V20, P465, DOI 10.1177/014920639402000208##PETTY R. E., 1986, ADV EXPT SOCIAL PSYC, P123, DOI DOI 10.1016/S0065-2601(08)60214-2##SALANOVA M, 2005, J APPL PSYCHOL, V90, P1217, DOI 10.1037/0021-9010.90.6.1217##SALANOVA M, 2002, J HAPPINESS STUD, V3, P71, DOI [DOI 10.1023/A:1015630930326, 10.1023/A]##SCHAUFELI W, 1998, BURNOUT COMPANION ST##SCHAUFELI W. B., 2001, GEDRAG ORGAN, V14, P229##SCHAUFELI W.B., 1996, MASLACH BURNOUT INVE##SCHAUFELI W.B., 2003, UTRECHT WORK ENGAGEM##SCHAUFELI WB, 2002, J CROSS CULT PSYCHOL, V33, P464, DOI 10.1177/0022022102033005003##SCHAUFELI WB, 2004, J ORGAN BEHAV, V25, P293, DOI 10.1002/JOB.248##SCHAUFELI WB, 2001, PSYCHOLOOG, V36, P422##SHIROTA A., 1989, INTERNATIONAL JOURNAL OF AQUACULTURE AND FISHERIES TECHNOLOGY, V1, P25##SIEGMAN AW, 1982, INTERACTION RHYTHMS, P249##SNIJDERS T.A.B., 1999, MULTILEVEL ANAL INTR##SONNENTAG S, 1994, J OCCUP ORGAN PSYCH, V67, P327, DOI 10.1111/J.2044-8325.1994.TB00571.X##TOTTERDELL P, 2000, J APPL PSYCHOL, V85, P848, DOI 10.1037/0021-9010.85.6.848##VAN DIERENDONCK D., 2000, UBOS UTRECHTSE BURNO##VAN VELDHOVEN M, 1994, METEN PSYCHOSOCIALE##WESTMAN M, 1999, J OCCUP HEALTH PSYCHOL, V4, P269, DOI 10.1037/1076-8998.4.3.269##WESTMAN M, 2001, HUM RELAT, V54, P717, DOI 10.1177/0018726701546002##WESTMAN M., 2002, RES OCCUPATIONAL STR, V2, P143, DOI DOI 10.1016/S1479-3555(02)02004-8##WOLPIN J, 1991, HUM RELAT, V44, P193, DOI 10.1177/001872679104400205",253,2020-11-20,NA,"ERASMUS UNIV#UNIV UTRECHT#UNIV UTRECHT","NETHERLANDS#NETHERLANDS#NETHERLANDS"
"J","WOS:000242916600005",2006,"THE KIT LIGAND/C-KIT RECEPTOR SYSTEM IN GOAT OVARIES: GENE EXPRESSION AND PROTEIN LOCALIZATION","RELATIVELY LITTLE INFORMATION IS AVAILABLE ON THE LOCAL FACTORS THAT REGULATE FOLLICULOGENESIS IN GOATS. TO EXAMINE THE POSSIBILITY THAT THE KIT LIGAND (KL) SYSTEM IS EXPRESSED THROUGHOUT THE FOLLICULOGENESIS, WE STUDIED THE PRESENCE AND DISTRIBUTION OF KL AND ITS RECEPTOR, C-KIT, IN GOAT OVARIES. OVARIES OF GOATS WERE COLLECTED AND EITHER FIXED IN PARAFORMALDEHYDE FOR IMMUNOHISTOCHERNICAL LOCALIZATION OF KL AND C-KIT PROTEINS, OR USED FOR THE ISOLATION OF FOLLICLES, LUTEAL CELLS, SURFACE EPITHELIUM AND MEDULLARY SAMPLES TO STUDY MRNA EXPRESSION FOR KL AND C-KIT, USING THE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION (RTPCR). KL PROTEIN AND MRNA WERE FOUND IN FOLLICLES AT ALL STAGES OF DEVELOPMENT, I.E. PRIMORDIAL, PRIMARY, SECONDARY, SMALL AND LARGE ANTRAL FOLLICLES, AS WELL AS IN CORPORA LUTEA, SURFACE EPITHELIUM AND MEDULLARY TISSUE. ANTRAL FOLLICLES EXPRESSED BOTH KL-1 AND KL-2 MRNAS, WHILE EARLIER STAGED FOLLICLES EXPRESSED KL-I TRANSCRIPT ONLY. KL PROTEIN WAS DEMONSTRATED IN GRANULOSA CELLS FROM THE PRIMORDIAL FOLLICLE ONWARD. ITS MRNA COULD BE DETECTED IN GRANULOSA CELLS ISOLATED FROM ANTRAL FOLLICLES AND OCCASIONALLY IN THEIR THECA CELLS. C-KIT MRNA WAS EXPRESSED IN ALL ANTRAL FOLLICULAR COMPARTMENTS AND AT ALL STAGES OF FOLLICULAR DEVELOPMENT. C-KIT PROTEIN WAS PREDOMINANTLY FOUND IN OOCYTES FROM THE PRIMORDIAL FOLLICLE STAGE ONWARDS, IN THECA CELLS OF ANTRAL FOLLICLES, AS WELL AS IN CORPORA LUTEA, SURFACE EPITHELIUM AND MEDULLARY TISSUE, PARTICULARLY IN THE WALL OF BLOOD VESSELS, WHICH MAY INDICATE THESE CELLS AS THE MAIN SITES OF ACTION OF KL. IT IS CONCLUDED THAT THE KL/C-KIT SYSTEM, IN GOAT OVARIES, IS WIDESPREAD AND THAT IT MAY BE INVOLVED IN THE REGULATION OF VARIOUS LOCAL PROCESSES, INCLUDING FOLLICULOGENESIS AND LUTEAL ACTIVITY.","STEM-CELL FACTOR; MESSENGER-RIBONUCLEIC-ACID; SURFACE EPITHELIAL-CELLS; C-KIT; FOLLICLE DEVELOPMENT; GROWTH-FACTOR; PREANTRAL FOLLICLES; TYROSINE KINASE; FETAL OVARIES; CORPUS-LUTEUM","C-KIT; FOLLICLES; GOAT; KIT LIGAND; OVARY","ZYGOTE","SILVA, JRV##VAN DEN HURK, R##VAN TOL, HTA##ROELEN, BAJ##FIGUEIREDO, JR","UNIV ESTADUAL CEARA, FAC VET MED, BR-60740000 FORTALEZA, CEARA, BRAZIL. UNIV UTRECHT, FAC VET MED, DEPT FARM ANIM HLTH, UTRECHT, NETHERLANDS.","CELL BIOLOGY; DEVELOPMENTAL BIOLOGY; REPRODUCTIVE BIOLOGY","CELL BIOLOGY; DEVELOPMENTAL BIOLOGY; REPRODUCTIVE BIOLOGY","ALLARD EK, 1996, BIOL REPROD, V55, P185, DOI 10.1095/BIOLREPROD55.1.185##BEDELL MA, 1995, GENE DEV, V9, P455, DOI 10.1101/GAD.9.4.455##BRANKIN VICTORIA, 2003, REPROD BIOL ENDOCRINOL, V1, P55, DOI 10.1186/1477-7827-1-55##BROUDY VC, 1997, BLOOD, V90, P1345, DOI 10.1182/BLOOD.V90.4.1345.1345_1345_1364##CLARK DE, 1996, J REPROD FERTIL, V106, P329, DOI 10.1530/JRF.0.1060329##DOLCI S, 1991, NATURE, V352, P809, DOI 10.1038/352809A0##DRIANCOURT MA, 2000, REV REPROD, V5, P143, DOI 10.1530/REVREPROD/5.3.143##ECKERY DC, 2002, BIOL REPROD, V66, P346, DOI 10.1095/BIOLREPROD66.2.346##EPPIG JJ, 2001, REPRODUCTION, V122, P829, DOI 10.1530/REP.0.1220829##GENTRY PC, 1996, BIOL REPROD, V54, P970, DOI 10.1095/BIOLREPROD54.5.970##GENTRY PC, 1998, BIOL REPROD, V59, P983, DOI 10.1095/BIOLREPROD59.4.983##GOUGEON A, 2000, MOL CELL ENDOCRINOL, V163, P33, DOI 10.1016/S0303-7207(00)00220-3##HORIE K, 1991, BIOL REPROD, V45, P547, DOI 10.1095/BIOLREPROD45.4.547##HOYER PE, 2005, MOL CELL ENDOCRINOL, V234, P1, DOI 10.1016/J.MCE.2004.09.012##HUANG CTF, 2001, BIOL REPROD, V64, P451, DOI 10.1095/BIOLREPROD64.2.451##HUANG EJ, 1993, DEV BIOL, V157, P100, DOI 10.1006/DBIO.1993.1115##HUANG EJ, 1992, MOL BIOL CELL, V3, P349##ISMAIL RS, 1996, MOL REPROD DEV, V43, P458, DOI 10.1002/(SICI)1098-2795(199604)43:4&LT;458::AID-MRD8&GT;3.0.CO;2-O##ISMAIL RS, 1999, ONCOGENE, V18, P4734, DOI 10.1038/SJ.ONC.1202865##JUENGEL JL, 2000, BIOL REPROD, V62, P1467, DOI 10.1095/BIOLREPROD62.6.1467##KANG JS, 2003, J HISTOCHEM CYTOCHEM, V51, P1447, DOI 10.1177/002215540305101105##KURODA H, 1988, DEV BIOL, V126, P71, DOI 10.1016/0012-1606(88)90240-0##LAITINEN M, 1995, ENDOCRINOLOGY, V136, P4407, DOI 10.1210/EN.136.10.4407##LUCCI CM, 1999, ANIM REPROD SCI, V56, P39, DOI 10.1016/S0378-4320(99)00031-7##MANOVA K, 1993, DEV BIOL, V157, P85, DOI 10.1006/DBIO.1993.1114##MANOVA K, 1990, DEVELOPMENT, V110, P1057##MCNATTY KP, 1999, J REPROD FERTIL, P3##MIYAMOTO T, 1997, ATHEROSCLEROSIS, V129, P207, DOI 10.1016/S0021-9150(96)06043-1##MOTRO B, 1993, DEV DYNAM, V197, P69, DOI 10.1002/AJA.1001970107##NILSSON E, 2001, J SOC GYNECOL INVEST, V8, PS17, DOI 10.1016/S1071-5576(00)00099-X##OTSUKA F, 2002, P NATL ACAD SCI USA, V99, P8060, DOI 10.1073/PNAS.122066899##PARROTT JA, 1999, ENDOCRINOLOGY, V140, P4262, DOI 10.1210/EN.140.9.4262##PARROTT JA, 2000, MOL REPROD DEV, V55, P55, DOI 10.1002/(SICI)1098-2795(200001)55:1&LT;55::AID-MRD8&GT;3.0.CO;2-L##PARROTT JA, 1997, ENDOCRINOLOGY, V138, P3819, DOI 10.1210/EN.138.9.3819##PARROTT JA, 2000, ENDOCRINOLOGY, V141, P2532, DOI 10.1210/EN.141.7.2532##REYNAUD K, 2000, MOL REPROD DEV, V56, P483, DOI 10.1002/1098-2795(200008)56:4&LT;483::AID-MRD6&GT;3.0.CO;2-O##SILVA JRV, 2005, MOL REPROD DEV, V70, P11, DOI 10.1002/MRD.20127##TISDALL DJ, 1997, J MOL ENDOCRINOL, V18, P127, DOI 10.1677/JME.0.0180127##TISDALL DJ, 1999, J REPROD FERTIL, V116, P277, DOI 10.1530/JRF.0.1160277##VAN DEN HURK R, 2005, THERIOGENOLOGY, V63, P1717, DOI 10.1016/J.THERIOGENOLOGY.2004.08.005##VAN TOL HTA, 1998, MOL REPROD DEV, V51, P315, DOI 10.1002/(SICI)1098-2795(199811)51:3&LT;315::AID-MRD11&GT;3.0.CO;2-1##VANDENHURK R, 1994, J REPROD FERTIL, V100, P137, DOI 10.1530/JRF.0.1000137##YOSHIDA H, 1997, DEV BIOL, V184, P122, DOI 10.1006/DBIO.1997.8503",36,2020-11-20,NA,"UNIV ESTADUAL CEARA#UNIV UTRECHT","BRAZIL#NETHERLANDS"
"J","WOS:000241792800421",2006,"HUMAN EMBRYONIC STEM CELL-DERIVED CARDIOMYOCYTES SURVIVE AND MATURE AFTER INTRAMYOCARDIAL TRANSPLANTATION IN THE MOUSE HEART",NA,NA,NA,"CIRCULATION","VAN LAAKE, LW##PASSIER, R##KLOOTS, J##LIPS, DJ##WARD-VAN OOSTWAARD, D##VAN DEN BRINK, SE##TERTOOLEN, LI##DOEVENDANS, PA##MUMMERY, CI","UNIV UTRECHT, MED CTR, UTRECHT, NETHERLANDS. HUBRECHT LAB, UTRECHT, NETHERLANDS.","CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE","CARDIOVASCULAR SYSTEM & CARDIOLOGY",NA,0,2020-11-20,NA,"UNIV UTRECHT#HUBRECHT LAB","NETHERLANDS#NETHERLANDS"
"J","WOS:000241792800491",2006,"THE GROWTH FACTOR PRESENTING ISOFORM CD44V3 IS HIGHLY EXPRESSED DURING COLLATERAL ARTERY GROWTH AND MEDIATES PERFUSION RESTORATION AFTER FEMORAL ARTERY LIGATION",NA,NA,NA,"CIRCULATION","BOT, PT##GRUNDMANN, SB##VAN ROYEN, N##VAN DER NEUT, R##PALS, ST##PASTERKAMP, G##PIEK, JJ##HOEFER, I","UNIV AMSTERDAM, ACAD MED CTR, NL-1105 AZ AMSTERDAM, NETHERLANDS. UNIV UTRECHT, MED CTR, UTRECHT, NETHERLANDS.","CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE","CARDIOVASCULAR SYSTEM & CARDIOLOGY",NA,0,2020-11-20,NA,"UNIV AMSTERDAM#UNIV UTRECHT","NETHERLANDS#NETHERLANDS"
"J","WOS:000241792801446",2006,"PRESERVATION OF LEFT VENTRICULAR FUNCTION AND ATTENUATION OF REMODELLING AFTER TRANSPLANTATION OF HUMAN EPICARDIUM-DERIVED CELLS INTO THE INFARCTED MOUSE HEART",NA,NA,NA,"CIRCULATION","WINTER, EM##GRAUSS, RW##HOGERS, B##VAN TUYN, J##VAN DER GEEST, R##STEIJN, RV##LIE-VENEMA, H##STEENDIJK, P","LEIDEN UNIV, MED CTR, LEIDEN, NETHERLANDS. UNIV UTRECHT, MED CTR, UTRECHT, NETHERLANDS.","CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE","CARDIOVASCULAR SYSTEM & CARDIOLOGY",NA,0,2020-11-20,NA,"LEIDEN UNIV#UNIV UTRECHT","NETHERLANDS#NETHERLANDS"
"J","WOS:000241792801502",2006,"ENDOVASCULAR STENTS ARE A POTENTIAL NEW INTRA-ARTERIAL DELIVERY PLATFORM FOR PRO-ARTERIOGENIC GROWTH FACTORS",NA,NA,NA,"CIRCULATION","GRUNDMANN, S##HOEFER, IE##VAN ROYEN, N##GONZALEZ, N##TIJSMA, EJ##PASTERKAMP, G##PIEK, JJ","UNIV AMSTERDAM, ACAD MED CTR, DEPT CARDIOL, NL-1105 AZ AMSTERDAM, NETHERLANDS. UNIV UTRECHT, DEPT EXPT CARDIOL, UTRECHT, NETHERLANDS. MEDTRON NEDERLANDS, BAKKEN RES CTR, MAASTRICHT, NETHERLANDS.","CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE","CARDIOVASCULAR SYSTEM & CARDIOLOGY",NA,0,2020-11-20,NA,"UNIV AMSTERDAM#UNIV UTRECHT#MEDTRON NEDERLANDS","NETHERLANDS#NETHERLANDS#NETHERLANDS"
"J","WOS:000241792801520",2006,"SHORT TERM ADMINISTRATION OF RECONSTITUTED APOAI DISCS INCREASES CIRCULATING PROGENITOR CELLS IN TYPE 2 DIABETES",NA,NA,NA,"CIRCULATION","VAN OOSTROM, O##NIEUWDORP, M##WESTERWEEL, PE##HOEFER, IE##STROES, ES##VERHAAR, MC","UNIV UTRECHT, MED CTR, DEPT VASC MED, UTRECHT, NETHERLANDS. ACAD MED CTR, DEPT VASC MED, AMSTERDAM, NETHERLANDS. UNIV UTRECHT, MED CTR, DEPT EXPT CARDIOL, UTRECHT, NETHERLANDS.","CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE","CARDIOVASCULAR SYSTEM & CARDIOLOGY",NA,0,2020-11-20,NA,"UNIV UTRECHT#ACAD MED CTR#UNIV UTRECHT","NETHERLANDS#NETHERLANDS#NETHERLANDS"
"J","WOS:000241792801666",2006,"HIGH IP-10 LEVELS IDENTIFY PLAQUES WITH A VULNERABLE PHENOTYPE",NA,NA,NA,"CIRCULATION","LIPTON, J##SEGERS, D##CHENG, C##DUCKERS, H##KRAMS, R##TEMPEL, D##BUSSER, E##DE KLEIJN, D##MOLL, FL##PASTERKAMP, G","ERASMUS MC, ROTTERDAM, NETHERLANDS. UNIV UTRECHT, MED CTR, UTRECHT, NETHERLANDS.","CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE","CARDIOVASCULAR SYSTEM & CARDIOLOGY",NA,0,2020-11-20,NA,"ERASMUS MC#UNIV UTRECHT","NETHERLANDS#NETHERLANDS"
"J","WOS:000241792803181",2006,"NOVEL ULTRASOUND-CONTRAST-AGENT DILUTION METHOD FOR ASSESSMENT OF LEFT VENTRICULAR EJECTION FRACTION",NA,NA,NA,"CIRCULATION","JANSEN, AH##MISCHI, M##VAN DANTZIG, JM##BRACKE, F##PEELS, K##VAN HEMEL, NM##KORSTEN, HH","CATHARINA HOSP, EINDHOVEN, NETHERLANDS. UNIV UTRECHT, UTRECHT, NETHERLANDS. TECH UNIV EINDHOVEN, NL-5600 MB EINDHOVEN, NETHERLANDS.","CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE","CARDIOVASCULAR SYSTEM & CARDIOLOGY",NA,0,2020-11-20,NA,"CATHARINA HOSP#UNIV UTRECHT#TECH UNIV EINDHOVEN","NETHERLANDS#NETHERLANDS#NETHERLANDS"
"J","WOS:000241792805330",2006,"EPICARDIAL ADIPOSE TISSUE IS ASSOCIATED WITH CARDIOVASCULAR RISK FACTORS AND CORONARY ARTERY CALCIFICATION: A POPULATION BASED STUDY",NA,NA,NA,"CIRCULATION","DE VOS, AM##PROKOP, M##ROOS, K##MEIJS, MF##RUTTEN, A##MOSTERD, A##CRAMER, MJM##VELTHUIS, BK##RENSING, BJ##DOEVENDANS, PA##VAN DER SCHOUW, YT##BOTS, ML","UNIV UTRECHT, MED CTR, JULIUS CTR, NL-3508 TC UTRECHT, NETHERLANDS. ST ANTONIUS HOSP, NIEUWEGEIN, NETHERLANDS.","CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE","CARDIOVASCULAR SYSTEM & CARDIOLOGY",NA,0,2020-11-20,NA,"UNIV UTRECHT#ST ANTONIUS HOSP","NETHERLANDS#NETHERLANDS"
"J","WOS:000241792805554",2006,"THE EFFECTS OF LOW-DOSE SIMVASTATIN AND EZETIMIBE COMPARED TO HIGH-DOSE SIMVASTATIN ON POSTPRANDIAL LIPIDS AND ENDOTHELIAL FUNCTION IN PATIENTS WITH THE METABOLIC SYNDROME",NA,NA,NA,"CIRCULATION","OLIJHOEK, JK##HAJER, GR##VAN DER GRAAT, Y##DALLINGA-THIE, GM##VISSEREN, FL","UNIV UTRECHT, MED CTR, UTRECHT, NETHERLANDS. ERASMUS UNIV, MED CTR, ROTTERDAM, NETHERLANDS. UNIV UTRECHT, MED CTR, UTRECHT, NETHERLANDS.","CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE","CARDIOVASCULAR SYSTEM & CARDIOLOGY",NA,0,2020-11-20,NA,"UNIV UTRECHT#ERASMUS UNIV#UNIV UTRECHT","NETHERLANDS#NETHERLANDS#NETHERLANDS"
"J","WOS:000241666800014",2006,"INDUCTION OF ORAL TOLERANCE TO OXIDIZED LOW-DENSITY LIPOPROTEIN AMELIORATES ATHEROSCLEROSIS","BACKGROUND - OXIDATION OF LOW-DENSITY LIPOPROTEIN ( LDL) AND THE SUBSEQUENT PROCESSING OF OXIDIZED LDL ( OXLDL) BY MACROPHAGES RESULTS IN ACTIVATION OF SPECIFIC T CELLS, WHICH CONTRIBUTES TO THE DEVELOPMENT OF ATHEROSCLEROSIS. ORAL TOLERANCE INDUCTION AND THE SUBSEQUENT ACTIVATION OF REGULATORY T CELLS MAY BE AN ADEQUATE THERAPY FOR THE TREATMENT OF ATHEROSCLEROSIS. METHODS AND RESULTS - TOLERANCE TO OXLDL AND MALONDIALDEHYDE-TREATED LDL ( MDA-LDL) WAS INDUCED IN LDL RECEPTOR(-/-) MICE FED A WESTERN-TYPE DIET BY ORAL ADMINISTRATION OF OXLDL OR MDA-LDL BEFORE THE INDUCTION OF ATHEROGENESIS. ORAL TOLERANCE TO OXLDL RESULTED IN A SIGNIFICANT ATTENUATION OF THE INITIATION ( 30% TO 71%; P < 0.05) AND PROGRESSION ( 45%; P < 0.05) OF ATHEROGENESIS. TOLERANCE TO OXLDL INDUCED A SIGNIFICANT INCREASE IN CD4(+)CD25(+)FOXP3(+) CELLS IN SPLEEN AND MESENTERIC LYMPH NODES, AND THESE CELLS SPECIFICALLY RESPONDED TO OXLDL WITH INCREASED TRANSFORMING GROWTH FACTOR-BETA PRODUCTION. TOLERANCE TO OXLDL ALSO INCREASED THE MRNA EXPRESSION OF FOXP3, CTLA-4, AND CD25 IN THE PLAQUE. IN CONTRAST, TOLERANCE TO MDA-LDL DID NOT AFFECT ATHEROGENESIS. CONCLUSIONS - OXLDL-SPECIFIC T CELLS, PRESENT IN LDL RECEPTOR(-/-) MICE AND IMPORTANT CONTRIBUTORS IN THE IMMUNE RESPONSE LEADING TO ATHEROSCLEROTIC PLAQUE, CAN BE COUNTERACTED BY OXLDL-SPECIFIC CD4(+)D25(+)FOXP3(+) REGULATORY T CELLS ACTIVATED VIA ORAL TOLERANCE INDUCTION TO OXLDL. WE CONCLUDE THAT THE INDUCTION OF ORAL TOLERANCE TO OXLDL MAY BE A PROMISING STRATEGY TO MODULATE THE IMMUNE RESPONSE DURING ATHEROGENESIS AND A NEW WAY TO TREAT ATHEROSCLEROSIS.","RECEPTOR-DEFICIENT MICE; REGULATORY T-CELLS; APOLIPOPROTEIN E-DEFICIENT; GROWTH-FACTOR-BETA; IN-VIVO; TRANSGENIC MICE; POTENTIAL ROLE; TGF-BETA; LYMPHOCYTES; ANTIGEN","ATHEROSCLEROSIS; IMMUNE SYSTEM; T CELLS; TOLERANCE INDUCTION","CIRCULATION","VAN PUIJVELDE, GHM##HAUER, AD##DE VOS, P##VAN DEN HEUVEL, R##VAN HERWIJNEN, MJC##VAN DER ZEE, R##VAN EDEN, W##VAN BERKEL, TJC##KUIPER, J","LEIDEN UNIV, DIV BIOPHARMACEUT, NL-2300 RA LEIDEN, NETHERLANDS. UNIV UTRECHT, DEPT INFECT DIS & IMMUNOL, NL-3508 TC UTRECHT, NETHERLANDS.","CARDIAC & CARDIOVASCULAR SYSTEMS; PERIPHERAL VASCULAR DISEASE","CARDIOVASCULAR SYSTEM & CARDIOLOGY","AIT-OUFELLA H, 2006, NAT MED, V12, P178, DOI 10.1038/NM1343##BENAGIANO M, 2003, P NATL ACAD SCI USA, V100, P6658, DOI 10.1073/PNAS.1135726100##CHANG MK, 2004, J EXP MED, V200, P1359, DOI 10.1084/JEM.20031763##CHEN WJ, 2003, CYTOKINE GROWTH F R, V14, P85, DOI 10.1016/S1359-6101(03)00003-0##CHEN YH, 1996, P NATL ACAD SCI USA, V93, P388, DOI 10.1073/PNAS.93.1.388##CHEN YH, 1995, NATURE, V376, P177, DOI 10.1038/376177A0##COBELENS PM, 2002, RHEUMATOLOGY, V41, P775, DOI 10.1093/RHEUMATOLOGY/41.7.775##DAVENPORT P, 2003, AM J PATHOL, V163, P1117, DOI 10.1016/S0002-9440(10)63471-2##ELHAGE R, 2003, CARDIOVASC RES, V59, P234, DOI 10.1016/S0008-6363(03)00343-2##FRIEDMAN A, 1996, ANN NY ACAD SCI, V778, P103, DOI 10.1111/J.1749-6632.1996.TB21119.X##GEORGE J, 2004, CARDIOVASC RES, V62, P603, DOI 10.1016/J.CARDIORES.2004.01.028##HANSSON GK, 2000, ANN NY ACAD SCI, V902, P53##HANSSON GK, 2001, ARTERIOSCL THROM VAS, V21, P1876, DOI 10.1161/HQ1201.100220##HARATS D, 2002, J AM COLL CARDIOL, V40, P1333, DOI 10.1016/S0735-1097(02)02135-6##HAUER AD, 2005, CIRCULATION, V112, P1054, DOI 10.1161/CIRCULATIONAHA.104.533463##HORI S, 2003, SCIENCE, V299, P1057, DOI 10.1126/SCIENCE.1079490##KEHRL JH, 1986, J EXP MED, V163, P1037, DOI 10.1084/JEM.163.5.1037##LIBBY P, 2002, NATURE, V420, P868, DOI 10.1038/NATURE01323##LIU LM, 1993, J EXP MED, V177, P1299, DOI 10.1084/JEM.177.5.1299##MA SW, 2004, P NATL ACAD SCI USA, V101, P5680, DOI 10.1073/PNAS.0307420101##MACDONALD TT, 1983, EUR J IMMUNOL, V13, P138, DOI 10.1002/EJI.1830130209##MALLAT Z, 2005, CURR OPIN LIPIDOL, V16, P518, DOI 10.1097/01.MOL.0000182532.11512.90##MARON R, 2002, CIRCULATION, V106, P1708, DOI 10.1161/01.CIR.0000029750.99462.30##MARON R, 2002, INT IMMUNOL, V14, P131, DOI 10.1093/INTIMM/14.2.131##MASSAGUE J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/ANNUREV.BIOCHEM.67.1.753##MATTINGLY JA, 1984, CELL IMMUNOL, V86, P46, DOI 10.1016/0008-8749(84)90357-5##MELAMED D, 1993, EUR J IMMUNOL, V23, P935, DOI 10.1002/EJI.1830230426##NAKAMURA K, 2001, J EXP MED, V194, P629, DOI 10.1084/JEM.194.5.629##PINDERSKI LJ, 2002, CIRC RES, V90, P1064, DOI 10.1161/01.RES.0000018941.10726.FA##REDGRAVE TG, 1975, ANAL BIOCHEM, V65, P42, DOI 10.1016/0003-2697(75)90488-1##ROSS R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207##SALONEN JT, 1992, LANCET, V339, P883, DOI 10.1016/0140-6736(92)90926-T##SCHIOPU A, 2004, CIRCULATION, V110, P2047, DOI 10.1161/01.CIR.0000143162.56057.B5##SCOTT FW, 2002, DIABETES, V51, P73, DOI 10.2337/DIABETES.51.1.73##SHI FD, 1999, J IMMUNOL, V162, P5757##STEMME S, 1995, P NATL ACAD SCI USA, V92, P3893, DOI 10.1073/PNAS.92.9.3893##TOUSSIROT ERIC A., 2002, CURRENT DRUG TARGETS - INFLAMMATION AND ALLERGY, V1, P45, DOI 10.2174/1568010023344850##VANBERKEL TJC, 1991, J BIOL CHEM, V266, P2282##VAZ N M, 1981, MEMORIAS DO INSTITUTO OSWALDO CRUZ, V76, P83##VON DER THUSEN JH, 2001, FASEB J, V15, P2730, DOI 10.1096/FJ.01-0483FJE##VON DER THUSEN JH, 2001, CIRCULATION, V103, P1164, DOI 10.1161/01.CIR.103.8.1164##WATSON AD, 1997, J BIOL CHEM, V272, P13597, DOI 10.1074/JBC.272.21.13597##WHITMAN SC, 2002, J INTERF CYTOK RES, V22, P661, DOI 10.1089/10799900260100141##ZHANG XM, 2001, J IMMUNOL, V167, P4245, DOI 10.4049/JIMMUNOL.167.8.4245",132,2020-11-20,NA,"LEIDEN UNIV#UNIV UTRECHT","NETHERLANDS#NETHERLANDS"
"J","WOS:000239162100003",2006,"ANTIBODY RESPONSES TO ASCARIS-DERIVED PROTEINS AND GLYCOLIPIDS: THE ROLE OF PHOSPHORYLCHOLINE","IN ADDITION TO PROTEINS, GLYCOLIPIDS CAN BE TARGETS OF ANTIBODY RESPONSES AND CONTRIBUTE TO HOST-PATHOGEN INTERACTION. FOLLOWING THE STRUCTURAL ANALYSIS OF ASCARIS LUMBRICOIDES-DERIVED GLYCOLIPIDS, THE ANTIBODY RESPONSES OF A GROUP OF CHILDREN WITH NO, LIGHT AND HEAVY INFECTIONS WERE ANALYSED. THE ROLE OF THE PHOSPHORYLCHOLINE MOIETY, PRESENT ON ASCARIS GLYCOPROTEINS AND GLYCOLIPIDS, IN ANTIBODY REACTIVITY OF THESE INFECTED INDIVIDUALS WAS DETERMINED. CHILDREN CARRYING HEAVY INFECTIONS SHOWED HIGHEST IGG REACTIVITY TO GLYCOLIPIDS COMPARED TO LIGHTLY OR NON-INFECTED CHILDREN. SUBSTANTIAL IGG ANTIBODY REACTIVITY TO BOTH (GLYCO)PROTEINS AND GLYCOLIPIDS WAS FOUND TO BE DIRECTED TO THE PHOSPHORYLCHOLINE MOIETY AS DETERMINED BY EITHER REMOVAL OF THIS GROUP OR A COMPETITION ASSAY. THIS WAS MOST PRONOUNCED FOR GLYCOLIPIDS, WHERE REMOVAL OF THE PHOSPHORYLCHOLINE MOIETIES BY HYDROFLUORIC ACID TREATMENT ABROGATED IGG ANTIBODY REACTIVITY. MEASUREMENT OF IGG4 AND IGE ISOTYPES SHOWED NO IGG4 REACTIVITY TO ASCARIS GLYCOLIPIDS, BUT RAISED IGE RESPONSES WERE DETECTED IN SUBJECTS WITH LIGHT OR NO ASCARIS INFECTIONS, SUGGESTING THAT IGE RESPONSES TO GLYCOLIPIDS MAY PLAY A ROLE IN CONTROLLING PARASITE BURDEN. DIFFERENCES FOUND IN ANTIBODY PROFILES TO GLYCOLIPIDS AND (GLYCO)PROTEINS, INDICATE THAT THESE DIFFERENT CLASSES OF COMPOUNDS MAY HAVE DISTINCT ROLES IN SHAPING OF AND INTERACTING WITH HUMORAL IMMUNE RESPONSES.","SCHISTOSOMA-MANSONI; ZWITTERIONIC GLYCOSPHINGOLIPIDS; STRUCTURAL ELUCIDATION; ANTIGENS; IGG4; IDENTIFICATION; LUMBRICOIDES; IGE; REINFECTION; RESISTANCE","ANTIBODY; ASCARIS; GLYCOLIPID; HELMINTH; IGE; IGG; PHOSPHORYLCHOLINE","PARASITE IMMUNOLOGY","VAN RIET, E##WUHRER, M##WAHYUNI, S##RETRA, K##DEELDER, AM##TIELENS, AGM##VAN DER KLEIJ, D##YAZDANBAKHSH, M","LEIDEN UNIV, MED CTR, DEPT PARASITOL, NL-2300 RC LEIDEN, NETHERLANDS. UNIV UTRECHT, FAC VET MED, DEPT BIOCHEM & CELL BIOL, UTRECHT, NETHERLANDS. HASANUDDIN UNIV, DEPT PARASITOL, MAKASSAR, INDONESIA. TNO DEF SECUR & SAFETY, BUSINESS UNIT BIOL & CHEM PROTECT, RIJSWIJK, NETHERLANDS.","IMMUNOLOGY; PARASITOLOGY","IMMUNOLOGY; PARASITOLOGY","BELPERRON AA, 2005, J IMMUNOL, V174, P5681, DOI 10.4049/JIMMUNOL.174.9.5681##BLIGH EG, 1959, CANADIAN JOURNAL OF, V37, P911, DOI DOI 10.1139/Y59-099##BRILES DE, 1981, NATURE, V294, P88, DOI 10.1038/294088A0##CUNDELL DR, 1995, NATURE, V377, P435, DOI 10.1038/377435A0##DEEHAN MR, 2002, PARASITE IMMUNOL, V24, P463, DOI 10.1046/J.1365-3024.2002.00489.X##DENNIS RD, 1996, PARASITOLOGY, V112, P295, DOI 10.1017/S0031182000065811##DESILVA NR, 1997, TROP MED INT HEALTH, V2, P519##FRIEDL CH, 2003, BIOCHEM J, V369, P89, DOI 10.1042/BJ20021074##GEIGER SM, 2002, PARASITE IMMUNOL, V24, P499, DOI 10.1046/J.1365-3024.2002.00600.X##GERDT S, 1999, EUR J BIOCHEM, V266, P952, DOI 10.1046/J.1432-1327.1999.00937.X##GRABITZKI J, 2005, EUR J MASS SPECTROM, V11, P335, DOI 10.1255/EJMS.728##GRIFFITTS JS, 2005, SCIENCE, V307, P922, DOI 10.1126/SCIENCE.1104444##HAGAN P, 1991, NATURE, V349, P243, DOI 10.1038/349243A0##HAGEL I, 1993, CLIN EXP IMMUNOL, V94, P80, DOI 10.1111/J.1365-2249.1993.TB05981.X##HARNETT MM, 1998, PARASITE IMMUNOL, V20, P551, DOI 10.1046/J.1365-3024.1998.00181.X##HARNETT W, 1999, IMMUNOL TODAY, V20, P125, DOI 10.1016/S0167-5699(98)01419-4##HOUSTON KM, 2002, MOL BIOCHEM PARASIT, V123, P55, DOI 10.1016/S0166-6851(02)00134-2##JULIAN E, 2004, CLIN DIAGN LAB IMMUN, V11, P70, DOI 10.1128/CDLI.11.1.70-76.2004##LAL RB, 1991, IMMUNOLOGY, V74, P333##LOCHNIT G, 2000, BIOL CHEM, V381, P839, DOI 10.1515/BC.2000.106##LOCHNIT G, 2005, INT J PARASITOL, V35, P911, DOI 10.1016/J.IJPARA.2005.02.015##LOCHNIT G, 1998, J BIOL CHEM, V273, P466, DOI 10.1074/JBC.273.1.466##MAIZELS RM, 2003, NAT REV IMMUNOL, V3, P733, DOI 10.1038/NRI1183##MCSHARRY C, 1999, INFECT IMMUN, V67, P484, DOI 10.1128/IAI.67.2.484-489.1999##PALMER DR, 1995, PARASITOLOGY, V111, P385, DOI 10.1017/S0031182000081944##ROBIJN MLM, 2005, PARASITOLOGY, V130, P67, DOI 10.1017/S0031182004006390##ROMARIS F, 2001, PARASITE IMMUNOL, V23, P313, DOI 10.1046/J.1365-3024.2001.00388.X##ROUSER G, 1969, METHOD ENZYMOL, V14, P272##SCHMIDT GD, 1996, FDN PARASITOLOGY, P419##SIMONSEN PE, 1996, AM J TROP MED HYG, V55, P69, DOI 10.4269/AJTMH.1996.55.69##SLOAN T, 1991, PARASITE IMMUNOL, V13, P447, DOI 10.1111/J.1365-3024.1991.TB00296.X##SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7##THOMAS PG, 2004, CELL MICROBIOL, V6, P13, DOI 10.1046/J.1462-5822.2003.00337.X##TURNER JD, 2005, MICROBES INFECT, V7, P990, DOI 10.1016/J.MICINF.2005.03.036##VAN DER KLEIJ D, 1999, INFECT IMMUN, V67, P5946, DOI 10.1128/IAI.67.11.5946-5950.1999##WEISS JB, 1986, J IMMUNOL, V136, P4275##WUHRER M, 2000, BIOCHEM J, V348, P417, DOI 10.1042/0264-6021:3480417##WUHRER M, 2004, RAPID COMMUN MASS SP, V18, P1741, DOI 10.1002/RCM.1546",22,2020-11-20,NA,"LEIDEN UNIV#UNIV UTRECHT#HASANUDDIN UNIV#TNO DEF SECUR SAFETY","NETHERLANDS#NETHERLANDS#INDONESIA#NETHERLANDS"
"J","WOS:000238848200007",2006,"FREEZING INFECTIVE-STAGE LARVAE FROM ANISAKIS SIMPLEX AND THEIR PRODUCE AT -20 DEGREES C FOR 24 H DOES NOT PREVENT THE OCCURRENCE OF AUTONOMIC IMBALANCE IN RAT ILEUM","IN THE PRESENT REPORT, WE ANALYZE THE EFFICACY OF THE SANITARY REGULATIONS TO KILL THE ANISAKIS SIMPLEX LARVAE (AS L3) (HEAT OR FREEZE) TO AVOID THE GASTROINTESTINAL ALTERATIONS THAT IT PROVOKES. WE STUDIED THE EFFECTS ON INTESTINAL CONTRACTILITY (MUSCULAR TONE, AMPLITUDE, AND FREQUENCY OF THE TWITCHES AND CHOLINERGIC AND ALPHA-ADRENERGIC STIMULUS) OF AS L3, THEIR CRUDE EXTRACTS (CE) AND EXCRETORY-SECRETORY PRODUCTS (ESP), UNTREATED OR HEATED (60 DEGREES C FOR 15 MIN) OR FROZEN (-20 DEGREES C FOR 24 H) USING RAT ILEUM AND AN ISOMETRIC SYSTEM. CARBACHOL AND NORADRENALINE HAVE BEEN USED AS CHOLINERGIC AND ALPHA-ADRENERGIC STIMULUS, RESPECTIVELY. WE DETERMINED THAT VIABLE AS L3, THEIR UNTREATED CE AND ESP, AS WELL AS ALL THEIR FROZEN COUNTERPARTS, ALTERED THE INTESTINAL CONTRACTILE ACTIVITY AND ITS AUTONOMIC CONTROL. IN CONTRAST, HEATED AS L3, CE, AND ESP WERE INCAPABLE OF PROVOKING ANY CHANGE IN RAT ILEUM MOTILITY, SUGGESTING AN INHIBITORY EFFECT BY THE HEATING PROCEDURE. IN CONCLUSION: 1) THE GASTROINTESTINAL ALTERATIONS PROVOKED BY AS ARE NOT NECESSARILY ASSOCIATED WITH A PRIOR INFECTION; AND 2) THE STORAGE OF THE SEAFOOD AT -20 DEGREES C DURING 24 H DOES NOT PREVENT THE INTESTINAL AUTONOMIC IMBALANCE PROVOKED BY AS, WHEREAS, THE PRIOR HEATING AT 60 DEGREES C FOR 15 MIN MAY COMPLETELY PREVENT SUCH PROCESS.","IMMUNE-RESPONSE; ALLERGENS; ANTIGENS; PARASITE; EXTRACT",NA,"PARASITOLOGY RESEARCH","SANCHEZ-MONSALVEZ, I##DE ARMAS-SERRA, C##BERNADINA, W##RODRIGUEZ-CAABEIRO, F","UNIV ALCALA DE HENARES, DEPT MICROBIOL & PARASITOL, FAC FARM, MADRID, SPAIN. UNIV UTRECHT, INST INFECTED DIS & IMMUNOL, UTRECHT, NETHERLANDS.","PARASITOLOGY","PARASITOLOGY","AUDICANA L, 1997, VET REC, V140, P235, DOI 10.1136/VR.140.9.235##AUDICANA M, 2000, ALLERGY, V55, P28, DOI 10.1034/J.1398-9995.2000.03405.X##AUDICANA MT, 2002, TRENDS PARASITOL, V18, P20, DOI 10.1016/S1471-4922(01)02152-3##BAEZA ML, 2004, CLIN EXP ALLERGY, V34, P296, DOI 10.1111/J.1365-2222.2004.01883.X##CABALLERO ML, 2004, PARASITOL RES, V93, P248, DOI 10.1007/S00436-004-1099-3##CUELLAR C, 2001, SCAND J IMMUNOL, V53, P483, DOI 10.1046/J.1365-3083.2001.00905.X##DASCHNER A, 2002, PARASITE IMMUNOL, V24, P243, DOI 10.1046/J.1365-3024.2002.00458.X##GARCIA M., 1996, ALLERGY (COPENHAGEN), V51, P139##KENNEDY MW, 2000, ALLERGY, V55, P7, DOI 10.1034/J.1398-9995.2000.03402.X##LOWRY OH, 1951, J BIOL CHEM, V193, P265##MURAOKA A, 1996, DIGEST DIS SCI, V41, P2362, DOI 10.1007/BF02100128##PERTEGUER MJ, 2001, PARASITOL RES, V87, P396, DOI 10.1007/S004360000362##PICHLER WJ, 1999, CLIN EXP ALLERGY, V29, P1161, DOI 10.1046/J.1365-2222.1999.00646.X##SANCHEZ-MONSALVEZ I, 2003, DIGEST DIS SCI, V48, P2342, DOI 10.1023/B:DDAS.0000007873.48287.F6##TERR AI, 1997, MED IMMUNOLOGY, P376##VAZQUEZ-LOPEZ C, 2002, DIGEST DIS SCI, V47, P935, DOI 10.1023/A:1014785210407",3,2020-11-20,NA,"UNIV ALCALA DE HENARES#UNIV UTRECHT","SPAIN#NETHERLANDS"
"J","WOS:000238655700005",2006,"HOUSE DUST MITE ALLERGEN REDUCTION AND ALLERGY AT 4 YR: FOLLOW UP OF THE PIAMA-STUDY","EXPOSURE TO HIGH ALLERGEN LEVELS IN EARLY LIFE IS A RISK FACTOR FOR THE DEVELOPMENT OF ALLERGY. WE PREVIOUSLY REPORTED LIMITED EFFECTS OF MITE ALLERGEN IMPERMEABLE MATTRESS COVERS IN THE PREVENTION AND INCIDENCE OF ASTHMA AND MITE ALLERGY (PIAMA) COHORT AT THE AGE OF 1 AND 2 YR. WE NOW PRESENT THE RESULTS OF FOLLOW-UP AT 4 YR OBJECTIVES. TO EXAMINE THE EFFECTS OF EARLY REDUCTION OF HOUSE DUST MITE (HDM) ALLERGEN EXPOSURE BY MEANS OF MATTRESS COVERS ON THE INCIDENCE OF ALLERGY AND ASTHMA SYMPTOMS IN THE PIAMA BIRTH COHORT AT THE AGE OF 4 YR. HIGH-RISK CHILDREN (ALLERGIC MOTHER) WERE PRENATALLY RECRUITED AND RANDOMLY ALLOCATED TO THREE GROUPS; RECEIVING MITE ALLERGEN IMPERMEABLE MATTRESS COVERS (N = 416), PLACEBO COVERS (N = 394) OR NO INTERVENTION (N = 472). AT 4 YR OF AGE, ATOPY WAS ASSESSED BY QUESTIONNAIRE; SPECIFIC IMMUNOGLOBULIN E (IGE) TO INHALANT AND FOOD ALLERGENS WAS MEASURED IN SERUM. DUST SAMPLES COLLECTED FROM THE CHILDREN'S MATTRESSES WERE ANALYSED FOR MITE ALLERGENS. DERMATOPHAGOIDES FARINAE1 ALLERGEN (DER F 1) LEVELS IN DUST WERE REDUCED IN THE ACTIVE GROUP. HOWEVER, DERMATOPHAGOIDES PTERONISSINUS 1 (DER P 1) LEVELS, SENSITIZATION AND ATOPIC SYMPTOMS WERE SIMILAR IN ALL GROUPS. WE FOUND NO EFFECT OF MITE ALLERGEN IMPERMEABLE MATTRESS COVERS ON SENSITIZATION AND ATOPY AT 4 YR. MOREOVER, THE ALLERGEN REDUCING EFFECTS OF THE COVERS HAD DISAPPEARED FOR ONE OF THE TWO MITE ALLERGENS THAT WERE MEASURED.","DER-P-I; CONTROLLED-TRIAL; EARLY-LIFE; ENVIRONMENTAL-CONTROL; RESPIRATORY SYMPTOMS; MATTRESS ENCASINGS; PRIMARY PREVENTION; EUROPE SPACE; BIRTH-COHORT; ASTHMA","MATTRESS COVERS; PREVENTION; IMMUNOGLOBULIN E; BIRTH COHORT; ATOPY; ATOPIC DERMATITIS; RHINITIS; WHEEZE","PEDIATRIC ALLERGY AND IMMUNOLOGY","CORVER, K##KERKHOF, M##BRUSSEE, JE##BRUNEKREEF, B##VAN STRIEN, RT##VOS, AP##SMIT, HA##GERRITSEN, J##NEIJENS, HJ##DE JONGSTE, JC","SOPHIA CHILDRENS UNIV HOSP, ERASMUS MC, DEPT PEDIAT, DIV RESP MED, ROTTERDAM, NETHERLANDS. UNIV GRONINGEN HOSP, DEPT PEDIAT RESP MED, GRONINGEN, NETHERLANDS. NATL INST PUBL HLTH & ENVIRONM, CTR PREVENT & HLTH SERV RES, NL-3720 BA BILTHOVEN, NETHERLANDS. UNIV UTRECHT, FAC VET MED, INST RISK ASSESSMENT SCI, UTRECHT, NETHERLANDS. UNIV UTRECHT, FAC SCI, INST RISK ASSESSMENT SCI, UTRECHT, NETHERLANDS. UNIV UTRECHT, UNIV MED CTR UTRECHT, UTRECHT, NETHERLANDS. UNIV MUNICH, INST OCCUPAT & ENVIRONM MED, UNIT OCCUPAT & ENVIRONM EPIDEMIOL & NET TEACHING, MUNICH, GERMANY.","ALLERGY; IMMUNOLOGY; PEDIATRICS","ALLERGY; IMMUNOLOGY; PEDIATRICS","ARSHAD SH, 2003, THORAX, V58, P489, DOI 10.1136/THORAX.58.6.489##ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483##BECKER A, 2004, J ALLERGY CLIN IMMUN, V113, P650, DOI 10.1016/J.JACI.2004.01.754##BOULAY ME, 2003, CURR OPIN ALLERGY CL, V3, P51, DOI 10.1097/01.ALL.0000053268.39029.19##BRUNEKREEF B, 2005, ALLERGY, V60, P1083, DOI 10.1111/J.1398-9995.2005.00881.X##BRUNEKREEF B, 2002, PEDIAT ALLERG IMM-UK, V13, P55, DOI 10.1034/J.1399-3038.13.S.15.1.X##CUSTOVIC A, 2001, LANCET, V358, P188, DOI 10.1016/S0140-6736(01)05406-X##HALMERBAUER G, 2002, PEDIAT ALLERG IMM-UK, V13, P47, DOI 10.1034/J.1399-3038.13.S.15.11.X##HALMERBAUER G, 2003, PEDIAT ALLERG IMM-UK, V14, P10, DOI 10.1034/J.1399-3038.2003.02069.X##HOLGATE ST, 1999, NATURE, V402, PB2, DOI 10.1038/35037000##HORAK F, 2004, CLIN EXP ALLERGY, V34, P1220, DOI 10.1111/J.1365-2222.2004.02024.X##JANSON C, 2001, EUR RESPIR J, V18, P598, DOI 10.1183/09031936.01.00205801##KOOPMAN LP, 2002, AM J RESP CRIT CARE, V166, P307, DOI 10.1164/RCCM.2106026##LAKWIJK N, 1998, CLIN EXP ALLERGY, V28, P454##MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301##O'CONNELL EJ, 2003, ANN ALLERG ASTHMA IM, V90, P53, DOI 10.1016/S1081-1206(10)61661-4##OWEN S, 1990, LANCET, V335, P396, DOI 10.1016/0140-6736(90)90219-U##PEAT JK, 2004, J ALLERGY CLIN IMMUN, V114, P807, DOI 10.1016/J.JACI.2004.06.057##PLATTSMILLS TAE, 1992, J ALLERGY CLIN IMMUN, V89, P1046, DOI 10.1016/0091-6749(92)90228-T##SIMPSON A, 2003, CLIN EXP ALLERGY, V33, P1183, DOI 10.1046/J.1365-2745.2003.01679.X##STAPEL SO, 2004, PEDIATR ALLERGY IMMU, V15, P230, DOI 10.1111/J.1399-3038.2004.00142.X##VAN STRIEN RT, 2003, CLIN EXP ALLERGY, V33, P490, DOI 10.1046/J.1365-2222.2003.01626.X##VANSTRIEN RT, 1995, CLIN EXP ALLERGY, V25, P1184, DOI 10.1111/J.1365-2222.1995.TB03042.X##VANSTRIEN RT, 1994, CLIN EXP ALLERGY, V24, P843, DOI 10.1111/J.1365-2222.1994.TB01807.X##VERHOEFF AP, 1994, CLIN EXP ALLERGY, V24, P1061, DOI 10.1111/J.1365-2222.1994.TB02744.X##VONMUTIUS E, 1996, PEDIATR ALLERGY IMMU, V7, P54##WOODCOCK A, 2004, AM J RESP CRIT CARE, V170, P433, DOI 10.1164/RCCM.200401-083OC##YUNGINGER JW, 1992, AM REV RESPIR DIS, V146, P888, DOI 10.1164/AJRCCM/146.4.888",73,2020-11-20,NA,"SOPHIA CHILDRENS UNIV HOSP#UNIV GRONINGEN HOSP#NATL INST PUBL HLTH ENVIRONM#UNIV UTRECHT#UNIV UTRECHT#UNIV UTRECHT#UNIV MUNICH","NETHERLANDS#NETHERLANDS#NETHERLANDS#NETHERLANDS#NETHERLANDS#NETHERLANDS#GERMANY"
"J","WOS:000240261300009",2006,"THE EFFECT OF ADMISSION TO A GERIATRIC WARD ON MEDICATION USE: 2002 VERSUS 1985","PURPOSE TO INVESTIGATE THE CHANGES IN PHARMACOTHERAPY OF PATIENTS DURING AND AFTER ADMISSION TO A GERIATRIC WARD IN 2002 AND TO INVESTIGATE IF THIS GOES ALONG WITH REDUCTION OF DRUGS. TO DESCRIBE THE DIFFERENCES OF THE ADMITTED PATIENTS AND THEIR MEDICATION IN 2002 COMPARED TO 1985. METHODS INCLUDED PATIENTS WERE ADMITTED TO THE GERIATRIC WARD OF A GENERAL HOSPITAL IN THE NETHERLANDS DURING 2002 (N = 258, MEAN AGE 84.2 YEARS). MEDICATION AT ADMISSION, DURING ADMISSION AND AT DISCHARGE WERE DESCRIBED AFTER RETROSPECTIVE REVIEWING OF MEDICAL CHARTS. A COMPARABLE STUDY WAS PERFORMED AT THE SAME WARD IN 1985. RESULTS IN 2002, MOST FREQUENTLY USED MEDICATION AT ADMISSION WAS ACETYLSALICYLIC ACID (30.2%). PANTOPRAZOLE WAS DURING ADMISSION USED IN 38.8% OF PATIENTS AND AT DISCHARGE IN 31.8%. FOLIC ACID THAT WAS AT ADMISSION USED BY 11.6% OF PATIENTS WAS AT DISCHARGE INCREASED TO 23.4%. AT DISCHARGE, VITAMIN D WAS USED IN 21.5% OF PATIENTS, WHEREAS LISINOPRIL WAS USED IN 17.8% OF PATIENTS. BOTH IN 1985 AND 2002 VITAMINS WERE ADDED AND USE OF ANTIBIOTICS WAS INCREASED DURING ADMISSION. A MEAN ADDITION OF 1.0 DRUG IN 1985 AND OF 0.7 DRUGS IN 2002 WAS OBSERVED. CONCLUSIONS GERIATRIC HOSPITAL ADMISSION RESULTED BOTH IN 1985 AND 2002 IN ADDITION OF MEDICATION. IN BOTH PERIODS REDUCTIONS IN MEDICATION WERE NULLIFIED BY ADDITION OF MEDICATION FOR REASON OF THERAPY OPTIMISATION. COMPARED TO 1985 ADMITTED PATIENTS RECEIVE MORE MEDICATION RESULTING FROM NEW INSIGHTS INTO PHARMACOTHERAPY AND MORE USE OF PREVENTIVE MEDICINE. COPYRIGHT (C) 2006 JOHN WILEY & SONS, LTD.","POLYPHARMACY; DEFICIENCY; FOLATE","DRUG THERAPY; OLDER PEOPLE; GERIATRIC WARD; HISTORICAL COHORT STUDY","PHARMACOEPIDEMIOLOGY AND DRUG SAFETY","FRANKFORT, SV##TULNER, LR##VAN CAMPEN, JPCM##KOKS, CHW##BEIJNEN, JH","SLOTERVAART HOSP, DEPT GERIATR MED, AMSTERDAM, NETHERLANDS. UNIV UTRECHT, DIV DRUG TOXICOL, DEPT BIOMED ANAL, FAC PHARMACEUT SCI, UTRECHT, NETHERLANDS.","PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH; PHARMACOLOGY & PHARMACY","PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH; PHARMACOLOGY & PHARMACY","CLARKE R, 2004, AGE AGEING, V33, P34, DOI 10.1093/AGEING/AFG109##FIGLIN E, 2003, BRIT J HAEMATOL, V123, P696, DOI 10.1046/J.1365-2141.2003.04658.X##GOLDSTEIN JL, 2004, DIGESTION, V69, P25, DOI 10.1159/000076554##HEMMINKI E, 1975, SCAND J SOC MED, V3, P87, DOI 10.1177/140349487500300207##LINJAKUMPU T, 2002, J CLIN EPIDEMIOL, V55, P809, DOI 10.1016/S0895-4356(02)00411-0##PORRO GB, 2000, DIGEST LIVER DIS, V32, P201##RAMPERSAUD GC, 2003, J AM COLL NUTR, V22, P1##REMME WJ, 2001, EUR HEART J, V22, P1527, DOI 10.1053/EUHJ.2001.2783##RIKKERT MGO, 1990, TIJDSCHR GERONTOL GE, V21, P51##ROLLASON V, 2003, DRUG AGING, V20, P817, DOI 10.2165/00002512-200320110-00003##SOUTHWORTH MR, 2003, AM J HEALTH-SYST PH, V60, PS7, DOI 10.1093/AJHP/60.SUPPL_4.S7##STEWART RB, 1994, DRUG AGING, V4, P449, DOI 10.2165/00002512-199404060-00002##THOMAS MK, 1998, NEW ENGL J MED, V338, P777, DOI 10.1056/NEJM199803193381201##VILARRASA N, 2005, ACTA DIABETOL, V42, P87, DOI 10.1007/S00592-005-0184-0##*WHO COL CTR DRUG, 1994, AN THER CHEM ATC CLA",0,2020-11-20,NA,"SLOTERVAART HOSP#UNIV UTRECHT","NETHERLANDS#NETHERLANDS"
"J","WOS:000240281200533",2006,"ROSUVASTATIN'S SAFETY PROFILE IS COMPARABLE TO THAT OF OTHER MARKETED STATINS: RESULTS FROM A HISTORICAL COHORT STUDY IN MORE THAN 45,000 DUTCH STATIN USERS",NA,NA,NA,"PHARMACOEPIDEMIOLOGY AND DRUG SAFETY","GOETTSCH, WG##HEINTJES, E##KASTELEIN, JJP##JOHANSSON, S##HERINGS, RMC","PHARMO INST, UTRECHT, NETHERLANDS. UNIV UTRECHT, UIPS, UTRECHT, NETHERLANDS. UNIV AMSTERDAM, ACAD MED CTR, NL-1105 AZ AMSTERDAM, NETHERLANDS. ASTRAZENECA AB, MOLNDAL, SWEDEN. SAHLGRENS UNIV HOSP, OSTRA, SWEDEN.","PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH; PHARMACOLOGY & PHARMACY","PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH; PHARMACOLOGY & PHARMACY",NA,0,2020-11-20,NA,"PHARMO INST#UNIV UTRECHT#UNIV AMSTERDAM#ASTRAZENECA AB#SAHLGRENS UNIV HOSP","NETHERLANDS#NETHERLANDS#NETHERLANDS#SWEDEN#SWEDEN"
"J","WOS:000240281200159",2006,"THE OSIAP EUROPE PROJECT: PRESENTATION OF A EUROPEAN PHARMACOEPIDEMIOLOGICAL SURVEY OF THE MISUSE OR ABUSE OF MARKETED DRUGS",NA,NA,NA,"PHARMACOEPIDEMIOLOGY AND DRUG SAFETY","LAPEYRE-MESTRE, M##GONY, M##BERGMAN, U##CARVAJAL, A##CONFORTI, A##HEERDINK, ER##MACIAS, D##STICHELE, RV","UNIV TOULOUSE 3, FAC MED, EA3696, UNIT PHARMACOEPIDEMOL, F-31062 TOULOUSE, FRANCE. KAROLINSKA INST, STOCKHOLM, SWEDEN. UNIV VALLADOLID, IST FARMACOEPIDEMIOL, VALLADOLID, SPAIN. UNIV VERONA, CTR PHARMACOVIGILANCE, I-37100 VERONA, ITALY. UNIV UTRECHT, DEPT PHARMACOEPIDEMIOL, UTRECHT, NETHERLANDS. STATE UNIV GHENT HOSP, PHARMACOL LAB, B-9000 GHENT, BELGIUM.","PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH; PHARMACOLOGY & PHARMACY","PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH; PHARMACOLOGY & PHARMACY",NA,0,2020-11-20,NA,"UNIV TOULOUSE#KAROLINSKA INST#UNIV VALLADOLID#UNIV VERONA#UNIV UTRECHT#STATE UNIV GHENT HOSP","FRANCE#SWEDEN#SPAIN#ITALY#NETHERLANDS#BELGIUM"
